{
  "file_name": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
  "total_pages": 97,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "8.992650032043457": 108,
      "27.937164306640625": 4,
      "23.021183013916016": 1,
      "17.985300064086914": 1,
      "17.02608299255371": 2,
      "14.2186279296875": 2,
      "14.028532981872559": 17,
      "13.816503524780273": 5,
      "11.030982971191406": 273,
      "12.94941520690918": 887,
      "11.99020004272461": 18,
      "32.013832092285156": 2,
      "20.02363395690918": 11,
      "15.946965217590332": 50,
      "14.987749099731445": 643,
      "9.951866149902344": 621,
      "6.354805946350098": 1,
      "18.944515228271484": 2,
      "20.98284912109375": 2
    },
    "heading_sizes": [
      32.013832092285156,
      27.937164306640625,
      20.98284912109375,
      20.02363395690918,
      18.944515228271484,
      17.02608299255371,
      15.946965217590332,
      14.987749099731445,
      14.2186279296875,
      14.028532981872559,
      13.816503524780273
    ]
  },
  "table_analysis": {
    "total_tables": 7,
    "tables_info": [
      {
        "bbox": [
          81.79566955566406,
          166.72210693359375,
          533.0318603515625,
          754.1242065429688
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          61.64658737182617,
          193.58843994140625,
          469.8333740234375,
          359.0076599121094
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          73.76002502441406,
          272.5821228027344,
          527.19921875,
          464.8040466308594
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          73.64009094238281,
          137.72947692871094,
          533.232421875,
          463.4855041503906
        ],
        "num_rows": 12,
        "num_cols": 3
      },
      {
        "bbox": [
          68.84268951416016,
          109.0807876586914,
          530.9522094726562,
          428.9532775878906
        ],
        "num_rows": 7,
        "num_cols": 3
      },
      {
        "bbox": [
          64.16522216796875,
          164.8198699951172,
          529.0335083007812,
          301.7471923828125
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          64.52503204345703,
          164.3404083251953,
          521.9570922851562,
          360.8056945800781
        ],
        "num_rows": 14,
        "num_cols": 5
      }
    ]
  },
  "text_blocks": [
    {
      "text": "발간등록번호",
      "font_size": 8.992650032043457,
      "font_name": "Haansoft Batang",
      "bbox": [
        97.86695861816406,
        76.3110122680664,
        151.83770751953125,
        85.30119323730469
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0661-01",
      "font_size": 8.992650032043457,
      "font_name": "Haansoft Batang",
      "bbox": [
        88.1522216796875,
        90.9350357055664,
        161.51919555664062,
        99.92521667480469
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정시스템",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        87.55255126953125,
        243.33323669433594,
        516.63134765625,
        271.2627258300781
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 및 임상시험계획서",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        87.55255126953125,
        288.1642761230469,
        516.63134765625,
        316.09375
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 가이드라인",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        192.49566650390625,
        332.8753967285156,
        402.38238525390625,
        360.80487060546875
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        198.25254821777344,
        377.5865478515625,
        396.56378173828125,
        405.5160217285156
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016. 12.",
      "font_size": 23.021183013916016,
      "font_name": "T4",
      "bbox": [
        251.62362670898438,
        518.1937255859375,
        343.20806884765625,
        545.7885131835938
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기심사부 체외진단기기과",
      "font_size": 17.985300064086914,
      "font_name": "MalgunGothicBold",
      "bbox": [
        166.94952392578125,
        704.3194580078125,
        427.80816650390625,
        728.2347412109375
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제․개정 이력",
      "font_size": 17.02608299255371,
      "font_name": "H2gtrE",
      "bbox": [
        249.2249298095703,
        82.60261535644531,
        345.65264892578125,
        99.62401580810547
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가",
      "font_size": 14.2186279296875,
      "font_name": "T7",
      "bbox": [
        69.44236755371094,
        137.25,
        525.3754272460938,
        155.2303466796875
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 14.2186279296875,
      "font_name": "T7",
      "bbox": [
        212.04507446289062,
        161.2238006591797,
        382.7860412597656,
        179.2041473388672
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제․개정번호",
      "font_size": 14.028532981872559,
      "font_name": "T7",
      "bbox": [
        64.64496612548828,
        217.80197143554688,
        431.04681396484375,
        234.63157653808594
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일자",
      "font_size": 14.028532981872559,
      "font_name": "T7",
      "bbox": [
        64.64496612548828,
        217.80197143554688,
        431.04681396484375,
        234.63157653808594
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 14.028532981872559,
      "font_name": "T7",
      "bbox": [
        64.64496612548828,
        217.80197143554688,
        431.04681396484375,
        234.63157653808594
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "B1-2016-5-053",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        64.88483428955078,
        269.70526123046875,
        237.6495361328125,
        286.53485107421875
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016.12.30",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        64.88483428955078,
        269.70526123046875,
        237.6495361328125,
        286.53485107421875
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정시스템 안전성·",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        251.4851531982422,
        530.3535766601562,
        304.75494384765625
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능 및 임상시험계획서 평가 가이드라인",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        251.4851531982422,
        530.3535766601562,
        304.75494384765625
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제정",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        251.4851531982422,
        530.3535766601562,
        304.75494384765625
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0661-01",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        64.76490020751953,
        337.67095947265625,
        144.94265747070312,
        354.5005798339844
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "「휴대용 혈액응고시간 측정시스템 안전성·성능",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        309.74151611328125,
        530.29248046875,
        387.4645690917969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 임상시험계획서 평가 가이드라인(민원인",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        309.74151611328125,
        530.29248046875,
        387.4645690917969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서)」 명칭 변경 및 제·개정 점검표 등 추가",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        309.74151611328125,
        530.29248046875,
        387.4645690917969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[근거: 「식품의약품안전처 지침서등의 관리에",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        309.74151611328125,
        530.29248046875,
        387.4645690917969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 규정」 개정, ‘17.5.1.]",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        309.74151611328125,
        530.29248046875,
        387.4645690917969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.02608299255371,
      "font_name": "H2hdrM",
      "bbox": [
        169.3482208251953,
        80.4449691772461,
        424.2100830078125,
        97.46636962890625
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.5152816772461,
        118.0552749633789,
        103.02421569824219,
        132.7233123779297
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        154.4762725830078,
        109.18497467041016,
        512.4031982421875,
        123.8530044555664
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        264.9364013671875,
        126.80571746826172,
        398.0680236816406,
        141.4737548828125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        166.34983825683594,
        144.90594482421875,
        427.57763671875,
        159.573974609375
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.76165008544922,
        307.08868408203125,
        114.77745819091797,
        321.7567138671875
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.79566955566406,
        324.5895690917969,
        103.86370849609375,
        339.2575988769531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        166.72210693359375,
        422.21209716796875,
        181.39013671875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.79881286621094,
        183.26400756835938,
        296.1605224609375,
        197.9320526123047
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        167.32144165039062,
        506.365234375,
        197.33270263671875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        167.32144165039062,
        506.365234375,
        197.33270263671875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        208.316650390625,
        530.2322387695312,
        222.98468017578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        224.85855102539062,
        534.1119995117188,
        256.0685119628906
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        224.85855102539062,
        534.1119995117188,
        256.0685119628906
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        257.8225402832031,
        525.1990966796875,
        272.4905700683594
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        278.67974853515625,
        314.51055908203125,
        293.3477783203125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.79881286621094,
        295.2216491699219,
        415.4958190917969,
        326.4316101074219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.79881286621094,
        295.2216491699219,
        415.4958190917969,
        326.4316101074219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        287.550048828125,
        506.365234375,
        317.5613098144531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        287.550048828125,
        506.365234375,
        317.5613098144531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        325.54852294921875,
        506.365234375,
        355.5597839355469
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        325.54852294921875,
        506.365234375,
        355.5597839355469
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        325.54852294921875,
        506.365234375,
        355.5597839355469
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        354.6766662597656,
        450.2768859863281,
        369.3446960449219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        370.1397705078125,
        209.20457458496094,
        384.80780029296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        354.6766662597656,
        506.365234375,
        384.80780029296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        354.6766662597656,
        506.365234375,
        384.80780029296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        383.9247131347656,
        506.365234375,
        413.93597412109375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        383.9247131347656,
        506.365234375,
        413.93597412109375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        383.9247131347656,
        506.365234375,
        413.93597412109375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        413.0528869628906,
        438.6431884765625,
        427.7209167480469
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        428.5159912109375,
        251.4247589111328,
        443.18402099609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        413.0528869628906,
        506.365234375,
        443.18402099609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        413.0528869628906,
        506.365234375,
        443.18402099609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        447.4552917480469,
        527.3955078125,
        478.6652526855469
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        447.4552917480469,
        527.3955078125,
        478.6652526855469
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.205745697021484,
        513.5031127929688,
        126.21337890625,
        528.171142578125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        531.1239013671875,
        102.30498504638672,
        545.7919311523438
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        488.09088134765625,
        446.6377868652344,
        502.7589111328125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        503.4341125488281,
        431.4099426269531,
        518.1021728515625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        488.09088134765625,
        533.0318603515625,
        518.1021728515625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        488.09088134765625,
        533.0318603515625,
        518.1021728515625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        526.56884765625,
        450.51708984375,
        541.2368774414062
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        542.031982421875,
        446.7575988769531,
        572.043212890625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 것입니까? (민원인용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        542.031982421875,
        446.7575988769531,
        572.043212890625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        534.3603515625,
        534.1112670898438,
        564.37158203125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        534.3603515625,
        534.1112670898438,
        564.37158203125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기타 확인",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.00314331054688,
        600.2882690429688,
        117.53630065917969,
        614.956298828125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.79566955566406,
        617.9090576171875,
        103.86370849609375,
        632.5770874023438
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        581.9483642578125,
        433.24578857421875,
        596.6163940429688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        597.2915649414062,
        335.6160888671875,
        611.9595947265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        581.9483642578125,
        506.365234375,
        611.9595947265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        581.9483642578125,
        506.365234375,
        611.9595947265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        621.9845581054688,
        530.2326049804688,
        636.652587890625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        638.5264892578125,
        370.6141357421875,
        653.1945190429688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        214.56370544433594,
        660.7022705078125,
        380.3232727050781,
        675.3703002929688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2017 년    5 월   31  일",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        210.2460479736328,
        694.9848022460938,
        373.23773193359375,
        709.65283203125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당자",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        328.981689453125,
        725.1917724609375,
        403.8124694824219,
        754.1242065429688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        328.981689453125,
        725.1917724609375,
        403.8124694824219,
        754.1242065429688
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우 승 민",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        448.0771484375,
        723.5136108398438,
        491.9733581542969,
        738.181640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오 현 주",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        447.71734619140625,
        741.1343994140625,
        492.33319091796875,
        755.8024291992188
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        73.07929229736328,
        524.5971069335938,
        91.73320770263672
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        102.44719696044922,
        529.5299072265625,
        121.10111236572266
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        131.8151092529297,
        488.9906311035156,
        150.46902465820312
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        171.2519989013672,
        524.595458984375,
        189.90591430664062
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        200.61990356445312,
        529.5289916992188,
        219.27381896972656
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 아님을 알려드립니다. 또한, 본 안내서는 2016년 12월 30일 현재의 과학적",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        229.98782348632812,
        524.5969848632812,
        248.64173889160156
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        259.355712890625,
        529.4103393554688,
        278.0096130371094
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        288.7236328125,
        488.27166748046875,
        307.3775329589844
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        340.7222595214844,
        529.029541015625,
        357.9412536621094
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        88.63196563720703,
        357.623779296875,
        524.4757690429688,
        391.7442932128906
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        88.63196563720703,
        357.623779296875,
        524.4757690429688,
        391.7442932128906
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        65.72438049316406,
        443.5698547363281,
        542.7020874023438,
        460.7888488769531
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단기기과에 문의하시기 바랍니다.",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        83.71463012695312,
        464.42706298828125,
        289.1183166503906,
        481.64605712890625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화번호: 043-719-4652~63",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        85.75352478027344,
        485.1643981933594,
        256.1170349121094,
        502.3833923339844
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스번호: 043-719-4650",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        85.75352478027344,
        505.9017028808594,
        232.13070678710938,
        523.1207275390625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 관련 법규 등",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        68.92467498779297,
        152.07757568359375,
        83.30895233154297
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 「의료기기법」",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        107.28275299072266,
        166.82958984375,
        121.66703033447266
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 「의료기기법 시행령」",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        128.85916137695312,
        208.8068389892578,
        143.2434539794922
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 「의료기기법 시행규칙」",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        150.43560791015625,
        220.8003387451172,
        164.81988525390625
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        172.01202392578125,
        421.859375,
        186.39630126953125
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 「의료기기 허가",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        193.58843994140625,
        172.8263397216797,
        207.97271728515625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신고",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        178.82308959960938,
        193.58843994140625,
        202.81008911132812,
        207.97271728515625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심사 등에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        208.8068389892578,
        193.58843994140625,
        409.8658447265625,
        207.97271728515625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 「의료기기 제조 및 품질관리 기준」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        215.16485595703125,
        361.891845703125,
        229.5491485595703
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        236.74127197265625,
        409.8658447265625,
        251.1255645751953
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        258.31768798828125,
        439.849609375,
        272.70196533203125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(9) 「의료기기의 전기",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        279.89410400390625,
        184.81983947753906,
        294.27838134765625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기계적 안전에 관한 공통기준 규격」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        190.81658935546875,
        279.89410400390625,
        469.8333740234375,
        294.27838134765625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        301.47052001953125,
        439.849609375,
        315.85479736328125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(11) 「의료기기의 안정성시험 기준」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        323.04693603515625,
        343.901611328125,
        337.43121337890625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(12) 「의료기기 표시",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        344.6233825683594,
        178.82308959960938,
        359.0076599121094
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기재 등에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        184.81983947753906,
        344.6233825683594,
        385.87884521484375,
        359.0076599121094
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(13) 「의료기기 기준규격」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        366.1997985839844,
        289.93084716796875,
        380.5840759277344
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목",
      "font_size": 32.013832092285156,
      "font_name": "T12",
      "bbox": [
        239.98992919921875,
        68.6849365234375,
        352.00921630859375,
        107.09097290039062
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차",
      "font_size": 32.013832092285156,
      "font_name": "T12",
      "bbox": [
        239.98992919921875,
        68.6849365234375,
        352.00921630859375,
        107.09097290039062
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 안전성·성능 평가",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        61.64658737182617,
        152.59323120117188,
        514.4210815429688,
        176.614990234375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 20.02363395690918,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        152.59323120117188,
        514.4210815429688,
        176.614990234375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 적용범위",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        189.2731475830078,
        507.3531188964844,
        208.3883056640625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        189.2731475830078,
        507.3531188964844,
        208.3883056640625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 약어 및 용어정리",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        218.0417022705078,
        507.3531188964844,
        237.1568603515625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        218.0417022705078,
        507.3531188964844,
        237.1568603515625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 휴대용 혈액응고시간 측정시스템 정의 및 분류",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        246.8102569580078,
        507.3531188964844,
        265.9254150390625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        246.8102569580078,
        507.3531188964844,
        265.9254150390625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 휴대용 혈액응고시간 측정시스템 관련 국내",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        275.578857421875,
        408.1383972167969,
        294.6940002441406
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외 규격",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        415.454833984375,
        275.578857421875,
        507.3531188964844,
        294.6940002441406
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        415.454833984375,
        275.578857421875,
        507.3531188964844,
        294.6940002441406
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 안전성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        304.347412109375,
        507.35247802734375,
        323.4625549316406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        304.347412109375,
        507.35247802734375,
        323.4625549316406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 성능 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        333.115966796875,
        507.35247802734375,
        352.2311096191406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        333.115966796875,
        507.35247802734375,
        352.2311096191406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 안정성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        361.884521484375,
        507.35247802734375,
        380.9996643066406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        361.884521484375,
        507.35247802734375,
        380.9996643066406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 참고 문헌",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        390.653076171875,
        507.35247802734375,
        409.7682189941406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "33",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        390.653076171875,
        507.35247802734375,
        409.7682189941406
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[별첨] 국내·외 연구동향",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        419.4216613769531,
        507.35247802734375,
        438.552734375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "35",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        419.4216613769531,
        507.35247802734375,
        438.552734375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 임상시험계획서 작성 및 평가",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        61.64658737182617,
        476.2395324707031,
        507.3448486328125,
        500.26129150390625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "37",
      "font_size": 20.02363395690918,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        476.2395324707031,
        507.3448486328125,
        500.26129150390625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        248.9850616455078,
        107.64236450195312,
        339.8957824707031,
        131.6440887451172
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        248.9850616455078,
        107.64236450195312,
        339.8957824707031,
        131.6440887451172
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        188.31419372558594,
        538.268310546875,
        206.27955627441406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        218.2814483642578,
        538.268310546875,
        236.2617950439453
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        248.2487030029297,
        538.268310546875,
        266.22906494140625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 사업」을 진행하고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        278.2159729003906,
        252.4631805419922,
        296.1963195800781
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        308.1832275390625,
        538.268310546875,
        326.16357421875
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        338.15045166015625,
        538.1782836914062,
        356.13079833984375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        368.1177062988281,
        538.1483154296875,
        386.08306884765625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        398.0849609375,
        538.268310546875,
        416.0503234863281
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로 하는 가이드라인이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        428.0522155761719,
        270.21356201171875,
        446.017578125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 1 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ",
      "font_size": 20.02363395690918,
      "font_name": "T10",
      "bbox": [
        68.36294555664062,
        76.95590209960938,
        288.20379638671875,
        100.97764587402344
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 평가",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        68.36294555664062,
        76.95590209960938,
        288.20379638671875,
        100.97764587402344
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 적용범위",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        139.86709594726562,
        152.6769561767578,
        155.80967712402344
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        191.4307861328125,
        538.1483154296875,
        209.4111328125
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        221.39804077148438,
        538.1483154296875,
        239.3634033203125
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 평가방법을 제시하고자 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        251.3652801513672,
        285.56524658203125,
        269.3306579589844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        311.2998046875,
        538.268310546875,
        329.2801513671875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        341.2670593261719,
        538.2682495117188,
        359.2474060058594
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "향후 추가되어야한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        371.23431396484375,
        198.492431640625,
        389.1996765136719
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 약어 및 용어정리",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        216.7222442626953,
        92.27911376953125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        127.90022277832031,
        538.1483154296875,
        145.86558532714844
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.11170196533203,
        157.8674774169922,
        535.8695678710938,
        175.8328399658203
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        187.834716796875,
        538.1483154296875,
        205.80007934570312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        217.80197143554688,
        538.1483154296875,
        235.767333984375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        247.7692108154297,
        538.1483154296875,
        265.7345886230469
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        277.7364807128906,
        118.49578094482422,
        295.70184326171875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        307.7037353515625,
        538.268310546875,
        325.6690979003906
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.23163604736328,
        337.6709899902344,
        529.5130004882812,
        355.6363525390625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        367.63824462890625,
        538.1483154296875,
        385.6036071777344
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 동결건조 물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        397.6054992675781,
        215.88299560546875,
        415.57086181640625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        427.57275390625,
        538.1483154296875,
        445.5381164550781
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 백분율로 나타낸 것",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.87183380126953,
        457.53997802734375,
        248.625244140625,
        475.5053405761719
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        487.5072326660156,
        538.1483154296875,
        505.47259521484375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공정으로 생산된 물질의 정의 된 양",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        517.4744873046875,
        328.6219177246094,
        535.4398803710938
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        547.4417114257812,
        538.268310546875,
        565.4071044921875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 포장상태의 IVD 제품이 안정성을 유지하는 기간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.03228759765625,
        577.408935546875,
        449.5163879394531,
        595.3743286132812
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        607.376220703125,
        538.268310546875,
        625.3416137695312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "올바른 사용을 위해 제조업체가 제공하는 정보",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.87183380126953,
        637.3434448242188,
        402.0221252441406,
        655.308837890625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        667.3107299804688,
        538.268310546875,
        685.276123046875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        697.2779541015625,
        518.47900390625,
        715.2433471679688
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 3 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        68.44519805908203,
        538.1483154296875,
        86.41056823730469
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        95.34832000732422,
        98.41244506835938,
        524.7156372070312,
        116.37781524658203
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        128.37969970703125,
        538.1483154296875,
        146.34506225585938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        158.34695434570312,
        534.070556640625,
        176.31231689453125
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.02578735351562,
        188.31419372558594,
        503.3671875,
        206.29454040527344
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        218.2814483642578,
        538.1483154296875,
        236.24681091308594
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가운데 일치도의 근접성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        248.2487030029297,
        249.82461547851562,
        266.2140808105469
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.02578735351562,
        278.2159729003906,
        538.1483154296875,
        296.18133544921875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정값",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        123.29317474365234,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과들의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        123.29317474365234,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘표준편차’ 또는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        123.29317474365234,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘변이계수’라는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        123.29317474365234,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        123.29317474365234,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량적으로 표현",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        123.29317474365234,
        338.15045166015625,
        238.55072021484375,
        356.1158142089844
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        368.1177062988281,
        531.4320068359375,
        386.08306884765625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        398.0849609375,
        538.268310546875,
        416.0503234863281
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비례하는 결과를 제공할 수 있는 능력",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        428.0522155761719,
        351.8892822265625,
        446.017578125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        458.01947021484375,
        520.7577514648438,
        475.9848327636719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        487.9867248535156,
        538.1483154296875,
        505.95208740234375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        517.9539184570312,
        538.1483154296875,
        535.9193115234375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        547.9212036132812,
        538.268310546875,
        565.8865966796875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        577.888427734375,
        464.5082702636719,
        595.8538208007812
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 4 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 휴대용 혈액응고시간 측정시스템 정의 및 분류",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        432.6052551269531,
        92.27911376953125
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 개요",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        151.39454650878906,
        112.97876739501953,
        169.3599090576172
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        181.36180114746094,
        538.268310546875,
        199.32716369628906
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        211.32904052734375,
        538.1483154296875,
        229.29440307617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        241.2963104248047,
        538.1483154296875,
        259.2616882324219
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자신의 INR을 측정할 수 있게 된다. 널리 알려진 개인용 혈당측정기와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        271.2635498046875,
        538.1483154296875,
        289.2289123535156
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        301.2308044433594,
        538.268310546875,
        319.1961669921875
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR을 모니터링 할 수 있다. 즉, 와파린 복용 환자가 최적의 항 응고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        331.19805908203125,
        538.268310546875,
        349.1634216308594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료효과를 볼 수 있는 환경이 조성된다. 항응고제는 환자 스스로의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        361.1653137207031,
        538.1483154296875,
        379.13067626953125
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.35157012939453,
        391.132568359375,
        538.1483154296875,
        409.0979309082031
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.35157012939453,
        421.0998229980469,
        538.1483154296875,
        439.065185546875
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사망까지 예방할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.35157012939453,
        451.06707763671875,
        249.82460021972656,
        469.0324401855469
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[그림 1] 혈액 응고 기전",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        230.15525817871094,
        683.9725341796875,
        371.0785827636719,
        699.49462890625
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: 가천의과학대학교 길병원)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        206.6479949951172,
        704.7098388671875,
        394.5688781738281,
        720.23193359375
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 5 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        84.50764465332031,
        538.1483154296875,
        102.47301483154297
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.91072845458984,
        114.47489929199219,
        538.1483154296875,
        132.4402618408203
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약 50만 명 정도로 추정된다. 더욱이 서구화, 고령화로 인해 심혈관",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.91072845458984,
        144.442138671875,
        538.1483154296875,
        162.40750122070312
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.91072845458984,
        174.40939331054688,
        538.268310546875,
        192.374755859375
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추세이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.91072845458984,
        204.37664794921875,
        147.99978637695312,
        222.34201049804688
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년도",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        159.15374755859375,
        283.72991943359375,
        179.3028564453125,
        295.658935546875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개요",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        89.47151184082031,
        303.748046875,
        109.6206283569336,
        315.67706298828125
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시장규모",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        271.772705078125,
        285.4080810546875,
        312.31085205078125,
        297.33709716796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연평균성장률",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        417.7336120605469,
        293.7989196777344,
        478.66070556640625,
        305.7279357910156
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2013",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        232.43402099609375,
        301.83013916015625,
        359.2450866699219,
        313.7591552734375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        232.43402099609375,
        301.83013916015625,
        359.2450866699219,
        313.7591552734375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세계 시장",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        318.252197265625,
        459.1546936035156,
        330.191162109375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "638",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        318.252197265625,
        459.1546936035156,
        330.191162109375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,001",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        318.252197265625,
        459.1546936035156,
        330.191162109375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9.4%",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        318.252197265625,
        459.1546936035156,
        330.191162109375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내 시장",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        334.31463623046875,
        459.1546936035156,
        346.25360107421875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.2",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        334.31463623046875,
        459.1546936035156,
        346.25360107421875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.5",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        334.31463623046875,
        459.1546936035156,
        346.25360107421875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.6%",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        112.13922119140625,
        334.31463623046875,
        459.1546936035156,
        346.25360107421875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 1] 혈액응고진단기기 시장규모 전망",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        176.304443359375,
        237.4604949951172,
        405.26007080078125,
        252.98255920410156
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(단위: 백만달러)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        421.69146728515625,
        263.8316650390625,
        497.1356201171875,
        275.7706298828125
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        387.2967529296875,
        538.268310546875,
        405.2621154785156
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        417.2640075683594,
        538.1483154296875,
        435.2293701171875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "걸리는 시간을 나타낸다. 프로트롬빈 시간의 측정 시기는 와파린 복용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        447.23126220703125,
        538.1483154296875,
        465.1966247558594
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        477.1985168457031,
        538.1483154296875,
        495.16387939453125
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        507.1657409667969,
        538.268310546875,
        525.1460571289062
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하는 것이 일반적이다. 휴대용 혈액응고시간 측정시스템은 환자",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        537.1329956054688,
        538.268310546875,
        555.098388671875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        567.1002197265625,
        538.1483154296875,
        585.0656127929688
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        597.0675048828125,
        538.1483154296875,
        615.0328979492188
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획기적으로 줄 일 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        81.43586730957031,
        627.0347290039062,
        263.0174560546875,
        645.0001220703125
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        657.001953125,
        538.1483154296875,
        674.9673461914062
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        82.39534759521484,
        686.96923828125,
        538.268310546875,
        704.9346313476562
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        82.39534759521484,
        716.9364624023438,
        538.1932983398438,
        734.90185546875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값으로 계산하여 화면에 표시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        82.39534759521484,
        746.9037475585938,
        311.59112548828125,
        764.869140625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        475.16070556640625,
        460.67041015625,
        487.0897216796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "업체명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        475.16070556640625,
        460.67041015625,
        487.0897216796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목허가번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        475.16070556640625,
        460.67041015625,
        487.0897216796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가/신고일",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        475.16070556640625,
        460.67041015625,
        487.0897216796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        475.16070556640625,
        460.67041015625,
        487.0897216796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        493.98016357421875,
        525.6751098632812,
        505.9091796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엘리어헬스케어(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        493.98016357421875,
        525.6751098632812,
        505.9091796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 14-1533호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        71.6011962890625,
        493.98016357421875,
        525.6751098632812,
        505.9091796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2014-03-31",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        493.98016357421875,
        525.6751098632812,
        505.9091796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Alere INRatio PT/INR Test Strip 외 1건",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        493.98016357421875,
        525.6751098632812,
        505.9091796875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        512.91943359375,
        511.8488464355469,
        524.8484497070312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        512.91943359375,
        511.8488464355469,
        524.8484497070312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 13-2183호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        71.6011962890625,
        512.91943359375,
        511.8488464355469,
        524.8484497070312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013-10-22",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        512.91943359375,
        511.8488464355469,
        524.8484497070312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguChek XS PT Test Strip",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        71.6011962890625,
        512.91943359375,
        511.8488464355469,
        524.8484497070312
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[표 3] 개인용 체외진단검사시약 II 국내업체 허가사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        138.04518127441406,
        422.7779541015625,
        451.07464599609375,
        438.300048828125
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(‘16.10.31 기준)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        443.7594909667969,
        448.6696472167969,
        531.1748657226562,
        464.1917419433594
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 제품 허가 현황",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        68.44519805908203,
        192.25579833984375,
        86.41056823730469
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        98.41244506835938,
        533.7706909179688,
        116.37781524658203
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        128.37969970703125,
        538.268310546875,
        146.34506225585938
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 국내 취급업체는 아래와 같다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        86.47313690185547,
        158.34695434570312,
        316.9881896972656,
        176.31231689453125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        261.3144226074219,
        459.23114013671875,
        273.2434387207031
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "업체명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        261.3144226074219,
        459.23114013671875,
        273.2434387207031
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목허가번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        261.3144226074219,
        459.23114013671875,
        273.2434387207031
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가/신고일",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        261.3144226074219,
        459.23114013671875,
        273.2434387207031
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모델명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        261.3144226074219,
        459.23114013671875,
        273.2434387207031
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        283.0107116699219,
        485.353515625,
        294.9397277832031
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        283.0107116699219,
        485.353515625,
        294.9397277832031
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수신 16-1507호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        73.04041290283203,
        283.0107116699219,
        485.353515625,
        294.9397277832031
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016-06-08",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        283.0107116699219,
        485.353515625,
        294.9397277832031
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguChek Pro II",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        283.0107116699219,
        485.353515625,
        294.9397277832031
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        304.8268737792969,
        478.0099182128906,
        316.7558898925781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        304.8268737792969,
        478.0099182128906,
        316.7558898925781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신 12-2233호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        73.04041290283203,
        304.8268737792969,
        478.0099182128906,
        316.7558898925781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012-11-26",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        304.8268737792969,
        478.0099182128906,
        316.7558898925781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguChek XS",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        304.8268737792969,
        478.0099182128906,
        316.7558898925781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        326.5231628417969,
        507.6482849121094,
        338.4521789550781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        326.5231628417969,
        507.6482849121094,
        338.4521789550781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신 12-2232호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        73.04041290283203,
        326.5231628417969,
        507.6482849121094,
        338.4521789550781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012-11-26",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        326.5231628417969,
        507.6482849121094,
        338.4521789550781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguChek XS PLUS Meter",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        326.5231628417969,
        507.6482849121094,
        338.4521789550781
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        348.3393249511719,
        487.93365478515625,
        360.2683410644531
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        348.3393249511719,
        487.93365478515625,
        360.2683410644531
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신 09-2040호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        73.04041290283203,
        348.3393249511719,
        487.93365478515625,
        360.2683410644531
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2009-11-25",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        348.3393249511719,
        487.93365478515625,
        360.2683410644531
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguChek XS Pro",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        348.3393249511719,
        487.93365478515625,
        360.2683410644531
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        375.5495910644531,
        352.5281066894531,
        387.4786071777344
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엘리어헬스케어(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        375.5495910644531,
        352.5281066894531,
        387.4786071777344
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신 09-1533호",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        73.04041290283203,
        375.5495910644531,
        352.5281066894531,
        387.4786071777344
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2009-09-09",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        375.5495910644531,
        352.5281066894531,
        387.4786071777344
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Alere INRatio2 PT/INR Home",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        374.91680908203125,
        365.6004638671875,
        513.76220703125,
        377.52947998046875
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "monitoring kit 외 1건",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        394.8260192871094,
        385.61859130859375,
        493.77239990234375,
        397.547607421875
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 2] 혈액응고시간분석기 국내업체 허가사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        159.75341796875,
        207.4932403564453,
        426.60791015625,
        223.0153045654297
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(‘16.10.31 기준)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        439.561767578125,
        233.50482177734375,
        526.9771118164062,
        249.02688598632812
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 국외 허가동향",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        575.9705200195312,
        181.34170532226562,
        593.9359130859375
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        605.9378051757812,
        538.268310546875,
        623.9031982421875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국제규격이 있음",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.5509262084961,
        635.905029296875,
        199.09210205078125,
        653.8704223632812
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        665.872314453125,
        538.1483154296875,
        683.8377075195312
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "응고분석기의 510(K)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.39209747314453,
        695.8395385742188,
        538.1783447265625,
        713.804931640625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "submission 가이던스 “510(K) Submission for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.39209747314453,
        695.8395385742188,
        538.1783447265625,
        713.804931640625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Coagulation Instruments – Guidance for Industry and FDA Staff”가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.39209747314453,
        725.8067626953125,
        538.268310546875,
        743.787109375
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발행 됨",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        88.39209747314453,
        68.44519805908203,
        137.80531311035156,
        86.41056823730469
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        98.41244506835938,
        538.268310546875,
        116.37781524658203
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        128.37969970703125,
        538.1483154296875,
        146.34506225585938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        158.34695434570312,
        538.1483154296875,
        176.31231689453125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해결하기 위해 잠재적인 해결책을 식별하기 위함",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        188.31419372558594,
        410.5375061035156,
        206.27955627441406
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        218.2814483642578,
        538.1483154296875,
        236.24681091308594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.03228759765625,
        248.2487030029297,
        538.1483154296875,
        266.2140808105469
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        88.03228759765625,
        278.2159729003906,
        441.6006774902344,
        296.18133544921875
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Roche사 CoaguChek XS",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        134.44712829589844,
        466.4102783203125,
        458.31573486328125,
        478.33929443359375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Alere사 INRatio2 PT/INR",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        134.44712829589844,
        466.4102783203125,
        458.31573486328125,
        478.33929443359375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: https://www.roche.de/)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        119.45526123046875,
        484.8701171875,
        469.2543029785156,
        496.79913330078125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: http://www.alere.com/)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        119.45526123046875,
        484.8701171875,
        469.2543029785156,
        496.79913330078125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[그림 2] 기허가 휴대용 혈액응고시간 측정시스템",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        151.35797119140625,
        507.04583740234375,
        437.0419616699219,
        522.5679321289062
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 8 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 휴대용 혈액응고시간 측정시스템 관련 국내외 규격",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        456.5922546386719,
        92.27911376953125
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 안전성에 관한 규격",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        122.86572265625,
        219.12124633789062,
        140.83108520507812
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        182.2008819580078,
        424.0902099609375,
        194.1298828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 평가 항목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        182.2008819580078,
        424.0902099609375,
        194.1298828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 표준 또는 적용 규격",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        182.2008819580078,
        424.0902099609375,
        194.1298828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        281.5722961425781,
        78.71742248535156,
        293.5013122558594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전기·기계적",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        98.22676086425781,
        272.5821228027344,
        150.63876342773438,
        284.5210876464844
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전에 관한 시험",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        98.22676086425781,
        290.5624694824219,
        175.94461059570312,
        302.4914855957031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-「의료기기의 전기·기계적 안전에 관한 공통기준규격」",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        200.53131103515625,
        200.66070556640625,
        449.63629150390625,
        212.5996551513672
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61010-1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "electrical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        218.64105224609375,
        527.078369140625,
        230.57005310058594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "measurement,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "control,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "laboratory",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "use",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "–",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Part",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1:",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "General",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        236.6214141845703,
        527.1322631835938,
        248.56036376953125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        254.60174560546875,
        257.7533874511719,
        266.53076171875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61010-2-101",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "electrical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        272.5821228027344,
        527.1983032226562,
        284.5111389160156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "measurement,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "control",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "laboratory",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "use – Part",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2-101:",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Particular",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        290.5624694824219,
        527.19921875,
        302.5014343261719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements for in vitro diagnostic (IVD) medical equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        308.5428161621094,
        482.2472229003906,
        320.4718322753906
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 17593 Clinical laboratory testing and in vitro medical devices –",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        200.53131103515625,
        326.5231628417969,
        527.1143188476562,
        338.4621276855469
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Requirements for in vitro monitoring systems for self-testing of oral",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        344.5035095214844,
        527.1322631835938,
        356.4325256347656
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "anticoagulant therapy",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        362.4838562011719,
        297.5572814941406,
        374.4128723144531
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        452.8650817871094,
        78.71742248535156,
        464.7940979003906
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전자파",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        98.22676086425781,
        443.8749084472656,
        127.61076354980469,
        455.8039245605469
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전에 관한 시험",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        98.22676086425781,
        461.8552551269531,
        175.94461059570312,
        473.7842712402344
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-「의료기기의 전자파안전에 관한 공통기준규격」",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        200.53131103515625,
        380.9436950683594,
        421.69146728515625,
        392.8826599121094
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61326-1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Electrical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "measurement,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "control",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        398.9240417480469,
        527.1805419921875,
        410.8530578613281
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "laboratory use – EMC requirements – Part 1: General requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        416.9043884277344,
        517.892822265625,
        428.8433532714844
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61326-2-6",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Electrical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "measurement,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "control",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        434.8847351074219,
        527.1795654296875,
        446.8137512207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "laboratory",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "use",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "–",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EMC",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "–",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Part",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2-6:",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Particular",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        452.8650817871094,
        527.19921875,
        464.8040466308594
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements – In vitro diagnostic (IVD) medical equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        470.8454284667969,
        479.96649169921875,
        482.7843933105469
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 17593 Clinical laboratory testing and in vitro medical devices –",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        200.53131103515625,
        488.8257751464844,
        527.1143188476562,
        500.7647399902344
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Requirements for in vitro monitoring systems for self-testing of oral",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        506.8061218261719,
        527.1322631835938,
        518.735107421875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "anticoagulant therapy",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        200.53131103515625,
        524.7864990234375,
        297.5572814941406,
        536.7154541015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        122.9333724975586,
        156.06944274902344,
        468.82635498046875,
        171.5915069580078
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.4686279296875,
        313.6467590332031,
        798.4177856445312
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 성능에 관한 규격",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        68.44519805908203,
        203.76956176757812,
        86.41056823730469
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        124.90350341796875,
        491.37371826171875,
        136.83250427246094
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격 번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        124.90350341796875,
        491.37371826171875,
        136.83250427246094
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        124.90350341796875,
        491.37371826171875,
        136.83250427246094
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        124.90350341796875,
        491.37371826171875,
        136.83250427246094
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        157.7476043701172,
        143.3623046875,
        169.67660522460938
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 17593",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        157.7476043701172,
        143.3623046875,
        169.67660522460938
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Clinical laboratory testing and in vitro medical devices",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        137.72947692871094,
        419.66583251953125,
        149.65847778320312
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Requirements for in vitro monitoring systems for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        157.7476043701172,
        419.6166076660156,
        169.68655395507812
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "self-testing of oral anticoagulant therapy",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        177.76573181152344,
        344.8106994628906,
        189.69473266601562
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경구용 항응고제 치료",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        137.72947692871094,
        533.23095703125,
        149.65847778320312
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 위한 자가 측정시스",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        157.7476043701172,
        533.2313232421875,
        169.67660522460938
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "템 평가규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        177.76573181152344,
        483.4583740234375,
        189.69473266601562
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        200.54083251953125,
        145.64163208007812,
        212.46983337402344
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP05",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        200.54083251953125,
        145.64163208007812,
        212.46983337402344
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        190.4718475341797,
        419.6400451660156,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        190.4718475341797,
        419.6400451660156,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Precision",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        190.4718475341797,
        419.6400451660156,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        190.4718475341797,
        419.6400451660156,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Quantitative",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        190.4718475341797,
        419.6400451660156,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Measurement",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        190.4718475341797,
        419.6400451660156,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Methods; Approved Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        210.48995971679688,
        297.7612609863281,
        222.41896057128906
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정밀도 평가방법에 대",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        190.4718475341797,
        533.2310180664062,
        202.40084838867188
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        210.48995971679688,
        517.2804565429688,
        222.41896057128906
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        233.26507568359375,
        145.64163208007812,
        245.19407653808594
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP06",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        233.26507568359375,
        145.64163208007812,
        245.19407653808594
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation of the Linearity of Quantitative Measurement",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        223.31594848632812,
        419.75848388671875,
        235.2449493408203
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Procedures; A Statistical Approach; Approved Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        243.33407592773438,
        416.8556823730469,
        255.26307678222656
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직선성 평가방법에 대",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        223.31594848632812,
        533.2310180664062,
        235.2449493408203
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        243.33407592773438,
        517.2804565429688,
        255.26307678222656
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        266.10919189453125,
        145.64163208007812,
        278.0382080078125
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP07",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        266.10919189453125,
        145.64163208007812,
        278.0382080078125
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Interference",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        256.0401916503906,
        419.71795654296875,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Testing",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        256.0401916503906,
        419.71795654296875,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "in",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        256.0401916503906,
        419.71795654296875,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Clinical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        256.0401916503906,
        419.71795654296875,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Chemistry;",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        256.0401916503906,
        419.71795654296875,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Approved",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        256.0401916503906,
        419.71795654296875,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        276.0583190917969,
        203.49227905273438,
        287.9873352050781
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질 반응에 대한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        256.0401916503906,
        533.23095703125,
        267.9692077636719
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        276.0583190917969,
        502.768310546875,
        287.9873352050781
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        298.83343505859375,
        145.64163208007812,
        310.762451171875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP17",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        298.83343505859375,
        145.64163208007812,
        310.762451171875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        288.8843078613281,
        419.6714782714844,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        288.8843078613281,
        419.6714782714844,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Detection",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        288.8843078613281,
        419.6714782714844,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Capability",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        288.8843078613281,
        419.6714782714844,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        288.8843078613281,
        419.6714782714844,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Clinical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        288.8843078613281,
        419.6714782714844,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Laboratory Measurement Procedures;",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        160.8328399658203,
        308.90240478515625,
        328.091552734375,
        320.8314208984375
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소검출한계 평가방법에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        288.8843078613281,
        533.232421875,
        300.8133239746094
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.96697998046875,
        308.90240478515625,
        519.7996826171875,
        320.8314208984375
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        131.80856323242188,
        101.64891052246094,
        465.82745361328125,
        117.17098999023438
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 안정성에 관한 규격",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        362.244140625,
        219.12124633789062,
        380.2095031738281
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.84431457519531,
        418.7024230957031,
        426.2490234375,
        430.6314392089844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성 평가 항목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.84431457519531,
        418.7024230957031,
        426.2490234375,
        430.6314392089844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 표준 또는 적용 규격",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.84431457519531,
        418.7024230957031,
        426.2490234375,
        430.6314392089844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.64009094238281,
        451.5465393066406,
        78.59748840332031,
        463.4755554199219
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개봉 전/후",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        97.86695861816406,
        441.4775390625,
        147.52005004882812,
        453.40655517578125
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안정성 평가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        97.86695861816406,
        461.49566650390625,
        151.35841369628906,
        473.4246826171875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-「의료기기의 안정성시험 기준」",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        201.85060119628906,
        431.5284118652344,
        350.4500732421875,
        443.4673767089844
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 23640 In vitro diagnostic medical devices – Evaluation of stability",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        201.85060119628906,
        451.5465393066406,
        529.9923095703125,
        463.4855041503906
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of in vitro diagnostic reagents",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        201.85060119628906,
        471.4447937011719,
        339.6687927246094,
        483.3738098144531
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        124.4925308227539,
        395.32794189453125,
        470.2650451660156,
        410.85003662109375
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 10 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 안전성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        208.68690490722656,
        92.27911376953125
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 전기",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        122.86572265625,
        112.97876739501953,
        140.83108520507812
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기계적 안전성 시험",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        121.25428009033203,
        122.86572265625,
        257.620361328125,
        140.83108520507812
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        152.83297729492188,
        153.87661743164062,
        170.79833984375
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(가) 의료기기의 전기·기계적 안전에 관한 공통기준규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        182.80023193359375,
        443.1598205566406,
        200.78057861328125
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(나) IEC 61010-1 Safety requirements for electrical equipment for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        212.76747131347656,
        538.1783447265625,
        230.7328338623047
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "measurement,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use–Part",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "General",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        242.73472595214844,
        538.1932983398438,
        260.715087890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.42286682128906,
        272.7019958496094,
        191.28134155273438,
        290.6673583984375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(다) IEC 61010-2-101 Safety requirements for electrical equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        302.66925048828125,
        538.2083129882812,
        320.6346130371094
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "measurement,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use–Part",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2–101:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        332.6365051269531,
        538.1483154296875,
        350.6168518066406
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Particular requirements for in vitro diagnostic (IVD) medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        362.6037292480469,
        538.1932983398438,
        380.569091796875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        392.57098388671875,
        175.64480590820312,
        410.5363464355469
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(라) ISO 17593 Clinical laboratory testing and in vitro medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        422.5382385253906,
        538.1932983398438,
        440.50360107421875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "devices – Requirements for in vitro monitoring systems for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        106.8620834350586,
        452.5054931640625,
        538.1783447265625,
        470.48583984375
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "self-testing of oral anticoagulant therapy",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        106.8620834350586,
        482.4727478027344,
        382.0229797363281,
        500.4381103515625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 :",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        512.43994140625,
        538.268310546875,
        530.4202880859375
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준은 「의료기기법」제2조에 따라 정의된 의료기기 중",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        512.43994140625,
        538.268310546875,
        530.4202880859375
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.03228759765625,
        542.4072265625,
        538.268310546875,
        560.3726196289062
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단용 분석기기(In vitro diagnostic equipment)에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        572.3744506835938,
        463.18896484375,
        590.33984375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.325679779052734,
        602.3417358398438,
        538.1483154296875,
        620.30712890625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 전기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.99339294433594,
        632.3089599609375,
        147.63998413085938,
        650.2743530273438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        152.67724609375,
        632.3089599609375,
        536.7091064453125,
        650.2743530273438
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 기준",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.325679779052734,
        662.2761840820312,
        147.87985229492188,
        680.2415771484375
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        692.2434692382812,
        538.268310546875,
        710.2088623046875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        99.54605102539062,
        722.210693359375,
        365.5618896484375,
        740.1760864257812
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 11 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        68.44519805908203,
        538.1483154296875,
        86.41056823730469
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해요인 보호시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.8653335571289,
        98.41244506835938,
        400.94268798828125,
        116.37781524658203
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        128.37969970703125,
        538.1483154296875,
        146.34506225585938
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내열성 시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.8653335571289,
        158.34695434570312,
        346.8520202636719,
        176.31231689453125
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        188.31419372558594,
        538.1483154296875,
        206.27955627441406
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험 방지시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.74539947509766,
        218.2814483642578,
        373.83740234375,
        236.24681091308594
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(마) 가스, 폭발, 파열에 대한 보호",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        70.04203796386719,
        248.2487030029297,
        538.1483154296875,
        266.2140808105469
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": IEC 61010-1의 13절에 기술된 가스,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.04203796386719,
        248.2487030029297,
        538.1483154296875,
        266.2140808105469
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.3855972290039,
        278.2159729003906,
        457.6719665527344,
        296.18133544921875
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        308.1832275390625,
        538.1483154296875,
        326.1485900878906
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        99.54605102539062,
        338.15045166015625,
        157.2347869873047,
        356.1158142089844
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        368.1177062988281,
        538.1483154296875,
        386.08306884765625
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "노출에 대한 보호의 결정 전후에 수행되어야 한다. 적합/부적합 기준은",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        398.0849609375,
        538.268310546875,
        416.0503234863281
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        428.0522155761719,
        538.1483154296875,
        446.017578125
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        458.01947021484375,
        538.1483154296875,
        475.99981689453125
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이루어야 한다. 제조업체 권고 기준물질 또는 적절한 대체물질이 성능",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        487.9867248535156,
        538.1483154296875,
        505.95208740234375
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에 사용되어야 한다. 측정시스템의 성능이 영향 받지 않았음을 검증",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        517.9539184570312,
        538.1483154296875,
        535.9193115234375
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        547.9212036132812,
        538.268310546875,
        565.8865966796875
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다. 평균",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        577.888427734375,
        538.1483154296875,
        595.8538208007812
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        100.14572143554688,
        607.855712890625,
        538.268310546875,
        625.8211059570312
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용기준과 비교되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.14572143554688,
        637.8229370117188,
        277.40966796875,
        655.788330078125
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 12 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(아) 진동과 충격에 대한 기계적 내성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        68.44519805908203,
        302.7159423828125,
        86.41056823730469
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 진동시험계획서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.7583999633789,
        98.41244506835938,
        192.73553466796875,
        116.3927993774414
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ (사)에 기술된 성능 시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        128.37969970703125,
        331.8601379394531,
        146.36004638671875
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        158.34695434570312,
        380.9135437011719,
        176.32730102539062
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 진동시험이 종료된 후, 성능시험을 반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        188.31419372558594,
        380.0740051269531,
        206.29454040527344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        218.2814483642578,
        502.04791259765625,
        236.2617950439453
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 낙하시험계획서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.7583999633789,
        248.2487030029297,
        192.73553466796875,
        266.22906494140625
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        278.2159729003906,
        520.39794921875,
        296.1963195800781
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        308.1832275390625,
        416.77410888671875,
        326.16357421875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        338.15045166015625,
        380.0740051269531,
        356.13079833984375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        368.1177062988281,
        524.5956420898438,
        386.0980529785156
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(자) 저장을 위한 장비의 온도 노출",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.04203796386719,
        398.0849609375,
        289.2832336425781,
        416.0503234863281
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 고온시험계획서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.7583999633789,
        428.0522155761719,
        192.73553466796875,
        446.0325622558594
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ (사)에 기술된 성능 시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        458.01947021484375,
        331.8601379394531,
        475.99981689453125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        83.47476196289062,
        487.9867248535156,
        538.1483154296875,
        505.9670715332031
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "놓는다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        517.9539184570312,
        150.03868103027344,
        535.9193115234375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        83.47476196289062,
        547.9212036132812,
        538.268310546875,
        565.9015502929688
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8시간 동안 놓아둔다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        577.888427734375,
        231.3546142578125,
        595.8538208007812
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        83.47476196289062,
        607.855712890625,
        538.1483154296875,
        625.8360595703125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        637.8229370117188,
        161.5524444580078,
        655.788330078125
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 13 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 저온시험계획서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.7583999633789,
        68.44519805908203,
        192.73553466796875,
        86.42555236816406
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ (사)에 기술된 성능 시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        98.41244506835938,
        331.8601379394531,
        116.3927993774414
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        83.47476196289062,
        128.37969970703125,
        538.1483154296875,
        146.36004638671875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "놓는다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        158.34695434570312,
        147.87985229492188,
        176.31231689453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        83.47476196289062,
        188.31419372558594,
        538.1483154296875,
        206.29454040527344
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "챔버에 8시간 동안 놓아둔다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        218.2814483642578,
        284.6057434082031,
        236.24681091308594
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        83.47476196289062,
        248.2487030029297,
        538.1483154296875,
        266.22906494140625
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        278.2159729003906,
        134.44712829589844,
        296.18133544921875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 장비의 습도 노출 시험계획서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.7583999633789,
        308.1832275390625,
        280.2880859375,
        326.1485900878906
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ (사)에 기술된 성능 시험을 수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        338.15045166015625,
        331.8601379394531,
        356.13079833984375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        368.1177062988281,
        437.4029541015625,
        386.0980529785156
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        398.0849609375,
        533.710693359375,
        416.0653076171875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        83.47476196289062,
        428.0522155761719,
        518.119140625,
        446.0325622558594
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤",
      "font_size": 14.987749099731445,
      "font_name": "T16",
      "bbox": [
        83.47476196289062,
        458.01947021484375,
        538.1483154296875,
        475.99981689453125
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        104.10357666015625,
        487.9867248535156,
        538.268310546875,
        505.95208740234375
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        104.10357666015625,
        517.9539184570312,
        159.87335205078125,
        535.9193115234375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 전자파 안전성 시험",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        577.888427734375,
        219.12124633789062,
        595.8538208007812
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        607.855712890625,
        153.87661743164062,
        625.8211059570312
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(가) 의료기기의 전자파 안전에 관한 공통기준규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        637.8229370117188,
        408.378662109375,
        655.788330078125
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(나) IEC 61326-1 Electrical equipment for measurement, control and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        667.7901611328125,
        538.163330078125,
        685.7555541992188
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMC",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "–",
      "font_size": 14.987749099731445,
      "font_name": "T16",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Part",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "General",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        697.7574462890625,
        538.1932983398438,
        715.73779296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        727.7246704101562,
        188.88262939453125,
        745.6900634765625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 14 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(다) IEC 61326-2-6 Electrical equipment for measurement, control",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        68.44519805908203,
        538.1932983398438,
        86.41056823730469
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "–",
      "font_size": 14.987749099731445,
      "font_name": "T16",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMC",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "–",
      "font_size": 14.987749099731445,
      "font_name": "T16",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Part",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2-6:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        98.41244506835938,
        538.2682495117188,
        116.3927993774414
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Particular requirements – In vitro diagnostic (IVD) medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        128.37969970703125,
        538.1932983398438,
        146.36004638671875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.90260314941406,
        158.34695434570312,
        175.88467407226562,
        176.31231689453125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(라) ISO 17593 Clinical laboratory testing and in vitro medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        188.31419372558594,
        538.1932983398438,
        206.27955627441406
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "devices – Requirements for in vitro monitoring systems for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        106.8620834350586,
        218.2814483642578,
        538.1783447265625,
        236.2617950439453
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "self-testing of oral anticoagulant therapy",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        106.8620834350586,
        248.2487030029297,
        382.0229797363281,
        266.2140808105469
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        294.2784118652344,
        538.268310546875,
        312.2437744140625
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.1522216796875,
        324.24566650390625,
        538.268310546875,
        342.2110290527344
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.1522216796875,
        354.2129211425781,
        119.095458984375,
        372.17828369140625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.92535400390625,
        384.18017578125,
        538.268310546875,
        402.1455383300781
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.1522216796875,
        414.14739990234375,
        538.1483154296875,
        432.1127624511719
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보증함에 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.1522216796875,
        444.1146545410156,
        190.3368377685547,
        462.08001708984375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 항목",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.92535400390625,
        474.0819091796875,
        156.27529907226562,
        492.0472717285156
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.24138641357422,
        504.0491638183594,
        538.268310546875,
        522.0145263671875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.38397216796875,
        534.016357421875,
        217.20228576660156,
        551.9817504882812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.24138641357422,
        563.983642578125,
        538.268310546875,
        581.9490356445312
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.38397216796875,
        593.9508666992188,
        217.20228576660156,
        611.916259765625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 15 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        655.9232177734375,
        374.91680908203125,
        667.8521728515625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        655.9232177734375,
        374.91680908203125,
        667.8521728515625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        674.8624267578125,
        376.7158203125,
        686.7914428710938
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        674.8624267578125,
        376.7158203125,
        686.7914428710938
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        693.8017578125,
        376.995849609375,
        705.7307739257812
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 - 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        693.8017578125,
        376.995849609375,
        705.7307739257812
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        712.7410888671875,
        376.995849609375,
        724.6700439453125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 - 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        712.7410888671875,
        376.995849609375,
        724.6700439453125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 7] INR 구간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        230.0353240966797,
        629.552001953125,
        322.2647399902344,
        645.0740966796875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 성능 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        59.60769271850586,
        76.33654022216797,
        192.73524475097656,
        92.27911376953125
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8330688476562,
        120.11202239990234
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.16034698486328,
        126.58494567871094,
        484.2970886230469,
        137.61288452148438
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 측정 반복성평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        142.04476928710938,
        196.57345581054688,
        160.0101318359375
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        172.0120086669922,
        153.87661743164062,
        189.9773712158203
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "①",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ISO",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17593",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Clinical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "testing",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vitro",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        201.97926330566406,
        538.1932983398438,
        219.95960998535156
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "devices – Requirements for in vitro monitoring systems for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        98.22676086425781,
        231.94651794433594,
        538.1783447265625,
        249.92686462402344
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "self-testing of oral anticoagulant therapy",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        98.22676086425781,
        261.9137878417969,
        373.38763427734375,
        279.879150390625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② CLSI EP05 Evaluation of Precision of Quantitative Measurement",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        291.88104248046875,
        538.2083129882812,
        309.86138916015625
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Methods; Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        321.8482666015625,
        299.087890625,
        339.8136291503906
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        351.8155212402344,
        473.3834533691406,
        369.7808837890625
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        381.78277587890625,
        520.9976196289062,
        399.7481384277344
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        411.7500305175781,
        153.87661743164062,
        429.71539306640625
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        441.71728515625,
        538.1483154296875,
        459.6976318359375
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시약으로 측정되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        471.6845397949219,
        271.29296875,
        489.64990234375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 검체의 준비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        501.6517639160156,
        173.30606079101562,
        519.632080078125
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.95124816894531,
        531.6190185546875,
        538.1483154296875,
        549.5844116210938
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.95124816894531,
        555.5927734375,
        538.268310546875,
        573.5731201171875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 INR 측정구간에 포함되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.95124816894531,
        579.5665893554688,
        352.96868896484375,
        597.531982421875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 16 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        68.44519805908203,
        391.46783447265625,
        86.42555236816406
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        98.41244506835938,
        387.7498474121094,
        116.3927993774414
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 최소 10대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        128.37969970703125,
        365.8017578125,
        146.36004638671875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        158.34695434570312,
        438.602294921875,
        176.32730102539062
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        188.31419372558594,
        153.87661743164062,
        206.27955627441406
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        218.2814483642578,
        538.1483154296875,
        236.24681091308594
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.90910339355469,
        248.2487030029297,
        538.1483154296875,
        266.22906494140625
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.90910339355469,
        278.2159729003906,
        364.30255126953125,
        296.18133544921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        308.1832275390625,
        538.1932983398438,
        326.1485900878906
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        338.15045166015625,
        258.22003173828125,
        356.1158142089844
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        71.12145233154297,
        368.1177062988281,
        538.1483154296875,
        386.08306884765625
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 모든 측정기가 측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        398.0849609375,
        421.3316650390625,
        416.0503234863281
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        428.0522155761719,
        538.1932983398438,
        446.017578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        458.01947021484375,
        330.9006652832031,
        475.9848327636719
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ ➂, ➃번을 9번 반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        487.9867248535156,
        260.1390075683594,
        505.95208740234375
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➅ 두 번째, 세 번째",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        71.12145233154297,
        517.9539184570312,
        538.1483154296875,
        535.9342651367188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트 검사지를 이용하여 ➁∼➄번의 과정을 반복",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        517.9539184570312,
        538.1483154296875,
        535.9342651367188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.3094253540039,
        547.9212036132812,
        262.41778564453125,
        565.8865966796875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        577.888427734375,
        153.87661743164062,
        595.8538208007812
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        607.855712890625,
        533.4708251953125,
        625.8360595703125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        637.8229370117188,
        538.1333618164062,
        655.8032836914062
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰구간)와 통합변동계수를 계산한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        667.7901611328125,
        340.4954528808594,
        685.7555541992188
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        91.75027465820312,
        697.7574462890625,
        538.1483154296875,
        715.7228393554688
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        727.7246704101562,
        460.130615234375,
        745.6900634765625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 17 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        653.0462646484375,
        374.91680908203125,
        664.9752807617188
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        653.0462646484375,
        374.91680908203125,
        664.9752807617188
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        671.985595703125,
        376.7158203125,
        683.9146118164062
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        671.985595703125,
        376.7158203125,
        683.9146118164062
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        690.9249267578125,
        376.995849609375,
        702.8538818359375
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 - 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        690.9249267578125,
        376.995849609375,
        702.8538818359375
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        709.8642578125,
        376.995849609375,
        721.793212890625
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 - 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        709.8642578125,
        376.995849609375,
        721.793212890625
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 9] INR 구간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        230.0353240966797,
        626.6751098632812,
        322.2647399902344,
        642.1972045898438
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        149.55894470214844,
        95.17598724365234,
        450.42254638671875,
        107.10498809814453
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        149.55894470214844,
        95.17598724365234,
        450.42254638671875,
        107.10498809814453
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변동계수(%CV)",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        149.55894470214844,
        95.17598724365234,
        450.42254638671875,
        107.10498809814453
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        125.93174743652344,
        111.3582992553711,
        431.4825744628906,
        123.29724884033203
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        125.93174743652344,
        111.3582992553711,
        431.4825744628906,
        123.29724884033203
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "≤ 11%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        125.93174743652344,
        111.3582992553711,
        431.4825744628906,
        123.29724884033203
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        125.93174743652344,
        127.42074584960938,
        431.4825744628906,
        139.3596954345703
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0 – 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        125.93174743652344,
        127.42074584960938,
        431.4825744628906,
        139.3596954345703
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "≤ 10%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        125.93174743652344,
        127.42074584960938,
        431.4825744628906,
        139.3596954345703
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        125.93174743652344,
        143.4832000732422,
        431.4825744628906,
        155.42214965820312
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 – 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        125.93174743652344,
        143.4832000732422,
        431.4825744628906,
        155.42214965820312
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤ 10%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        125.93174743652344,
        143.4832000732422,
        431.4825744628906,
        155.42214965820312
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 8] 측정 반복성 결과 예시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        203.88949584960938,
        70.24323272705078,
        371.1982421875,
        85.76531219482422
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 중간측정정밀도 평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        181.12205505371094,
        227.15689086914062,
        199.08741760253906
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        205.09585571289062,
        153.87661743164062,
        223.06121826171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "①",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ISO",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17593",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Clinical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "testing",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vitro",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        235.0631103515625,
        538.1932983398438,
        253.04345703125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "devices – Requirements for in vitro monitoring systems for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        98.22676086425781,
        265.0303649902344,
        538.1783447265625,
        283.0107116699219
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "self-testing of oral anticoagulant therapy",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        98.22676086425781,
        294.99761962890625,
        373.38763427734375,
        312.9629821777344
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② CLSI EP05 Evaluation of Precision of Quantitative Measurement",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        324.9648742675781,
        538.2083129882812,
        342.9452209472656
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Methods; Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        354.93212890625,
        299.087890625,
        372.8974914550781
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        384.8993835449219,
        473.3834533691406,
        402.86474609375
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        414.86663818359375,
        535.6296997070312,
        432.8320007324219
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        444.8338623046875,
        153.87661743164062,
        462.7992248535156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        474.8011169433594,
        538.1483154296875,
        492.7814636230469
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.0695571899414,
        504.7684020996094,
        538.268310546875,
        522.7337646484375
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설계되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        534.735595703125,
        205.80845642089844,
        552.7009887695312
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        564.7028198242188,
        538.2682495117188,
        582.6831665039062
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래 표와 같이 INR 측정구간이 포함되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.02903747558594,
        594.6701049804688,
        429.72711181640625,
        612.635498046875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 18 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➂ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        68.44519805908203,
        391.46783447265625,
        86.41056823730469
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        98.41244506835938,
        387.7498474121094,
        116.3927993774414
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 최소 10대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        128.37969970703125,
        365.8017578125,
        146.36004638671875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        158.34695434570312,
        438.602294921875,
        176.31231689453125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        204.37664794921875,
        538.1483154296875,
        222.34201049804688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.39209747314453,
        234.34390258789062,
        538.1483154296875,
        252.30926513671875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1회 반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.39209747314453,
        264.3111572265625,
        179.42276000976562,
        282.2765197753906
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        294.2784118652344,
        538.1483154296875,
        312.2437744140625
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준물질을 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.90910339355469,
        324.24566650390625,
        538.1483154296875,
        342.22601318359375
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.90910339355469,
        354.2129211425781,
        364.30255126953125,
        372.17828369140625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        384.18017578125,
        538.1932983398438,
        402.1455383300781
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        414.14739990234375,
        258.22003173828125,
        432.1127624511719
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        71.12145233154297,
        444.1146545410156,
        538.1483154296875,
        462.08001708984375
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 모든 측정기가 측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        474.0819091796875,
        421.3316650390625,
        492.0472717285156
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        504.0491638183594,
        538.1932983398438,
        522.0145263671875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        534.016357421875,
        330.9006652832031,
        551.9817504882812
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        563.983642578125,
        538.1483154296875,
        581.9639892578125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        593.9508666992188,
        157.83445739746094,
        611.916259765625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다. 평가기간 내내 같은",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        623.9181518554688,
        538.1483154296875,
        641.8984985351562
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정기, 동일한 3개 로트 검사지를 사용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.26890563964844,
        653.8853759765625,
        392.307373046875,
        671.8507690429688
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        683.8526611328125,
        153.87661743164062,
        701.8180541992188
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        713.8198852539062,
        538.1483154296875,
        731.8002319335938
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계산한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.02903747558594,
        743.787109375,
        157.7145233154297,
        761.7525024414062
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        147.28018188476562,
        215.7642059326172,
        448.2627258300781,
        227.69320678710938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        147.28018188476562,
        215.7642059326172,
        448.2627258300781,
        227.69320678710938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변동계수(%CV)",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        147.28018188476562,
        215.7642059326172,
        448.2627258300781,
        227.69320678710938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        231.82664489746094,
        429.20330810546875,
        243.76559448242188
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        231.82664489746094,
        429.20330810546875,
        243.76559448242188
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤ 11%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        123.65298461914062,
        231.82664489746094,
        429.20330810546875,
        243.76559448242188
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        247.88909912109375,
        429.20330810546875,
        259.82806396484375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 – 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        123.65298461914062,
        247.88909912109375,
        429.20330810546875,
        259.82806396484375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤ 10%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        123.65298461914062,
        247.88909912109375,
        429.20330810546875,
        259.82806396484375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        264.0714111328125,
        429.20330810546875,
        276.0103759765625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 – 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        123.65298461914062,
        264.0714111328125,
        429.20330810546875,
        276.0103759765625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤ 10%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        123.65298461914062,
        264.0714111328125,
        429.20330810546875,
        276.0103759765625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 10] 중간 정밀도 결과 예시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        201.13099670410156,
        190.7115936279297,
        369.5201721191406,
        206.23365783691406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        68.44519805908203,
        538.268310546875,
        86.42555236816406
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통합변동계수를 계산한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        98.41244506835938,
        255.34161376953125,
        116.37781524658203
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        91.0306625366211,
        128.37969970703125,
        538.268310546875,
        146.34506225585938
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        158.34695434570312,
        453.054443359375,
        176.31231689453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 직선성 평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        337.6709899902344,
        165.99005126953125,
        355.6363525390625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        367.63824462890625,
        538.23828125,
        385.6036071777344
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Measurement Procedures",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        397.6054992675781,
        251.12890625,
        415.57086181640625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        427.57275390625,
        473.3834533691406,
        445.5381164550781
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        457.53997802734375,
        491.9733581542969,
        475.5053405761719
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        487.5072326660156,
        153.87661743164062,
        505.47259521484375
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        517.4744873046875,
        538.1483154296875,
        535.454833984375
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 5∼7개의 INR 값에 대하여 시험되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.18949127197266,
        547.4417114257812,
        418.2133483886719,
        565.4220581054688
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        577.408935546875,
        391.46783447265625,
        595.3743286132812
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        607.376220703125,
        387.7498474121094,
        625.3565673828125
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 최소 10대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        637.3434448242188,
        365.8017578125,
        655.3237915039062
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        667.3107299804688,
        438.602294921875,
        685.276123046875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        697.2779541015625,
        153.87661743164062,
        715.2433471679688
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        727.2452392578125,
        538.1483154296875,
        745.2106323242188
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.90910339355469,
        68.44519805908203,
        538.1483154296875,
        86.42555236816406
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.90910339355469,
        98.41244506835938,
        364.30255126953125,
        116.37781524658203
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        128.37969970703125,
        538.1932983398438,
        146.34506225585938
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        158.34695434570312,
        258.22003173828125,
        176.31231689453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        188.31419372558594,
        538.268310546875,
        206.27955627441406
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장착하고, 모든 측정기가 측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        218.2814483642578,
        457.4320983886719,
        236.24681091308594
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        248.2487030029297,
        538.1932983398438,
        266.2140808105469
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        278.2159729003906,
        330.9006652832031,
        296.18133544921875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ ➂∼➃번의 과정을 4회 반복한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        308.1832275390625,
        314.7094421386719,
        326.16357421875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        338.15045166015625,
        538.1483154296875,
        356.13079833984375
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        368.1177062988281,
        154.35633850097656,
        386.08306884765625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        398.0849609375,
        153.87661743164062,
        416.0503234863281
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        428.0522155761719,
        538.268310546875,
        446.0325622558594
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균을 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        458.01947021484375,
        206.88787841796875,
        475.9848327636719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        487.9867248535156,
        538.1483154296875,
        505.9670715332031
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        517.9539184570312,
        538.268310546875,
        535.9193115234375
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에러율(%)을 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        547.9212036132812,
        243.34811401367188,
        565.8865966796875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 선형회귀 분석을 통하여 상관계수를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        577.888427734375,
        402.0221252441406,
        595.8538208007812
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 최소검출한계",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        637.8229370117188,
        174.02569580078125,
        655.788330078125
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        667.7901611328125,
        538.1932983398438,
        685.7555541992188
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": CLSI EP17 Evaluation of Detection Capability for Clinical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        667.7901611328125,
        538.1932983398438,
        685.7555541992188
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Laboratory Measurement Procedures;",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        697.7574462890625,
        316.0287170410156,
        715.7228393554688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        727.7246704101562,
        473.3834533691406,
        745.6900634765625
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        68.44519805908203,
        538.1483154296875,
        86.41056823730469
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질의 최소량을 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        98.41244506835938,
        229.9154052734375,
        116.37781524658203
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        188.31419372558594,
        153.87661743164062,
        206.27955627441406
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 최소검출한계 설정 배경을 제시해야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        218.2814483642578,
        372.8778991699219,
        236.24681091308594
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        248.2487030029297,
        538.268310546875,
        266.2140808105469
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법 등)에 대한 실험 프로토콜을 제시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.3094253540039,
        278.2159729003906,
        376.11614990234375,
        296.18133544921875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        308.1832275390625,
        391.46783447265625,
        326.1485900878906
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        338.15045166015625,
        387.7498474121094,
        356.13079833984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 1대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        368.1177062988281,
        322.2653503417969,
        386.0980529785156
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        398.0849609375,
        153.87661743164062,
        416.0503234863281
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        428.0522155761719,
        538.268310546875,
        446.017578125
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.86858367919922,
        458.01947021484375,
        538.268310546875,
        475.99981689453125
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.86858367919922,
        487.9867248535156,
        365.26202392578125,
        505.95208740234375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        517.9539184570312,
        538.1483154296875,
        535.9193115234375
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.54930114746094,
        547.9212036132812,
        286.40478515625,
        565.8865966796875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다. (※비고:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        577.888427734375,
        538.1483154296875,
        595.8687744140625
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        607.855712890625,
        538.1483154296875,
        625.8211059570312
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        637.8229370117188,
        441.3008117675781,
        655.788330078125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        667.7901611328125,
        538.268310546875,
        685.7705078125
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        95.10845184326172,
        697.7574462890625,
        229.67552185058594,
        715.7228393554688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        727.7246704101562,
        535.7496337890625,
        745.6900634765625
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        727.7246704101562,
        535.7496337890625,
        745.6900634765625
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        395.3279724121094,
        374.91680908203125,
        407.2569885253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        395.3279724121094,
        374.91680908203125,
        407.2569885253906
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        411.3904113769531,
        376.7158203125,
        423.3194274902344
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        411.3904113769531,
        376.7158203125,
        423.3194274902344
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        427.5727233886719,
        376.995849609375,
        439.5017395019531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 - 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        427.5727233886719,
        376.995849609375,
        439.5017395019531
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        443.6351623535156,
        376.995849609375,
        455.5641784667969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 - 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        443.6351623535156,
        376.995849609375,
        455.5641784667969
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 11] INR 구간 예시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        211.80520629882812,
        370.39520263671875,
        340.49566650390625,
        385.91729736328125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 적혈구용적률 영향평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        68.44519805908203,
        242.38864135742188,
        86.41056823730469
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        98.41244506835938,
        538.0433959960938,
        116.37781524658203
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": CLSI EP07 Interference Testing in Clinical Chemistry Approved",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        98.41244506835938,
        538.0433959960938,
        116.37781524658203
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        128.37969970703125,
        143.4122772216797,
        146.34506225585938
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        158.34695434570312,
        435.2441101074219,
        176.31231689453125
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        188.31419372558594,
        519.0786743164062,
        206.27955627441406
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        218.2814483642578,
        146.32070922851562,
        236.24681091308594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        248.2487030029297,
        538.1483154296875,
        266.22906494140625
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        278.2159729003906,
        538.1782836914062,
        296.18133544921875
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        338.15045166015625,
        533.890625,
        356.13079833984375
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        487.26751708984375,
        361.8439025878906,
        505.24786376953125
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        517.2347412109375,
        358.4857177734375,
        535.215087890625
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 1대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        547.2019653320312,
        299.1178894042969,
        565.1823120117188
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        577.1692504882812,
        404.66070556640625,
        595.1495971679688
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        607.136474609375,
        146.32070922851562,
        625.1018676757812
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        637.1036987304688,
        538.1483154296875,
        655.069091796875
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지 포장용기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.91072845458984,
        667.0709838867188,
        538.1483154296875,
        685.0513305664062
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.91072845458984,
        697.0382080078125,
        283.22650146484375,
        715.0036010742188
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 23 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        68.44519805908203,
        538.1483154296875,
        86.41056823730469
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값과 적혈구용적률을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        91.2705307006836,
        98.41244506835938,
        366.5213623046875,
        116.37781524658203
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        128.37969970703125,
        538.268310546875,
        146.34506225585938
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기가 측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        158.34695434570312,
        316.5084533691406,
        176.31231689453125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        188.31419372558594,
        538.1483154296875,
        206.27955627441406
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.43099212646484,
        218.2814483642578,
        212.88462829589844,
        236.24681091308594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        69.80216979980469,
        248.2487030029297,
        350.57000732421875,
        266.22906494140625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        278.2159729003906,
        538.1483154296875,
        296.1963195800781
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.31105041503906,
        308.1832275390625,
        146.2007598876953,
        326.1485900878906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        338.15045166015625,
        146.32070922851562,
        356.1158142089844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        368.1177062988281,
        538.1483154296875,
        386.0980529785156
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준편차를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.71138000488281,
        398.0849609375,
        218.76144409179688,
        416.0503234863281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        428.0522155761719,
        538.268310546875,
        446.0325622558594
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        458.01947021484375,
        538.1483154296875,
        475.9848327636719
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        487.9867248535156,
        146.68051147460938,
        505.95208740234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 간섭평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        547.9212036132812,
        143.56219482421875,
        565.8865966796875
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        577.888427734375,
        538.0433959960938,
        595.8538208007812
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": CLSI EP07 Interference Testing in Clinical Chemistry Approved",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        577.888427734375,
        538.0433959960938,
        595.8538208007812
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        607.855712890625,
        145.33123779296875,
        625.8211059570312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        637.8229370117188,
        435.2441101074219,
        655.788330078125
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        667.7901611328125,
        536.1094360351562,
        685.7705078125
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        68.44519805908203,
        146.32070922851562,
        86.41056823730469
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 검체의 준비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        98.41244506835938,
        163.95114135742188,
        116.3927993774414
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        76.39859771728516,
        128.37969970703125,
        401.1825866699219,
        146.36004638671875
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        204.84898376464844,
        185.07774353027344,
        396.14532470703125,
        197.00674438476562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        204.84898376464844,
        185.07774353027344,
        396.14532470703125,
        197.00674438476562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        181.22178649902344,
        201.2600555419922,
        397.82440185546875,
        213.18905639648438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        181.22178649902344,
        201.2600555419922,
        397.82440185546875,
        213.18905639648438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        181.22178649902344,
        217.32249450683594,
        398.224853515625,
        229.25149536132812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 - 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        181.22178649902344,
        217.32249450683594,
        398.224853515625,
        229.25149536132812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        181.22178649902344,
        233.38494873046875,
        398.224853515625,
        245.31394958496094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 - 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        181.22178649902344,
        233.38494873046875,
        398.224853515625,
        245.31394958496094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 12] INR 구간 예시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        233.03370666503906,
        160.14498901367188,
        361.7241516113281,
        175.66705322265625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        76.39859771728516,
        262.0336608886719,
        456.11279296875,
        280.0140075683594
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        292.0008850097656,
        538.268310546875,
        309.9812316894531
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 동일한 부피의 용질이 대조시료에 첨가한다. (※비고: 시료 기질의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        97.26728057861328,
        321.9681396484375,
        538.1483154296875,
        339.948486328125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        97.26728057861328,
        351.9353942871094,
        435.3040771484375,
        369.9007568359375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        381.90264892578125,
        361.8439025878906,
        399.88299560546875
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        411.8699035644531,
        358.4857177734375,
        429.8502502441406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        441.837158203125,
        365.0821533203125,
        459.8175048828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 장비 및 시약",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        471.8044128417969,
        170.54757690429688,
        489.769775390625
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 병원용 혈액응고시간 측정 기준장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        501.7716369628906,
        315.6689147949219,
        519.751953125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        76.39859771728516,
        531.7388916015625,
        538.268310546875,
        549.71923828125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는 고농도를 사용 할 것을 권장한다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        96.66761016845703,
        561.7061157226562,
        349.43060302734375,
        579.6715087890625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        591.6734008789062,
        146.32070922851562,
        609.6387939453125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        621.640625,
        538.1483154296875,
        639.6060180664062
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시료와 대조시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.91072845458984,
        651.6078491210938,
        538.268310546875,
        669.5881958007812
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.91072845458984,
        681.5751342773438,
        341.63482666015625,
        699.54052734375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        711.5423583984375,
        538.268310546875,
        729.5077514648438
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        91.2705307006836,
        741.5096435546875,
        270.813232421875,
        759.4750366210938
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        68.44519805908203,
        538.268310546875,
        86.41056823730469
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비가 완료되었는지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        98.41244506835938,
        282.8067321777344,
        116.37781524658203
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        128.37969970703125,
        538.1483154296875,
        146.34506225585938
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.43099212646484,
        158.34695434570312,
        212.88462829589844,
        176.31231689453125
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        69.80216979980469,
        188.31419372558594,
        350.57000732421875,
        206.29454040527344
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        218.2814483642578,
        538.268310546875,
        236.2617950439453
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다. (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        248.2487030029297,
        538.1483154296875,
        266.22906494140625
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        278.2159729003906,
        538.23828125,
        296.18133544921875
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다. 간섭",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        308.1832275390625,
        538.1483154296875,
        326.1485900878906
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        338.15045166015625,
        538.1483154296875,
        356.1158142089844
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여-응답 기법을 적용하여 재평가 한다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        368.1177062988281,
        332.0400390625,
        386.08306884765625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        398.0849609375,
        146.32070922851562,
        416.0503234863281
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        428.0522155761719,
        538.1483154296875,
        446.0325622558594
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.31105041503906,
        458.01947021484375,
        498.0900573730469,
        475.9848327636719
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        487.9867248535156,
        538.1483154296875,
        505.9670715332031
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준편차를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        517.9539184570312,
        221.87974548339844,
        535.9193115234375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        69.80216979980469,
        547.9212036132812,
        469.3056640625,
        565.8865966796875
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사. 사용자 성능평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        607.855712890625,
        196.57345581054688,
        625.8211059570312
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        637.8229370117188,
        538.1932983398438,
        655.788330078125
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "devices – Requirements for in vitro monitoring systems for self-testing",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        86.59307098388672,
        667.7901611328125,
        538.1782836914062,
        685.7705078125
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of oral anticoagulant therapy",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        86.59307098388672,
        697.7574462890625,
        266.76544189453125,
        715.7228393554688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 26 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.205745697021484,
        68.44519805908203,
        435.2441101074219,
        86.41056823730469
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        98.41244506835938,
        538.268310546875,
        116.37781524658203
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        86.59307098388672,
        128.37969970703125,
        534.4303588867188,
        146.34506225585938
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        158.34695434570312,
        146.32070922851562,
        176.31231689453125
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        188.31419372558594,
        538.1483154296875,
        206.29454040527344
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        218.2814483642578,
        516.0802612304688,
        236.24681091308594
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        248.2487030029297,
        538.1483154296875,
        266.22906494140625
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용적률(Hct) 범위에 해당되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        278.2159729003906,
        307.6332702636719,
        296.18133544921875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 교육 자료를 제공받아야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        338.15045166015625,
        304.99468994140625,
        356.1158142089844
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        368.1177062988281,
        361.8439025878906,
        386.08306884765625
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 1종 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        398.0849609375,
        358.4857177734375,
        416.0653076171875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 6대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        428.0522155761719,
        299.1178894042969,
        446.0325622558594
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        458.01947021484375,
        404.66070556640625,
        475.9848327636719
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        487.9867248535156,
        538.1483154296875,
        505.95208740234375
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 평가되어야 한다. 참가자들이 기기 사용법을 올바르게 이해했는지를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        517.9539184570312,
        538.268310546875,
        535.9193115234375
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가하는데 도움이 되도록 설문지가 구성되어야 한다. 실제 시험결과에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        547.9212036132812,
        538.268310546875,
        565.8865966796875
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 주지 않도록 설문은 시험 후 수행되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        577.888427734375,
        413.17608642578125,
        595.8538208007812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        607.855712890625,
        146.32070922851562,
        625.8211059570312
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다. (※비고:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        69.80216979980469,
        637.8229370117188,
        538.1483154296875,
        655.8032836914062
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        667.7901611328125,
        507.385009765625,
        685.7555541992188
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        697.7574462890625,
        538.268310546875,
        715.7228393554688
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        727.7246704101562,
        263.37725830078125,
        745.6900634765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 27 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        117.77616882324219,
        454.18365478515625,
        136.16929626464844,
        466.1126708984375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 사용자 측정결과와",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        188.8976287841797,
        444.2345275878906,
        300.3173828125,
        456.1635437011719
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문가 측정결과의 차이",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        188.8976287841797,
        464.2526550292969,
        300.3172607421875,
        476.1816711425781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 사용자 측정결과 평균과",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        353.5683898925781,
        444.2345275878906,
        490.17437744140625,
        456.1635437011719
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문가 측정결과 평균의 차이",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        353.5683898925781,
        464.2526550292969,
        490.17437744140625,
        476.1816711425781
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0–4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        102.66436004638672,
        490.8635559082031,
        370.4351501464844,
        502.8025207519531
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95% 측정 결과 값이 ± 0.5 이내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        102.66436004638672,
        490.8635559082031,
        370.4351501464844,
        502.8025207519531
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "≤ 10%",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        102.66436004638672,
        490.8635559082031,
        370.4351501464844,
        502.8025207519531
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 13] 허용범위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        257.50042724609375,
        415.8255615234375,
        351.6484375,
        431.34765625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        68.44519805908203,
        538.268310546875,
        86.41056823730469
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여 INR 값을 2회 반복 측정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        98.41244506835938,
        331.7402038574219,
        116.37781524658203
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        128.37969970703125,
        538.268310546875,
        146.34506225585938
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여 INR 값을 2회 반복 측정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        158.34695434570312,
        329.2215576171875,
        176.31231689453125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        188.31419372558594,
        538.268310546875,
        206.27955627441406
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비를 이용하여 INR 값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        218.2814483642578,
        375.39654541015625,
        236.24681091308594
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        248.2487030029297,
        146.32070922851562,
        266.2140808105469
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        69.80216979980469,
        278.2159729003906,
        538.1483154296875,
        296.1963195800781
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.43099212646484,
        308.1832275390625,
        538.1932983398438,
        326.1485900878906
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값의 차이를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.43099212646484,
        338.15045166015625,
        226.0774688720703,
        356.1158142089844
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        69.80216979980469,
        368.1177062988281,
        449.5163879394531,
        386.0980529785156
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아. 기준물질/보정물질",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        571.535400390625,
        208.9267578125,
        589.5007934570312
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        601.5026245117188,
        529.1531982421875,
        619.468017578125
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        631.4699096679688,
        538.1483154296875,
        649.435302734375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        661.4371337890625,
        523.1564331054688,
        679.4025268554688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 28 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        489.66485595703125,
        374.91680908203125,
        501.5938720703125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        489.66485595703125,
        374.91680908203125,
        501.5938720703125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        505.8471984863281,
        376.7158203125,
        517.7761840820312
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        505.8471984863281,
        376.7158203125,
        517.7761840820312
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        521.90966796875,
        376.995849609375,
        533.838623046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 - 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        521.90966796875,
        376.995849609375,
        533.838623046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        537.9720458984375,
        376.995849609375,
        549.9010620117188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 - 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        537.9720458984375,
        376.995849609375,
        549.9010620117188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 14] INR 구간 예시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        213.60423278808594,
        464.73211669921875,
        338.6968688964844,
        480.25421142578125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 안정성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        216.7222442626953,
        92.27911376953125
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 개봉 전 안정성평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        132.93472290039062,
        208.6868896484375,
        150.90008544921875
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        162.9019775390625,
        153.87661743164062,
        180.86734008789062
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 「의료기기의 안정성시험 기준」(식약처 고시)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        192.8692169189453,
        400.8827209472656,
        210.8495635986328
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② ISO 23640 In vitro diagnostic medical devices – Evaluation of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        222.8364715576172,
        538.08837890625,
        240.8168182373047
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "stability of in vitro diagnostic reagents",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.26890563964844,
        252.80372619628906,
        359.31024169921875,
        270.76910400390625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        282.77099609375,
        473.3834533691406,
        300.7363586425781
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        312.7382507324219,
        538.268310546875,
        330.70361328125
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        342.7054748535156,
        538.268310546875,
        360.67083740234375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정한 한계 이내로 유지되는지 평가하기 위함",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        372.6727294921875,
        405.86004638671875,
        390.6380920410156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        402.6399841308594,
        153.87661743164062,
        420.6053466796875
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        432.60723876953125,
        526.634521484375,
        450.58758544921875
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        581.6043701171875,
        538.1483154296875,
        599.5697631835938
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        611.5716552734375,
        538.2682495117188,
        629.5370483398438
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        641.5388793945312,
        538.1782836914062,
        659.5042724609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고시간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        641.5388793945312,
        538.1782836914062,
        659.5042724609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정검사지의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        641.5388793945312,
        538.1782836914062,
        659.5042724609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관조건(온도,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        641.5388793945312,
        538.1782836914062,
        659.5042724609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "습도)을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        641.5388793945312,
        538.1782836914062,
        659.5042724609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        641.5388793945312,
        538.1782836914062,
        659.5042724609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        671.506103515625,
        538.1483154296875,
        689.4714965820312
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        701.473388671875,
        538.1483154296875,
        719.4387817382812
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는지 평가되어야 한다. 성능 관련 시험의 측정 시험간격은 시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        731.4406127929688,
        538.1483154296875,
        749.406005859375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        68.44519805908203,
        538.1483154296875,
        86.41056823730469
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        98.41244506835938,
        157.4746551513672,
        116.37781524658203
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        128.37969970703125,
        538.1483154296875,
        146.34506225585938
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        158.34695434570312,
        538.1483154296875,
        176.31231689453125
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        188.31419372558594,
        538.1483154296875,
        206.27955627441406
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        218.2814483642578,
        538.1483154296875,
        236.24681091308594
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        248.2487030029297,
        538.1483154296875,
        266.2140808105469
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        278.2159729003906,
        538.1483154296875,
        296.18133544921875
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가되어야 한다. 성능시험의 측정 시기는 시험개시와 중간시점 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마지막시점을 포함하여 3회 시점으로 설정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        338.15045166015625,
        387.0302429199219,
        356.1158142089844
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        368.1177062988281,
        391.46783447265625,
        386.08306884765625
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 3개 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        398.0849609375,
        387.7498474121094,
        416.0653076171875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 3대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.0522155761719,
        322.2653503417969,
        446.0325622558594
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        458.01947021484375,
        153.87661743164062,
        475.9848327636719
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        487.9867248535156,
        538.268310546875,
        505.95208740234375
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.86858367919922,
        517.9539184570312,
        538.1483154296875,
        535.9342651367188
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.86858367919922,
        547.9212036132812,
        365.26202392578125,
        565.8865966796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        577.888427734375,
        538.1932983398438,
        595.8538208007812
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        607.855712890625,
        258.22003173828125,
        625.8211059570312
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        71.12145233154297,
        637.8229370117188,
        538.268310546875,
        655.788330078125
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 모든 측정기가 측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        667.7901611328125,
        427.5682678222656,
        685.7555541992188
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        697.7574462890625,
        538.1932983398438,
        715.7228393554688
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        727.7246704101562,
        331.8601379394531,
        745.6900634765625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 30 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        68.44519805908203,
        538.268310546875,
        86.42555236816406
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        95.10845184326172,
        98.41244506835938,
        229.67552185058594,
        116.37781524658203
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        128.37969970703125,
        538.1483154296875,
        146.36004638671875
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        158.34695434570312,
        153.0370635986328,
        176.31231689453125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        188.31419372558594,
        538.268310546875,
        206.27955627441406
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        218.2814483642578,
        121.13435363769531,
        236.24681091308594
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 시험간격 시점에서 기준장비로 측정한 기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        248.2487030029297,
        369.6396789550781,
        266.22906494140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        278.2159729003906,
        538.268310546875,
        296.1963195800781
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.0695571899414,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값 편차 및 %편차를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        338.15045166015625,
        324.3042297363281,
        356.1158142089844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 개봉 후 안정성평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        398.0849609375,
        208.6868896484375,
        416.0503234863281
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        428.0522155761719,
        153.87661743164062,
        446.017578125
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "①「의료기기의 안정성시험 기준」(식약처 고시)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        458.01947021484375,
        393.6866149902344,
        475.99981689453125
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② ISO 23640 In vitro diagnostic medical devices – Evaluation of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        487.9867248535156,
        538.08837890625,
        505.9670715332031
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "stability of in vitro diagnostic reagents",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.26890563964844,
        517.9539184570312,
        359.31024169921875,
        535.9193115234375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        547.9212036132812,
        473.3834533691406,
        565.8865966796875
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        577.888427734375,
        538.268310546875,
        595.8538208007812
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        607.855712890625,
        538.268310546875,
        625.8211059570312
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정한 한계 이내로 유지되는지 평가하기 위함",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        637.8229370117188,
        403.9410705566406,
        655.788330078125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        667.7901611328125,
        153.87661743164062,
        685.7555541992188
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        697.7574462890625,
        526.634521484375,
        715.73779296875
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 31 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        121.18756103515625,
        374.91680908203125,
        133.11656188964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.6204833984375,
        121.18756103515625,
        374.91680908203125,
        133.11656188964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비 치료적 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        137.25,
        376.7158203125,
        149.1790008544922
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        137.25,
        376.7158203125,
        149.1790008544922
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "낮은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        153.4323272705078,
        376.995849609375,
        165.361328125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 - 3.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        153.4323272705078,
        376.995849609375,
        165.361328125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높은 치료 범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        159.9932861328125,
        169.49476623535156,
        376.995849609375,
        181.42376708984375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.1 - 4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        159.9932861328125,
        169.49476623535156,
        376.995849609375,
        181.42376708984375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 15] INR 구간 예시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        209.88624572753906,
        96.25480651855469,
        342.41412353515625,
        111.77688598632812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        213.1270751953125,
        538.268310546875,
        231.09243774414062
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건에 보관하여 안정성시험을 실시되어야 한다. 휴대용 혈액응고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.66923522949219,
        243.09434509277344,
        538.268310546875,
        261.0597229003906
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.66923522949219,
        273.06158447265625,
        538.268310546875,
        291.0269470214844
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.66923522949219,
        303.0288391113281,
        538.268310546875,
        320.99420166015625
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.66923522949219,
        332.99609375,
        538.1483154296875,
        350.9614562988281
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.66923522949219,
        362.9633483886719,
        538.1483154296875,
        380.9287109375
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하여 3회 시점으로 설정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.66923522949219,
        392.93060302734375,
        310.87152099609375,
        410.8959655761719
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 휴대용 혈액응고시간 측정기 및 검사지 시료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        422.8978576660156,
        391.46783447265625,
        440.86322021484375
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 혈액응고시간 측정검사지: 1종 로트 검사지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        452.8651123046875,
        387.7498474121094,
        470.845458984375
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 혈액응고시간 측정기: 3대 측정기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        482.83233642578125,
        322.2653503417969,
        500.81268310546875
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        512.799560546875,
        153.87661743164062,
        530.7649536132812
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        542.766845703125,
        538.268310546875,
        560.7322387695312
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.86858367919922,
        572.7340698242188,
        538.1483154296875,
        590.7144165039062
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장용기 또는 포장지를 벗기지 않는다.)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.86858367919922,
        602.7012939453125,
        365.26202392578125,
        620.6666870117188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        632.6685791015625,
        538.1932983398438,
        650.6339721679688
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        662.6358032226562,
        258.22003173828125,
        680.6011962890625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        71.12145233154297,
        692.6030883789062,
        538.268310546875,
        710.5684814453125
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 모든 측정기가 측정가능 상태인지 확인한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        722.5703125,
        427.5682678222656,
        740.5357055664062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 32 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        68.44519805908203,
        538.1932983398438,
        86.41056823730469
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값을 측정하고 그 결과를 기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        98.41244506835938,
        331.8601379394531,
        116.37781524658203
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        128.37969970703125,
        538.1483154296875,
        146.36004638671875
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        158.34695434570312,
        153.0370635986328,
        176.31231689453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        188.31419372558594,
        153.87661743164062,
        206.27955627441406
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        218.2814483642578,
        538.268310546875,
        236.2617950439453
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 및 표준편차를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        248.2487030029297,
        294.2005615234375,
        266.2140808105469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        278.2159729003906,
        538.268310546875,
        296.1963195800781
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.0695571899414,
        308.1832275390625,
        538.268310546875,
        326.1485900878906
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 INR 값 편차 및 %편차를 산출한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        338.15045166015625,
        359.56512451171875,
        356.1158142089844
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 33 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 참고 문헌",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        160.712890625,
        92.27911376953125
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 의료기기 품목 및 품목별 등급에 관한 규정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        133.17446899414062,
        313.3895263671875,
        148.696533203125
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        159.18603515625,
        453.4728088378906,
        174.72105407714844
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 개인용 혈당측정 시스템 표준시험방법 가이드라인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        185.19761657714844,
        346.8506164550781,
        200.7196807861328
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 의료기기 기준규격 (66. 개인용 혈당측정시스템)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        211.0893096923828,
        333.2820739746094,
        226.6113739013672
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        237.10089111328125,
        538.1113891601562,
        252.6359100341797
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for in vitro monitoring systems for self-testing of oral anticoagulant therapy",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        263.1124572753906,
        497.83013916015625,
        278.6345520019531
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        289.004150390625,
        538.146240234375,
        304.5391845703125
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "diagnostic reagents",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        315.0157165527344,
        180.58444213867188,
        330.5378112792969
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        341.0273132324219,
        538.1022338867188,
        356.5623474121094
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "monitoring systems for self-testing in managing diabetes mellitus",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        366.91900634765625,
        438.92431640625,
        382.44110107421875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        392.9305725097656,
        538.1228637695312,
        408.4526672363281
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and laboratory use- Part 1: General requirements",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        418.942138671875,
        347.65521240234375,
        434.4642333984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        444.8338623046875,
        538.2424926757812,
        460.35595703125
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control and laboratory use – Part 2-101: Particular requirements for in vitro",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        470.8454284667969,
        538.146240234375,
        486.3804626464844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "diagnostic (IVD) medical equipment",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        496.85699462890625,
        277.6493835449219,
        512.3790893554688
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        522.7487182617188,
        538.1483764648438,
        538.2837524414062
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMC requirements – Part 1: General requirements",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.19761657714844,
        548.76025390625,
        360.12786865234375,
        564.2952880859375
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        574.7718505859375,
        538.1483764648438,
        590.306884765625
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        600.66357421875,
        538.131103515625,
        616.1986083984375
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "medical equipment",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        626.6751098632812,
        180.5019989013672,
        642.1972045898438
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EP-05",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Evaluation",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Precision",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Quantitative",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Measurement",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Methods;",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        652.6867065429688,
        538.2427368164062,
        668.2088012695312
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        82.63521575927734,
        678.5784301757812,
        193.77142333984375,
        694.1005249023438
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        704.5899658203125,
        519.280029296875,
        720.112060546875
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        730.6015625,
        491.208984375,
        746.1236572265625
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 34 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        538.1220703125,
        84.3268814086914
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        83.59469604492188,
        94.81637573242188,
        194.61044311523438,
        110.33845520019531
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        120.70807647705078,
        538.1300048828125,
        136.24310302734375
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Instruments",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.3564453125,
        146.71966552734375,
        143.28460693359375,
        162.24172973632812
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "더. Public Workshop – Point of Care Prothrombin Time/International Normalized",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        172.73123168945312,
        538.2427978515625,
        188.26625061035156
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.75677490234375,
        198.62294006347656,
        432.9387512207031,
        214.14500427246094
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.63450622558594,
        538.1478271484375,
        240.1565704345703
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Systems for Over-the-Counter Use",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.07768249511719,
        250.6460723876953,
        265.25067138671875,
        266.16815185546875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "머. 의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        276.53778076171875,
        538.148193359375,
        292.07281494140625
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산업협회, 이승노)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.95774841308594,
        302.5493469238281,
        171.72964477539062,
        318.0714416503906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버. Plesch W, Wolf T, Breitenbeck N, et al. Results of the performance verification of",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        328.5609130859375,
        538.2510375976562,
        344.0830078125
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the CoaguChek XS system. Thromb Res 2008;123:381-389",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        354.45263671875,
        389.16033935546875,
        369.9747314453125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서. Douketis JD, Lane A, Milne J, Ginsberg JS. Accuracy of a portable International",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        380.4642028808594,
        538.2003784179688,
        395.9862976074219
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Normalization Ratio monitor in outpatients receiving long-time oral anticoagulant",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        406.47576904296875,
        538.1455688476562,
        421.99786376953125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "therapy: comparison with a laboratory reference standard using clinically relevant",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        432.36749267578125,
        538.2670288085938,
        447.88958740234375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "criteria for agreement. ThrombRes1998;92:11-7.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        458.3790588378906,
        330.2743835449219,
        473.9011535644531
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        484.390625,
        538.1207885742188,
        499.9127197265625
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "clinical usefulness of the CoaguChekS and XS Point of Care devices when starting",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.75677490234375,
        510.2823486328125,
        538.248779296875,
        525.804443359375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "warfarin in a hospital outreach setting. ThrombRes2009;123:909-13.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.75677490234375,
        536.2938842773438,
        443.0126037597656,
        551.8159790039062
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 35 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[별첨] 국내·외 연구동향",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        245.74652099609375,
        92.27911376953125
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        63.205745697021484,
        127.90022277832031,
        393.9864807128906,
        145.86558532714844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        157.8674774169922,
        538.1483154296875,
        175.8478240966797
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        187.834716796875,
        538.1483154296875,
        205.80007934570312
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        217.80197143554688,
        538.1483154296875,
        235.767333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절실한 상태이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        247.7692108154297,
        194.4146270751953,
        265.7345886230469
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 국내외 개발동향",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.205745697021484,
        277.7364807128906,
        187.09860229492188,
        295.70184326171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        307.7037353515625,
        538.268310546875,
        325.68408203125
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다. 기존 대형병원에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        336.2325744628906,
        538.1483154296875,
        354.19793701171875
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        364.6415100097656,
        538.1483154296875,
        382.60687255859375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        393.17034912109375,
        538.268310546875,
        411.1357116699219
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능해지도록 개발 중이다. 즉, 병원에서 환자 측정 시, 채취된 샘플을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        421.69915771484375,
        538.1483154296875,
        439.6645202636719
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        450.1081237792969,
        538.1483154296875,
        468.073486328125
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        478.6369323730469,
        538.1483154296875,
        496.602294921875
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다. 또한, 기존",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        507.1657409667969,
        538.1483154296875,
        525.131103515625
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        535.57470703125,
        538.1483154296875,
        553.5401000976562
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        564.103515625,
        538.1483154296875,
        582.0689086914062
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.14897155761719,
        592.63232421875,
        538.1483154296875,
        610.5977172851562
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.14897155761719,
        621.041259765625,
        493.05279541015625,
        639.0066528320312
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        649.5701293945312,
        538.268310546875,
        667.5504760742188
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.42936706542969,
        679.537353515625,
        538.268310546875,
        697.5027465820312
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부터 전달받는 시스템이 운영 중이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.42936706542969,
        709.5045776367188,
        318.66729736328125,
        727.469970703125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        739.4718627929688,
        538.1483154296875,
        757.4522094726562
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 36 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다. 부작용을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.11007690429688,
        68.44519805908203,
        538.1483154296875,
        86.41056823730469
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.11007690429688,
        98.41244506835938,
        538.268310546875,
        116.37781524658203
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 진단 후 맞춤형 상담을 제공 중이다. 또한, 판매 기업이 환자 교육을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.11007690429688,
        128.37969970703125,
        538.268310546875,
        146.34506225585938
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.11007690429688,
        158.34695434570312,
        538.1483154296875,
        176.31231689453125
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애쓰고 있다. 그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.11007690429688,
        188.31419372558594,
        538.1483154296875,
        206.27955627441406
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.11007690429688,
        218.2814483642578,
        538.1483154296875,
        236.24681091308594
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서비스 확대에 좀 더 집중하고 있는 실정이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.11007690429688,
        248.2487030029297,
        360.164794921875,
        266.2140808105469
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 37 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        224.15504455566406,
        527.7139892578125,
        239.67710876464844
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.15872192382812,
        250.16661071777344,
        397.4386901855469,
        265.6886901855469
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅱ",
      "font_size": 20.02363395690918,
      "font_name": "T10",
      "bbox": [
        68.36294555664062,
        76.95590209960938,
        388.1096496582031,
        100.97764587402344
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 작성 및 평가",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        68.36294555664062,
        76.95590209960938,
        388.1096496582031,
        100.97764587402344
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상시험의 제목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        59.60769271850586,
        143.1035614013672,
        200.6512451171875,
        159.046142578125
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        175.85110473632812,
        541.8339233398438,
        186.87904357910156
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        197.78713989257812,
        301.63604736328125,
        208.81507873535156
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        401.8008728027344,
        538.14892578125,
        417.3229675292969
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        427.8124694824219,
        538.1483764648438,
        443.3345642089844
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        453.70416259765625,
        538.1224365234375,
        469.22625732421875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단일설계, 전향적 품목허가용 비교확증임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        479.7157287597656,
        320.1068420410156,
        495.2378234863281
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        505.727294921875,
        446.75830078125,
        521.2493896484375
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        531.6190185546875,
        400.1029357910156,
        547.154052734375
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.6060676574707,
        557.6305541992188,
        440.30352783203125,
        573.1526489257812
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        583.6421508789062,
        476.3814697265625,
        599.1642456054688
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        609.5338745117188,
        492.6927490234375,
        625.0559692382812
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 38 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        335.2735900878906,
        486.45635986328125,
        350.7956848144531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        335.2735900878906,
        486.45635986328125,
        350.7956848144531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        335.2735900878906,
        486.45635986328125,
        350.7956848144531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        335.2735900878906,
        486.45635986328125,
        350.7956848144531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        356.7301330566406,
        520.0381469726562,
        372.2651672363281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        356.7301330566406,
        520.0381469726562,
        372.2651672363281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        356.7301330566406,
        520.0381469726562,
        372.2651672363281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        356.7301330566406,
        520.0381469726562,
        372.2651672363281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        378.1866760253906,
        520.0381469726562,
        393.7217102050781
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        378.1866760253906,
        520.0381469726562,
        393.7217102050781
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        378.1866760253906,
        520.0381469726562,
        393.7217102050781
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        378.1866760253906,
        520.0381469726562,
        393.7217102050781
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        173.690185546875,
        527.7142333984375,
        189.22520446777344
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        199.58189392089844,
        527.7147216796875,
        215.1039581298828
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시기관으로 지정받은 곳이어야 함",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        225.5934600830078,
        288.20379638671875,
        241.1155242919922
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 임상시험기관의 명칭 및 소재지",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        320.58624267578125,
        92.27911376953125
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        270.9039306640625,
        86.09606170654297,
        286.426025390625
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 임상시험 실시기관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        296.9154968261719,
        186.018310546875,
        312.4375915527344
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 39 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        137.84934997558594,
        424.4240417480469,
        153.3714141845703
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        163.74105834960938,
        530.806396484375,
        179.26312255859375
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        189.7526397705078,
        530.7120361328125,
        205.2747039794922
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경험이 있는 자가 선정되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.1992416381836,
        215.7642059326172,
        267.18927001953125,
        231.28627014160156
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        241.65591430664062,
        530.71240234375,
        257.177978515625
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.9982681274414,
        267.66748046875,
        530.7120971679688,
        283.1895751953125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.9982681274414,
        293.6790466308594,
        530.7133178710938,
        309.2011413574219
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.9982681274414,
        319.57073974609375,
        530.7120971679688,
        335.09283447265625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고 시험조정자를 선정할 수 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.9982681274414,
        345.5823059082031,
        281.701416015625,
        361.1044006347656
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        371.5939025878906,
        530.7114868164062,
        387.1159973144531
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성할 수 있음",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.2381362915039,
        397.485595703125,
        165.7498779296875,
        413.0076904296875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.07904052734375,
        503.1273193359375,
        93.19419860839844
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        430.6893005371094,
        86.09606170654297,
        446.2113952636719
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 시험책임자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        456.7008972167969,
        142.00274658203125,
        472.2229919433594
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        486.9078674316406,
        400.10284423828125,
        502.4299621582031
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        486.9078674316406,
        400.10284423828125,
        502.4299621582031
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        486.9078674316406,
        400.10284423828125,
        502.4299621582031
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        486.9078674316406,
        400.10284423828125,
        502.4299621582031
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        486.9078674316406,
        400.10284423828125,
        502.4299621582031
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.7305908203125,
        496.65081787109375,
        518.265625
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        502.7305908203125,
        496.65081787109375,
        518.265625
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.7305908203125,
        496.65081787109375,
        518.265625
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.7305908203125,
        496.65081787109375,
        518.265625
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.7305908203125,
        496.65081787109375,
        518.265625
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 시험담당자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        532.9375610351562,
        142.00274658203125,
        548.4596557617188
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.14453125,
        402.9812927246094,
        578.6666259765625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.14453125,
        402.9812927246094,
        578.6666259765625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.14453125,
        402.9812927246094,
        578.6666259765625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.14453125,
        402.9812927246094,
        578.6666259765625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.14453125,
        402.9812927246094,
        578.6666259765625
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        578.96728515625,
        499.5292663574219,
        594.5023193359375
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        578.96728515625,
        499.5292663574219,
        594.5023193359375
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        578.96728515625,
        499.5292663574219,
        594.5023193359375
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        578.96728515625,
        499.5292663574219,
        594.5023193359375
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        578.96728515625,
        499.5292663574219,
        594.5023193359375
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.6701049804688,
        499.5292663574219,
        610.2051391601562
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        594.6701049804688,
        499.5292663574219,
        610.2051391601562
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.6701049804688,
        499.5292663574219,
        610.2051391601562
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.6701049804688,
        499.5292663574219,
        610.2051391601562
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△-△△△-△△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.6701049804688,
        499.5292663574219,
        610.2051391601562
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.4927978515625,
        499.5292663574219,
        626.02783203125
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        610.4927978515625,
        499.5292663574219,
        626.02783203125
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.4927978515625,
        499.5292663574219,
        626.02783203125
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.4927978515625,
        499.5292663574219,
        626.02783203125
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□-□□□-□□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.4927978515625,
        499.5292663574219,
        626.02783203125
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 공동연구자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        640.6998291015625,
        142.00189208984375,
        656.221923828125
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        670.9067993164062,
        405.73980712890625,
        686.4288940429688
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        670.9067993164062,
        405.73980712890625,
        686.4288940429688
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        670.9067993164062,
        405.73980712890625,
        686.4288940429688
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        670.9067993164062,
        405.73980712890625,
        686.4288940429688
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        670.9067993164062,
        405.73980712890625,
        686.4288940429688
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.7294921875,
        502.28778076171875,
        702.2645263671875
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        686.7294921875,
        502.28778076171875,
        702.2645263671875
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.7294921875,
        502.28778076171875,
        702.2645263671875
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.7294921875,
        502.28778076171875,
        702.2645263671875
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.7294921875,
        502.28778076171875,
        702.2645263671875
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 40 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.15045166015625,
        414.25518798828125,
        353.67254638671875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.15045166015625,
        414.25518798828125,
        353.67254638671875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.15045166015625,
        414.25518798828125,
        353.67254638671875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.15045166015625,
        414.25518798828125,
        353.67254638671875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.15045166015625,
        414.25518798828125,
        353.67254638671875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.7301330566406,
        510.80316162109375,
        372.2651672363281
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        356.7301330566406,
        510.80316162109375,
        372.2651672363281
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.7301330566406,
        510.80316162109375,
        372.2651672363281
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.7301330566406,
        510.80316162109375,
        372.2651672363281
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.7301330566406,
        510.80316162109375,
        372.2651672363281
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        137.84934997558594,
        530.71142578125,
        153.38436889648438
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.15872192382812,
        163.74105834960938,
        438.2165832519531,
        179.26312255859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        189.7526397705078,
        530.71240234375,
        205.2747039794922
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께 관리함. 임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.83943939208984,
        215.7642059326172,
        530.71240234375,
        231.28627014160156
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직명 등 인적사항을 기재함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.83943939208984,
        241.65591430664062,
        235.406494140625,
        257.177978515625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        504.5662536621094,
        92.27911376953125
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        274.859619140625,
        86.09606170654297,
        290.3817138671875
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 의료기기 관리자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        300.8711853027344,
        173.4254150390625,
        316.3932800292969
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 41 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        140.96595764160156,
        527.7124633789062,
        156.48802185058594
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조업자 또는 수입업자가 해당됨. 의뢰자는 임상시험모니터 요원을 지정하여야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        166.85765075683594,
        527.8080444335938,
        182.3797149658203
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        192.86923217773438,
        527.713134765625,
        208.39129638671875
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        218.88079833984375,
        455.8470153808594,
        234.40286254882812
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 임상시험 의뢰자의 성명 및 주소",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        328.62188720703125,
        92.27911376953125
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        254.8415069580078,
        86.09606170654297,
        270.36358642578125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 의뢰자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        280.8530578613281,
        116.81611633300781,
        296.3751525878906
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.49847412109375,
        400.10284423828125,
        328.02056884765625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.49847412109375,
        400.10284423828125,
        328.02056884765625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.49847412109375,
        400.10284423828125,
        328.02056884765625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.49847412109375,
        400.10284423828125,
        328.02056884765625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(주) ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        331.07818603515625,
        496.65081787109375,
        346.61322021484375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        331.07818603515625,
        496.65081787109375,
        346.61322021484375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        331.07818603515625,
        496.65081787109375,
        346.61322021484375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        331.07818603515625,
        496.65081787109375,
        346.61322021484375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 모니터요원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        362.7236022949219,
        142.00189208984375,
        378.2456970214844
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.3690185546875,
        394.4659118652344,
        409.89111328125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.3690185546875,
        394.4659118652344,
        409.89111328125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.3690185546875,
        394.4659118652344,
        409.89111328125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.3690185546875,
        394.4659118652344,
        409.89111328125
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(주) ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        412.9486999511719,
        491.0138854980469,
        428.4837341308594
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        412.9486999511719,
        491.0138854980469,
        428.4837341308594
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        412.9486999511719,
        491.0138854980469,
        428.4837341308594
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        412.9486999511719,
        491.0138854980469,
        428.4837341308594
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 임상시험 수탁업체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        444.5941162109375,
        186.01889038085938,
        460.1162109375
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.2395324707031,
        394.4659118652344,
        491.7616271972656
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.2395324707031,
        394.4659118652344,
        491.7616271972656
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.2395324707031,
        394.4659118652344,
        491.7616271972656
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.2395324707031,
        394.4659118652344,
        491.7616271972656
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(주) ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        494.8192138671875,
        491.0138854980469,
        510.354248046875
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        494.8192138671875,
        491.0138854980469,
        510.354248046875
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        494.8192138671875,
        491.0138854980469,
        510.354248046875
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        494.8192138671875,
        491.0138854980469,
        510.354248046875
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        552.4761962890625,
        538.1478271484375,
        568.01123046875
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기재함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.35807037353516,
        578.367919921875,
        162.3660888671875,
        593.8900146484375
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 42 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        150.9150848388672,
        530.5908813476562,
        166.43714904785156
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술 하는 것을 말함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        176.92665100097656,
        198.22665405273438,
        192.44871520996094
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        202.818359375,
        530.5665283203125,
        218.34042358398438
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.27865600585938,
        228.82992553710938,
        530.5921630859375,
        244.35198974609375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.27865600585938,
        254.8415069580078,
        530.4716186523438,
        270.36358642578125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함께 기재함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.27865600585938,
        280.7331848144531,
        148.8134307861328,
        296.2552795410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 임상시험의 목적 및 배경",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.07904052734375,
        271.29296875,
        93.19419860839844
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        313.9368896484375,
        537.6683349609375,
        329.458984375
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 검증",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        339.948486328125,
        104.22322845458984,
        355.4705810546875
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        365.9600524902344,
        538.1477661132812,
        381.4821472167969
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.07930755615234,
        391.85174560546875,
        538.2420043945312,
        407.37384033203125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.07930755615234,
        417.86334228515625,
        538.1233520507812,
        433.38543701171875
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.07930755615234,
        443.8749084472656,
        538.1474609375,
        459.3970031738281
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템 정확도 평가를 통해 검증하는 것이 목적이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.07930755615234,
        469.7666015625,
        380.40789794921875,
        485.2886962890625
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 배경",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        521.7897338867188,
        104.22322845458984,
        537.3118286132812
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        547.6814575195312,
        538.1483764648438,
        563.2035522460938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다. 한 외국",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        573.6930541992188,
        538.1488037109375,
        589.2151489257812
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        599.70458984375,
        538.1478271484375,
        615.2266845703125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "했다는 보고도 있다. PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        625.5963134765625,
        538.1478271484375,
        641.118408203125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        651.60791015625,
        538.1483764648438,
        667.1300048828125
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필수검사이다. 국제정상화비율(international normalized ratio, INR)의 도입으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        677.6194458007812,
        538.1478271484375,
        693.1415405273438
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        703.5111694335938,
        538.1474609375,
        719.0332641601562
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        729.522705078125,
        538.147216796875,
        745.0447998046875
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 43 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다. 이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        538.1477661132812,
        84.3268814086914
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        94.81637573242188,
        538.1472778320312,
        110.33845520019531
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        120.70807647705078,
        538.1483764648438,
        136.2301483154297
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        146.71966552734375,
        443.373779296875,
        162.24172973632812
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최초로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국산화된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PT측정기로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기존",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1480712890625,
        188.2532958984375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        198.62294006347656,
        538.1483764648438,
        214.14500427246094
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.63450622558594,
        504.66058349609375,
        240.1565704345703
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        250.6460723876953,
        538.1478271484375,
        266.16815185546875
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        276.53778076171875,
        538.122802734375,
        292.05987548828125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        302.5493469238281,
        538.2510375976562,
        318.0714416503906
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        328.5609130859375,
        538.1477661132812,
        344.0830078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        354.45263671875,
        491.70758056640625,
        369.9747314453125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 44 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        60.20737075805664,
        610.2530517578125,
        149.6788787841797,
        622.1820678710938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명 칭",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        60.20737075805664,
        610.2530517578125,
        149.6788787841797,
        622.1820678710938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배합",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.02081298828125,
        601.262939453125,
        203.169921875,
        613.19189453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목적",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        183.02081298828125,
        619.2432861328125,
        203.169921875,
        631.1722412109375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성분명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        289.283203125,
        610.2530517578125,
        529.3931274414062,
        622.1820678710938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분량",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        289.283203125,
        610.2530517578125,
        529.3931274414062,
        622.1820678710938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        289.283203125,
        610.2530517578125,
        529.3931274414062,
        622.1820678710938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        289.283203125,
        610.2530517578125,
        529.3931274414062,
        622.1820678710938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        78.19761657714844,
        694.880615234375,
        134.08773803710938,
        706.8095703125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스트립",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        694.880615234375,
        134.08773803710938,
        706.8095703125
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        646.6932373046875,
        352.3157958984375,
        658.6222534179688
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "친수성필름-상판(pore size: xx)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        646.6932373046875,
        352.3157958984375,
        658.6222534179688
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "00±00 X 00±00",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.74822998046875,
        637.703125,
        458.6715087890625,
        649.6420288085938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "mm/device",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.74822998046875,
        655.6834716796875,
        441.5615234375,
        667.6124267578125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격 1 strip",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        461.5098876953125,
        683.1334228515625,
        535.236572265625,
        697.8193969726562
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "x 50개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        504.0867919921875,
        703.8707275390625,
        533.4708862304688,
        715.7997436523438
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        683.1334228515625,
        297.67864990234375,
        695.0624389648438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양면접착필름-중판",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        172.94627380371094,
        683.1334228515625,
        297.67864990234375,
        695.0624389648438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "00±00 X 00±00",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.74822998046875,
        674.143310546875,
        458.6715087890625,
        686.0822143554688
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "mm/device",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.74822998046875,
        692.1236572265625,
        441.5615234375,
        704.0526123046875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        719.5736083984375,
        276.57012939453125,
        731.5026245117188
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PET필름-하판",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        172.94627380371094,
        719.5736083984375,
        276.57012939453125,
        731.5026245117188
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "00±00 X 00±00",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.74822998046875,
        710.58349609375,
        458.6715087890625,
        722.5223999023438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "mm/device",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.74822998046875,
        728.5638427734375,
        441.5615234375,
        740.4927978515625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응부 주성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        138.88473510742188,
        749.5408935546875,
        500.4891357421875,
        761.4797973632812
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Thromboplastin",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        138.88473510742188,
        749.5408935546875,
        500.4891357421875,
        761.4797973632812
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OO±OO ㎍/㎖ 자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        138.88473510742188,
        749.5408935546875,
        500.4891357421875,
        761.4797973632812
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        523.8876342773438,
        92.27911376953125
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7.1. 임상시험용 의료기기 사용 목적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        141.0858154296875,
        264.6962585449219,
        156.60787963867188
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        174.04978942871094,
        533.35009765625,
        189.5718536376953
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상 질환 또는 적응증을 포함하도록 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.39859771728516,
        200.06137084960938,
        312.5246887207031,
        215.58343505859375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        233.1452178955078,
        538.1464233398438,
        248.6672821044922
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        259.0368957519531,
        538.1480712890625,
        274.5589904785156
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도움을 주는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        285.0484619140625,
        246.34555053710938,
        300.570556640625
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7.2. 임상시험용 의료기기 정보",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        327.00262451171875,
        233.15335083007812,
        342.52471923828125
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        357.2096252441406,
        527.5681762695312,
        372.7317199707031
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        383.22119140625,
        522.0511474609375,
        398.7432861328125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.2.1. 임상시험용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        413.42816162109375,
        217.4412841796875,
        428.95025634765625
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        439.31988525390625,
        86.09606170654297,
        454.84197998046875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 코드명/품목명:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        465.3314514160156,
        166.08407592773438,
        480.8535461425781
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        491.343017578125,
        402.0065612792969,
        506.8651123046875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        517.2347412109375,
        448.1810302734375,
        532.7568359375
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 제조회사: ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        62.84593963623047,
        543.2462768554688,
        177.62371826171875,
        558.7813110351562
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 원자재:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        569.2578735351562,
        120.62870788574219,
        584.7799682617188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        73.23995971679688,
        500.4891357421875,
        85.17890930175781
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "coagulation",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        73.23995971679688,
        500.4891357421875,
        85.17890930175781
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "factor VIIa",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        73.23995971679688,
        500.4891357421875,
        85.17890930175781
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OO±OO ㎍/㎖ 자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        73.23995971679688,
        500.4891357421875,
        85.17890930175781
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        89.90174865722656,
        500.4891357421875,
        101.8406982421875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "VII",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        89.90174865722656,
        500.4891357421875,
        101.8406982421875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "deficient plasma",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        89.90174865722656,
        500.4891357421875,
        101.8406982421875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OO±OO ㎍/㎖ 자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        89.90174865722656,
        500.4891357421875,
        101.8406982421875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        108.36157989501953,
        500.4891357421875,
        120.30052947998047
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Thrombin",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        108.36157989501953,
        500.4891357421875,
        120.30052947998047
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OO±OO ㎍/㎖ 자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        108.36157989501953,
        500.4891357421875,
        120.30052947998047
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        126.82139587402344,
        500.4891357421875,
        138.76034545898438
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "heparin",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        126.82139587402344,
        500.4891357421875,
        138.76034545898438
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OO±OO ㎍/㎖ 자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        126.82139587402344,
        500.4891357421875,
        138.76034545898438
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보조성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        145.28123474121094,
        211.92552185058594,
        157.21023559570312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(안정제)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        163.26158142089844,
        208.5137176513672,
        175.19058227539062
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "gentamicin",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        220.44052124023438,
        154.2714080810547,
        500.4891357421875,
        166.20040893554688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        220.44052124023438,
        154.2714080810547,
        500.4891357421875,
        166.20040893554688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        220.44052124023438,
        154.2714080810547,
        500.4891357421875,
        166.20040893554688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        181.72140502929688,
        211.92552185058594,
        193.65040588378906
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(보존제)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        199.70175170898438,
        208.5137176513672,
        211.63075256347656
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5-chloro-2-methyl-4-isothiazol",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        220.44052124023438,
        190.71157836914062,
        500.4891357421875,
        202.6405792236328
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-3-one 적량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        220.44052124023438,
        190.71157836914062,
        500.4891357421875,
        202.6405792236328
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        220.44052124023438,
        190.71157836914062,
        500.4891357421875,
        202.6405792236328
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        172.94627380371094,
        218.1615753173828,
        211.92552185058594,
        230.090576171875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(보존제)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        172.94627380371094,
        236.14193725585938,
        208.5137176513672,
        248.07093811035156
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2-methyl-4-isothiazol-3-one",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        220.44052124023438,
        227.15176391601562,
        500.4891357421875,
        239.0807647705078
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        220.44052124023438,
        227.15176391601562,
        500.4891357421875,
        239.0807647705078
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자사규격",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        220.44052124023438,
        227.15176391601562,
        500.4891357421875,
        239.0807647705078
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        277.2569885253906,
        454.55303955078125,
        292.7790832519531
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 구조: 혈액응고 시간 측정기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        485.82904052734375,
        240.46908569335938,
        501.35113525390625
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 46 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구조",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        85.0339126586914,
        265.38995361328125,
        410.4176025390625,
        277.3189697265625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        85.0339126586914,
        265.38995361328125,
        410.4176025390625,
        277.3189697265625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세부구성",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        85.0339126586914,
        265.38995361328125,
        410.4176025390625,
        277.3189697265625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외관상 특징",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        85.0339126586914,
        265.38995361328125,
        410.4176025390625,
        277.3189697265625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        139.36447143554688,
        284.6888732910156,
        159.03378295898438,
        296.6178894042969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주입부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        139.36447143554688,
        302.6692199707031,
        168.62860107421875,
        314.5982360839844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필름",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        181.70152282714844,
        284.6888732910156,
        201.2509307861328,
        296.6178894042969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(상판)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        181.70152282714844,
        302.6692199707031,
        207.55422973632812,
        314.5982360839844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        234.71279907226562,
        284.6888732910156,
        530.9522094726562,
        296.6178894042969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하면 모세관 현상을 통하여 반응부로이동.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        234.71279907226562,
        302.6692199707031,
        421.0419006347656,
        314.5982360839844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        139.36447143554688,
        351.5757751464844,
        168.62901306152344,
        363.5047912597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필름 및",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        181.70152282714844,
        342.5856018066406,
        215.7630615234375,
        354.5146179199219
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시약층",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        181.70152282714844,
        360.5659484863281,
        210.96566772460938,
        372.4949645996094
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액응고",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시간",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결정을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응챔버와",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유용성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        324.6052551269531,
        530.8327026367188,
        336.5342712402344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(quality control) 확인을 위한 반응챔버를 포함.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        234.71279907226562,
        342.5856018066406,
        444.7890319824219,
        354.5146179199219
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        360.5659484863281,
        530.9522094726562,
        372.4949645996094
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응 발생",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        378.5462951660156,
        268.89422607421875,
        390.4753112792969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전극부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        139.36447143554688,
        408.0340881347656,
        168.62860107421875,
        419.9631042480469
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필름",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        181.70152282714844,
        399.0439147949219,
        201.2509307861328,
        410.9729309082031
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(하판)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        181.70152282714844,
        417.0242614746094,
        207.55422973632812,
        428.9532775878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        234.71279907226562,
        399.0439147949219,
        530.9521484375,
        410.9729309082031
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인식",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        234.71279907226562,
        417.0242614746094,
        254.38209533691406,
        428.9532775878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "#",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        70.88158416748047,
        70.72270965576172,
        404.06103515625,
        82.6517105102539
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        70.88158416748047,
        70.72270965576172,
        404.06103515625,
        82.6517105102539
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역할 및 기능",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        70.88158416748047,
        70.72270965576172,
        404.06103515625,
        82.6517105102539
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "①",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        68.84268951416016,
        83.42882537841797,
        423.97021484375,
        95.3677749633789
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화면(LCD 디스플레이)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        68.84268951416016,
        83.42882537841797,
        423.97021484375,
        95.3677749633789
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정된 수치와 기타 기기의 설정값 등을 표시",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.84268951416016,
        83.42882537841797,
        423.97021484375,
        95.3677749633789
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "②",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        68.84268951416016,
        109.0807876586914,
        78.79729461669922,
        121.01973724365234
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전원버튼",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        96.1878662109375,
        96.25480651855469,
        384.87139892578125,
        108.18380737304688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 전원 on/off 및 설정 값 저장",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.1878662109375,
        96.25480651855469,
        384.87139892578125,
        108.18380737304688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "메모리 버튼",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        96.1878662109375,
        109.0807876586914,
        361.124267578125,
        121.0097885131836
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메모리 모드 및 셋팅 모드 전환",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.1878662109375,
        109.0807876586914,
        361.124267578125,
        121.0097885131836
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "∧/ ˅ 버튼",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        96.1878662109375,
        121.90676879882812,
        511.04296875,
        133.84571838378906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.1878662109375,
        121.90676879882812,
        511.04296875,
        133.84571838378906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        68.84268951416016,
        134.73275756835938,
        462.709228515625,
        146.6717071533203
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정검사지 삽입구",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.84268951416016,
        134.73275756835938,
        462.709228515625,
        146.6717071533203
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.84268951416016,
        134.73275756835938,
        462.709228515625,
        146.6717071533203
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        68.84268951416016,
        147.55874633789062,
        448.19708251953125,
        159.49769592285156
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배터리 커버",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        68.84268951416016,
        147.55874633789062,
        448.19708251953125,
        159.49769592285156
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배터리부 덮개로 본체에 배터리 교환 시 열고 닫음",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.84268951416016,
        147.55874633789062,
        448.19708251953125,
        159.49769592285156
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        68.84268951416016,
        160.26486206054688,
        307.8731689453125,
        172.2038116455078
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "코드스트립 삽입구",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.84268951416016,
        160.26486206054688,
        307.8731689453125,
        172.2038116455078
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "코드 스트립 삽입구",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.84268951416016,
        160.26486206054688,
        307.8731689453125,
        172.2038116455078
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액응고 시간 측정검사지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        184.23866271972656,
        214.32266235351562,
        199.76072692871094
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        210.25022888183594,
        538.1483764648438,
        225.7722930908203
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.87995910644531,
        236.14193725585938,
        537.1629638671875,
        251.66400146484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 치수/중량: 크기:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        457.53997802734375,
        175.43899536132812,
        473.06207275390625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        483.4316711425781,
        416.87811279296875,
        498.9667053222656
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        509.4432373046875,
        349.35369873046875,
        524.978271484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) 성능: 혈액응고 시간 측정기 측정 사양",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        535.454833984375,
        303.43524169921875,
        550.9769287109375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        62.48613357543945,
        564.702880859375,
        288.68359375,
        576.6318359375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능항목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        62.48613357543945,
        564.702880859375,
        288.68359375,
        576.6318359375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        62.48613357543945,
        564.702880859375,
        288.68359375,
        576.6318359375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        80.47638702392578,
        580.285888671875,
        204.9689178466797,
        592.2247924804688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요검체량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.47638702392578,
        580.285888671875,
        204.9689178466797,
        592.2247924804688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15㎕",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        80.47638702392578,
        580.285888671875,
        204.9689178466797,
        592.2247924804688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        80.47638702392578,
        595.8687744140625,
        341.0153503417969,
        607.8077392578125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정결과범위",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.47638702392578,
        595.8687744140625,
        341.0153503417969,
        607.8077392578125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PT : 9.6 - 96 sec / INR : 0.8–7.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        80.47638702392578,
        595.8687744140625,
        341.0153503417969,
        607.8077392578125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        80.47638702392578,
        611.5716552734375,
        233.99314880371094,
        623.5006103515625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정시간",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.47638702392578,
        611.5716552734375,
        233.99314880371094,
        623.5006103515625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "60 초 이내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.47638702392578,
        611.5716552734375,
        233.99314880371094,
        623.5006103515625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        80.47638702392578,
        627.1546630859375,
        238.79055786132812,
        639.0836181640625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효기간",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.47638702392578,
        627.1546630859375,
        238.79055786132812,
        639.0836181640625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24개월 이내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.47638702392578,
        627.1546630859375,
        238.79055786132812,
        639.0836181640625
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8) 보관조건:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        652.5668334960938,
        133.2218780517578,
        668.0889282226562
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간 측정기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        678.4585571289062,
        189.13690185546875,
        693.9806518554688
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "온도",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        207.12774658203125,
        706.2681884765625,
        380.433837890625,
        718.1971435546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "습도",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        207.12774658203125,
        706.2681884765625,
        380.433837890625,
        718.1971435546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작동 환경",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        720.0531005859375,
        356.9133605957031,
        731.9920043945312
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10~40 ℃",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        61.64658737182617,
        720.0531005859375,
        356.9133605957031,
        731.9920043945312
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15~80 % RH",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        720.0531005859375,
        356.9133605957031,
        731.9920043945312
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관/운반 환경",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        734.5572509765625,
        356.9133605957031,
        746.4961547851562
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-10℃~60 ℃",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        61.64658737182617,
        734.5572509765625,
        356.9133605957031,
        746.4961547851562
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15~80 % RH",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        734.5572509765625,
        356.9133605957031,
        746.4961547851562
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 47 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간 측정검사지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        68.80480194091797,
        214.32266235351562,
        84.3268814086914
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "온도",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        207.12774658203125,
        96.61441802978516,
        380.433837890625,
        108.54341888427734
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "습도",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        207.12774658203125,
        96.61441802978516,
        380.433837890625,
        108.54341888427734
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작동 환경",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        109.44039916992188,
        356.9133605957031,
        121.37934875488281
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10~35 ℃",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        61.64658737182617,
        109.44039916992188,
        356.9133605957031,
        121.37934875488281
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20~80 % RH",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        109.44039916992188,
        356.9133605957031,
        121.37934875488281
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관/운반 환경",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        122.26638793945312,
        356.9133605957031,
        134.20533752441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10℃~40 ℃",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        61.64658737182617,
        122.26638793945312,
        356.9133605957031,
        134.20533752441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20~80 % RH",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        122.26638793945312,
        356.9133605957031,
        134.20533752441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7.3. 임상시험용 의료기기 사용방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        172.13189697265625,
        258.339111328125,
        187.65396118164062
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        198.14346313476562,
        86.09606170654297,
        213.66552734375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[1] 전원 버튼을 눌러 측정기를 켭니다. 검사지의 측정기 접촉부를(전극부) 검사지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        224.03517150878906,
        538.1477661132812,
        239.55723571777344
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "삽입부에 삽입합니다. (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.07443237304688,
        250.04673767089844,
        538.1474609375,
        265.5688171386719
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자동으로 켜지게 됩니다.) 검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        84.07443237304688,
        276.05828857421875,
        538.1483764648438,
        291.58038330078125
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정기가 자동으로 켜지게 됩니다. 이때 검사지가 구부러지지 않도록 주의하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.07443237304688,
        301.95001220703125,
        538.1497802734375,
        317.47210693359375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주십시오. 코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.07443237304688,
        327.9615783691406,
        538.1477661132812,
        343.4836730957031
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표시가 나타나며 측정온도로 세팅합니다. 측정기와 검사지 코드번호가 일치하",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.07443237304688,
        353.97314453125,
        538.1477661132812,
        369.4952392578125
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.07443237304688,
        379.8648681640625,
        538.1480712890625,
        395.386962890625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 코드번호를 입력합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.07443237304688,
        405.8764343261719,
        250.87811279296875,
        421.3985290527344
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        431.88800048828125,
        538.1483764648438,
        447.41009521484375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈기를 사용하여 혈액을 채취합니다. 검사지 중간 부분의 혈액 투입부에 혈액",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        83.95449829101562,
        457.7796936035156,
        538.1480712890625,
        473.3017883300781
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방울을 떨어뜨립니다. (혈액 투입 대기시간은 120초 입니다.) 만약 측정기가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        83.95449829101562,
        483.7912902832031,
        538.1474609375,
        499.3133850097656
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        83.95449829101562,
        509.8028564453125,
        538.1483764648438,
        525.324951171875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        83.95449829101562,
        535.694580078125,
        538.1480712890625,
        551.2166748046875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        83.95449829101562,
        561.7061157226562,
        137.53953552246094,
        577.2282104492188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        587.7177124023438,
        538.1480712890625,
        603.2398071289062
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과가 화면에 나타납니다. 측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        83.95449829101562,
        613.6094360351562,
        538.14794921875,
        629.1315307617188
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        83.95449829101562,
        639.6209716796875,
        538.1483154296875,
        655.14306640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        83.95449829101562,
        665.632568359375,
        136.10032653808594,
        681.1546630859375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[4] 측정기 결과를 확인합니다. 측정 수치와(PT, INR), 검사 날짜 및 시간이 함께",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        691.5242309570312,
        538.1483764648438,
        707.0463256835938
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타납니다. 측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.5541763305664,
        717.5358276367188,
        538.1483764648438,
        733.0579223632812
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시되고 꺼집니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.5541763305664,
        743.5474243164062,
        182.15536499023438,
        759.0695190429688
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 48 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 7.4. 임상시험용 의료기기의 공급 및 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        68.80480194091797,
        338.4562683105469,
        84.3268814086914
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        89.54214477539062,
        538.1474609375,
        105.06422424316406
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 상태로 공급 소모품인 검사지는 별도 구매. 낱개포장 된 검사지가 1박스 당",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        115.55371856689453,
        538.1483764648438,
        131.07579040527344
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "48개가 동봉. 임상시험 종료 후 남은 제품은 폐기한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        141.56529235839844,
        403.195556640625,
        157.0873565673828
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 49 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 피험자의 선정기준/제외기준 · 인원 및 근거",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        153.79193115234375,
        334.0189514160156,
        169.3269500732422
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.6836395263672,
        530.5923461914062,
        195.20570373535156
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.55905151367188,
        205.69520568847656,
        530.5924682617188,
        221.21726989746094
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "격한 피험자의 선정기준과 제외기준을 제시하여야 함. 이때 임상시험 참여와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        231.706787109375,
        530.5933837890625,
        247.22885131835938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.55905151367188,
        257.5984802246094,
        530.4725341796875,
        273.1205749511719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        283.61004638671875,
        530.5924682617188,
        299.13214111328125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. 또한,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        309.6216125488281,
        530.5665283203125,
        325.1437072753906
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        335.5133361816406,
        530.5924682617188,
        351.0354309082031
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        361.52490234375,
        530.5665283203125,
        377.0469970703125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        387.5364685058594,
        530.5924682617188,
        403.0585632324219
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        413.42816162109375,
        475.2764892578125,
        428.95025634765625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 피험자 수: 시험대상수 산출시 일반적인 고려사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        439.43975830078125,
        362.44268798828125,
        454.96185302734375
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        465.4513244628906,
        530.5921630859375,
        480.9734191894531
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.79891967773438,
        491.343017578125,
        530.5924072265625,
        506.8651123046875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        517.3546142578125,
        530.5665283203125,
        532.876708984375
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.79891967773438,
        543.3661499023438,
        530.59130859375,
        558.8882446289062
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.79891967773438,
        569.2578735351562,
        530.5918579101562,
        584.7799682617188
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        595.2694702148438,
        428.38189697265625,
        610.7915649414062
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 피험자의 선정기준·제외기준·인원 및 그 근거",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.07904052734375,
        439.20196533203125,
        93.19419860839844
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 성별, 나이, 교육정도(동의능력). 흡연여부, 알코올 혹은 약 남용자, 사회 경제적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        634.3467407226562,
        538.1477661132812,
        649.8688354492188
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.9626235961914,
        660.2384643554688,
        503.3412780761719,
        675.7605590820312
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        686.25,
        86.09606170654297,
        701.7720947265625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8.1. 피험자 선정기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        712.2615966796875,
        176.54342651367188,
        727.78369140625
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        738.1533203125,
        368.1745300292969,
        753.6754150390625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 50 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 수 비율a %",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        146.32069396972656,
        720.8922119140625,
        421.091796875,
        732.8211669921875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        146.32069396972656,
        720.8922119140625,
        421.091796875,
        732.8211669921875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-15",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        736.594970703125,
        423.2506103515625,
        748.5239868164062
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        174.2655487060547,
        736.594970703125,
        423.2506103515625,
        748.5239868164062
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15-40",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        752.05810546875,
        418.6127014160156,
        763.9871215820312
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0-2.8",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        752.05810546875,
        418.6127014160156,
        763.9871215820312
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        68.80480194091797,
        431.4058837890625,
        84.3268814086914
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 경구용 항응고제를 복용한 적이 없는 정상인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        94.81637573242188,
        337.0167541503906,
        110.33845520019531
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8.2. 피험자 제외기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        146.71966552734375,
        176.54342651367188,
        162.24172973632812
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 피험자의 임상정보를 알 수 없는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        172.73123168945312,
        299.2378234863281,
        188.2532958984375
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        198.62294006347656,
        538.1477661132812,
        214.14500427246094
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "35% 이하 또는 50% 이상인 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        78.79729461669922,
        224.63450622558594,
        264.57659912109375,
        240.1565704345703
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        250.6460723876953,
        537.5487060546875,
        266.16815185546875
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8.3. 목표대상자 수 및 그 근거",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        302.5493469238281,
        233.15362548828125,
        318.0714416503906
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        335.6331787109375,
        529.3925170898438,
        351.1552734375
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.27865600585938,
        361.52490234375,
        122.18785858154297,
        377.0469970703125
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 연구가설",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        387.5364685058594,
        142.48190307617188,
        403.0585632324219
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 유의수준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        413.54803466796875,
        142.48190307617188,
        429.07012939453125
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 통계적 검정 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        439.43975830078125,
        192.85519409179688,
        454.96185302734375
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        70.76165008544922,
        465.4513244628906,
        380.4165344238281,
        480.9734191894531
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        491.462890625,
        529.3930053710938,
        506.9849853515625
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.11007690429688,
        517.3546142578125,
        525.0494995117188,
        532.876708984375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        550.4384155273438,
        437.0172424316406,
        565.9605102539062
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        576.4500122070312,
        481.77886962890625,
        591.9850463867188
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        602.3417358398438,
        506.70758056640625,
        617.8767700195312
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        628.353271484375,
        538.147216796875,
        643.8883056640625
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야 한다(표 1). 6.0을 넘는 INR 값은 제외하는 것이 좋다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.99664306640625,
        654.3648681640625,
        448.1711730957031,
        669.886962890625
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 시스템 정확도 확인용 검체의 INR 값",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        178.22340393066406,
        696.3190307617188,
        416.6541748046875,
        711.8411254882812
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 51 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15-40",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        74.91812896728516,
        418.6127014160156,
        86.84712982177734
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9-3.7",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        74.91812896728516,
        418.6127014160156,
        86.84712982177734
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10-30",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        90.5010986328125,
        418.6127014160156,
        102.43009948730469
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.8-4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        174.2655487060547,
        90.5010986328125,
        418.6127014160156,
        102.43009948730469
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-10b",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        173.90574645996094,
        106.20393371582031,
        418.6127014160156,
        118.1329345703125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.6-6.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        173.90574645996094,
        106.20393371582031,
        418.6127014160156,
        118.1329345703125
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.43424224853516,
        120.34848022460938,
        510.80267333984375,
        132.27748107910156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.43424224853516,
        138.32882690429688,
        511.4454040527344,
        150.25782775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.43424224853516,
        156.30917358398438,
        461.6998596191406,
        168.23817443847656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        202.09913635253906,
        538.1483764648438,
        217.62120056152344
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 추가위치로의 연구 확대가 필수적일 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.99664306640625,
        228.1107177734375,
        375.8503723144531,
        243.63278198242188
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 52 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        153.79193115234375,
        536.2291259765625,
        169.31399536132812
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.6836395263672,
        536.2276611328125,
        195.20570373535156
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        205.69520568847656,
        458.84539794921875,
        221.21726989746094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 임상시험기간",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.07904052734375,
        183.38002014160156,
        93.19419860839844
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        241.77578735351562,
        538.1466064453125,
        257.2978515625
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일로부터 6개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        79.6368408203125,
        267.66748046875,
        193.335205078125,
        283.1895751953125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        293.6790466308594,
        389.4289245605469,
        309.2011413574219
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 통계처리 기간 : 약 1 개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        319.69061279296875,
        238.31085205078125,
        335.21270751953125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 결과보고서 작성기간 : 약 1 개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.84593963623047,
        345.5823059082031,
        276.0903625488281,
        361.1044006347656
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 53 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.33654022216797,
        532.5227661132812,
        92.27911376953125
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        529.839599609375,
        120.11202239990234
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.16034698486328,
        126.70481872558594,
        300.7965087890625,
        137.73275756835938
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.1. 시험방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        141.0858154296875,
        138.76393127441406,
        156.60787963867188
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        171.2928009033203,
        533.3506469726562,
        186.8148651123047
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        61.64658737182617,
        197.18450927734375,
        533.3509521484375,
        212.70657348632812
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계별 조작 순서, 병용 요법 등을 기술함. 임상 시험을 위한 피험자 동의 및 준비,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        223.1960906982422,
        533.3250122070312,
        238.71815490722656
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        249.20765686035156,
        474.2223815917969,
        264.729736328125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        279.4146423339844,
        86.09606170654297,
        294.9367370605469
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10.1.1 시험기기 대조기기 정보",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        305.30633544921875,
        233.15335083007812,
        320.82843017578125
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        331.3179016113281,
        373.5802307128906,
        346.8399963378906
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        356.01092529296875,
        500.96820068359375,
        371.53302001953125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(허가 번호, 품목명, 모델명 기재)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        131.92849731445312,
        380.7039489746094,
        322.9676818847656,
        396.2260437011719
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.1.2. 시험방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        429.3707580566406,
        148.23876953125,
        444.8928527832031
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 피험자 동의 및 준비",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        455.38232421875,
        203.76925659179688,
        470.9044189453125
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        481.2740173339844,
        538.1480712890625,
        496.7961120605469
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        507.28558349609375,
        538.2423706054688,
        522.8076782226562
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. 또한 동의를 서명한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        533.2971801757812,
        538.1488647460938,
        548.8192749023438
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연월일을 기록한다. 또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        559.1889038085938,
        538.1488647460938,
        574.7109985351562
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 대한 사항을 확인할 수 있도록 해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        585.200439453125,
        378.00921630859375,
        600.7225341796875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 인구학적 조사, 병력조사 요법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        627.3943481445312,
        257.2602844238281,
        642.9164428710938
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        653.2860717773438,
        538.1224365234375,
        668.8081665039062
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        679.297607421875,
        431.1404113769531,
        694.8197021484375
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 인구학적 정보: 성명, 나이, 성별",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        705.3092041015625,
        274.0511779785156,
        720.84423828125
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        731.200927734375,
        447.23760986328125,
        746.7359619140625
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 54 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        68.80480194091797,
        390.508056640625,
        84.33982849121094
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 피험자 식별코드 부여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        120.70807647705078,
        210.12582397460938,
        136.2301483154297
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        146.71966552734375,
        538.1483154296875,
        162.2546844482422
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.63196563720703,
        172.73123168945312,
        486.9101867675781,
        188.2532958984375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        198.62294006347656,
        490.8680419921875,
        214.157958984375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 피험자 식별코드는 아래의 방법에 따라 기입한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        224.63450622558594,
        374.5310974121094,
        240.16952514648438
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        250.6460723876953,
        479.739990234375,
        266.16815185546875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) KFDA-12-34-56",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        276.53778076171875,
        184.55609130859375,
        292.05987548828125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 검체 채취 및 보관 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        328.5609130859375,
        222.59906005859375,
        344.0830078125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        354.45263671875,
        538.2423706054688,
        369.9876708984375
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.87183380126953,
        380.4642028808594,
        538.1480712890625,
        395.9862976074219
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.87183380126953,
        406.47576904296875,
        141.7372589111328,
        421.99786376953125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        432.36749267578125,
        525.5292358398438,
        447.90252685546875
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        458.3790588378906,
        538.1480712890625,
        473.9140930175781
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        484.390625,
        538.2423706054688,
        499.9127197265625
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "남은 혈장검체는 -70°C 이하로 냉동 보관한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        510.2823486328125,
        350.6640319824219,
        525.8173828125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        562.3054809570312,
        140.80340576171875,
        577.8275756835938
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        588.1972045898438,
        538.1224365234375,
        603.7192993164062
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 55 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 수 비율a %",
      "font_size": 9.951866149902344,
      "font_name": "T4",
      "bbox": [
        129.05006408691406,
        384.4198913574219,
        402.9815673828125,
        401.3833923339844
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "INR 값",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        129.05006408691406,
        384.4198913574219,
        402.9815673828125,
        401.3833923339844
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-15",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        405.037353515625,
        405.14044189453125,
        416.96636962890625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        156.15536499023438,
        405.037353515625,
        405.14044189453125,
        416.96636962890625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15-40",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        420.7402038574219,
        400.5025329589844,
        432.6692199707031
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0-2.8",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        420.7402038574219,
        400.5025329589844,
        432.6692199707031
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15-40",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        436.3231506347656,
        400.5025329589844,
        448.2521667480469
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.9-3.7",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        436.3231506347656,
        400.5025329589844,
        448.2521667480469
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-30",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        451.9061279296875,
        400.5025329589844,
        463.83514404296875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.8-4.5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        451.9061279296875,
        400.5025329589844,
        463.83514404296875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1-10b",
      "font_size": 6.354805946350098,
      "font_name": "T2",
      "bbox": [
        156.87498474121094,
        466.1705322265625,
        400.5025329589844,
        479.5379943847656
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.6-6.0",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        156.87498474121094,
        466.1705322265625,
        400.5025329589844,
        479.5379943847656
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a. 범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        66.4439926147461,
        481.8733825683594,
        488.325439453125,
        493.8023986816406
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        66.4439926147461,
        499.8537292480469,
        493.3351745605469,
        511.7827453613281
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        81.07605743408203,
        517.8341064453125,
        458.3416748046875,
        529.7630615234375
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10.2. 설계방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        138.76393127441406,
        84.3268814086914
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        99.01179504394531,
        529.392822265625,
        114.53387451171875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음. 피험자 배정과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        125.02336883544922,
        529.3925170898438,
        140.54544067382812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        150.9150848388672,
        529.3931274414062,
        166.43714904785156
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림(Blinding) 전략이 잘 포함되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        176.92665100097656,
        284.9396667480469,
        192.44871520996094
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10.2.1. 피험자군 또는 대조군 설정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        223.0762176513672,
        261.4580078125,
        238.59828186035156
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.9626235961914,
        249.08778381347656,
        533.5908203125,
        264.622802734375
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        275.0993347167969,
        533.2139892578125,
        290.6214294433594
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        300.9910583496094,
        538.1502075195312,
        316.5260925292969
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함해야 한다(표 1). 6.0을 넘는 INR 값은 제외하는 것이 좋다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.95287322998047,
        327.00262451171875,
        451.88916015625,
        342.52471923828125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 1. 시스템 정확도 확인용 검체의 INR 값",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        178.22340393066406,
        368.956787109375,
        416.6541748046875,
        384.4788818359375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        579.4467163085938,
        538.1483764648438,
        594.9688110351562
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우, 추가위치로의 연구 확대가 필수적일 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.95287322998047,
        605.4583129882812,
        380.16802978515625,
        620.9804077148438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 56 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        176.92665100097656,
        532.151611328125,
        192.44871520996094
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        202.818359375,
        532.151611328125,
        218.34042358398438
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        228.82992553710938,
        532.1517944335938,
        244.35198974609375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        254.8415069580078,
        532.1511840820312,
        270.36358642578125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        280.7331848144531,
        532.271240234375,
        296.2552795410156
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        306.7447509765625,
        508.25860595703125,
        322.266845703125
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 관찰항목, 임상검사항목 및 관찰검사방법",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.33654022216797,
        397.703857421875,
        92.27911376953125
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.1. 관찰항목",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        141.0858154296875,
        138.76449584960938,
        156.60787963867188
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.64496612548828,
        355.89105224609375,
        94.13170623779297,
        371.41314697265625
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스크리닝 및 검사일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        219.84085083007812,
        386.9371337890625,
        316.1488342285156,
        400.1596374511719
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        121.61408996582031,
        411.98974609375,
        281.4653625488281,
        425.2122497558594
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문1",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        121.61408996582031,
        411.98974609375,
        281.4653625488281,
        425.2122497558594
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경과일수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.21701049804688,
        431.2886657714844,
        280.50543212890625,
        444.51116943359375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Day0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        116.21701049804688,
        431.2886657714844,
        280.50543212890625,
        444.51116943359375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Visit",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        126.77129364013672,
        447.8305969238281,
        148.81614685058594,
        461.0531005859375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "window",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        117.89610290527344,
        469.7666015625,
        157.6593780517578,
        482.9891052246094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        266.1357727050781,
        458.7386474609375,
        269.799072265625,
        471.9611511230469
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관찰형태",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.21701049804688,
        486.30853271484375,
        278.8489685058594,
        499.5310363769531
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.21701049804688,
        486.30853271484375,
        278.8489685058594,
        499.5310363769531
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동의서 취득",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        108.30130004882812,
        505.487548828125,
        272.2788391113281,
        518.7100830078125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        108.30130004882812,
        505.487548828125,
        272.2788391113281,
        518.7100830078125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선정/제외기준 확인",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        88.99176788330078,
        524.7864990234375,
        272.2788391113281,
        538.009033203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        88.99176788330078,
        524.7864990234375,
        272.2788391113281,
        538.009033203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인구학적 정보",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        543.9655151367188,
        272.2788391113281,
        557.1880493164062
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        102.90422821044922,
        543.9655151367188,
        272.2788391113281,
        557.1880493164062
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과거병력 및 병용약물 조사",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        70.88158416748047,
        563.14453125,
        272.2788391113281,
        576.3670654296875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.88158416748047,
        563.14453125,
        272.2788391113281,
        576.3670654296875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 채취",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        113.57844543457031,
        582.3236083984375,
        272.2788391113281,
        595.546142578125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        113.57844543457031,
        582.3236083984375,
        272.2788391113281,
        595.546142578125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 검사 및 분석",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        92.23001098632812,
        601.5026245117188,
        272.2788391113281,
        614.7251586914062
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        92.23001098632812,
        601.5026245117188,
        272.2788391113281,
        614.7251586914062
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.2. 관찰검사방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        654.3648681640625,
        163.95025634765625,
        669.886962890625
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11.2.1 방문1 (스크리닝 및 검사일)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        680.37646484375,
        260.1217346191406,
        695.8985595703125
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험 설명 및 동의 및 스크리닝",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        706.2681274414062,
        298.15838623046875,
        721.7902221679688
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        732.2797241210938,
        538.1474609375,
        747.8018188476562
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 57 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        68.80480194091797,
        538.1480712890625,
        84.3268814086914
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법정대리인에게 상세히 설명한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        94.81637573242188,
        261.1925354003906,
        110.33845520019531
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        120.70807647705078,
        538.1477661132812,
        136.2301483154297
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다. 대상자에게",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        146.71966552734375,
        538.1481323242188,
        162.24172973632812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다. 스크리닝",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1483764648438,
        188.2532958984375
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호는 다음과 같이 구성된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        198.62294006347656,
        239.12448120117188,
        214.14500427246094
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 스크리닝",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        224.63450622558594,
        413.1751708984375,
        240.16952514648438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호: SXX(XX:일련번호), 예)S01,02,03…………",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        75.43911743164062,
        224.63450622558594,
        413.1751708984375,
        240.16952514648438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 선정/제외기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        250.6460723876953,
        167.42837524414062,
        266.16815185546875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        276.53778076171875,
        538.1488037109375,
        292.05987548828125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 제외기준을 검토하여 피험자 식별코드를 부여한다. 피험자 식별코드는 아래의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        302.5493469238281,
        538.1483764648438,
        318.0714416503906
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법에 따라 기입한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        328.5609130859375,
        184.55406188964844,
        344.0830078125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.03878784179688,
        354.45263671875,
        535.481689453125,
        369.9747314453125
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 인구학적 정보",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        380.4642028808594,
        165.98974609375,
        395.9862976074219
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        406.47576904296875,
        412.31060791015625,
        421.99786376953125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 과거병력 및 병용약물",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        432.36749267578125,
        247.785400390625,
        447.88958740234375
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        432.36749267578125,
        247.785400390625,
        447.88958740234375
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        458.3790588378906,
        538.1474609375,
        473.9011535644531
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        484.390625,
        446.8518981933594,
        499.9127197265625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 검체 채취 및 임상시험 시행",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        510.2823486328125,
        247.785400390625,
        525.804443359375
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        536.2938842773438,
        538.1483764648438,
        551.8159790039062
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        562.3054809570312,
        141.61732482910156,
        577.8275756835938
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        588.1972045898438,
        538.1224365234375,
        603.7192993164062
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        92.70975494384766,
        614.208740234375,
        538.1488037109375,
        629.7308349609375
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.70975494384766,
        640.2203369140625,
        144.9755096435547,
        655.742431640625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        666.112060546875,
        529.7269897460938,
        681.6341552734375
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        692.1235961914062,
        538.1470336914062,
        707.6456909179688
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        718.1351928710938,
        538.1224365234375,
        733.6572875976562
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "남은 혈장검체는 -70°C 이하로 냉동 보관한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        744.02685546875,
        351.2637023925781,
        759.5618896484375
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 58 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 1 (INR)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        288.44366455078125,
        78.8738021850586,
        473.4806213378906,
        92.0963134765625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 2 (INR)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        288.44366455078125,
        78.8738021850586,
        473.4806213378906,
        92.0963134765625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "...",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        288.44366455078125,
        78.8738021850586,
        473.4806213378906,
        92.0963134765625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        113.39608001708984,
        203.52999877929688,
        126.61859130859375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모세혈관혈액",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        113.39608001708984,
        203.52999877929688,
        126.61859130859375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Lot A-1st",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        220.32058715820312,
        92.65873718261719,
        271.4165954589844,
        147.35592651367188
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lot A-2nd",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        220.32058715820312,
        92.65873718261719,
        271.4165954589844,
        147.35592651367188
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lot B-1st",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        220.32058715820312,
        92.65873718261719,
        271.4165954589844,
        147.35592651367188
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Lot B-2nd",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        220.32058715820312,
        92.65873718261719,
        271.4165954589844,
        147.35592651367188
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        158.9462890625,
        118.25619506835938,
        172.16880798339844
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구연산처리",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        144.4017333984375,
        147.9183349609375,
        198.13302612304688,
        161.14085388183594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈장",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        160.4730224609375,
        169.8543701171875,
        182.18136596679688,
        183.07688903808594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1st",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        239.150390625,
        147.9183349609375,
        252.56005859375,
        161.14085388183594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2nd",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        236.75169372558594,
        165.77882385253906,
        254.9853973388672,
        179.0013427734375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 관찰항목 검사 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        210.84957885742188,
        197.53265380859375,
        226.37164306640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험기기에서 PT 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        236.86114501953125,
        214.9232177734375,
        252.38320922851562
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        262.8727111816406,
        538.1481323242188,
        278.4077453613281
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 그 결과를 데이터 수집용지에 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.86858367919922,
        288.764404296875,
        351.2637023925781,
        304.2864990234375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        314.7760009765625,
        538.1492919921875,
        330.31103515625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해 시행한다. 반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        95.22838592529297,
        340.7875671386719,
        538.1492919921875,
        356.3096618652344
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        95.22838592529297,
        366.67926025390625,
        538.14794921875,
        382.20135498046875
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중반기에 기기를 순환한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        95.22838592529297,
        392.6908264160156,
        244.7614288330078,
        408.2129211425781
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 대조기기에서 PT 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        418.7024230957031,
        214.9232177734375,
        434.2245178222656
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.67898559570312,
        444.5941162109375,
        538.1488037109375,
        460.129150390625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터 수집용지에 기록한다. 대조기기의 결과 값은 기준 값으로 간주한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.62871551513672,
        470.6056823730469,
        529.1273193359375,
        486.1277770996094
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 적혈구 부피비(적혈구용적률) 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        496.61724853515625,
        283.5260314941406,
        512.1393432617188
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        522.5089721679688,
        538.1486206054688,
        538.0440063476562
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        94.26890563964844,
        548.5205688476562,
        538.1483764648438,
        564.0426635742188
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용지에 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.26890563964844,
        574.5321044921875,
        191.03054809570312,
        590.05419921875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 59 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        155.11048889160156,
        528.7675170898438,
        170.63255310058594
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12. 예측되는 부작용 및 사용 시 주의사항",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        59.60769271850586,
        76.33654022216797,
        369.8792419433594,
        92.27911376953125
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        529.839599609375,
        120.11202239990234
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        126.70481872558594,
        300.67657470703125,
        137.73275756835938
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        195.74607849121094,
        86.09606170654297,
        211.2681427001953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12.1 예측되는 부작용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        221.75765991210938,
        179.66204833984375,
        237.27972412109375
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.6060676574707,
        247.7692413330078,
        538.1224365234375,
        263.29132080078125
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈종, 출혈점(피부표면",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        80.23651123046875,
        273.6609191894531,
        538.1487426757812,
        289.1830139160156
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.23651123046875,
        273.6609191894531,
        538.1487426757812,
        289.1830139160156
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부작용 증세가 발생할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        299.6724853515625,
        248.9591522216797,
        315.194580078125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 혈관미주신경 반응",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        325.6840515136719,
        192.2559814453125,
        341.2061462402344
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. 침에 찔리자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        351.5757751464844,
        538.1485595703125,
        367.0978698730469
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        377.58734130859375,
        538.1224365234375,
        393.10943603515625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. 어지럽고 메스껍고,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        403.5989074707031,
        538.1224365234375,
        419.1210021972656
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        85.0339126586914,
        429.4906311035156,
        538.1483764648438,
        445.0127258300781
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의식을 잃어 쓰러지게 된다. 이것은 혈관미주신경 반응에 의해 일어나며 피 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        455.502197265625,
        538.1487426757812,
        471.0242919921875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사침에 대한 공포심과 관련이 있다. 채혈에 대한 두려움 등 과민한 정신적인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        481.5137634277344,
        538.1483764648438,
        497.0358581542969
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        507.40545654296875,
        538.149169921875,
        522.9275512695312
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        533.4170532226562,
        538.1478271484375,
        548.9391479492188
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 의식 소실이 유발되는 것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        559.4285888671875,
        272.9461669921875,
        574.95068359375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        585.3203125,
        109.74018859863281,
        600.8424072265625
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        611.3319091796875,
        538.1488037109375,
        626.866943359375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴식을 취하면 대부분 회복된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        637.3434448242188,
        276.544189453125,
        652.8655395507812
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        663.2351684570312,
        538.1483764648438,
        678.7702026367188
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이 중요하다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        689.2467651367188,
        174.11972045898438,
        704.7688598632812
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.71625518798828,
        715.25830078125,
        511.1370544433594,
        730.7933349609375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        741.1500244140625,
        538.148193359375,
        756.68505859375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 60 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        91.99014282226562,
        68.80480194091797,
        538.1483764648438,
        84.3268814086914
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료진에게 알리고 적절히 조치할 수 있도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        91.99014282226562,
        94.81637573242188,
        371.53271484375,
        110.33845520019531
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 피하 출혈 및 혈종",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        120.70807647705078,
        192.2559814453125,
        136.2301483154297
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        146.71966552734375,
        538.1483764648438,
        162.24172973632812
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고여서 생긴 것이다. 주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.75352478027344,
        172.73123168945312,
        530.6864624023438,
        188.2532958984375
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        198.62294006347656,
        109.74018859863281,
        214.14500427246094
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        224.63450622558594,
        538.1483764648438,
        240.16952514648438
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "압박 지혈을 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        250.6460723876953,
        189.11158752441406,
        266.16815185546875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        276.53778076171875,
        538.1488037109375,
        292.07281494140625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        302.5493469238281,
        440.0155944824219,
        318.0714416503906
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        328.5609130859375,
        538.148193359375,
        344.0830078125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 부작용에 대한 내용은 해당사항 없다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        354.45263671875,
        343.3479919433594,
        369.9747314453125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.2 사용상의 주의사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        396.4067687988281,
        192.25491333007812,
        411.9288635253906
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 측정기 주의사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        63.08580780029297,
        422.4183654785156,
        177.74420166015625,
        437.9404602050781
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시 체외진단용으로 사용해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        448.429931640625,
        300.05145263671875,
        463.9520263671875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.68223571777344,
        474.3216247558594,
        538.1488647460938,
        489.8437194824219
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여서는 안됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.71625518798828,
        500.33319091796875,
        194.38873291015625,
        515.8552856445312
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.56230163574219,
        526.3447875976562,
        538.1480712890625,
        541.8668823242188
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.71625518798828,
        552.2364501953125,
        121.70812225341797,
        567.758544921875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        578.248046875,
        538.1483764648438,
        593.7701416015625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합니다. 합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        604.2596435546875,
        538.1488647460938,
        619.78173828125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 미칠 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.03878784179688,
        630.1513061523438,
        228.57020568847656,
        645.6734008789062
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확한 측정을 위해 습기 찬 장소는 피해야 합니다. 예상치 못한 온습도의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        656.1629028320312,
        538.1488647460938,
        671.6849975585938
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        682.1744995117188,
        538.1488647460938,
        697.6965942382812
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 주십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.03878784179688,
        708.066162109375,
        163.68536376953125,
        723.5882568359375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.56230163574219,
        734.0777587890625,
        536.1094360351562,
        749.599853515625
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 61 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        68.80480194091797,
        437.4969787597656,
        84.3268814086914
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        94.81637573242188,
        431.0204772949219,
        110.33845520019531
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 검사지 주의사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        63.08580780029297,
        146.71966552734375,
        177.74420166015625,
        162.24172973632812
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다. 직사광선이나 열을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.56230163574219,
        172.73123168945312,
        538.1483764648438,
        188.26625061035156
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피합니다. 냉장 또는 냉동보관을 피해 주십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        82.03553771972656,
        198.62294006347656,
        367.6947937011719,
        214.14500427246094
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 사용기한이 지난 검사지는 사용하지 않습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        224.63450622558594,
        356.30096435546875,
        240.1565704345703
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 검사지는 반드시 마른 손으로 만져야 합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        250.6460723876953,
        349.8244934082031,
        266.16815185546875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        276.53778076171875,
        508.8583068847656,
        292.05987548828125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 혈액샘플은 채혈 즉시 검사지에 주입해야합니다. 그렇지 않으면 혈액의 응고가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.56230163574219,
        302.5493469238281,
        538.1477661132812,
        318.0714416503906
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시작되어 부정확한 결과를 얻을 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.3564453125,
        328.5609130859375,
        341.6689147949219,
        344.0830078125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        354.45263671875,
        440.7352294921875,
        369.9747314453125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.56230163574219,
        380.4642028808594,
        538.1502075195312,
        395.9862976074219
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.43586730957031,
        406.47576904296875,
        134.54116821289062,
        421.99786376953125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 대조기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        63.08580780029297,
        458.3790588378906,
        132.28883361816406,
        473.9011535644531
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        484.390625,
        492.6670837402344,
        499.9127197265625
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        510.2823486328125,
        536.6832275390625,
        525.804443359375
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        536.2938842773438,
        492.42718505859375,
        551.8159790039062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 사용기한이 지난 시약은 사용하지 않습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        562.3054809570312,
        343.3479919433594,
        577.8275756835938
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.56230163574219,
        588.1972045898438,
        538.1488647460938,
        603.7192993164062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        614.208740234375,
        538.1483764648438,
        629.7437744140625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에 검사를 시행해야 합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.55580139160156,
        640.2203369140625,
        260.11309814453125,
        655.742431640625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.56230163574219,
        666.112060546875,
        511.0171203613281,
        681.6470947265625
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 62 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        153.79193115234375,
        530.5918579101562,
        169.31399536132812
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.6836395263672,
        530.591552734375,
        195.20570373535156
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. “중지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        205.69520568847656,
        530.5921630859375,
        221.21726989746094
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        231.706787109375,
        530.5914916992188,
        247.22885131835938
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. 또 “탈락”",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        257.5984802246094,
        530.5665283203125,
        273.1205749511719
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        283.61004638671875,
        530.5922241210938,
        299.13214111328125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        309.6216125488281,
        530.5924682617188,
        325.1437072753906
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        335.5133361816406,
        420.226318359375,
        351.0354309082031
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13. 중지·탈락 기준",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.33654022216797,
        218.04153442382812,
        92.27911376953125
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        381.54302978515625,
        86.09606170654297,
        397.06512451171875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        407.5545959472656,
        538.1480712890625,
        423.0766906738281
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        433.566162109375,
        538.1483764648438,
        449.0882568359375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        459.4578857421875,
        538.1480102539062,
        474.97998046875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직접적인 위해를 발생시키지 않는다. 그러므로 아래 중지기준에 따라 본 임상시험의 일시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        485.4694519042969,
        538.1482543945312,
        500.9915466308594
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중지 후 재개 가능하다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        511.48101806640625,
        176.8782196044922,
        527.0031127929688
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13.1.1 중지 기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        563.38427734375,
        151.357666015625,
        578.9063720703125
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        589.3958740234375,
        538.1474609375,
        604.91796875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시킬 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        615.28759765625,
        158.88796997070312,
        630.8096923828125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        641.2991333007812,
        538.1484375,
        656.8212280273438
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1. 참조).",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.1165771484375,
        667.3107299804688,
        512.3369750976562,
        682.8328247070312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중지기준",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        90.7907943725586,
        123.46508026123047,
        372.6383056640625,
        136.68759155273438
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중지처리",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        90.7907943725586,
        123.46508026123047,
        372.6383056640625,
        136.68759155273438
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 제공",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        82.87508392333984,
        164.8198699951172,
        141.88320922851562,
        178.04238891601562
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        96.1878662109375,
        186.87576293945312,
        128.5705108642578,
        200.09828186035156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외부 오염",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        88.1522216796875,
        208.81179809570312,
        136.4861297607422,
        222.03431701660156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        179.90249633789062,
        142.88385009765625,
        522.4369506835938,
        156.1063690185547
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        173.7858123779297,
        164.8198699951172,
        528.5540771484375,
        178.04238891601562
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상검체 폐기절차에 따라 즉각 폐기한다.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        248.3853759765625,
        186.87576293945312,
        453.8119812011719,
        200.09828186035156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        206.52806091308594,
        208.81179809570312,
        495.69134521484375,
        222.03431701660156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험책임자, 및 임상시험의뢰자에게 보고한다.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        228.35623168945312,
        230.74781799316406,
        473.84112548828125,
        243.9703369140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발적 의사에 의해",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.16522216796875,
        244.5327606201172,
        160.59307861328125,
        257.7552795410156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험에 대한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        72.20086669921875,
        266.5886535644531,
        152.55743408203125,
        279.8111572265625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참여를 거부한 경우",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        64.16522216796875,
        288.5246887207031,
        160.59295654296875,
        301.7471923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        173.18614196777344,
        244.5327606201172,
        529.0335083007812,
        257.7552795410156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        188.17800903320312,
        266.5886535644531,
        514.0421752929688,
        279.8111572265625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        183.02081298828125,
        288.5246887207031,
        519.1765747070312,
        301.7471923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 1. 중지 기준 및 처리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        226.43727111816406,
        94.81637573242188,
        368.320068359375,
        110.33845520019531
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13.1.2 중지 처리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        328.0814514160156,
        151.357666015625,
        343.6035461425781
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        354.093017578125,
        538.1474609375,
        369.6151123046875
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시킬 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        379.9847106933594,
        158.88796997070312,
        395.5068054199219
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        405.9963073730469,
        538.1483764648438,
        421.5184020996094
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "삽입할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.1165771484375,
        432.00787353515625,
        168.6027069091797,
        447.52996826171875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        457.8995666503906,
        538.1483764648438,
        473.4216613769531
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.1165771484375,
        483.9111633300781,
        538.1483764648438,
        499.4332580566406
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 보정 후 분석을 시행하도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.1165771484375,
        509.9227294921875,
        313.843994140625,
        525.44482421875
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13.2.1 탈락 기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        561.8259887695312,
        152.19775390625,
        577.3480834960938
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        587.8375854492188,
        538.1483764648438,
        603.3596801757812
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 탈락시킨다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.95612335205078,
        613.729248046875,
        179.51678466796875,
        629.2513427734375
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.96587371826172,
        639.7408447265625,
        402.11614990234375,
        655.262939453125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        665.75244140625,
        538.1483764648438,
        681.2745361328125
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탈락시킨다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.99664306640625,
        691.6441040039062,
        146.7745361328125,
        707.1661987304688
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 아래 표 2. 의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.96587371826172,
        717.6557006835938,
        516.5341186523438,
        733.1777954101562
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 64 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 수 비율 %",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        126.65135955810547,
        95.29586029052734,
        402.5018615722656,
        108.51837158203125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        126.65135955810547,
        95.29586029052734,
        402.5018615722656,
        108.51837158203125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10-15",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        114.83450317382812,
        404.7806396484375,
        128.0570068359375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        153.39686584472656,
        114.83450317382812,
        404.7806396484375,
        128.0570068359375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15-40",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        134.25328063964844,
        399.7200622558594,
        147.47579956054688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0-2.8",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        134.25328063964844,
        399.7200622558594,
        147.47579956054688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15-40",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        153.67205810546875,
        399.7200622558594,
        166.8945770263672
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.9-3.7",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        153.67205810546875,
        399.7200622558594,
        166.8945770263672
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10-30",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        173.210693359375,
        399.7200622558594,
        186.43321228027344
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.8-4.5",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        153.39686584472656,
        173.210693359375,
        399.7200622558594,
        186.43321228027344
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1-10",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        192.62948608398438,
        399.7200622558594,
        205.8520050048828
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.6-6.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        156.15536499023438,
        192.62948608398438,
        399.7200622558594,
        205.8520050048828
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 2. 시스템 정확도 확인용 검체의 INR 값",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        170.78744506835938,
        68.80480194091797,
        423.97021484375,
        84.3268814086914
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.96587371826172,
        226.43255615234375,
        447.8113708496094,
        241.95462036132812
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        252.44410705566406,
        538.1483764648438,
        267.9661865234375
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다. 증례기록서에 탈락의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        278.4556884765625,
        538.1483764648438,
        293.977783203125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유를 기재한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.55580139160156,
        304.3473815917969,
        180.11647033691406,
        319.8694763183594
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 65 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 구간",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        87.4326171875,
        573.9328002929688,
        457.8571472167969,
        587.1553344726562
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용차이(결과의 90%)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        87.4326171875,
        573.9328002929688,
        457.8571472167969,
        587.1553344726562
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용편차(평균차이)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        87.4326171875,
        573.9328002929688,
        457.8571472167969,
        587.1553344726562
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0 미만",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        90.5509262084961,
        598.1463012695312,
        420.30975341796875,
        611.3798217773438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "±0.5",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        598.1463012695312,
        420.30975341796875,
        611.3798217773438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        598.1463012695312,
        420.30975341796875,
        611.3798217773438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2.0-4.5",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        622.239990234375,
        421.5494384765625,
        635.4735107421875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "±30%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        622.239990234375,
        421.5494384765625,
        635.4735107421875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "±0.3",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        622.239990234375,
        421.5494384765625,
        635.4735107421875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.6-6.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        646.3336181640625,
        420.30975341796875,
        659.55615234375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        646.3336181640625,
        420.30975341796875,
        659.55615234375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        646.3336181640625,
        420.30975341796875,
        659.55615234375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NA = 해당 없다.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        667.6703491210938,
        149.53688049316406,
        680.8928833007812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        150.9150848388672,
        533.3504028320312,
        166.43714904785156
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.67898559570312,
        176.92665100097656,
        533.3499755859375,
        192.44871520996094
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준을 제시함. 그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.67898559570312,
        202.818359375,
        533.3504028320312,
        218.34042358398438
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.67898559570312,
        228.82992553710938,
        531.2861328125,
        244.35198974609375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        254.8415069580078,
        533.3504638671875,
        270.36358642578125
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.27865600585938,
        280.7331848144531,
        463.5228576660156,
        296.2552795410156
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        306.7447509765625,
        533.3511962890625,
        322.266845703125
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법과 기준을 제시함. 의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        332.75634765625,
        533.3511352539062,
        348.2784423828125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시하는 병원은 2군데 이상이어야 한다. 기관에 따라 임상시험결과에 차이가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        358.6480407714844,
        533.3504028320312,
        374.1701354980469
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        384.65960693359375,
        533.3509521484375,
        400.18170166015625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 경우는 이를 반영하여 분석결과를 제시해야함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.1992416381836,
        410.67120361328125,
        374.2912292480469,
        426.19329833984375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14. 유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.33654022216797,
        532.5227661132812,
        92.27911376953125
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.1. 유효성(성능)의 평가기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        469.7666015625,
        228.95504760742188,
        485.2886962890625
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.48613357543945,
        495.7781677246094,
        538.1483764648438,
        511.3002624511719
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.39697265625,
        521.7897338867188,
        498.78375244140625,
        537.3118286132812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 성능 기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        251.62362670898438,
        547.6814575195312,
        343.253662109375,
        563.2035522460938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.48613357543945,
        710.9430541992188,
        385.9249267578125,
        726.4651489257812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 66 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 값",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        77.83781433105469,
        525.6255493164062,
        451.5552673339844,
        538.8480834960938
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목표 검체 수 비율a (%)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        77.83781433105469,
        525.6255493164062,
        451.5552673339844,
        538.8480834960938
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실제 검체수 비율 (%)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        77.83781433105469,
        525.6255493164062,
        451.5552673339844,
        538.8480834960938
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        77.83781433105469,
        525.6255493164062,
        451.5552673339844,
        538.8480834960938
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0 미만",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        549.71923828125,
        209.98556518554688,
        562.9417724609375
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10-15",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        549.71923828125,
        209.98556518554688,
        562.9417724609375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0-2.8",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        573.8129272460938,
        209.98556518554688,
        587.0354614257812
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15-40",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        573.8129272460938,
        209.98556518554688,
        587.0354614257812
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.9-3.7",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        597.9065551757812,
        209.98556518554688,
        611.1290893554688
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15-40",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        597.9065551757812,
        209.98556518554688,
        611.1290893554688
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.8-4.5",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        622.000244140625,
        209.98556518554688,
        635.2227783203125
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10-30",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        622.000244140625,
        209.98556518554688,
        635.2227783203125
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.6-6.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        646.0939331054688,
        207.3465576171875,
        659.3164672851562
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-10",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        646.0939331054688,
        207.3465576171875,
        659.3164672851562
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14.2. 유효성(성능) 평가방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        94.81637573242188,
        216.36184692382812,
        110.33845520019531
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.48613357543945,
        120.70807647705078,
        538.1487426757812,
        136.2301483154297
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템 정확도 평가에서 제외할 수 없다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        83.83456420898438,
        146.71966552734375,
        296.2135314941406,
        162.24172973632812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        172.73123168945312,
        538.2423706054688,
        188.2532958984375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사과정과 결과를 보고서에 문서화한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        198.62294006347656,
        307.0076904296875,
        214.14500427246094
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        224.63450622558594,
        538.1487426757812,
        240.1565704345703
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.67411041259766,
        250.6460723876953,
        538.1224365234375,
        266.16815185546875
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.67411041259766,
        276.53778076171875,
        516.8939208984375,
        292.05987548828125
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        302.5493469238281,
        538.1224365234375,
        318.0714416503906
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        84.19436645507812,
        328.5609130859375,
        538.1483764648438,
        344.0830078125
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 결과를 보고한다. 도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        354.45263671875,
        538.14794921875,
        369.9747314453125
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        380.4642028808594,
        110.31429290771484,
        395.9862976074219
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 아래의 결과를 보고한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.48613357543945,
        432.36749267578125,
        216.45677185058594,
        447.88958740234375
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 분석한 총 검체수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        458.3790588378906,
        179.78341674804688,
        473.9011535644531
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 대조기기를 통해 측정한 INR 값 구간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        484.390625,
        290.0027160644531,
        499.9127197265625
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        682.2943725585938,
        452.8572692871094,
        697.8164672851562
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 시스템 정확도 평가결과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        708.305908203125,
        215.2840576171875,
        723.8280029296875
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        734.1976318359375,
        533.35107421875,
        749.7197265625
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 67 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 구간",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        77.95774841308594,
        496.73712158203125,
        479.0204772949219,
        509.9596252441406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.3 INR 이내",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        77.95774841308594,
        496.73712158203125,
        479.0204772949219,
        509.9596252441406
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.5 INR 이내",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        77.95774841308594,
        496.73712158203125,
        479.0204772949219,
        509.9596252441406
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 INR 차이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        77.95774841308594,
        496.73712158203125,
        479.0204772949219,
        509.9596252441406
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0 미만",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        81.07605743408203,
        515.1969604492188,
        121.37422180175781,
        528.4194946289062
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 구간",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        80.95612335205078,
        547.8013305664062,
        498.6898193359375,
        561.0238647460938
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10% 이내",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        80.95612335205078,
        547.8013305664062,
        498.6898193359375,
        561.0238647460938
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20% 이내",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        80.95612335205078,
        547.8013305664062,
        498.6898193359375,
        561.0238647460938
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30% 이내",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        80.95612335205078,
        547.8013305664062,
        498.6898193359375,
        561.0238647460938
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 INR 차이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        80.95612335205078,
        547.8013305664062,
        498.6898193359375,
        561.0238647460938
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.0-4.5",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        89.11170196533203,
        569.9771118164062,
        119.31402587890625,
        583.1996459960938
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.6-6.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        89.11170196533203,
        592.15283203125,
        119.31402587890625,
        605.3753662109375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 최소허용 시스템 정확도 (ISO 17593 근거)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.48613357543945,
        94.81637573242188,
        311.5738525390625,
        110.33845520019531
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        120.70807647705078,
        538.1483764648438,
        136.2301483154297
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능기준을 만족해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.31430053710938,
        146.71966552734375,
        221.3740997314453,
        162.24172973632812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        172.73123168945312,
        376.9298095703125,
        188.2532958984375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        198.62294006347656,
        538.1475830078125,
        214.14500427246094
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균의 차이(편차)를 구한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.07443237304688,
        224.63450622558594,
        235.1666259765625,
        240.1565704345703
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        250.6460723876953,
        538.1476440429688,
        266.18109130859375
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체의 90% 이상이어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.75352478027344,
        276.53778076171875,
        248.35948181152344,
        292.05987548828125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        302.5493469238281,
        538.1470947265625,
        318.0843811035156
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체의 90% 이상이어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        328.5609130859375,
        243.2022705078125,
        344.0830078125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        354.45263671875,
        538.1224365234375,
        369.9876708984375
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR 이하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        87.19274139404297,
        380.4642028808594,
        194.86846923828125,
        395.9862976074219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        406.47576904296875,
        538.1490478515625,
        421.99786376953125
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.43424224853516,
        432.36749267578125,
        135.02090454101562,
        447.88958740234375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        458.3790588378906,
        496.2651062011719,
        473.9011535644531
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 상관성 비교",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.48613357543945,
        644.2958984375,
        149.31948852539062,
        659.8179931640625
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.36294555664062,
        670.1875610351562,
        538.14892578125,
        685.7096557617188
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 선형회귀분석 및 상관분석을 시행한다. 신뢰구간을 포함한 선형회귀선의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.39372253417969,
        696.1991577148438,
        538.1477661132812,
        711.7212524414062
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기울기와 y 절편값 및 상관계수를 구한다. 대조기기의 측정결과는 반복측정의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.39372253417969,
        722.210693359375,
        538.1467895507812,
        737.7327880859375
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균값이어도 된다. 시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.39372253417969,
        748.1024169921875,
        538.1483764648438,
        763.62451171875
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 68 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.39372253417969,
        68.80480194091797,
        163.68536376953125,
        84.3268814086914
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.36294555664062,
        94.81637573242188,
        538.2531127929688,
        110.33845520019531
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도표를 이용하여 확인한다. 시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.99339294433594,
        120.70807647705078,
        538.028564453125,
        136.2301483154297
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각에 대해 확인한다. 차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.99339294433594,
        146.71966552734375,
        538.1478271484375,
        162.24172973632812
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "95%를 포함하는 구간을 보고한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        172.73123168945312,
        266.3497314453125,
        188.2532958984375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        224.63450622558594,
        113.92098236083984,
        240.1565704345703
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 69 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 이상사례에 대한 인과관계 평가기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        150.9150848388672,
        289.6435546875,
        166.43714904785156
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        176.92665100097656,
        530.5927124023438,
        192.44871520996094
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        202.818359375,
        530.5927124023438,
        218.34042358398438
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        228.82992553710938,
        530.5929565429688,
        244.35198974609375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        254.8415069580078,
        530.593505859375,
        270.37652587890625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록하여야 함. 따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        280.7331848144531,
        530.59130859375,
        296.2552795410156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 평가기준을 제시하여야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.03878784179688,
        306.7447509765625,
        261.7922058105469,
        322.266845703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.33654022216797,
        520.87744140625,
        92.27911376953125
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        529.839599609375,
        120.11202239990234
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        126.70481872558594,
        300.67657470703125,
        137.73275756835938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        349.8976135253906,
        86.09606170654297,
        365.4197082519531
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 피험자 안전성(해당사항 없음)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        375.9091796875,
        244.53018188476562,
        391.4312744140625
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        401.9207458496094,
        538.147216796875,
        417.4428405761719
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        427.8124694824219,
        538.1483764648438,
        443.3345642089844
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        453.82403564453125,
        465.20196533203125,
        469.34613037109375
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 시험자안전성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        505.727294921875,
        148.23822021484375,
        521.2493896484375
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        531.7388916015625,
        538.1480712890625,
        547.260986328125
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않기 때문에 해당 의료기기에 의한 감염위험성은 없다. 다만, 검체가 감염성 물질을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        557.7504272460938,
        538.1492919921875,
        573.2725219726562
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        583.6421508789062,
        538.1483764648438,
        599.1642456054688
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 사용시 주의사항을 참고하여 취급해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        609.6537475585938,
        327.9963073730469,
        625.1758422851562
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 70 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의서 버전 또는 버전 날짜:",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        86.71300506591797,
        379.5052490234375,
        502.3879089355469,
        392.7277526855469
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Version",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        86.71300506591797,
        379.5052490234375,
        502.3879089355469,
        392.7277526855469
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "_______________",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        86.71300506591797,
        379.5052490234375,
        502.3879089355469,
        392.7277526855469
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "date ______________",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        86.71300506591797,
        379.5052490234375,
        502.3879089355469,
        392.7277526855469
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 제목:",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        67.40347290039062,
        437.4019775390625,
        497.2506103515625,
        450.6244812011719
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        67.40347290039062,
        437.4019775390625,
        497.2506103515625,
        450.6244812011719
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        297.31884765625,
        459.3380126953125,
        340.37579345703125,
        472.5605163574219
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구책임자:",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        503.92926025390625,
        448.502197265625,
        517.1517944335938
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(성명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        503.92926025390625,
        448.502197265625,
        517.1517944335938
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(소속)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        503.92926025390625,
        448.502197265625,
        517.1517944335938
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(연락처)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        503.92926025390625,
        448.502197265625,
        517.1517944335938
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구담당자:",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        550.078857421875,
        448.502197265625,
        563.3013916015625
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(성명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        550.078857421875,
        448.502197265625,
        563.3013916015625
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(소속)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        550.078857421875,
        448.502197265625,
        563.3013916015625
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(연락처)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.76490020751953,
        550.078857421875,
        448.502197265625,
        563.3013916015625
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인체유래물 기증자의 권리에 대한 문의처",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        614.32861328125,
        380.0740051269531,
        627.5511474609375
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자보호",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        80.71625518798828,
        614.32861328125,
        380.0740051269531,
        627.5511474609375
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구윤리담당자",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        315.6689147949219,
        636.2646484375,
        390.7483215332031,
        649.4871826171875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(연락처)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        409.338134765625,
        614.32861328125,
        448.502197265625,
        627.5511474609375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        153.79193115234375,
        530.591552734375,
        169.31399536132812
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.6836395263672,
        530.5924682617188,
        195.20570373535156
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        205.69520568847656,
        530.5918579101562,
        221.21726989746094
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        231.706787109375,
        530.5665283203125,
        247.22885131835938
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        257.5984802246094,
        530.5921630859375,
        273.1205749511719
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규칙 [별표 3])에서 정하고 있음. 이에 따른 피험자 동의서 서식을 제시하여야",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        283.61004638671875,
        530.59130859375,
        299.13214111328125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        309.6216125488281,
        465.3218994140625,
        325.1437072753906
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16. 피험자 동의서 서식",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        59.60769271850586,
        76.33654022216797,
        233.99317932128906,
        92.27911376953125
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        529.839599609375,
        120.11202239990234
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        126.70481872558594,
        300.67657470703125,
        137.73275756835938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        329.6397399902344,
        86.09606170654297,
        345.1618347167969
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구과제 피험자 설명문 및 동의서",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        175.82470703125,
        346.18170166015625,
        418.3332824707031,
        364.1470642089844
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        658.560302734375,
        538.2683715820312,
        671.7828369140625
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        67.52340698242188,
        680.496337890625,
        342.3923645019531,
        693.7188720703125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 71 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 참여 권유",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        129.28993225097656,
        84.3268814086914
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        94.81637573242188,
        538.1483764648438,
        110.33845520019531
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        120.70807647705078,
        538.1474609375,
        136.2301483154297
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차를 따를 것입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        146.71966552734375,
        202.90411376953125,
        162.24172973632812
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        172.73123168945312,
        538.1497802734375,
        188.2532958984375
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "읽어보셔야 합니다. 이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        198.62294006347656,
        538.148193359375,
        214.14500427246094
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        224.63450622558594,
        538.1485595703125,
        240.1565704345703
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요합니다. 충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        250.6460723876953,
        538.1483764648438,
        266.16815185546875
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "든지 질문하여 주십시오. 귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        276.53778076171875,
        538.2423706054688,
        292.05987548828125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        302.5493469238281,
        535.48388671875,
        318.0714416503906
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 인체 유래물이란?",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        354.45263671875,
        172.44781494140625,
        369.9747314453125
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        380.4642028808594,
        538.1482543945312,
        395.9862976074219
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. 본 동의서에서는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.11982727050781,
        406.47576904296875,
        538.1470336914062,
        421.99786376953125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“검체”라는 용어로 부릅니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.11982727050781,
        432.36749267578125,
        235.76629638671875,
        447.88958740234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 연구의 목적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        484.390625,
        141.8828125,
        499.9127197265625
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        510.2823486328125,
        538.1484375,
        525.804443359375
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        536.2938842773438,
        538.148193359375,
        551.8159790039062
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.52015686035156,
        562.3054809570312,
        534.8842163085938,
        577.8275756835938
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        588.1972045898438,
        538.1477661132812,
        603.7192993164062
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.59957122802734,
        614.208740234375,
        538.14794921875,
        629.7308349609375
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.59957122802734,
        640.2203369140625,
        538.1473388671875,
        655.742431640625
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확도를 평가하는 것입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.59957122802734,
        666.112060546875,
        236.2460479736328,
        681.6341552734375
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 72 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 연구 방법 및 절차",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        179.66262817382812,
        84.3268814086914
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. 문진에는 허혈성심",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        93.49781799316406,
        538.1474609375,
        109.0198974609375
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        118.19083404541016,
        538.1478271484375,
        133.71290588378906
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요법과 같은 병용약물에 대한 질문이 포함됩니다. 이 후 손가락 끝에서 모세혈",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        142.88385009765625,
        538.1483764648438,
        158.40591430664062
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        167.57687377929688,
        538.1488037109375,
        183.09893798828125
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합니다. 본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        192.26988220214844,
        538.1488037109375,
        207.7919464111328
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        216.962890625,
        526.0089721679688,
        232.48495483398438
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 예상되는 위험 및 불편",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        266.3489074707031,
        204.84896850585938,
        281.8710021972656
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        292.3604736328125,
        538.1488037109375,
        307.882568359375
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.35969543457031,
        318.252197265625,
        538.1476440429688,
        333.7742919921875
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부작용이 나타날 수 있습니다. 그러나 이는 보통 일시적인 증상으로 금방 해소될",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        74.35969543457031,
        344.2637634277344,
        538.1483764648438,
        359.7858581542969
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.35969543457031,
        370.27532958984375,
        513.6557006835938,
        385.79742431640625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 연구에 참여함으로써 기대되는 이익",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        420.86004638671875,
        280.40802001953125,
        436.38214111328125
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        445.5530700683594,
        538.1486206054688,
        461.0751647949219
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "트롬빈 시간을 확인할 수 있을 것으로 기대합니다. 또한 궁극적으로는 프로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        470.24609375,
        538.1488647460938,
        485.7681884765625
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        494.9390869140625,
        538.1478271484375,
        510.461181640625
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        519.632080078125,
        538.1483764648438,
        535.1541748046875
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        544.3251342773438,
        538.1483764648438,
        559.8472290039062
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.52015686035156,
        569.0181274414062,
        127.5849380493164,
        584.5402221679688
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 검체의 처리 및 제공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        618.4041748046875,
        192.25552368164062,
        633.92626953125
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        644.4157104492188,
        454.1679382324219,
        659.9378051757812
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        670.4273071289062,
        538.1483154296875,
        685.9494018554688
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        696.3190307617188,
        538.1480102539062,
        711.8411254882812
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        73.76002502441406,
        722.33056640625,
        538.1483764648438,
        737.8526611328125
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정할 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        748.3421630859375,
        185.6334686279297,
        763.8642578125
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 73 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        68.80480194091797,
        538.2423706054688,
        84.3268814086914
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.11982727050781,
        94.81637573242188,
        538.1477661132812,
        110.33845520019531
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.11982727050781,
        120.70807647705078,
        538.1488037109375,
        136.2301483154297
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. 만약",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.11982727050781,
        146.71966552734375,
        538.1488037109375,
        162.24172973632812
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.11982727050781,
        172.73123168945312,
        470.2392272949219,
        188.2532958984375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 자유의사에 의한 연구 참여 동의 및 철회",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        224.63450622558594,
        311.8306884765625,
        240.1565704345703
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        250.6460723876953,
        538.1488037109375,
        266.16815185546875
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에도 전혀 불이익은 없습니다. 또한 참여에 동의한 이후에도 언제라도 아무런",
      "font_size": 12.94941520690918,
      "font_name": "T19",
      "bbox": [
        74.35969543457031,
        276.53778076171875,
        538.1483764648438,
        292.05987548828125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불이익 없이 연구 참여를 중단할 수 있습니다. 동의 철회를 원할 경우 귀하의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.35969543457031,
        302.5493469238281,
        538.1488037109375,
        318.0714416503906
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        74.35969543457031,
        328.5609130859375,
        538.1483764648438,
        344.0830078125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.35969543457031,
        354.45263671875,
        538.1483154296875,
        369.9747314453125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 폐기됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.35969543457031,
        380.4642028808594,
        170.28179931640625,
        395.9862976074219
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 개인정보 보호",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        432.36749267578125,
        154.47628784179688,
        447.88958740234375
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        458.3790588378906,
        538.1485595703125,
        473.9011535644531
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. 이렇게 수집된 개인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        484.390625,
        538.1477661132812,
        499.9127197265625
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        510.2823486328125,
        538.1483764648438,
        525.804443359375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료에 접근할 수 있습니다. 수집된 개인정보 중 개인식별정보는 연구에 직접",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        536.2938842773438,
        538.1488037109375,
        551.8159790039062
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        562.3054809570312,
        538.1492919921875,
        577.8275756835938
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하를 연결하기 위한 목적으로만 사용됩니다. 귀하의 개인정보는 연구 목적을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        588.1972045898438,
        538.1492919921875,
        603.7192993164062
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        614.208740234375,
        538.1483154296875,
        629.7308349609375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.40022277832031,
        640.2203369140625,
        113.67247772216797,
        655.742431640625
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 74 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 :",
      "font_size": 11.030982971191406,
      "font_name": "T4",
      "bbox": [
        64.52503204345703,
        480.4349365234375,
        106.12040710449219,
        493.6574401855469
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(성명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        524.4268798828125,
        490.4142150878906,
        537.6494140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(서명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        524.4268798828125,
        490.4142150878906,
        537.6494140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(날짜)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        524.4268798828125,
        490.4142150878906,
        537.6494140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "년",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        524.4268798828125,
        490.4142150878906,
        537.6494140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "월",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        524.4268798828125,
        490.4142150878906,
        537.6494140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        524.4268798828125,
        490.4142150878906,
        537.6494140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법정 대리인(필요 시):",
      "font_size": 11.030982971191406,
      "font_name": "T4",
      "bbox": [
        64.52503204345703,
        568.4188232421875,
        174.483154296875,
        581.641357421875
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(성명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        612.2908325195312,
        490.4142150878906,
        625.5133666992188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(서명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        612.2908325195312,
        490.4142150878906,
        625.5133666992188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(날짜)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        612.2908325195312,
        490.4142150878906,
        625.5133666992188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "년",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        612.2908325195312,
        490.4142150878906,
        625.5133666992188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "월",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        612.2908325195312,
        490.4142150878906,
        625.5133666992188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        612.2908325195312,
        490.4142150878906,
        625.5133666992188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(피험자와의 관계)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        224.03857421875,
        656.2827758789062,
        311.29656982421875,
        669.5053100585938
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구자:",
      "font_size": 11.030982971191406,
      "font_name": "T4",
      "bbox": [
        64.52503204345703,
        678.2188110351562,
        100.84326171875,
        691.4413452148438
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(성명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        722.2107543945312,
        490.4142150878906,
        735.4332885742188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(서명)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        722.2107543945312,
        490.4142150878906,
        735.4332885742188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(날짜)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        722.2107543945312,
        490.4142150878906,
        735.4332885742188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "년",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        722.2107543945312,
        490.4142150878906,
        735.4332885742188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "월",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        722.2107543945312,
        490.4142150878906,
        735.4332885742188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        722.2107543945312,
        490.4142150878906,
        735.4332885742188
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 연구대상자 동의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        173.42572021484375,
        84.3268814086914
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        94.81637573242188,
        538.1483764648438,
        110.49299621582031
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.99664306640625,
        120.70807647705078,
        433.89892578125,
        136.2301483154297
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        146.71966552734375,
        534.7642822265625,
        162.39627075195312
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        172.73123168945312,
        538.1477661132812,
        188.4078369140625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        79.51690673828125,
        198.62294006347656,
        538.1480712890625,
        214.14500427246094
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.51690673828125,
        224.63450622558594,
        520.2521362304688,
        240.1565704345703
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        250.6460723876953,
        478.7546081542969,
        266.32269287109375
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        276.53778076171875,
        538.1480712890625,
        292.21441650390625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의서의 사본을 제공받을 것임을 알고 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.3564453125,
        302.5493469238281,
        366.8552551269531,
        318.0714416503906
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        354.45263671875,
        538.147216796875,
        369.9747314453125
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 사용될 것임을 의미합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        380.4642028808594,
        242.36273193359375,
        395.9862976074219
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        426.61376953125,
        420.8298645019531,
        439.8362731933594
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 75 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. 피해자 보상에 대한 규약",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.33654022216797,
        281.9671936035156,
        92.27911376953125
      ],
      "page_num": 82,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        148.15809631347656,
        530.5921630859375,
        163.68016052246094
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하여 원칙과 절차를 수립하여 제시함. 피해자 보상에 대한 규약에는 보상원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        174.04978942871094,
        530.5918579101562,
        189.5718536376953
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. 이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        200.06137084960938,
        530.5924682617188,
        215.58343505859375
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        226.07293701171875,
        530.5921630859375,
        241.59500122070312
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위 등을 작성함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        251.9646453857422,
        168.48277282714844,
        267.4867248535156
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        303.9877624511719,
        85.85619354248047,
        319.5098571777344
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        329.9993591308594,
        538.147216796875,
        345.5214538574219
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        356.01092529296875,
        538.1480712890625,
        371.53302001953125
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없으므로 피험자 보상 규정은 없음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        381.9026184082031,
        261.1925354003906,
        397.4247131347656
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 76 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        151.8740234375,
        530.4729614257812,
        167.39608764648438
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        177.76573181152344,
        530.5921630859375,
        193.2877960205078
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하여 원칙과 절차를 수립하여 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        203.77731323242188,
        306.88775634765625,
        219.29937744140625
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18. 임상시험 후 피험자의 진료에 관한 사항",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.33654022216797,
        393.8665466308594,
        92.27911376953125
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.08407592773438,
        541.8339233398438,
        120.11202239990234
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.70481872558594,
        301.63604736328125,
        137.73275756835938
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        221.03843688964844,
        85.85619354248047,
        236.5605010986328
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        262.9925842285156,
        538.1480712890625,
        278.5146789550781
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        288.88427734375,
        538.1483764648438,
        304.4063720703125
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        314.8958435058594,
        129.02415466308594,
        330.4179382324219
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 77 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. 피험자의 안전보호에 관한 대책",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        64.64496612548828,
        70.58282470703125,
        326.94281005859375,
        86.52539825439453
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        123.5849380493164,
        533.3508911132812,
        139.1070098876953
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        149.5965118408203,
        445.4126892089844,
        165.1185760498047
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19.1. 임상시험 실시기관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        194.78713989257812,
        195.37322998046875,
        210.3092041015625
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        220.7987060546875,
        538.1477661132812,
        236.32077026367188
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        246.81028747558594,
        538.1483764648438,
        262.3323669433594
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        272.70196533203125,
        415.6687927246094,
        288.22406005859375
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.2. 임상시험심사위원회",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        324.7251281738281,
        201.73068237304688,
        340.2472229003906
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        350.6168212890625,
        538.1483764648438,
        366.138916015625
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되어 있어야 한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.3564453125,
        376.6283874511719,
        538.1483764648438,
        392.1504821777344
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.3564453125,
        402.63995361328125,
        538.1483764648438,
        418.16204833984375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 그 이유의 타당성을 면밀히 검토하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.3564453125,
        428.53167724609375,
        365.7758483886719,
        444.05377197265625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        454.5432434082031,
        538.1477661132812,
        470.0653381347656
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        480.5548095703125,
        538.1483154296875,
        496.076904296875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        506.446533203125,
        538.1480712890625,
        521.9686279296875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        532.4580688476562,
        496.2651062011719,
        547.9801635742188
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19.3. 시험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        584.3613891601562,
        126.17105102539062,
        599.8834838867188
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        610.3729248046875,
        538.2423706054688,
        625.89501953125
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        78.31755065917969,
        635.0659790039062,
        538.1483764648438,
        650.5880737304688
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        659.7589721679688,
        478.0350036621094,
        675.2810668945312
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        684.4519653320312,
        538.1489868164062,
        699.9740600585938
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        709.14501953125,
        538.1485595703125,
        724.6671142578125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        733.8380126953125,
        538.1483764648438,
        749.360107421875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 78 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        68.80480194091797,
        538.1480712890625,
        84.3268814086914
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        93.49781799316406,
        151.09219360351562,
        109.0198974609375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        118.19083404541016,
        538.1483764648438,
        133.71290588378906
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적극적으로 대응한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.39697265625,
        142.88385009765625,
        202.18450927734375,
        158.40591430664062
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.4. 의뢰자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        191.55067443847656,
        126.17105102539062,
        207.07273864746094
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        216.24368286132812,
        538.1469116210938,
        231.7657470703125
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        240.9366912841797,
        460.6444396972656,
        256.4587707519531
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        265.62969970703125,
        538.1490478515625,
        281.15179443359375
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차에 따라 이루어지도록 하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        290.3227233886719,
        307.4874267578125,
        305.8448181152344
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        315.0157165527344,
        538.1482543945312,
        330.5378112792969
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        339.708740234375,
        538.1480712890625,
        355.2308349609375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험 실시상의 문제점 등에 따라 결정되어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        364.4017639160156,
        371.052978515625,
        379.9238586425781
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.5. 모니터링",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        413.1884460449219,
        138.76393127441406,
        428.7105407714844
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        437.8814392089844,
        538.1475830078125,
        453.4035339355469
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        462.574462890625,
        538.1224365234375,
        478.0965576171875
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록 되는지 여부를 검토, 확인하는 활동을 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        487.2674865722656,
        373.5716247558594,
        502.7895812988281
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        511.96051025390625,
        538.1473388671875,
        527.4826049804688
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방문과 전화 등을 통해서 이루어 질 것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        536.6535034179688,
        332.5538330078125,
        552.1755981445312
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        561.3464965820312,
        538.1483764648438,
        576.8685913085938
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자와 상의한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        587.2382202148438,
        188.5119171142578,
        602.7603149414062
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19.6. 임상시험계획서의 변경",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        639.2613525390625,
        220.5601806640625,
        654.783447265625
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        665.153076171875,
        538.1483764648438,
        680.6751708984375
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.71788024902344,
        691.1646728515625,
        538.1483764648438,
        706.686767578125
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        77.71788024902344,
        717.1762084960938,
        538.1483764648438,
        732.6983032226562
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        743.0679321289062,
        496.9847412109375,
        758.5900268554688
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 79 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.80480194091797,
        538.1473388671875,
        84.3268814086914
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        94.81637573242188,
        175.31906127929688,
        110.33845520019531
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        120.70807647705078,
        538.2423706054688,
        136.2301483154297
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        146.71966552734375,
        538.1483764648438,
        162.24172973632812
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "르게 임상시험을 실시하여서는 안된다. 만일 피험자에게 발생한 즉각적 위험요소",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        172.73123168945312,
        538.1473388671875,
        188.2532958984375
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        198.62294006347656,
        538.1483764648438,
        214.14500427246094
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        224.63450622558594,
        538.1487426757812,
        240.1565704345703
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        250.6460723876953,
        538.14794921875,
        266.16815185546875
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여야 한다. 그리고 임상시험심사위원회 위원장이나 간사가 승인한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        276.53778076171875,
        538.1483764648438,
        292.05987548828125
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서를 의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        276.53778076171875,
        538.1483764648438,
        292.05987548828125
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뢰자에게 보내야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        302.5493469238281,
        207.46163940429688,
        318.0714416503906
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        328.5609130859375,
        538.1477661132812,
        344.0830078125
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것은 아니며 행정상 변경이 필요하다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.91722869873047,
        354.45263671875,
        296.0935974121094,
        369.9747314453125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.7. 피험자 동의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        406.47576904296875,
        157.59429931640625,
        421.99786376953125
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        432.36749267578125,
        538.1473388671875,
        447.88958740234375
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.71788024902344,
        458.3790588378906,
        538.1480712890625,
        473.9011535644531
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.71788024902344,
        484.390625,
        538.147216796875,
        499.9127197265625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여함을 확인하는 절차를 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        510.2823486328125,
        276.064453125,
        525.804443359375
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        536.2938842773438,
        538.1482543945312,
        551.8159790039062
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.95774841308594,
        562.3054809570312,
        533.9246826171875,
        577.8275756835938
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        588.1972045898438,
        538.1483154296875,
        603.7192993164062
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        614.208740234375,
        538.1483764648438,
        629.7308349609375
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        640.2203369140625,
        538.1483764648438,
        655.742431640625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있도록 대답해 주어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.19761657714844,
        666.112060546875,
        257.5944519042969,
        681.6341552734375
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19.8. 피험자 기록의 비밀보장",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        718.1351928710938,
        226.9161376953125,
        733.6572875976562
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        744.02685546875,
        538.1477661132812,
        759.5489501953125
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 80 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.03716278076172,
        68.80480194091797,
        447.3316345214844,
        84.3268814086914
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        94.81637573242188,
        538.147216796875,
        110.33845520019531
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        120.70807647705078,
        538.1224365234375,
        136.2301483154297
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        146.71966552734375,
        538.1480712890625,
        162.24172973632812
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        172.73123168945312,
        538.1482543945312,
        188.2532958984375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. 이러한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        198.62294006347656,
        538.1483764648438,
        214.14500427246094
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보들은 기밀로 보관되어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        224.63450622558594,
        276.9040222167969,
        240.1565704345703
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        250.6460723876953,
        538.1480712890625,
        266.16815185546875
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.19761657714844,
        276.53778076171875,
        417.1080322265625,
        292.05987548828125
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.9. 기록의 보존",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        328.5609130859375,
        157.59429931640625,
        344.0830078125
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        354.45263671875,
        538.147216796875,
        369.9747314453125
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지하도록 한다. 제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        380.4642028808594,
        538.1480712890625,
        395.9992370605469
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        406.47576904296875,
        538.1477661132812,
        421.99786376953125
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 끝난 날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        432.36749267578125,
        538.145751953125,
        447.88958740234375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.19761657714844,
        458.3790588378906,
        535.48388671875,
        473.9011535644531
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 81 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.07904052734375,
        519.0782470703125,
        93.19419860839844
      ],
      "page_num": 88,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        135.3321075439453,
        530.5921630859375,
        150.8541717529297
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        161.22381591796875,
        530.5919189453125,
        176.74588012695312
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        187.23538208007812,
        530.5914306640625,
        202.7574462890625
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        213.24696350097656,
        432.81951904296875,
        228.76902770996094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20.1. 임상시험용 의료기기의 사용 및 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        251.2454376220703,
        297.91845703125,
        266.76751708984375
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        274.619873046875,
        538.2423706054688,
        290.1419677734375
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        297.99432373046875,
        538.1483154296875,
        313.51641845703125
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험용”이라는 문구가 있어야한다. 임상시험용 의료기기 관리자는 임상시험에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        321.3687744140625,
        538.1481323242188,
        336.890869140625
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        344.74322509765625,
        538.1470947265625,
        360.26531982421875
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        368.1177062988281,
        175.79879760742188,
        383.6398010253906
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20.2. 임상시험용 의료기기의 공급과 취급",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        414.8666076660156,
        291.8018493652344,
        430.3887023925781
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        438.2410583496094,
        538.145751953125,
        453.7631530761719
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        79.27703094482422,
        461.6155090332031,
        538.1483764648438,
        477.1376037597656
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.27703094482422,
        484.9899597167969,
        107.67572784423828,
        500.5120544433594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        508.36444091796875,
        538.1480712890625,
        523.8994750976562
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        531.7388916015625,
        538.1483764648438,
        547.260986328125
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        555.1133422851562,
        538.2423706054688,
        570.6354370117188
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반납 및 폐기에 관한 기록을 작성·보관하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        578.48779296875,
        385.56512451171875,
        594.0228271484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        601.8622436523438,
        538.14599609375,
        617.3843383789062
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.67736053466797,
        625.2366943359375,
        538.1483764648438,
        640.7587890625
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록을 작성·보관하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.67736053466797,
        648.6111450195312,
        255.79544067382812,
        664.1461791992188
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        671.985595703125,
        538.1483764648438,
        687.5076904296875
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        695.3600463867188,
        538.147216796875,
        710.8821411132812
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        718.7344970703125,
        538.1480712890625,
        734.256591796875
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        742.1089477539062,
        440.3753967285156,
        757.6310424804688
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 82 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "21. 참고문헌",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.07904052734375,
        160.7126007080078,
        93.19419860839844
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        133.41419982910156,
        501.9280700683594,
        146.63671875
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        69.92210388183594,
        158.70655822753906,
        531.9061889648438,
        171.9290771484375
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        69.92210388183594,
        183.99891662597656,
        533.704345703125,
        197.2324676513672
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of oral anticoagulant therapy)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        69.92210388183594,
        209.29127502441406,
        218.10577392578125,
        222.5137939453125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. Plesch W, Wolf T, Breitenbeck N, et al. Results of the performance verification of the",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        234.58363342285156,
        538.144775390625,
        247.80615234375
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CoaguChek XS system. Thromb Res 2008;123:381-389.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        72.20086669921875,
        256.6395263671875,
        338.315185546875,
        269.8620300292969
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG. Evaluation of CoaguChek XS for",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        278.5755615234375,
        538.1774291992188,
        291.7980651855469
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "measuring prothrombin time in patients receiving long-term oral anticoagulant therapy.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        71.841064453125,
        300.5115661621094,
        538.2460327148438,
        313.73406982421875
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Korean J Lab Med 2007;27:177-81.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        71.841064453125,
        322.5674743652344,
        240.44956970214844,
        335.78997802734375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        344.5035095214844,
        538.1448974609375,
        357.72601318359375
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "monitors: is a periodical control of their performance useful? Thromb Res 2009;123:775-9.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        71.36132049560547,
        366.4395446777344,
        518.6973876953125,
        379.66204833984375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 83 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시기관 및 책임 연구자 (소속과/직위/성명)",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        106.3823471069336,
        280.25372314453125,
        431.6930847167969,
        295.78875732421875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0000 병원 000 과/교수/000",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        189.25743103027344,
        310.2209777832031,
        348.8916015625,
        325.7560119628906
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver. 1.0",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        245.26707458496094,
        340.1882019042969,
        292.76080322265625,
        355.7232360839844
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 이니셜(영문)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.3984832763672,
        428.9954528808594,
        250.54795837402344,
        443.6634826660156
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 식별번호",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        159.15374755859375,
        467.2336730957031,
        241.66867065429688,
        481.9017028808594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        70.60612487792969,
        541.8339233398438,
        81.63407135009766
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        92.54214477539062,
        301.63604736328125,
        103.57009887695312
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증례기록서(예시)",
      "font_size": 20.02363395690918,
      "font_name": "T10",
      "bbox": [
        215.2833251953125,
        139.88711547851562,
        378.5697937011719,
        163.90887451171875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 84 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Case Report Form 작성 지침",
      "font_size": 18.944515228271484,
      "font_name": "T10",
      "bbox": [
        161.19264221191406,
        76.35655212402344,
        435.3634338378906,
        99.08370971679688
      ],
      "page_num": 91,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 지침 사항",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        251.74356079101562,
        108.00196838378906,
        345.29248046875,
        119.94091796875
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 검정색 볼펜을 사용하여 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        146.7196502685547,
        305.5281677246094,
        159.9532012939453
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        168.6556854248047,
        420.9056396484375,
        181.8892364501953
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정해진 칸 이외의 여백에 기록하지 마십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        190.59170532226562,
        308.1667175292969,
        203.82525634765625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        65.12470245361328,
        212.64759826660156,
        412.0304260253906,
        225.8811492919922
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        65.12470245361328,
        234.58363342285156,
        531.8396606445312,
        247.8171844482422
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Unknown)”과 같이 분명한 이유를 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        78.43749237060547,
        256.5196533203125,
        357.5799560546875,
        269.7532043457031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        278.5755615234375,
        426.4226379394531,
        291.8091125488281
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례 기록서 수정 방법",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        243.94778442382812,
        323.0469665527344,
        353.08819580078125,
        334.9859313964844
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        361.644775390625,
        532.5113525390625,
        374.8783264160156
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유에 대하여 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        78.67736053466797,
        383.7006530761719,
        251.6773681640625,
        396.9342041015625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.6",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        195.97378540039062,
        405.6366882324219,
        346.42120361328125,
        418.8702392578125
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10/03/30 홍길동(오기)",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        195.97378540039062,
        405.6366882324219,
        346.42120361328125,
        418.8702392578125
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) Hb 8.6 → Hb 8.6",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        105.06305694580078,
        427.5727233886719,
        215.523193359375,
        440.8062744140625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        65.12470245361328,
        471.56463623046875,
        503.900634765625,
        484.7981872558594
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증례기록서 작성에 대한 세부사항",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        217.68202209472656,
        516.0360107421875,
        379.3536376953125,
        527.9749755859375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        554.7537231445312,
        478.47442626953125,
        567.9872436523438
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        76.03878784179688,
        576.6897583007812,
        441.8942565917969,
        589.9232788085938
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        598.6257934570312,
        471.5181884765625,
        611.8593139648438
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        620.6817016601562,
        532.5113525390625,
        633.9152221679688
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        79.75677490234375,
        642.6177368164062,
        153.81040954589844,
        655.8512573242188
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 85 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 이니셜(영문)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        65.00476837158203,
        100.45022583007812,
        487.11517333984375,
        112.37922668457031
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자식별코드",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.00476837158203,
        100.45022583007812,
        487.11517333984375,
        112.37922668457031
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 방문일 (YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        65.00476837158203,
        100.45022583007812,
        487.11517333984375,
        112.37922668457031
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "◈ 피험자에게 서면 동의를 받았습니까?",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        87.19274139404297,
        123.10546875,
        464.1484375,
        135.04441833496094
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        87.19274139404297,
        123.10546875,
        464.1484375,
        135.04441833496094
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        87.19274139404297,
        123.10546875,
        464.1484375,
        135.04441833496094
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서면 동의 일자(YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        117.89610290527344,
        154.0316619873047,
        250.36343383789062,
        165.96066284179688
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 인구학적 정보",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        207.01376342773438,
        144.76113891601562,
        218.9527130126953
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생년월일(YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        71.96099853515625,
        236.74127197265625,
        174.32467651367188,
        248.67027282714844
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성별",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        199.931640625,
        236.74127197265625,
        510.80316162109375,
        252.05490112304688
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 남",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        199.931640625,
        236.74127197265625,
        510.80316162109375,
        252.05490112304688
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 여",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        199.931640625,
        236.74127197265625,
        510.80316162109375,
        252.05490112304688
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 측정된 기록의 정보",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        288.5246887207031,
        170.7870330810547,
        300.4636535644531
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나이",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        311.179931640625,
        82.15506744384766,
        323.118896484375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 채취일",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        335.3934631347656,
        118.73482513427734,
        347.3324279785156
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 혈관 질환 유무",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        379.9847412109375,
        149.678955078125,
        391.9237060546875
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        405.037353515625,
        97.60087585449219,
        416.976318359375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        211.80520629882812,
        398.4149475097656,
        474.8988952636719,
        408.36407470703125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 뇌졸중 □ 기타:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        211.80520629882812,
        414.4773864746094,
        368.2760009765625,
        424.426513671875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        431.5284118652344,
        91.87995147705078,
        443.4673767089844
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "◈ 경구용 항응고제 복용 유무",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        476.1196594238281,
        207.2477569580078,
        488.0586242675781
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        501.17230224609375,
        97.60087585449219,
        513.1112670898438
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 와파린 (용법:       mg/day)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        211.80520629882812,
        494.5498962402344,
        373.2987060546875,
        504.4990234375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타(예, NOACs 등)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        211.80520629882812,
        510.6123352050781,
        391.66357421875,
        520.5614624023438
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        524.7864990234375,
        91.87995147705078,
        536.7254028320312
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "◈ 병력조사",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        61.64658737182617,
        566.6207275390625,
        414.5718078613281,
        578.5497436523438
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과거 1년 이내 및 현재의 병력이 있습니까",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        587.9573974609375,
        457.3121337890625,
        599.8864135742188
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 예    □ 아니오",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        61.64658737182617,
        587.9573974609375,
        457.3121337890625,
        599.8864135742188
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "NO",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        609.17431640625,
        446.15771484375,
        621.103271484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단명",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        609.17431640625,
        446.15771484375,
        621.103271484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생년월",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        61.64658737182617,
        609.17431640625,
        446.15771484375,
        621.103271484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지속여부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        609.17431640625,
        446.15771484375,
        621.103271484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수술여부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        609.17431640625,
        446.15771484375,
        621.103271484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        626.3155517578125,
        528.7334594726562,
        646.1558837890625
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 예    □ 아니오",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        61.64658737182617,
        626.3155517578125,
        528.7334594726562,
        646.1558837890625
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 예 →  수술명 :(    )",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        626.3155517578125,
        528.7334594726562,
        646.1558837890625
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 아니오 수술일 :(    )",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        410.5375061035156,
        642.258056640625,
        528.7334594726562,
        654.1870727539062
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        663.1153564453125,
        390.388427734375,
        675.0443115234375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 예    □ 아니오",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        61.64658737182617,
        663.1153564453125,
        390.388427734375,
        675.0443115234375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 예 →  수술명 :(    )",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        410.5375061035156,
        655.0841064453125,
        528.7334594726562,
        667.0130615234375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오 수술일 :(    )",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        410.5375061035156,
        671.026611328125,
        528.7334594726562,
        682.9556274414062
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 검사 결과",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        709.984130859375,
        123.6530532836914,
        721.9230346679688
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Hematocrit (%):",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        732.7295532226562,
        285.80859375,
        742.6787109375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "%",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        732.7295532226562,
        285.80859375,
        742.6787109375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PT (INR):",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        754.0662231445312,
        284.6389465332031,
        764.015380859375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INR",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        754.0662231445312,
        284.6389465332031,
        764.015380859375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 86 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        70.60612487792969,
        541.8339233398438,
        81.63407135009766
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        84.87052917480469,
        301.63604736328125,
        95.89848327636719
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례 서식지(예시)",
      "font_size": 20.98284912109375,
      "font_name": "T10",
      "bbox": [
        183.98028564453125,
        160.1449737548828,
        409.8718566894531,
        185.31747436523438
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Special form)",
      "font_size": 20.98284912109375,
      "font_name": "Haansoft Batang",
      "bbox": [
        224.39837646484375,
        230.2420196533203,
        370.4189758300781,
        251.21908569335938
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 87 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SPECIAL FORM 이상사례서식지",
      "font_size": 18.944515228271484,
      "font_name": "T10",
      "bbox": [
        143.202392578125,
        76.35655212402344,
        453.3533020019531,
        99.08370971679688
      ],
      "page_num": 94,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ ‘이상 의료기기’의 반응",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        124.06442260742188,
        184.09974670410156,
        136.0033721923828
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        140.12686157226562,
        532.9911499023438,
        150.91506958007812
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. 이용 가능한 임상시험용 의료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        154.51113891601562,
        532.9911499023438,
        165.29934692382812
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기 정보를 참고하여 인과관계를 평가한다.",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        168.8954315185547,
        258.6158447265625,
        179.6836395263672
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ ‘중증도’ 판정 참고기준",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        197.5441131591797,
        184.09974670410156,
        209.48306274414062
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 경증 (mild)",
      "font_size": 8.992650032043457,
      "font_name": "T10",
      "bbox": [
        76.5185317993164,
        213.6065673828125,
        139.85020446777344,
        224.394775390625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        227.9908447265625,
        532.9911499023438,
        238.779052734375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수 있는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        242.3751220703125,
        143.80206298828125,
        253.163330078125
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중증도 (moderate)",
      "font_size": 8.992650032043457,
      "font_name": "T10",
      "bbox": [
        76.5185317993164,
        256.7593994140625,
        170.7928466796875,
        267.547607421875
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        271.1436767578125,
        438.0025939941406,
        281.931884765625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 중증 (severe)",
      "font_size": 8.992650032043457,
      "font_name": "T10",
      "bbox": [
        76.5185317993164,
        285.5279541015625,
        149.4435272216797,
        296.316162109375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        299.9122314453125,
        357.1664123535156,
        310.700439453125
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ ‘의료기기와의 관련성’ 판정 참고기준",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        328.5609436035156,
        248.9845733642578,
        340.4999084472656
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 평가 불가능 (Unknown)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        344.7432556152344,
        189.1431884765625,
        355.5314636230469
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        359.1275329589844,
        444.5990295410156,
        369.9157409667969
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 관련성이 없음 (Not related)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        373.5118103027344,
        205.45526123046875,
        384.3000183105469
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        387.8960876464844,
        416.6541748046875,
        398.6842956542969
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 관련성이 적음 (Unlikely)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        402.2803649902344,
        192.7412567138672,
        413.0685729980469
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        416.6646423339844,
        532.9911499023438,
        427.4528503417969
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        431.0489196777344,
        107.94149780273438,
        441.8371276855469
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4)관련성이 의심됨 (Possible)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        445.4331970214844,
        196.57974243164062,
        456.2214050292969
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        459.8175048828125,
        532.9911499023438,
        470.605712890625
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        474.2017822265625,
        532.9911499023438,
        484.989990234375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생하였을 가능성이 있는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        488.5860595703125,
        220.32058715820312,
        499.374267578125
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5)관련성이 많음 (Probable)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        502.9703369140625,
        189.6238250732422,
        513.758544921875
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        517.3546142578125,
        532.9911499023438,
        528.142822265625
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        531.7388916015625,
        332.5797424316406,
        542.527099609375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 관련성이 명백함(Definite)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        546.1231689453125,
        195.02059936523438,
        556.911376953125
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        81.55580139160156,
        560.5074462890625,
        532.9911499023438,
        571.295654296875
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        574.8917236328125,
        532.9911499023438,
        585.679931640625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특징으로는 합리적인 설명을 할 수 없는 경우.",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        89.95124816894531,
        589.2760009765625,
        280.92376708984375,
        600.064208984375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 중대한 이상사례/ 이상 의료기기의 반응",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        617.9246826171875,
        263.25732421875,
        629.8636474609375
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 사망을 초래하거나 생명을 위협하는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        633.9871215820312,
        255.34161376953125,
        644.7753295898438
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 입원 또는 입원 기간의 연장이 필요한 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        76.5185317993164,
        648.3713989257812,
        264.216796875,
        659.1596069335938
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 88 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 이니셜(영문)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        67.04366302490234,
        101.85903930664062,
        485.5559997558594,
        111.80816650390625
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자식별코드",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        67.04366302490234,
        101.85903930664062,
        485.5559997558594,
        111.80816650390625
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 방문일 (YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        67.04366302490234,
        101.85903930664062,
        485.5559997558594,
        111.80816650390625
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참 고 코 드",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        268.5344543457031,
        141.68515014648438,
        328.9817199707031,
        154.918701171875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        70.28190612792969,
        164.3404083251953,
        97.26728057861328,
        175.1286163330078
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "범위",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        74.7195053100586,
        178.7246856689453,
        92.70975494384766,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        118.85558319091797,
        164.3404083251953,
        145.84097290039062,
        175.1286163330078
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        123.29317474365234,
        178.7246856689453,
        141.28341674804688,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기와의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        179.30282592773438,
        164.3404083251953,
        233.2735595703125,
        175.1286163330078
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        192.85548400878906,
        178.7246856689453,
        219.84085083007812,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        266.3756408691406,
        164.3404083251953,
        311.35125732421875,
        175.1286163330078
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 조치",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        268.6543884277344,
        171.5325469970703,
        517.3995971679688,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        268.6543884277344,
        171.5325469970703,
        517.3995971679688,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        268.6543884277344,
        171.5325469970703,
        517.3995971679688,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중대성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        268.6543884277344,
        171.5325469970703,
        517.3995971679688,
        189.5128936767578
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 국소",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        227.8709716796875,
        93.66923522949219,
        238.6591796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 전신",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        242.2552490234375,
        93.66923522949219,
        253.04345703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 경증",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        113.09870147705078,
        220.6788330078125,
        142.36285400390625,
        231.467041015625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 중등",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        113.09870147705078,
        235.0631103515625,
        142.36285400390625,
        245.851318359375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 중증",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        113.09870147705078,
        249.4473876953125,
        142.36285400390625,
        260.235595703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 평가 불가능",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        161.67237854003906,
        199.1024169921875,
        222.3594970703125,
        209.890625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 관련성이 없음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        161.67237854003906,
        213.4866943359375,
        231.3546142578125,
        224.27490234375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 관련성이 적음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        161.67237854003906,
        227.8709716796875,
        231.3546142578125,
        238.6591796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 관련성이 의심됨",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        161.67237854003906,
        242.2552490234375,
        240.3497314453125,
        253.04345703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 관련성이 많음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        161.67237854003906,
        256.6395263671875,
        231.3546142578125,
        267.427734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 관련성이 명백함",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        161.67237854003906,
        271.0238037109375,
        240.3497314453125,
        281.81201171875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 이식체",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        261.2184143066406,
        213.4866943359375,
        299.3577575683594,
        224.27490234375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "삽입유지",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        270.21356201171875,
        227.8709716796875,
        306.19403076171875,
        238.6591796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 이식체",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        261.2184143066406,
        242.2552490234375,
        299.3577575683594,
        253.04345703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제거",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        270.21356201171875,
        256.6395263671875,
        288.20379638671875,
        267.427734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 치료하지 않음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        326.70294189453125,
        213.4866943359375,
        396.3851623535156,
        224.27490234375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 약물치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        326.70294189453125,
        227.8709716796875,
        373.9573059082031,
        238.6591796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 비약물치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        326.70294189453125,
        242.2552490234375,
        382.95245361328125,
        253.04345703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 수술적치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        326.70294189453125,
        256.6395263671875,
        382.95245361328125,
        267.427734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 회복",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        417.7336120605469,
        213.4866943359375,
        446.99774169921875,
        224.27490234375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 진행중",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        417.7336120605469,
        227.8709716796875,
        455.99285888671875,
        238.6591796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 후유증",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        417.7336120605469,
        242.2552490234375,
        455.99285888671875,
        253.04345703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 사망",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        417.7336120605469,
        256.6395263671875,
        446.99774169921875,
        267.427734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 중대하지",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        474.8226623535156,
        220.6788330078125,
        521.9570922851562,
        231.467041015625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        483.8177795410156,
        235.0631103515625,
        501.8080139160156,
        245.851318359375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 중대함",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        474.8226623535156,
        249.4473876953125,
        512.9619750976562,
        260.235595703125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        80.1165771484375,
        328.4410705566406,
        98.10682678222656,
        339.2292785644531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응명",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        75.55905151367188,
        342.8253479003906,
        102.54442596435547,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생일.",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        135.166748046875,
        321.2489318847656,
        164.346923828125,
        332.0371398925781
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종료일",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        136.24615478515625,
        335.6332092285156,
        163.23153686523438,
        346.4214172363281
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(yy/mm/dd)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        125.09220123291016,
        350.0174865722656,
        174.51141357421875,
        360.8056945800781
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지속시간",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        189.6172332763672,
        321.2489318847656,
        225.59771728515625,
        332.0371398925781
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(hours/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        192.7355499267578,
        335.6332092285156,
        222.5091094970703,
        346.4214172363281
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "minutes)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        189.8571014404297,
        350.0174865722656,
        225.36386108398438,
        360.8056945800781
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        240.589599609375,
        328.4410705566406,
        267.5749816894531,
        339.2292785644531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "범위",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        245.1471405029297,
        342.8253479003906,
        263.13739013671875,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        278.48907470703125,
        328.4410705566406,
        305.47442626953125,
        339.2292785644531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        283.0466003417969,
        342.8253479003906,
        301.0368347167969,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기와의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        314.8293762207031,
        328.4410705566406,
        350.80987548828125,
        339.2292785644531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        319.2669677734375,
        342.8253479003906,
        346.2523193359375,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기에",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        368.56024169921875,
        328.4410705566406,
        395.5456237792969,
        339.2292785644531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 조치",
      "font_size": 8.992650032043457,
      "font_name": "T21",
      "bbox": [
        361.8439025878906,
        335.6332092285156,
        505.0462646484375,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        361.8439025878906,
        335.6332092285156,
        505.0462646484375,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        361.8439025878906,
        335.6332092285156,
        505.0462646484375,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중대성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        361.8439025878906,
        335.6332092285156,
        505.0462646484375,
        353.6135559082031
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        385.13909912109375,
        155.4657440185547,
        395.92730712890625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        385.13909912109375,
        155.4657440185547,
        395.92730712890625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        399.52337646484375,
        155.4657440185547,
        410.31158447265625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        399.52337646484375,
        155.4657440185547,
        410.31158447265625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        432.7270812988281,
        155.4657440185547,
        443.5152893066406
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        432.7270812988281,
        155.4657440185547,
        443.5152893066406
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        447.11138916015625,
        155.4657440185547,
        457.89959716796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        447.11138916015625,
        155.4657440185547,
        457.89959716796875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        480.4349670410156,
        155.4657440185547,
        491.2231750488281
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        480.4349670410156,
        155.4657440185547,
        491.2231750488281
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        494.8192443847656,
        155.4657440185547,
        505.6074523925781
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        494.8192443847656,
        155.4657440185547,
        505.6074523925781
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        528.142822265625,
        155.4657440185547,
        538.9310302734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        528.142822265625,
        155.4657440185547,
        538.9310302734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        542.527099609375,
        155.4657440185547,
        553.3153076171875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        542.527099609375,
        155.4657440185547,
        553.3153076171875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        575.8507080078125,
        155.4657440185547,
        586.638916015625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        575.8507080078125,
        155.4657440185547,
        586.638916015625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        590.2349853515625,
        155.4657440185547,
        601.023193359375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.9268798828125,
        590.2349853515625,
        155.4657440185547,
        601.023193359375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 89 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)",
      "font_size": 15.946965217590332,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        73.40022277832031,
        438.8698425292969,
        521.4202270507812,
        460.07470703125
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        483.8709411621094,
        354.406494140625,
        497.10406494140625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        483.8709411621094,
        354.406494140625,
        497.10406494140625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처 식품의약품안전처 식품의약품안전평가원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.52178192138672,
        483.8709411621094,
        354.406494140625,
        497.10406494140625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        509.52288818359375,
        227.63662719726562,
        522.7560424804688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        509.52288818359375,
        227.63662719726562,
        522.7560424804688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일 2016년 12월",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.52178192138672,
        509.52288818359375,
        227.63662719726562,
        522.7560424804688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        535.1748657226562,
        199.57135009765625,
        548.4080200195312
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        535.1748657226562,
        199.57135009765625,
        548.4080200195312
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        535.1748657226562,
        199.57135009765625,
        548.4080200195312
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "손여원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.52178192138672,
        535.1748657226562,
        199.57135009765625,
        548.4080200195312
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편 집 위 원 장 정희교",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.52178192138672,
        560.8268432617188,
        199.57135009765625,
        574.0599975585938
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        587.078125,
        527.7354736328125,
        608.22265625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "집",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        587.078125,
        527.7354736328125,
        608.22265625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        587.078125,
        527.7354736328125,
        608.22265625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        587.078125,
        527.7354736328125,
        608.22265625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.52178192138672,
        587.078125,
        527.7354736328125,
        608.22265625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "김윤영, 김서윤, 김민정",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        169.5880889892578,
        603.020751953125,
        273.713623046875,
        616.25390625
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        676.0209350585938,
        159.39361572265625,
        689.2540893554688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        676.0209350585938,
        159.39361572265625,
        689.2540893554688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.52178192138672,
        676.0209350585938,
        159.39361572265625,
        689.2540893554688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        169.5880889892578,
        642.2178955078125,
        520.5173950195312,
        655.4510498046875
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        169.5880889892578,
        659.47900390625,
        272.9921569824219,
        672.712158203125
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 체외진단기기과",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        169.5880889892578,
        676.7401733398438,
        314.4686279296875,
        689.9733276367188
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화: 043-719-4652~63",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        169.5880889892578,
        694.0012817382812,
        278.2120056152344,
        707.2344360351562
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스: 043-719-4650",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        169.5880889892578,
        711.38232421875,
        260.10260009765625,
        724.615478515625
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 90 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.4686279296875,
        316.52520751953125,
        798.4177856445312
      ],
      "page_num": 97,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        115.1375961303711,
        362.53839111328125,
        479.6787414550781,
        379.75738525390625
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        232.43402099609375,
        383.2757568359375,
        362.3251953125,
        400.4947509765625
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 의료기기심사부 체외진단기기과",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        135.04681396484375,
        404.1329345703125,
        459.8318176269531,
        421.3519287109375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TEL : 043-719-4652~63  FAX : 043-719-4650",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        159.87335205078125,
        424.87030029296875,
        434.9461669921875,
        442.08929443359375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "http://www.mfds.go.kr/medicaldevice",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        188.17800903320312,
        445.6076354980469,
        406.6734619140625,
        462.8266296386719
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016. 12.\n의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다. 주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다. | 95%를 포함하는 구간을 보고한다. | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까? | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다. |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다. | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다. 냉장 또는 냉동보관을 피해 주십시오. | 조사과정과 결과를 보고서에 문서화한다. | 1. 평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다. | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2. 관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1. 이식체 | 1. 치료하지 않음 | 1. 회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다. | 한다. | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다. | 장비를 이용하여 INR 값을 측정하고 기록한다. | 그 결과를 기록한다. | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다. | 위험 방지시험에 관한 요구사항이 적용된다. | 챔버에 8시간 동안 놓아둔다. | 1. 경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1. 중대하지 |\n| 평균의 차이(편차)를 구한다. | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3. 관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다. | 삽입유지 | 2. 약물치료 | 2. 진행중 |\n| 2. 중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4. 관련성이 의심됨 | 2. 이식체 | 3. 비약물치료 | 3. 후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다. | 압박 지혈을 한다. | 평균 및 표준편차를 산출한다. | 절실한 상태이다. | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3. 중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2. 중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5. 관련성이 많음 | requirements | 제거 | 4. 수술적치료 | 4. 사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다. | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6. 관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다. | 전체의 90% 이상이어야 한다. | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다. | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다. | 방법 등)에 대한 실험 프로토콜을 제시한다. | 포장용기 또는 포장지를 벗기지 않는다.) | 값을 측정하고 그 결과를 기록한다. | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. | 한다. | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다. | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동. |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다. | 기록한다. | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일. | 지속시간 |\n| 여부 | 포함해야 한다(표 1). 6.0을 넘는 INR 값은 제외하는 것이 좋다. | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다. | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다. | ㉮ (사)에 기술된 성능 시험을 수행한다. | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다. | 값의 차이를 산출한다. | INR 값 편차 및 %편차를 산출한다. | 대한 INR 값 편차 및 %편차를 산출한다. | 마지막시점을 포함하여 3회 시점으로 설정한다. | 값을 측정하고 기록한다. | 적용된다. | 정량적으로 표현 | Ver. 1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함. | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.) | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다. | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다. | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다. | 유지하여야 한다. | 투여-응답 기법을 적용하여 재평가 한다.) | 기록한다. | 내용입니까? | 표 1. 시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다. | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다. | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다. | 중반기에 기기를 순환한다. | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다. | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다. | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다. | 수집한다. | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다. | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다. | 보고한다. | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까? | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다. | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다. | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다. | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다. | 평균을 산출한다. | 값을 측정하고 그 결과를 기록한다. | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다. | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다. | 데이터 수집용지에 기록한다. 대조기기의 결과 값은 기준 값으로 간주한다. | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다. |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다. | 포장용기 또는 포장지를 벗기지 않는다.) | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다. | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다. | stability of in vitro diagnostic reagents | 반복한다. | 놓는다. | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다. | 값을 측정하고 그 결과를 기록한다. | 사항이 적용된다. |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다. | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다. | 측정가능 상태인지 확인한다. | 에러율(%)을 산출한다. | 포장용기 또는 포장지를 벗기지 않는다.) | 표 1. 성능 기준 |\n| 주십시오. | 으로 의식 소실이 유발되는 것이다. | 수 있는 고농도를 사용 할 것을 권장한다.) |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다. | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다. | / | / |\n| 같이 INR 측정구간에 포함되어야 한다. | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다. | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다. | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우. | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다. | 수행한다. | 사항이 적용된다. | 민원인을 구속하는 내용이 있습니까? |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다. | 포장용기 또는 포장지를 벗기지 않는다.) | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다. | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다. | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다. | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다. | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.) | 허용기준과 비교되어야 한다. | 반복한다. | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다. | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다. | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음. |\n| 주십시오. | 값을 측정하고 기록한다. |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.) | 신뢰구간)와 통합변동계수를 계산한다. | 하고, 모든 측정기가 측정가능 상태인지 확인한다. | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다. | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.) | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1. 시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다. |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다. | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다. | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다. | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다. | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) | 값을 측정하고 그 결과를 기록한다. | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. 또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. 관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다. | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함. | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. | 제공하여 원칙과 절차를 수립하여 제시함. |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. | 경험이 있는 자가 선정되어야 함. | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. | ➀ 최소검출한계 설정 배경을 제시해야 한다. |\n| 10.2.1. 피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다. | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. | - 사용기한이 지난 검사지는 사용하지 않습니다. | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다. | 35% 이하 또는 50% 이상인 경우 |\n| 1. 국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다. |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2. 전신 | 직명 등 인적사항을 기재함. | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함. | - 검사지는 반드시 마른 손으로 만져야 합니다. | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다. | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system. Thromb Res 2008;123:381-389. | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4. 휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. | 1 | 함께 기재함. | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다. |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다. | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함. | 산업협회, 이승노) | 뢰자에게 보내야 한다. | 동의서의 사본을 제공받을 것임을 알고 있습니다. | 사유를 기재한다. |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. | ➄ ➂∼➃번의 과정을 4회 반복한다. | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81. |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다. |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ. 안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1. 적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. 약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. 휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5. 안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6. 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7. 안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8. 참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ. 임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n- - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. 적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n<!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n- - 2 -\n<!-- PAGE_9 -->\n###### 2. 약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3. 휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가. 개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다. 널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다. 즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다. 항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다. 더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다. 프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다. 휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n<!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n- - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나. 제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다. 국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4. 휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가. 안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음.**\n| the CoaguChek XS system. Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다. | 피험자의 부작용에 대한 내용은 해당사항 없다. |\n| 수 있다. | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다. | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다. | 시킬 수 있다. |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. | 사유에 대하여 기록하여 주십시오. |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다.**\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함. | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.**\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다. | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다. | 는 그 이유의 타당성을 면밀히 검토하여야 한다. |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나. 성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉. 임상시험 종료 후 남은 제품은 폐기한다. | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다. | 적극적으로 대응한다. | Instruments | 시스템 정확도 평가에서 제외할 수 없다. | 성능기준을 만족해야 한다. | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. 이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함. | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다. | 사용하여 INR 값을 2회 반복 측정한다. | 그 결과를 기록한다. | 기기가 측정가능 상태인지 확인한다. | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) | 기록한다. | 기록한다. | 값을 측정하고 기록한다. | 내열성 시험에 관한 요구사항이 적용된다. | 놓는다. | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다.**\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다. | 기술 하는 것을 말함. |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다. | 함께 관리함. 임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다. | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함. 이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함. 따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. 또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다. 안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5. 안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가. 전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n<!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n<!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다. 적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다. 매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다. 제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다. 측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다. 평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n<!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n<!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n<!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나. 전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6. 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가. 측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n<!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n<!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n<!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나. 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다. 평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n- - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n<!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다. 직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n<!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n<!-- PAGE_27 -->\n###### 라. 최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n- - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다. (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n- - 22 -\n<!-- PAGE_29 -->\n###### 마. 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n<!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다. (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n<!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n<!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바. 간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n<!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n<!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다. (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n- - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n<!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n<!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다. (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다. 간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n<!-- PAGE_32 -->\n###### 사. 사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n<!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다. 참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다. 실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다. (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n<!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n<!-- PAGE_34 -->\n###### 아. 기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n<!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7. 안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가. 개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n<!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n<!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n<!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다. 성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n<!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n<!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다. 성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n<!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나. 개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n<!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n- - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다. 휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n<!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다. (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n<!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8. 참고 문헌\n\n- 가. 의료기기 품목 및 품목별 등급에 관한 규정\n- 나. 체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다. 개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라. 의료기기 기준규격 (66. 개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머. 의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al. Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS. Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement. ThrombRes1998;92:11-7.\n\n- 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting. ThrombRes2009;123:909-13.\n\n- - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다. 기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다. 즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n<!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다. 또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n<!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다. 부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다. 또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다. 그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1. 임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2. 임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가. 임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n- - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가. 시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나. 시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. 공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가. 의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨. 의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5. 임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가. 의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나. 모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다. 임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n- - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6. 임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가. 검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n- 나. 배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다. 한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다. PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다. 국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다. 이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n- - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1. 임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2. 임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1. 임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까? | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.**\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오.**\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다.**\n**monitors: is a periodical control of their performance useful? Thromb Res 2009;123:775-9.**\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.**\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3. 임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다. 검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다. (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.) 검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다. 이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오. 코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다. 측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다. 검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다. (혈액 투입 대기시간은 120초 입니다.) 만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다. 측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다. 측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다. 측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n- - 48 -\n- 가. 7.4. 임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매. 낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n<!-- PAGE_56 -->\n###### 8. 피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). 흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n예시)\n\n- 8.1. 피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n- - 50 -\n15-40\n\n- 2.0-2.8\n- 1. 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2. 경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2. 피험자 제외기준\n- 1. 피험자의 임상정보를 알 수 없는 경우\n- 2. 직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3. Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3. 목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n- ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1). 6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n- - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9. 임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가. 식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1. 시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함. 임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2. 시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. 또한 동의를 서명한\n\n연월일을 기록한다. 또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n- (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n- ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n- ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n- - 55 -\na. 범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\nb. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n- 10.2. 설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음. 피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n<!-- PAGE_63 -->\n###### 11. 관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1. 관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2. 관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다. 대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다. 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다. 피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n- - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n- (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n- - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다. 반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n<!-- PAGE_66 -->\n###### 12. 예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. 침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. 어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다. 이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. 채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n- - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n- - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다. 합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n정확한 측정을 위해 습기 찬 장소는 피해야 합니다. 예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n- - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n- - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다. 직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다. 그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n- - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n- - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n- - 사용기한이 지난 시약은 사용하지 않습니다.\n- - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n- - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n- - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. 또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13. 중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다. 그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n- 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1. 참조).\n\n- - 63 -\n표 1. 중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n- 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n4) 아래 표 2. 의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n- - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2. 시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다. 증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n- - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함. 그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함. 의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다. 기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14. 유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1. 유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n- - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2. 유효성(성능) 평가방법\n- 가. 데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다. 도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나. 아래의 결과를 보고한다.\n1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다. 최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.**\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다.**\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오.**\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n- 라. 상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다. 신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다. 대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다. 시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다. 시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다. 차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1. 피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n- 2. 시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. 다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n- - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음. 이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16. 피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n- - 71 -\n- 1. 참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다. 이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다. 충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오. 귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n- 2. 인체 유래물이란?\n- - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. 본 동의서에서는\n\n- 3. 연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n- - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n- - 72 -\n- 4. 연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. 문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다. 이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다. 본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5. 예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. 그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6. 연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다. 또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n- 7. 검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n- - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n- - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. 만약\n\n- 8. 자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. 또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. 동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9. 개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. 이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다. 수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. 귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n- - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10. 연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\nü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n* 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n- - 75 -\n<!-- PAGE_82 -->\n###### 17. 피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함. 피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. 이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n- - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18. 임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n- - 77 -\n<!-- PAGE_84 -->\n###### 19. 피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n- 19.1. 임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2. 임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n- 19.3. 시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n- (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4. 의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5. 모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n- 19.6. 임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n- - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다. 만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다. 그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7. 피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n- 19.8. 피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. 이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9. 기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다. 제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n- - 81 -\n<!-- PAGE_88 -->\n###### 20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1. 임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다. 임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2. 임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n- (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 21. 참고문헌\n\n- 1. KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2. Plesch W, Wolf T, Breitenbeck N, et al. Results of the performance verification of the\n- 3. Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG. Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n- 4. Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n- - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n- - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 162,
        "word_count": 30,
        "page_number": 1,
        "window_text": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
        "original_sentence": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "12.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 1,
        "window_text": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다. ",
        "original_sentence": "12.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 709,
        "word_count": 122,
        "page_number": 2,
        "window_text": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다. ",
        "original_sentence": "의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 128,
        "word_count": 23,
        "page_number": 3,
        "window_text": "발간등록번호\n\n안내서-0661-01\n\n<!-- PAGE_1 -->\n## 휴대용 혈액응고시간 측정시스템\n\n<!-- PAGE_1 -->\n## 안전성·성능 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 평가 가이드라인\n\n<!-- PAGE_1 -->\n## (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.  | 95%를 포함하는 구간을 보고한다. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 154,
        "word_count": 49,
        "page_number": 3,
        "window_text": "12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.  | 95%를 포함하는 구간을 보고한다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. ",
        "original_sentence": "등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 67,
        "window_text": "의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-053\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 휴대용 혈액응고시간 측정시스템 안전성·\n\n<!-- PAGE_2 -->\n###### 성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### 제정\n\n<!-- PAGE_2 -->\n###### 안내서-0661-01\n\n<!-- PAGE_2 -->\n###### 「휴대용 혈액응고시간 측정시스템 안전성·성능\n\n<!-- PAGE_2 -->\n###### 및 임상시험계획서 평가 가이드라인(민원인\n\n<!-- PAGE_2 -->\n###### 안내서)」 명칭 변경 및 제·개정 점검표 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.  | 95%를 포함하는 구간을 보고한다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "| 95%를 포함하는 구간을 보고한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 13,
        "window_text": "<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험계획서 평가\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.  | 95%를 포함하는 구간을 보고한다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까?  | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다. ",
        "original_sentence": "| 95%를 포함하는 구간을 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 20,
        "window_text": "등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| 높은 치료 범위 | 3.1 - 4.5 | 혈장 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.  | 95%를 포함하는 구간을 보고한다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까?  | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다. ",
        "original_sentence": "| 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 117,
        "word_count": 26,
        "page_number": 6,
        "window_text": "주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴 것이다.  | 95%를 포함하는 구간을 보고한다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까?  | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다.  | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. ",
        "original_sentence": "| 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 38,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| 95%를 포함하는 구간을 보고한다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까?  | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다.  | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다. ",
        "original_sentence": "| 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "|\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까?  | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다.  | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다.  냉장 또는 냉동보관을 피해 주십시오. ",
        "original_sentence": "|\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 67,
        "word_count": 18,
        "page_number": 14,
        "window_text": "| 10-30 | 3.8-4.5 |\n| 정도 | self-testing of oral anticoagulant therapy | 보조성분 | 관련성 | 템 평가규격 |\n| 검체의 | 지침서ㆍ안내서가 있습니까?  | 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다.  | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다.  냉장 또는 냉동보관을 피해 주십시오.  | 조사과정과 결과를 보고서에 문서화한다. ",
        "original_sentence": "| 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 195,
        "word_count": 42,
        "page_number": 16,
        "window_text": "| 구간 | INR 값 | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다.  | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다.  냉장 또는 냉동보관을 피해 주십시오.  | 조사과정과 결과를 보고서에 문서화한다.  | 1. ",
        "original_sentence": "| Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "냉장 또는 냉동보관을 피해 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 54,
        "window_text": "|\n| ㉰ 진동시험이 종료된 후, 성능시험을 반복한다.  | 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다.  냉장 또는 냉동보관을 피해 주십시오.  | 조사과정과 결과를 보고서에 문서화한다.  | 1.  평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다. ",
        "original_sentence": "냉장 또는 냉동보관을 피해 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "| 조사과정과 결과를 보고서에 문서화한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 20,
        "window_text": "| 해결하기 위해 잠재적인 해결책을 식별하기 위함 | ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다.  냉장 또는 냉동보관을 피해 주십시오.  | 조사과정과 결과를 보고서에 문서화한다.  | 1.  평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다.  | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2. ",
        "original_sentence": "| 조사과정과 결과를 보고서에 문서화한다. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| Evaluation | of | Precision | of | Quantitative | Measurement | [표 10] 중간 정밀도 결과 예시 | 5-chloro-2-methyl-4-isothiazol | -3-one 적량 | 자사규격 |\n| 1-10 | 4.6-6.0 | 신고 | 심사 등에 관한 규정」(식약처 고시) |\n| 피합니다.  냉장 또는 냉동보관을 피해 주십시오.  | 조사과정과 결과를 보고서에 문서화한다.  | 1.  평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다.  | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2.  관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 77,
        "word_count": 20,
        "page_number": 6,
        "window_text": "냉장 또는 냉동보관을 피해 주십시오.  | 조사과정과 결과를 보고서에 문서화한다.  | 1.  평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다.  | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2.  관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1.  이식체 | 1. ",
        "original_sentence": "평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 193,
        "word_count": 48,
        "page_number": 3,
        "window_text": "| 조사과정과 결과를 보고서에 문서화한다.  | 1.  평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다.  | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2.  관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1.  이식체 | 1.  치료하지 않음 | 1. ",
        "original_sentence": "| [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 36,
        "word_count": 12,
        "page_number": 6,
        "window_text": "| 1.  평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다.  | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2.  관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "이식체 | 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 6,
        "window_text": "평가 불가능 | (보존제) | 비 치료적 범위 | 2.0 미만 | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 |\n| 추세이다.  | [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2.  관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.  | 한다. ",
        "original_sentence": "이식체 | 1. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "치료하지 않음 | 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| [표 2] 혈액응고시간분석기 국내업체 허가사항 |\n| 외부 오염 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Methods; Approved Guideline | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 | 한 기준 가이드라인 |\n| 구간 | INR 값 | 변동계수(%CV) | 2.  관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.  | 한다.  | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다. ",
        "original_sentence": "치료하지 않음 | 1. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 50,
        "word_count": 11,
        "page_number": 3,
        "window_text": "관련성이 없음 | 낮은 치료 범위 | 2.0 - 3.0 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.  | 한다.  | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.  | 장비를 이용하여 INR 값을 측정하고 기록한다. ",
        "original_sentence": "회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 20,
        "window_text": "이식체 | 1.  치료하지 않음 | 1.  회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.  | 한다.  | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.  | 장비를 이용하여 INR 값을 측정하고 기록한다.  | 그 결과를 기록한다. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "| 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 9,
        "window_text": "치료하지 않음 | 1.  회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.  | 한다.  | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.  | 장비를 이용하여 INR 값을 측정하고 기록한다.  | 그 결과를 기록한다.  | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
        "original_sentence": "| 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "| 장비를 이용하여 INR 값을 측정하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 20,
        "window_text": "회복 |\n| ㉱ IEC 60068-2-64에 기술된 진동시험에 관한 요구사항이 적용된다.  | 한다.  | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.  | 장비를 이용하여 INR 값을 측정하고 기록한다.  | 그 결과를 기록한다.  | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 위험 방지시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 장비를 이용하여 INR 값을 측정하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| 한다.  | 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.  | 장비를 이용하여 INR 값을 측정하고 기록한다.  | 그 결과를 기록한다.  | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 위험 방지시험에 관한 요구사항이 적용된다.  | 챔버에 8시간 동안 놓아둔다. ",
        "original_sentence": "| 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| 장착하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 20,
        "window_text": "| 되어야 하며 최소 60명 피험자가 시험에 참가하도록 선정되어야 한다.  | 장비를 이용하여 INR 값을 측정하고 기록한다.  | 그 결과를 기록한다.  | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 위험 방지시험에 관한 요구사항이 적용된다.  | 챔버에 8시간 동안 놓아둔다.  | 1. ",
        "original_sentence": "| 장착하고, 모든 측정기가 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "| 위험 방지시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 장비를 이용하여 INR 값을 측정하고 기록한다.  | 그 결과를 기록한다.  | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 위험 방지시험에 관한 요구사항이 적용된다.  | 챔버에 8시간 동안 놓아둔다.  | 1.  경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1. ",
        "original_sentence": "| 위험 방지시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| 챔버에 8시간 동안 놓아둔다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 6,
        "window_text": "| 그 결과를 기록한다.  | 장착하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 위험 방지시험에 관한 요구사항이 적용된다.  | 챔버에 8시간 동안 놓아둔다.  | 1.  경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1.  중대하지 |\n| 평균의 차이(편차)를 구한다. ",
        "original_sentence": "| 챔버에 8시간 동안 놓아둔다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "| 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 장착하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 위험 방지시험에 관한 요구사항이 적용된다.  | 챔버에 8시간 동안 놓아둔다.  | 1.  경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1.  중대하지 |\n| 평균의 차이(편차)를 구한다.  | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 92,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| 위험 방지시험에 관한 요구사항이 적용된다.  | 챔버에 8시간 동안 놓아둔다.  | 1.  경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1.  중대하지 |\n| 평균의 차이(편차)를 구한다.  | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3.  관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다. ",
        "original_sentence": "경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "중대하지 |\n| 평균의 차이(편차)를 구한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 6,
        "window_text": "| 챔버에 8시간 동안 놓아둔다.  | 1.  경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1.  중대하지 |\n| 평균의 차이(편차)를 구한다.  | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3.  관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다.  | 삽입유지 | 2. ",
        "original_sentence": "중대하지 |\n| 평균의 차이(편차)를 구한다. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 141,
        "word_count": 29,
        "page_number": 16,
        "window_text": "| 1.  경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1.  중대하지 |\n| 평균의 차이(편차)를 구한다.  | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3.  관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다.  | 삽입유지 | 2.  약물치료 | 2. ",
        "original_sentence": "| 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 54,
        "word_count": 10,
        "page_number": 9,
        "window_text": "경증 | 보조성분 | IEC | 61010-1 | Safety | requirements | for | electrical | equipment | for | 1.  중대하지 |\n| 평균의 차이(편차)를 구한다.  | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3.  관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다.  | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 2. ",
        "original_sentence": "관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "| 삽입유지 | 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 6,
        "window_text": "중대하지 |\n| 평균의 차이(편차)를 구한다.  | 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3.  관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다.  | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 2.  중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4. ",
        "original_sentence": "| 삽입유지 | 2. "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "약물치료 | 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 예시) | Evaluation of the Linearity of Quantitative Measurement | 2-methyl-4-isothiazol-3-one | 적량 | 자사규격 |\n| 비 치료적 범위 | 2.0 미만 | ≤ 11% | 3.  관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다.  | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 2.  중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4.  관련성이 의심됨 | 2. ",
        "original_sentence": "약물치료 | 2. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "진행중 |\n| 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 11,
        "word_count": 4,
        "page_number": 6,
        "window_text": "관련성이 적음 | (Special form) | 임상시험책임자, 및 임상시험의뢰자에게 보고한다.  | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 2.  중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4.  관련성이 의심됨 | 2.  이식체 | 3. ",
        "original_sentence": "진행중 |\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 192,
        "word_count": 55,
        "page_number": 6,
        "window_text": "| 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 2.  중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4.  관련성이 의심됨 | 2.  이식체 | 3.  비약물치료 | 3. ",
        "original_sentence": "중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "관련성이 의심됨 | 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 6,
        "window_text": "약물치료 | 2.  진행중 |\n| 2.  중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4.  관련성이 의심됨 | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다. ",
        "original_sentence": "관련성이 의심됨 | 2. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "이식체 | 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 13,
        "window_text": "진행중 |\n| 2.  중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4.  관련성이 의심됨 | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다.  | 압박 지혈을 한다. ",
        "original_sentence": "이식체 | 3. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "비약물치료 | 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 13,
        "window_text": "중등 | (보존제) | [표 1] 혈액응고진단기기 시장규모 전망 | 높은 치료 범위 | 3.1 - 4.5 | 성별 | □ 남 | □ 여 | measurement, | control, | and | laboratory | use | – | Part | 1: | General | (‘16.10.31 기준) | 않음 |\n| 수 있는 경우 | 4.  관련성이 의심됨 | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다.  | 압박 지혈을 한다.  | 평균 및 표준편차를 산출한다. ",
        "original_sentence": "비약물치료 | 3. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 148,
        "word_count": 34,
        "page_number": 1,
        "window_text": "관련성이 의심됨 | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다.  | 압박 지혈을 한다.  | 평균 및 표준편차를 산출한다.  | 절실한 상태이다. ",
        "original_sentence": "후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "| 압박 지혈을 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 20,
        "window_text": "이식체 | 3.  비약물치료 | 3.  후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다.  | 압박 지혈을 한다.  | 평균 및 표준편차를 산출한다.  | 절실한 상태이다.  | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3. ",
        "original_sentence": "| 압박 지혈을 한다. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "| 평균 및 표준편차를 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 6,
        "window_text": "비약물치료 | 3.  후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다.  | 압박 지혈을 한다.  | 평균 및 표준편차를 산출한다.  | 절실한 상태이다.  | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3.  중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2. ",
        "original_sentence": "| 평균 및 표준편차를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "| 절실한 상태이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 42,
        "window_text": "후유증 |\n| Procedures; A Statistical Approach; Approved Guideline | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 | 한 기준 가이드라인 |\n| 서비스 확대에 좀 더 집중하고 있는 실정이다.  | 압박 지혈을 한다.  | 평균 및 표준편차를 산출한다.  | 절실한 상태이다.  | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3.  중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2.  중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5. ",
        "original_sentence": "| 절실한 상태이다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "| 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 65,
        "word_count": 12,
        "page_number": 10,
        "window_text": "| 압박 지혈을 한다.  | 평균 및 표준편차를 산출한다.  | 절실한 상태이다.  | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3.  중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2.  중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5.  관련성이 많음 | requirements | 제거 | 4. ",
        "original_sentence": "| 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 39,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| 평균 및 표준편차를 산출한다.  | 절실한 상태이다.  | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3.  중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2.  중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5.  관련성이 많음 | requirements | 제거 | 4.  수술적치료 | 4. ",
        "original_sentence": "중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 120,
        "word_count": 23,
        "page_number": 16,
        "window_text": "| 절실한 상태이다.  | 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3.  중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2.  중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5.  관련성이 많음 | requirements | 제거 | 4.  수술적치료 | 4.  사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다. ",
        "original_sentence": "중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "관련성이 많음 | requirements | 제거 | 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| 가운데 일치도의 근접성 | self-testing of oral anticoagulant therapy | 3.  중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2.  중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5.  관련성이 많음 | requirements | 제거 | 4.  수술적치료 | 4.  사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6. ",
        "original_sentence": "관련성이 많음 | requirements | 제거 | 4. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "수술적치료 | 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 6,
        "window_text": "중증 | 낮은 치료 범위 | 2.0 – 3.0 | ≤ 10% | 2.  중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5.  관련성이 많음 | requirements | 제거 | 4.  수술적치료 | 4.  사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6.  관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다. ",
        "original_sentence": "수술적치료 | 4. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 163,
        "word_count": 25,
        "page_number": 15,
        "window_text": "중대함 |\n| stability of in vitro diagnostic reagents | Interference | Testing | in | Clinical | Chemistry; | Approved | 5.  관련성이 많음 | requirements | 제거 | 4.  수술적치료 | 4.  사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6.  관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.  | 전체의 90% 이상이어야 한다. ",
        "original_sentence": "사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 88,
        "word_count": 22,
        "page_number": 3,
        "window_text": "관련성이 많음 | requirements | 제거 | 4.  수술적치료 | 4.  사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6.  관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.  | 전체의 90% 이상이어야 한다.  | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다. ",
        "original_sentence": "| 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 6,
        "window_text": "수술적치료 | 4.  사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6.  관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.  | 전체의 90% 이상이어야 한다.  | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.  | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다. ",
        "original_sentence": "관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "| 전체의 90% 이상이어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 20,
        "window_text": "사망 |\n| self-testing of oral anticoagulant therapy | (사유 :                                                                 ) |\n| 구조 | 명칭 | 세부구성 | 외관상 특징 | 1회 반복한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6.  관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.  | 전체의 90% 이상이어야 한다.  | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.  | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다.  | 방법 등)에 대한 실험 프로토콜을 제시한다. ",
        "original_sentence": "| 전체의 90% 이상이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 183,
        "word_count": 42,
        "page_number": 6,
        "window_text": "| 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 경우, 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 | (단위: 백만달러) |\n**6.  관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.  | 전체의 90% 이상이어야 한다.  | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.  | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다.  | 방법 등)에 대한 실험 프로토콜을 제시한다.  | 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "| 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "| 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 9,
        "window_text": "관련성이 명백함**\n| 사용자가 오류 메시지를, 관리실패 또는 절차상 오류를 무시한 이유를 조사한다.  | 전체의 90% 이상이어야 한다.  | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.  | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다.  | 방법 등)에 대한 실험 프로토콜을 제시한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 값을 측정하고 그 결과를 기록한다. ",
        "original_sentence": "| 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "| 방법 등)에 대한 실험 프로토콜을 제시한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 20,
        "window_text": "| 전체의 90% 이상이어야 한다.  | 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.  | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다.  | 방법 등)에 대한 실험 프로토콜을 제시한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 값을 측정하고 그 결과를 기록한다.  | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 방법 등)에 대한 실험 프로토콜을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 23,
        "window_text": "| 전기·기계적 | requirements | Guideline | IEC | 61010-2-101 | Safety | requirements | for | electrical | equipment | for | 외 규격 | 8 | 기준 가이드라인 |\n| ㉮ 낙하 내구성을 평가하기 위해 (사)에 기술된 성능 시험을 수행한다.  | 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다.  | 방법 등)에 대한 실험 프로토콜을 제시한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 값을 측정하고 그 결과를 기록한다.  | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | 한다. ",
        "original_sentence": "| 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "| 값을 측정하고 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 20,
        "window_text": "| 이후에 향후 일반용(가정용)으로 확대하여 FDA 승인됨 | 시험 | 용적률(Hct) 범위에 해당되어야 한다.  | 방법 등)에 대한 실험 프로토콜을 제시한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 값을 측정하고 그 결과를 기록한다.  | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | 한다.  | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다. ",
        "original_sentence": "| 값을 측정하고 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "| 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 방법 등)에 대한 실험 프로토콜을 제시한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 값을 측정하고 그 결과를 기록한다.  | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | 한다.  | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다.  | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. ",
        "original_sentence": "| 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "| 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| 포장용기 또는 포장지를 벗기지 않는다.)  | 값을 측정하고 그 결과를 기록한다.  | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | 한다.  | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다.  | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "| 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 174,
        "word_count": 43,
        "page_number": 9,
        "window_text": "| 값을 측정하고 그 결과를 기록한다.  | 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | 한다.  | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다.  | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. ",
        "original_sentence": "| 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 9,
        "window_text": "| 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | 한다.  | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다.  | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동. ",
        "original_sentence": "| 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "| measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 183,
        "word_count": 38,
        "page_number": 15,
        "window_text": "| 한다.  | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다.  | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동.  |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다. ",
        "original_sentence": "| measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "| 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 68,
        "word_count": 19,
        "page_number": 6,
        "window_text": "| 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 기계적 안전에 관한 공통기준 규격」(식약처 고시) |\n| 혈액 | 년도 | 필름 | 반응부와 미세통로로 이어져있는 혈액 주입부에 혈액샘플을 주입 | 시장규모 |\n| 하고 그 결과를 데이터 수집용지에 기록한다.  | 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동.  |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.  | 기록한다. ",
        "original_sentence": "| 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 53,
        "window_text": "| 안전에 관한 시험 | Evaluation | of | Detection | Capability | for | Clinical | 보고하고, 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동.  |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.  | 기록한다.  | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일. ",
        "original_sentence": "| 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "|\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 39,
        "word_count": 9,
        "page_number": 6,
        "window_text": "| measurement, | control | and | laboratory | use – Part | 2-101: | Particular | □ 예 | ■ 아니오 |\n| self-testing of oral anticoagulant therapy | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동.  |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.  | 기록한다.  | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일.  | 지속시간 |\n| 여부 | 포함해야 한다(표 1). ",
        "original_sentence": "|\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| 연평균성장률 |\n| 2013 | 2018 |\n| 개요 | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동.  |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.  | 기록한다.  | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일.  | 지속시간 |\n| 여부 | 포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다. ",
        "original_sentence": "| 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 205,
        "word_count": 38,
        "page_number": 16,
        "window_text": "| 주입부 | (상판) | 하면 모세관 현상을 통하여 반응부로이동.  |\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.  | 기록한다.  | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일.  | 지속시간 |\n| 여부 | 포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| 지속시간 |\n| 여부 | 포함해야 한다(표 1). ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 30,
        "word_count": 9,
        "page_number": 3,
        "window_text": "|\n| ㉯ IEC 61010-1의 8절에 기술된 낙하시험을 수행한다.  | 기록한다.  | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일.  | 지속시간 |\n| 여부 | 포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다. ",
        "original_sentence": "| 지속시간 |\n| 여부 | 포함해야 한다(표 1). "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "6.0을 넘는 INR 값은 제외하는 것이 좋다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 22,
        "window_text": "| 기록한다.  | Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일.  | 지속시간 |\n| 여부 | 포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다.  | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다. ",
        "original_sentence": "6.0을 넘는 INR 값은 제외하는 것이 좋다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| Laboratory Measurement Procedures; | 0000 병원 000 과/교수/000 | requirements for in vitro diagnostic (IVD) medical equipment | 대한 기준 가이드라인 |\n| Methods; Approved Guideline | 세계 시장 | 638 | 1,001 | 9.4% | 발생일.  | 지속시간 |\n| 여부 | 포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다.  | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.  | ㉮ (사)에 기술된 성능 시험을 수행한다. ",
        "original_sentence": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "| □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 170,
        "word_count": 45,
        "page_number": 3,
        "window_text": "| 지속시간 |\n| 여부 | 포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다.  | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.  | ㉮ (사)에 기술된 성능 시험을 수행한다.  | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 149,
        "word_count": 47,
        "page_number": 45,
        "window_text": "6.0을 넘는 INR 값은 제외하는 것이 좋다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다.  | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.  | ㉮ (사)에 기술된 성능 시험을 수행한다.  | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다.  | 값의 차이를 산출한다. ",
        "original_sentence": "| 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "| ㉮ (사)에 기술된 성능 시험을 수행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다.  | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.  | ㉮ (사)에 기술된 성능 시험을 수행한다.  | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다.  | 값의 차이를 산출한다.  | INR 값 편차 및 %편차를 산출한다. ",
        "original_sentence": "| ㉮ (사)에 기술된 성능 시험을 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "| (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 9,
        "window_text": "| □ 예 | ■ 아니오 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | 혈액응고 | 시간 | 결정을 | 위한 | 반응챔버와 | 측정 | 결과의 | 유용성 | 증례 기록서 수정 방법 |\n| 전체의 90% 이상이어야 한다.  | 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.  | ㉮ (사)에 기술된 성능 시험을 수행한다.  | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다.  | 값의 차이를 산출한다.  | INR 값 편차 및 %편차를 산출한다.  | 대한 INR 값 편차 및 %편차를 산출한다. ",
        "original_sentence": "| (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 값의 차이를 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| 증상의 | 증상의 | 기기와의 | 기기에 |\n| 기관명 | 소재지 | 전화 | 팩스 | 국내 시장 | 10.2 | 12.5 | 3.6% | 종료일 | (hours/ | 대한 조치 | 치료 | 결과 | 중대성 |\n| ㉰ 낙하시험이 종료된 후, 성능시험을 반복한다.  | ㉮ (사)에 기술된 성능 시험을 수행한다.  | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다.  | 값의 차이를 산출한다.  | INR 값 편차 및 %편차를 산출한다.  | 대한 INR 값 편차 및 %편차를 산출한다.  | 마지막시점을 포함하여 3회 시점으로 설정한다. ",
        "original_sentence": "| 값의 차이를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| INR 값 편차 및 %편차를 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| ㉮ (사)에 기술된 성능 시험을 수행한다.  | (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다.  | 값의 차이를 산출한다.  | INR 값 편차 및 %편차를 산출한다.  | 대한 INR 값 편차 및 %편차를 산출한다.  | 마지막시점을 포함하여 3회 시점으로 설정한다.  | 값을 측정하고 기록한다. ",
        "original_sentence": "| INR 값 편차 및 %편차를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| 대한 INR 값 편차 및 %편차를 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| (프로트롬빈 시간, Prothrombin Time)을 국제적으로 표준화한 단위 | 되는 교육 자료를 제공받아야 한다.  | 값의 차이를 산출한다.  | INR 값 편차 및 %편차를 산출한다.  | 대한 INR 값 편차 및 %편차를 산출한다.  | 마지막시점을 포함하여 3회 시점으로 설정한다.  | 값을 측정하고 기록한다.  | 적용된다. ",
        "original_sentence": "| 대한 INR 값 편차 및 %편차를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| 마지막시점을 포함하여 3회 시점으로 설정한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 13,
        "window_text": "| 값의 차이를 산출한다.  | INR 값 편차 및 %편차를 산출한다.  | 대한 INR 값 편차 및 %편차를 산출한다.  | 마지막시점을 포함하여 3회 시점으로 설정한다.  | 값을 측정하고 기록한다.  | 적용된다.  | 정량적으로 표현 | Ver. ",
        "original_sentence": "| 마지막시점을 포함하여 3회 시점으로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 값을 측정하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| INR 값 편차 및 %편차를 산출한다.  | 대한 INR 값 편차 및 %편차를 산출한다.  | 마지막시점을 포함하여 3회 시점으로 설정한다.  | 값을 측정하고 기록한다.  | 적용된다.  | 정량적으로 표현 | Ver.  1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함. ",
        "original_sentence": "| 값을 측정하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 18,
        "window_text": "| 대한 INR 값 편차 및 %편차를 산출한다.  | 마지막시점을 포함하여 3회 시점으로 설정한다.  | 값을 측정하고 기록한다.  | 적용된다.  | 정량적으로 표현 | Ver.  1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함.  | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.) ",
        "original_sentence": "| 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "| 정량적으로 표현 | Ver. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 10,
        "window_text": "| 마지막시점을 포함하여 3회 시점으로 설정한다.  | 값을 측정하고 기록한다.  | 적용된다.  | 정량적으로 표현 | Ver.  1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함.  | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)  | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다. ",
        "original_sentence": "| 정량적으로 표현 | Ver. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 166,
        "word_count": 35,
        "page_number": 6,
        "window_text": "| 값을 측정하고 기록한다.  | 적용된다.  | 정량적으로 표현 | Ver.  1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함.  | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)  | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다.  | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "| 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 51,
        "word_count": 15,
        "page_number": 20,
        "window_text": "| 적용된다.  | 정량적으로 표현 | Ver.  1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함.  | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)  | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다.  | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.) "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "| (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 78,
        "word_count": 18,
        "page_number": 16,
        "window_text": "| 정량적으로 표현 | Ver.  1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함.  | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)  | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다.  | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.  | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다. ",
        "original_sentence": "| (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 55,
        "word_count": 10,
        "page_number": 16,
        "window_text": "1.0 |\n| 연구과제 피험자 설명문 및 동의서 | 필름 및 | 기재 등에 관한 규정」(식약처 고시) | Requirements for in vitro monitoring systems for self-testing of oral | (quality control) 확인을 위한 반응챔버를 포함.  | 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)  | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다.  | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.  | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.  | 유지하여야 한다. ",
        "original_sentence": "| Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 316,
        "word_count": 74,
        "page_number": 3,
        "window_text": "| 범위 | 정도 | 관련성 |\n| 변화를 최소화하기 위해 혈액 시료는 최소로 희석한다.)  | (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다.  | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.  | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.  | 유지하여야 한다.  | 투여-응답 기법을 적용하여 재평가 한다.) ",
        "original_sentence": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 19,
        "window_text": "| (yy/mm/dd) | 반응부 | minutes) |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 한다.  | Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.  | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.  | 유지하여야 한다.  | 투여-응답 기법을 적용하여 재평가 한다.)  | 기록한다. ",
        "original_sentence": "| ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| 유지하여야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 20,
        "window_text": "| Methods; Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.  | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.  | 유지하여야 한다.  | 투여-응답 기법을 적용하여 재평가 한다.)  | 기록한다.  | 내용입니까? ",
        "original_sentence": "| 유지하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| 투여-응답 기법을 적용하여 재평가 한다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 20,
        "window_text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | □ 예 | ■ 아니오 |\n| 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | 시약층 | anticoagulant therapy | 챔버에 혈액응고 시약 고정화, 혈액샘플과 혼합되어 혈액응고 반 |\n| (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | Alere INRatio2 PT/INR Home |\n| ㉱ IEC 61010-1의 8절에 기술된 낙하시험에 관한 요구사항이 적용된다.  | ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.  | 유지하여야 한다.  | 투여-응답 기법을 적용하여 재평가 한다.)  | 기록한다.  | 내용입니까?  | 표 1. ",
        "original_sentence": "| 투여-응답 기법을 적용하여 재평가 한다.) "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| ㉯ 각 휴대용혈액응고시간 측정기를 습도 챔버에 놓는다.  | 유지하여야 한다.  | 투여-응답 기법을 적용하여 재평가 한다.)  | 기록한다.  | 내용입니까?  | 표 1.  시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다. ",
        "original_sentence": "| 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 내용입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 3,
        "window_text": "| 유지하여야 한다.  | 투여-응답 기법을 적용하여 재평가 한다.)  | 기록한다.  | 내용입니까?  | 표 1.  시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다.  | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다. ",
        "original_sentence": "| 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "| 표 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 투여-응답 기법을 적용하여 재평가 한다.)  | 기록한다.  | 내용입니까?  | 표 1.  시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다.  | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다.  | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "| 표 1. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 78,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| 기록한다.  | 내용입니까?  | 표 1.  시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다.  | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다.  | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다. ",
        "original_sentence": "시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "| 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 124,
        "word_count": 26,
        "page_number": 77,
        "window_text": "| 내용입니까?  | 표 1.  시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다.  | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다.  | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다.  | 중반기에 기기를 순환한다. ",
        "original_sentence": "| 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "| (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 110,
        "word_count": 30,
        "page_number": 6,
        "window_text": "| 표 1.  시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다.  | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다.  | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다.  | 중반기에 기기를 순환한다.  | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다. ",
        "original_sentence": "| (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 93,
        "word_count": 27,
        "page_number": 3,
        "window_text": "시스템 정확도 확인용 검체의 INR 값 | [표 11] INR 구간 예시 |\n**설정한 한계 이내로 유지되는지 평가하기 위함**\n| 한다.  | 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다.  | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다.  | 중반기에 기기를 순환한다.  | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다.  | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "| 중반기에 기기를 순환한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| 동의서 버전 또는 버전 날짜: | Version | _______________ | date ______________ | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | INR 이하여야 한다.  | (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다.  | 중반기에 기기를 순환한다.  | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다.  | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다. ",
        "original_sentence": "| 중반기에 기기를 순환한다. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 92,
        "word_count": 25,
        "page_number": 1,
        "window_text": "| (허가 번호, 품목명, 모델명 기재) | -「의료기기의 전자파안전에 관한 공통기준규격」 | 응 발생 |\n| 검체 수 비율a % | INR 값 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다.  | 중반기에 기기를 순환한다.  | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다.  | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다.  | 수집한다. ",
        "original_sentence": "| equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 55,
        "word_count": 10,
        "page_number": 16,
        "window_text": "| □ 예 | ■ 아니오 | / | / | 스크리닝 및 검사일 | 오송보건의료행정타운 | monitoring kit 외 1건 |\n| 포함하여 3회 시점으로 설정한다.  | 중반기에 기기를 순환한다.  | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다.  | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다.  | 수집한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다. ",
        "original_sentence": "| Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "| / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 181,
        "word_count": 44,
        "page_number": 6,
        "window_text": "| 중반기에 기기를 순환한다.  | equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다.  | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다.  | 수집한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다. ",
        "original_sentence": "| / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "| 수집한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| equipment | [표 6] 휴대용 혈액응고시간 측정시스템 안정성 관련 시험 규격 | 구간 | INR 값 |\n| 또는 동결건조 물질 | 표준편차를 산출한다.  | Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다.  | 수집한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.  | 보고한다. ",
        "original_sentence": "| 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 130,
        "word_count": 33,
        "page_number": 1,
        "window_text": "| Measurement Procedures | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다.  | 수집한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.  | 보고한다.  | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까? ",
        "original_sentence": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 299,
        "word_count": 73,
        "page_number": 3,
        "window_text": "| / | / | 필름 | IEC | 61326-1 | Electrical | equipment | for | measurement, | control | and | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | 반응부에서 발생하는 신호를 측정기에 전달,혈액과 검사지 삽입 |\n| 하여 코드번호를 입력합니다.  | 수집한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.  | 보고한다.  | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까?  | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다. ",
        "original_sentence": "| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| 보고한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| 수집한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.  | 보고한다.  | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까?  | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다.  | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "| 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "| 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 76,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 10-15 | 2.0 미만 | 11.6 | 10/03/30 홍길동(오기) |\n| 방문일 | 방문1 | 전극부 | 비 치료적 범위 | 2.0 미만 |\n| 값을 측정하고 기록한다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.  | 보고한다.  | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까?  | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다.  | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "| 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 189,
        "word_count": 46,
        "page_number": 6,
        "window_text": "| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (하판) | laboratory use – EMC requirements – Part 1: General requirements | □ 뇌졸중 □ 기타: | 인식 | [표 13] 허용범위 | □ 예 | ■ 아니오 |\n| 15-40 | 2.0-2.8 |\n| [표 3] 개인용 체외진단검사시약 II 국내업체 허가사항 | TEL : 043-719-4652~63  FAX : 043-719-4650 |\n| ㉱ 휴대용 혈액응고시간 측정기를 습도 챔버에 48시간 동안 놓아둔다.  | 보고한다.  | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까?  | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다.  | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다. ",
        "original_sentence": "| 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 61,
        "word_count": 16,
        "page_number": 3,
        "window_text": "| 보고한다.  | 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까?  | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다.  | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다.  | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다. ",
        "original_sentence": "| 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| 경우 | 비례하는 결과를 제공할 수 있는 능력 | 예) Hb 8.6 → Hb 8.6 | 경과일수 | Day0 | 정리한 자료입니까?  | 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다.  | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다.  | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다.  | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "| / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 121,
        "word_count": 29,
        "page_number": 6,
        "window_text": "| 피험자 이니셜(영문) | 낮은 치료 범위 | 2.0 - 3.0 | -「의료기기의 안정성시험 기준」 |\n| / | / | 15-40 | 2.9-3.7 | IEC | 61326-2-6 | Electrical | equipment | for | measurement, | control | and |\n**개봉 전/후**\n| 보증함에 있다.  | 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다.  | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다.  | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.  | 평균을 산출한다. ",
        "original_sentence": "| / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "| Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 228,
        "word_count": 50,
        "page_number": 6,
        "window_text": "| 전자파 | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다.  | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다.  | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.  | 평균을 산출한다.  | 값을 측정하고 그 결과를 기록한다. ",
        "original_sentence": "| Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "| 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 54,
        "word_count": 15,
        "page_number": 7,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다.  | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다.  | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.  | 평균을 산출한다.  | 값을 측정하고 그 결과를 기록한다.  | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다. ",
        "original_sentence": "| 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "| 평균을 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 20,
        "window_text": "| / | / | 높은 치료 범위 | 3.1 - 4.5 | http://www.mfds.go.kr/medicaldevice | 일반 사용자 측정결과와 | 일반 사용자 측정결과 평균과 |\n| 사망까지 예방할 수 있다.  | Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다.  | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.  | 평균을 산출한다.  | 값을 측정하고 그 결과를 기록한다.  | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다.  | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다. ",
        "original_sentence": "| 평균을 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| 값을 측정하고 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 20,
        "window_text": "| Visit | 10-30 | 3.8-4.5 | ISO 23640 In vitro diagnostic medical devices – Evaluation of stability | (‘16.10.31 기준) |\n| INR | laboratory | use | – | EMC | requirements | – | Part | 2-6: | Particular |\n| ㉮ (사)에 기술된 성능 시험을 수행한다.  | 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.  | 평균을 산출한다.  | 값을 측정하고 그 결과를 기록한다.  | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다.  | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다.  | 데이터 수집용지에 기록한다. ",
        "original_sentence": "| 값을 측정하고 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 57,
        "word_count": 16,
        "page_number": 9,
        "window_text": "| 대한 백분율로 나타낸 것 | 실시하여 각 시약 로트에 대해 개별적으로 결과를 제시해야 한다.  | 평균을 산출한다.  | 값을 측정하고 그 결과를 기록한다.  | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다.  | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다.  | 데이터 수집용지에 기록한다.  대조기기의 결과 값은 기준 값으로 간주한다. ",
        "original_sentence": "| 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 147,
        "word_count": 35,
        "page_number": 6,
        "window_text": "| 평균을 산출한다.  | 값을 측정하고 그 결과를 기록한다.  | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다.  | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다.  | 데이터 수집용지에 기록한다.  대조기기의 결과 값은 기준 값으로 간주한다.  | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
        "original_sentence": "| Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "| 데이터 수집용지에 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| 값을 측정하고 그 결과를 기록한다.  | 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다.  | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다.  | 데이터 수집용지에 기록한다.  대조기기의 결과 값은 기준 값으로 간주한다.  | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다. ",
        "original_sentence": "| 데이터 수집용지에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "대조기기의 결과 값은 기준 값으로 간주한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 20,
        "window_text": "| 안정성 평가 | 안전에 관한 시험 | - | 임상시험 |\n| 체외진단기기과에 문의하시기 바랍니다.  | Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다.  | 데이터 수집용지에 기록한다.  대조기기의 결과 값은 기준 값으로 간주한다.  | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "대조기기의 결과 값은 기준 값으로 간주한다. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 195,
        "word_count": 39,
        "page_number": 15,
        "window_text": "| Roche사 CoaguChek XS | Alere사 INRatio2 PT/INR | 1-10b | 4.6-6.0 | 피험자 식별번호 | 전문가 측정결과의 차이 | [표 14] INR 구간 예시 | 전문가 측정결과 평균의 차이 |\n| 시약으로 측정되어야 한다.  | 데이터 수집용지에 기록한다.  대조기기의 결과 값은 기준 값으로 간주한다.  | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "|\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 182,
        "word_count": 33,
        "page_number": 15,
        "window_text": "| 데이터 수집용지에 기록한다.  대조기기의 결과 값은 기준 값으로 간주한다.  | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다. ",
        "original_sentence": "|\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "| 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 23,
        "window_text": "대조기기의 결과 값은 기준 값으로 간주한다.  | window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다.  | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. ",
        "original_sentence": "| 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 284,
        "word_count": 70,
        "page_number": 6,
        "window_text": "| window | requirements – In vitro diagnostic (IVD) medical equipment | of in vitro diagnostic reagents |\n| 기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상태 또는 시험 절차/조건에 의해 | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  |\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다.  | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다. ",
        "original_sentence": "| 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "(공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 161,
        "word_count": 34,
        "page_number": 1,
        "window_text": "|\n| self-testing of oral anticoagulant therapy | / | / |\n| 전화번호: 043-719-4652~63 | 관찰형태 | 내원 | (출처: https://www.roche.de/) | (출처: http://www.alere.com/) |\n| 발생하였을 가능성이 있는 경우 | 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다.  | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다.  | stability of in vitro diagnostic reagents | 반복한다. ",
        "original_sentence": "(공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "| □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 9,
        "window_text": "| 포장용기 또는 포장지를 벗기지 않는다.)  | 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다.  | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다.  | stability of in vitro diagnostic reagents | 반복한다.  | 놓는다. ",
        "original_sentence": "| □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 3,
        "window_text": "| 2.0–4.5 | 95% 측정 결과 값이 ± 0.5 이내 | ≤ 10% | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 구간 | INR 값 | ISO 17593 Clinical laboratory testing and in vitro medical devices – | □ 예(☞지침서) | ■ 아니오 |\n| / | / | □ 와파린 (용법:       mg/day) |\n| 팩스번호: 043-719-4650 | 동의서 취득 | O | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다.  | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다.  | stability of in vitro diagnostic reagents | 반복한다.  | 놓는다.  | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다. ",
        "original_sentence": "| 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "| stability of in vitro diagnostic reagents | 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 52,
        "word_count": 9,
        "page_number": 16,
        "window_text": "(공무원용) | [그림 2] 기허가 휴대용 혈액응고시간 측정시스템 | 비 치료적 범위 | 2.0 미만 | Requirements for in vitro monitoring systems for self-testing of oral |\n| 남은 혈장검체는 -70°C 이하로 냉동 보관한다.  | □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다.  | stability of in vitro diagnostic reagents | 반복한다.  | 놓는다.  | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다.  | 값을 측정하고 그 결과를 기록한다. ",
        "original_sentence": "| stability of in vitro diagnostic reagents | 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "| 놓는다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 19,
        "window_text": "| □ 기타(예, NOACs 등) |\n| 공정으로 생산된 물질의 정의 된 양 | 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다.  | stability of in vitro diagnostic reagents | 반복한다.  | 놓는다.  | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다.  | 값을 측정하고 그 결과를 기록한다.  | 사항이 적용된다. ",
        "original_sentence": "| 놓는다. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "| 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 168,
        "word_count": 48,
        "page_number": 6,
        "window_text": "| 증례기록서 작성에 대한 세부사항 |\n| 표준편차를 산출한다.  | stability of in vitro diagnostic reagents | 반복한다.  | 놓는다.  | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다.  | 값을 측정하고 그 결과를 기록한다.  | 사항이 적용된다.  |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
        "original_sentence": "| 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "| 값을 측정하고 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 20,
        "window_text": "| stability of in vitro diagnostic reagents | 반복한다.  | 놓는다.  | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다.  | 값을 측정하고 그 결과를 기록한다.  | 사항이 적용된다.  |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다. ",
        "original_sentence": "| 값을 측정하고 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| 사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 3,
        "window_text": "| 놓는다.  | 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다.  | 값을 측정하고 그 결과를 기록한다.  | 사항이 적용된다.  |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다.  | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다. ",
        "original_sentence": "| 사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "|\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| 낮은 치료 범위 | 2.0 - 3.0 |\n| 선정/제외기준 확인 | O | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | anticoagulant therapy |\n| 구분 | 기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | / | / |\n| 설계되어야 한다.  | 값을 측정하고 그 결과를 기록한다.  | 사항이 적용된다.  |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다.  | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다.  | 측정가능 상태인지 확인한다. ",
        "original_sentence": "|\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "(민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 64,
        "word_count": 18,
        "page_number": 6,
        "window_text": "| 값을 측정하고 그 결과를 기록한다.  | 사항이 적용된다.  |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다.  | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다.  | 측정가능 상태인지 확인한다.  | 에러율(%)을 산출한다. ",
        "original_sentence": "(민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "| 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 42,
        "word_count": 15,
        "page_number": 20,
        "window_text": "| 사항이 적용된다.  |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다.  | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다.  | 측정가능 상태인지 확인한다.  | 에러율(%)을 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "| 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "| 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 20,
        "window_text": "|\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다.  | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다.  | 측정가능 상태인지 확인한다.  | 에러율(%)을 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 표 1. ",
        "original_sentence": "| 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "| 에러율(%)을 산출한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 20,
        "window_text": "(민원인용) | 높은 치료 범위 | 3.1 - 4.5 |\n| 으로 5∼7개의 INR 값에 대하여 시험되어야 한다.  | 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다.  | 측정가능 상태인지 확인한다.  | 에러율(%)을 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 표 1.  성능 기준 |\n| 주십시오. ",
        "original_sentence": "| 에러율(%)을 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "| 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 23,
        "window_text": "| 인구학적 정보 | O | / | / |\n| 하고, 그 결과를 기록한다.  | 측정가능 상태인지 확인한다.  | 에러율(%)을 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 표 1.  성능 기준 |\n| 주십시오.  | 으로 의식 소실이 유발되는 것이다. ",
        "original_sentence": "| 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| 표 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 측정가능 상태인지 확인한다.  | 에러율(%)을 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 표 1.  성능 기준 |\n| 주십시오.  | 으로 의식 소실이 유발되는 것이다.  | 수 있는 고농도를 사용 할 것을 권장한다.) ",
        "original_sentence": "| 표 1. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "성능 기준 |\n| 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 54,
        "window_text": "| 에러율(%)을 산출한다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 표 1.  성능 기준 |\n| 주십시오.  | 으로 의식 소실이 유발되는 것이다.  | 수 있는 고농도를 사용 할 것을 권장한다.)  |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다. ",
        "original_sentence": "성능 기준 |\n| 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "| 으로 의식 소실이 유발되는 것이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 66,
        "window_text": "| 포장용기 또는 포장지를 벗기지 않는다.)  | 표 1.  성능 기준 |\n| 주십시오.  | 으로 의식 소실이 유발되는 것이다.  | 수 있는 고농도를 사용 할 것을 권장한다.)  |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다.  | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다. ",
        "original_sentence": "| 으로 의식 소실이 유발되는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "| 수 있는 고농도를 사용 할 것을 권장한다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 20,
        "window_text": "| 표 1.  성능 기준 |\n| 주십시오.  | 으로 의식 소실이 유발되는 것이다.  | 수 있는 고농도를 사용 할 것을 권장한다.)  |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다.  | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다.  | / | / |\n| 같이 INR 측정구간에 포함되어야 한다. ",
        "original_sentence": "| 수 있는 고농도를 사용 할 것을 권장한다.) "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "|\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 51,
        "word_count": 8,
        "page_number": 15,
        "window_text": "성능 기준 |\n| 주십시오.  | 으로 의식 소실이 유발되는 것이다.  | 수 있는 고농도를 사용 할 것을 권장한다.)  |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다.  | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다.  | / | / |\n| 같이 INR 측정구간에 포함되어야 한다.  | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다. ",
        "original_sentence": "|\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 152,
        "word_count": 36,
        "page_number": 6,
        "window_text": "| 으로 의식 소실이 유발되는 것이다.  | 수 있는 고농도를 사용 할 것을 권장한다.)  |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다.  | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다.  | / | / |\n| 같이 INR 측정구간에 포함되어야 한다.  | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다.  | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다. ",
        "original_sentence": "| 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| / | / |\n| 같이 INR 측정구간에 포함되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 35,
        "word_count": 11,
        "page_number": 20,
        "window_text": "| 수 있는 고농도를 사용 할 것을 권장한다.)  |\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다.  | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다.  | / | / |\n| 같이 INR 측정구간에 포함되어야 한다.  | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다.  | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다.  | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우. ",
        "original_sentence": "| / | / |\n| 같이 INR 측정구간에 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "| 영향을 주지 않도록 설문은 시험 후 수행되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 9,
        "window_text": "|\n| 진단용 분석기기(In vitro diagnostic equipment)에 적용한다.  | 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다.  | / | / |\n| 같이 INR 측정구간에 포함되어야 한다.  | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다.  | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다.  | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우.  | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다. ",
        "original_sentence": "| 영향을 주지 않도록 설문은 시험 후 수행되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| 2.0-4.5 |\n| INR 구간 | 허용차이(결과의 90%) | 허용편차(평균차이) | 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간 | 기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 임상적 상태에 대하여 알려진 | 용지에 기록한다.  | / | / |\n| 같이 INR 측정구간에 포함되어야 한다.  | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다.  | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다.  | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우.  | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다.  | 수행한다. ",
        "original_sentence": "| 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "| 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 99,
        "word_count": 30,
        "page_number": 3,
        "window_text": "| / | / |\n| 같이 INR 측정구간에 포함되어야 한다.  | 영향을 주지 않도록 설문은 시험 후 수행되어야 한다.  | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다.  | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우.  | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다.  | 수행한다.  | 사항이 적용된다. ",
        "original_sentence": "| 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "| / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 41,
        "word_count": 13,
        "page_number": 20,
        "window_text": "| 영향을 주지 않도록 설문은 시험 후 수행되어야 한다.  | 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다.  | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우.  | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다.  | 수행한다.  | 사항이 적용된다.  | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| 수행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| 일으켜 혈병이 생성되기까지의 시간을 측정하는 검사법 | 8시간 동안 놓아둔다.  | 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우.  | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다.  | 수행한다.  | 사항이 적용된다.  | 민원인을 구속하는 내용이 있습니까?  |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다. ",
        "original_sentence": "| 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "| 사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 3,
        "window_text": "| 검체 채취 | O | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | □ 예 | ■ 아니오 |\n| 4.6-6.0 | 특징으로는 합리적인 설명을 할 수 없는 경우.  | / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다.  | 수행한다.  | 사항이 적용된다.  | 민원인을 구속하는 내용이 있습니까?  |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  | 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "| 사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "| 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 3,
        "window_text": "| / | / |\n| 아래 표와 같이 INR 측정구간이 포함되어야 한다.  | 수행한다.  | 사항이 적용된다.  | 민원인을 구속하는 내용이 있습니까?  |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다. ",
        "original_sentence": "| 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "|\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 78,
        "word_count": 26,
        "page_number": 6,
        "window_text": "| 수행한다.  | 사항이 적용된다.  | 민원인을 구속하는 내용이 있습니까?  |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다.  | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다. ",
        "original_sentence": "|\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 23,
        "window_text": "| 사항이 적용된다.  | 민원인을 구속하는 내용이 있습니까?  |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다.  | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.  | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다. ",
        "original_sentence": "| 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "| 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 16,
        "window_text": "| 민원인을 구속하는 내용이 있습니까?  |\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다.  | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.  | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다.  | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다. ",
        "original_sentence": "| 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "| 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 77,
        "word_count": 22,
        "page_number": 3,
        "window_text": "|\n| 2.0 미만 | ±0.5 | NA | 검체 검사 및 분석 | O | 배합 |\n| 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  | 포장용기 또는 포장지를 벗기지 않는다.)  | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다.  | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.  | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다.  | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다.  | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.) ",
        "original_sentence": "| 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "| 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 178,
        "word_count": 49,
        "page_number": 6,
        "window_text": "| 포장용기 또는 포장지를 벗기지 않는다.)  | 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다.  | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.  | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다.  | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다.  | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)  | 허용기준과 비교되어야 한다. ",
        "original_sentence": "| 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "| 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 47,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| 김윤영, 김서윤, 김민정 |\n| Guideline | 값을 측정하고 기록한다.  | 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.  | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다.  | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다.  | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)  | 허용기준과 비교되어야 한다.  | 반복한다. ",
        "original_sentence": "| 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 33,
        "word_count": 11,
        "page_number": 28,
        "window_text": "| 성분명 | 분량 | 규격 | 비고 |\n**(연락처)**\n| 사항 | 있으며 대중화를 위해 가격 인하를 위한 연구개발에 집중하고 있다.  | 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다.  | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다.  | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)  | 허용기준과 비교되어야 한다.  | 반복한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
        "original_sentence": "| 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.) "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| 허용기준과 비교되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 18,
        "window_text": "| 2.0-4.5 | ±30% | ±0.3 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 목적 |\n**[표 9] INR 구간**\n| 하여 전기 | [표 7] INR 구간 |\n| 올바른 사용을 위해 제조업체가 제공하는 정보 | 국제규격이 있음 | 휴식을 취하면 대부분 회복된다.  | 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다.  | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)  | 허용기준과 비교되어야 한다.  | 반복한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다. ",
        "original_sentence": "| 허용기준과 비교되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 19,
        "window_text": "| 연구윤리담당자 |\n| 설정한 한계 이내로 유지되는지 평가하기 위함 | 수집한다.  | 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)  | 허용기준과 비교되어야 한다.  | 반복한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다.  | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다. ",
        "original_sentence": "| 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 계에 대한 각각의 결과 값을 비교 제시 할 수 있다.)  | 허용기준과 비교되어야 한다.  | 반복한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다.  | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.  | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음. ",
        "original_sentence": "| 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "| 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 168,
        "word_count": 41,
        "page_number": 6,
        "window_text": "| 허용기준과 비교되어야 한다.  | 반복한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다.  | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.  | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음.  |\n| 주십시오. ",
        "original_sentence": "| 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "| 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 112,
        "word_count": 34,
        "page_number": 22,
        "window_text": "| 반복한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다.  | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.  | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음.  |\n| 주십시오.  | 값을 측정하고 기록한다. ",
        "original_sentence": "| 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "| 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다.  | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.  | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음.  |\n| 주십시오.  | 값을 측정하고 기록한다.  |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "| 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "|\n| 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 54,
        "window_text": "| 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 오송보건의료행정타운 | 00±00 X 00±00 | □ 아니오 수술일 :(    ) |\n| 4.6-6.0 | NA | NA | 지지체 | 친수성필름-상판(pore size: xx) |\n| 측정기, 동일한 3개 로트 검사지를 사용한다.  | 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.  | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음.  |\n| 주십시오.  | 값을 측정하고 기록한다.  |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)  | 신뢰구간)와 통합변동계수를 계산한다. ",
        "original_sentence": "|\n| 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| 값을 측정하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| 구간 | INR 값 | 구간 | INR 값 | (피험자와의 관계) | mm/device | □ 예 →  수술명 :(    ) |\n| 물질 제공 또는 검사실에서 설정하는 방법 등을 제시할 수 있다.  | 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음.  |\n| 주십시오.  | 값을 측정하고 기록한다.  |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)  | 신뢰구간)와 통합변동계수를 계산한다.  | 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
        "original_sentence": "| 값을 측정하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "|\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 42,
        "word_count": 11,
        "page_number": 23,
        "window_text": "| 식품의약품안전평가원 | 상기 사항에 대하여 확인하였음.  |\n| 주십시오.  | 값을 측정하고 기록한다.  |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)  | 신뢰구간)와 통합변동계수를 계산한다.  | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "|\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "| 신뢰구간)와 통합변동계수를 계산한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 23,
        "word_count": 4,
        "page_number": 20,
        "window_text": "|\n| 주십시오.  | 값을 측정하고 기록한다.  |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)  | 신뢰구간)와 통합변동계수를 계산한다.  | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다. ",
        "original_sentence": "| 신뢰구간)와 통합변동계수를 계산한다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "| 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 20,
        "window_text": "| 값을 측정하고 기록한다.  |\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)  | 신뢰구간)와 통합변동계수를 계산한다.  | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다.  | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.) ",
        "original_sentence": "| 하고, 모든 측정기가 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 144,
        "word_count": 38,
        "page_number": 3,
        "window_text": "|\n| 측정 검사지는 사용 전까지 포장용기 또는 포장지를 벗기지 않는다.)  | 신뢰구간)와 통합변동계수를 계산한다.  | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다.  | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.)  | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1. ",
        "original_sentence": "| 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "|\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 51,
        "word_count": 15,
        "page_number": 6,
        "window_text": "| 신뢰구간)와 통합변동계수를 계산한다.  | 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다.  | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.)  | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1.  시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다. ",
        "original_sentence": "|\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "| 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 94,
        "word_count": 25,
        "page_number": 6,
        "window_text": "| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다.  | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.)  | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1.  시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다.  |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다. ",
        "original_sentence": "| 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.) "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "| 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 52,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| 비 치료적 범위 | 2.0 미만 | □ 아니오 수술일 :(    ) |\n| 비 치료적 범위 | 2.0 미만 | 의료기기심사부 체외진단기기과 | 00±00 X 00±00 |\n| Approved Guideline | 포장용기 또는 포장지를 벗기지 않는다.)  |\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다.  | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.)  | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1.  시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다.  |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다.  | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 131,
        "word_count": 27,
        "page_number": 3,
        "window_text": "|\n| 지지체 | 양면접착필름-중판 | [그림 1] 혈액 응고 기전 |\n| 것이 중요하다.  | 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.)  | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1.  시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다.  |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다.  | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다.  | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
        "original_sentence": "시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "|\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 58,
        "word_count": 16,
        "page_number": 11,
        "window_text": "| 낮은 치료 범위 | 2.0 - 3.0 | mm/device |\n| 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사 수행능 | 또는 포장지를 벗기지 않는다.)  | 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1.  시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다.  |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다.  | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다.  | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다. ",
        "original_sentence": "|\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 108,
        "word_count": 30,
        "page_number": 6,
        "window_text": "| 낮은 치료 범위 | 2.0 - 3.0 | 전화: 043-719-4652~63 | 표 1.  시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다.  |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다.  | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다.  | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) ",
        "original_sentence": "| 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "| 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 70,
        "word_count": 20,
        "page_number": 20,
        "window_text": "시스템 정확도 확인용 검체의 INR 값 | 2017 년    5 월   31  일 |\n| of oral anticoagulant therapy | Laboratory Measurement Procedures; | 그 결과를 기록한다.  |\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다.  | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다.  | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 값을 측정하고 그 결과를 기록한다. ",
        "original_sentence": "| 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "| 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 46,
        "word_count": 14,
        "page_number": 3,
        "window_text": "|\n| (출처: 가천의과학대학교 길병원) | 온도 | 습도 |\n| 부터 전달받는 시스템이 운영 중이다.  | 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다.  | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 값을 측정하고 그 결과를 기록한다.  | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
        "original_sentence": "| 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "| 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 높은 치료 범위 | 3.1 - 4.5 | 팩스: 043-719-4650 | 00±00 X 00±00 |\n| 높은 치료 범위 | 3.1 - 4.5 |\n| 보호시험에 관한 요구사항이 적용된다.  | 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 값을 측정하고 그 결과를 기록한다.  | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
        "original_sentence": "| 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "| 값을 측정하고 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 20,
        "window_text": "| 검체 수 비율a % | INR 값 | 지지체 | PET필름-하판 |\n| 하고, 모든 측정기가 측정가능 상태인지 확인한다.  | 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 값을 측정하고 그 결과를 기록한다.  | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
        "original_sentence": "| 값을 측정하고 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "| requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 75,
        "word_count": 16,
        "page_number": 6,
        "window_text": "| 담당자 | 확  인(부서장) | 우 승 민 |\n| 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 값을 측정하고 그 결과를 기록한다.  | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. ",
        "original_sentence": "| requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 2,
        "window_text": "| 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 값을 측정하고 그 결과를 기록한다.  | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 226,
        "word_count": 48,
        "page_number": 4,
        "window_text": "| 값을 측정하고 그 결과를 기록한다.  | requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. ",
        "original_sentence": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 172,
        "word_count": 34,
        "page_number": 4,
        "window_text": "| requirements | mm/device |\n| 10-15 | 2.0 미만 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다. ",
        "original_sentence": "<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 166,
        "word_count": 38,
        "page_number": 4,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다.  | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함. ",
        "original_sentence": "또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 100,
        "word_count": 22,
        "page_number": 4,
        "window_text": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 휴대용 혈액응고시간 측정시스템 안전성·성능 및 임상시험\n\n<!-- PAGE_4 -->\n###### 계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에 대하여\n\n<!-- PAGE_4 -->\n###### 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다.  | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함.  | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. ",
        "original_sentence": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 165,
        "word_count": 39,
        "page_number": 5,
        "window_text": "<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다.  | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함.  | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 제공하여 원칙과 절차를 수립하여 제시함. ",
        "original_sentence": "관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "| 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 75,
        "word_count": 22,
        "page_number": 6,
        "window_text": "또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다.  | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함.  | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 제공하여 원칙과 절차를 수립하여 제시함.  |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. ",
        "original_sentence": "| 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "| Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 129,
        "word_count": 27,
        "page_number": 15,
        "window_text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다.  | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함.  | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 제공하여 원칙과 절차를 수립하여 제시함.  |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. ",
        "original_sentence": "| Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "| 제공하여 원칙과 절차를 수립하여 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 6,
        "window_text": "관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n- (4) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)\n**[표 시작]**\n\n**(5) 「의료기기 허가**\n| □ ‘중증도’ 판정 참고기준 | 번호는 다음과 같이 구성된다.  | 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함.  | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 제공하여 원칙과 절차를 수립하여 제시함.  |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함. ",
        "original_sentence": "| 제공하여 원칙과 절차를 수립하여 제시함. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "|\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 125,
        "word_count": 30,
        "page_number": 6,
        "window_text": "| 2 | CLSI EP05 | 제품의 특성에 따라 자율적으로 설정이 가능함 | - 치료 | 대상 질환 또는 적응증을 포함하도록 함.  | Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 제공하여 원칙과 절차를 수립하여 제시함.  |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. ",
        "original_sentence": "|\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "| 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| Ratio Devices for Monitoring Warfarin Therapy, March 18, 2016 |\n| ◈ 인구학적 정보 | (1) 관련 규격 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 제공하여 원칙과 절차를 수립하여 제시함.  |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | ➀ 최소검출한계 설정 배경을 제시해야 한다. ",
        "original_sentence": "| 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "| 경험이 있는 자가 선정되어야 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 46,
        "window_text": "| 제공하여 원칙과 절차를 수립하여 제시함.  |\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | ➀ 최소검출한계 설정 배경을 제시해야 한다.  |\n| 10.2.1. ",
        "original_sentence": "| 경험이 있는 자가 선정되어야 함. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 70,
        "word_count": 17,
        "page_number": 6,
        "window_text": "|\n| (6) 관찰항목 검사 방법 | of oral anticoagulant therapy) |\n| (6) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | ➀ 최소검출한계 설정 배경을 제시해야 한다.  |\n| 10.2.1.  피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다. ",
        "original_sentence": "| 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "| ➀ 최소검출한계 설정 배경을 제시해야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 20,
        "window_text": "| 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | ➀ 최소검출한계 설정 배경을 제시해야 한다.  |\n| 10.2.1.  피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.  | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. ",
        "original_sentence": "| ➀ 최소검출한계 설정 배경을 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "|\n| 10.2.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 경험이 있는 자가 선정되어야 함.  | 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | ➀ 최소검출한계 설정 배경을 제시해야 한다.  |\n| 10.2.1.  피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.  | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | - 사용기한이 지난 검사지는 사용하지 않습니다. ",
        "original_sentence": "|\n| 10.2.1. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 57,
        "word_count": 15,
        "page_number": 6,
        "window_text": "| 1) 경증 (mild) |\n| (4) 시험 조건 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | ➀ 최소검출한계 설정 배경을 제시해야 한다.  |\n| 10.2.1.  피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.  | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | - 사용기한이 지난 검사지는 사용하지 않습니다.  | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다. ",
        "original_sentence": "피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "| ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 20,
        "window_text": "| ➀ 최소검출한계 설정 배경을 제시해야 한다.  |\n| 10.2.1.  피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.  | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | - 사용기한이 지난 검사지는 사용하지 않습니다.  | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다.  | 35% 이하 또는 50% 이상인 경우 |\n| 1. ",
        "original_sentence": "| ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "| - 사용기한이 지난 검사지는 사용하지 않습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 20,
        "window_text": "|\n| 10.2.1.  피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.  | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | - 사용기한이 지난 검사지는 사용하지 않습니다.  | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다.  | 35% 이하 또는 50% 이상인 경우 |\n| 1.  국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다. ",
        "original_sentence": "| - 사용기한이 지난 검사지는 사용하지 않습니다. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "| - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 87,
        "word_count": 17,
        "page_number": 6,
        "window_text": "피험자군 또는 대조군 설정 | 5) 적혈구 부피비가 35% 이하 또는 50% 이상인 경우 탈락시킨다.  | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | - 사용기한이 지난 검사지는 사용하지 않습니다.  | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다.  | 35% 이하 또는 50% 이상인 경우 |\n| 1.  국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2. ",
        "original_sentence": "| - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "| 35% 이하 또는 50% 이상인 경우 |\n| 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 30,
        "word_count": 10,
        "page_number": 6,
        "window_text": "| ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | - 사용기한이 지난 검사지는 사용하지 않습니다.  | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다.  | 35% 이하 또는 50% 이상인 경우 |\n| 1.  국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2.  전신 | 직명 등 인적사항을 기재함. ",
        "original_sentence": "| 35% 이하 또는 50% 이상인 경우 |\n| 1. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 57,
        "window_text": "| - 사용기한이 지난 검사지는 사용하지 않습니다.  | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다.  | 35% 이하 또는 50% 이상인 경우 |\n| 1.  국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2.  전신 | 직명 등 인적사항을 기재함.  | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. ",
        "original_sentence": "국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "|\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 98,
        "word_count": 24,
        "page_number": 5,
        "window_text": "| - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 실시기관으로 지정받은 곳이어야 함 | 정보들은 기밀로 보관되어야 한다.  | 35% 이하 또는 50% 이상인 경우 |\n| 1.  국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2.  전신 | 직명 등 인적사항을 기재함.  | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함. ",
        "original_sentence": "|\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "전신 | 직명 등 인적사항을 기재함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 35% 이하 또는 50% 이상인 경우 |\n| 1.  국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2.  전신 | 직명 등 인적사항을 기재함.  | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함.  | - 검사지는 반드시 마른 손으로 만져야 합니다. ",
        "original_sentence": "전신 | 직명 등 인적사항을 기재함. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "| 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 38,
        "word_count": 7,
        "page_number": 9,
        "window_text": "국소 | 경우, 추가위치로의 연구 확대가 필수적일 수 있다.  |\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2.  전신 | 직명 등 인적사항을 기재함.  | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함.  | - 검사지는 반드시 마른 손으로 만져야 합니다.  | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다. ",
        "original_sentence": "| 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "|\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 6,
        "window_text": "|\n| (7) 「의료기기 임상시험계획 승인에 관한 규정」(식약처 고시) | 1) 시험기기에서 PT 측정 | 생년월일(YY/MM/DD) | 3 | CLSI EP06 |\n| 2.  전신 | 직명 등 인적사항을 기재함.  | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함.  | - 검사지는 반드시 마른 손으로 만져야 합니다.  | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.  | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. ",
        "original_sentence": "|\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| - 검사지는 반드시 마른 손으로 만져야 합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 20,
        "window_text": "전신 | 직명 등 인적사항을 기재함.  | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함.  | - 검사지는 반드시 마른 손으로 만져야 합니다.  | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.  | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system. ",
        "original_sentence": "| - 검사지는 반드시 마른 손으로 만져야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 20,
        "window_text": "| 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  |\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함.  | - 검사지는 반드시 마른 손으로 만져야 합니다.  | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.  | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system.  Thromb Res 2008;123:381-389. ",
        "original_sentence": "| ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "| ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 59,
        "word_count": 16,
        "page_number": 6,
        "window_text": "|\n**자발적 의사에 의해**\n| (2) 선정/제외기준 | (6) 결과 제시 | 범위 등을 작성함.  | - 검사지는 반드시 마른 손으로 만져야 합니다.  | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.  | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system.  Thromb Res 2008;123:381-389.  | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. ",
        "original_sentence": "| ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "| ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 72,
        "word_count": 13,
        "page_number": 9,
        "window_text": "| - 검사지는 반드시 마른 손으로 만져야 합니다.  | ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.  | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system.  Thromb Res 2008;123:381-389.  | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. ",
        "original_sentence": "| ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "Thromb Res 2008;123:381-389. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 29,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.  | ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system.  Thromb Res 2008;123:381-389.  | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4. ",
        "original_sentence": "Thromb Res 2008;123:381-389. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "| 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 55,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| ① 시험간격 시점에서 기준장비로 측정한 기 | 는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system.  Thromb Res 2008;123:381-389.  | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4.  휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. ",
        "original_sentence": "| 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "|\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 114,
        "word_count": 29,
        "page_number": 5,
        "window_text": "| ② 낙하시험계획서 | Systems for Over-the-Counter Use |\n| CoaguChek XS system.  Thromb Res 2008;123:381-389.  | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4.  휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. ",
        "original_sentence": "|\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "|\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 159,
        "word_count": 40,
        "page_number": 6,
        "window_text": "Thromb Res 2008;123:381-389.  | 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4.  휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. ",
        "original_sentence": "|\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 57,
        "word_count": 11,
        "page_number": 1,
        "window_text": "| 2) 중증도 (moderate) | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4.  휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | 1 | 함께 기재함. ",
        "original_sentence": "휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "| 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 9,
        "window_text": "|\n| (8) 「의료기기 임상시험 기본문서 관리에 관한 규정」(식약처 고시) | 번호 | 업체명 | 품목허가번호 | 허가/신고일 | 모델명 | ㉯ 각 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  |\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4.  휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | 1 | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. ",
        "original_sentence": "| 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "|\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 5,
        "window_text": "|\n| 임상시험에 대한 | 4 | CLSI EP07 |\n| 승인일로부터 6개월 | · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 |\n| 4) 모양및구조: 혈액응고 시간 측정기 및 혈액응고 시간측정 검사지 | 예) KFDA-12-34-56 | 4.  휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | 1 | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다. ",
        "original_sentence": "|\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "| 1 | 함께 기재함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 6,
        "window_text": "휴대용 혈액응고시간 측정시스템 관련 국내 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | 1 | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다.  |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다. ",
        "original_sentence": "| 1 | 함께 기재함. "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "| 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  |\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | 1 | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다.  |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함. ",
        "original_sentence": "| 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "|\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 73,
        "word_count": 19,
        "page_number": 13,
        "window_text": "|\n| (9) 「의료기기의 전기 | (2) 국내외 개발동향 | 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | 1 | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다.  |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함.  | 산업협회, 이승노) | 뢰자에게 보내야 한다. ",
        "original_sentence": "|\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "|\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 118,
        "word_count": 31,
        "page_number": 6,
        "window_text": "| 1 | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다.  |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함.  | 산업협회, 이승노) | 뢰자에게 보내야 한다.  | 동의서의 사본을 제공받을 것임을 알고 있습니다. ",
        "original_sentence": "|\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "| · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 81,
        "window_text": "| 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  |\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다.  |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함.  | 산업협회, 이승노) | 뢰자에게 보내야 한다.  | 동의서의 사본을 제공받을 것임을 알고 있습니다.  | 사유를 기재한다. ",
        "original_sentence": "| · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| 산업협회, 이승노) | 뢰자에게 보내야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 20,
        "window_text": "|\n**3) 중증 (severe)**\n| ◈ 측정된 기록의 정보 | 참여를 거부한 경우 | 절차에 따라 이루어지도록 하여야 한다.  |\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함.  | 산업협회, 이승노) | 뢰자에게 보내야 한다.  | 동의서의 사본을 제공받을 것임을 알고 있습니다.  | 사유를 기재한다.  |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. ",
        "original_sentence": "| 산업협회, 이승노) | 뢰자에게 보내야 한다. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "| 동의서의 사본을 제공받을 것임을 알고 있습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 50,
        "window_text": "|\n**(1) 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월**\n| (10) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 5 | CLSI EP17 | 부작용 증세가 발생할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함.  | 산업협회, 이승노) | 뢰자에게 보내야 한다.  | 동의서의 사본을 제공받을 것임을 알고 있습니다.  | 사유를 기재한다.  |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | ➄ ➂∼➃번의 과정을 4회 반복한다. ",
        "original_sentence": "| 동의서의 사본을 제공받을 것임을 알고 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "| 사유를 기재한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 20,
        "window_text": "| · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 |\n| 대한 평가기준을 제시하여야 함.  | 산업협회, 이승노) | 뢰자에게 보내야 한다.  | 동의서의 사본을 제공받을 것임을 알고 있습니다.  | 사유를 기재한다.  |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | ➄ ➂∼➃번의 과정을 4회 반복한다.  | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81. ",
        "original_sentence": "| 사유를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "|\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 73,
        "word_count": 20,
        "page_number": 45,
        "window_text": "| 산업협회, 이승노) | 뢰자에게 보내야 한다.  | 동의서의 사본을 제공받을 것임을 알고 있습니다.  | 사유를 기재한다.  |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | ➄ ➂∼➃번의 과정을 4회 반복한다.  | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81.  |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다. ",
        "original_sentence": "|\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "| ➄ ➂∼➃번의 과정을 4회 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 6,
        "window_text": "| 동의서의 사본을 제공받을 것임을 알고 있습니다.  | 사유를 기재한다.  |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | ➄ ➂∼➃번의 과정을 4회 반복한다.  | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81.  |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다.  |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. ",
        "original_sentence": "| ➄ ➂∼➃번의 과정을 4회 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "| ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 182,
        "word_count": 40,
        "page_number": 9,
        "window_text": "| 사유를 기재한다.  |\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | ➄ ➂∼➃번의 과정을 4회 반복한다.  | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81.  |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다.  |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ. ",
        "original_sentence": "| ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "|\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 112,
        "word_count": 30,
        "page_number": 6,
        "window_text": "|\n| 나이 | 회사명 | 대표이사 | 소재지 | 전화 | 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | ➄ ➂∼➃번의 과정을 4회 반복한다.  | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81.  |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다.  |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1. ",
        "original_sentence": "|\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "|\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 47,
        "word_count": 12,
        "page_number": 63,
        "window_text": "| ➄ ➂∼➃번의 과정을 4회 반복한다.  | ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81.  |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다.  |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. ",
        "original_sentence": "|\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "|\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 224,
        "word_count": 58,
        "page_number": 6,
        "window_text": "| ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료 | ➂ 장비의 습도 노출 시험계획서 |\n**diagnostic reagents**\n**(2) 통계처리 기간 : 약 1 개월**\n| (11) 「의료기기의 안정성시험 기준」(식약처 고시) | (1) 혈관미주신경 반응 | Korean J Lab Med 2007;27:177-81.  |\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다.  |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. ",
        "original_sentence": "|\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 61,
        "word_count": 12,
        "page_number": 6,
        "window_text": "|\n| 시험기기 : 휴대용 혈액응고시간 측정기(제품명: 미정) | (4) 검체 채취 및 보관 방법 | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 시작되어 부정확한 결과를 얻을 수 있습니다.  |\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5. ",
        "original_sentence": "안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 58,
        "word_count": 11,
        "page_number": 6,
        "window_text": "|\n| 검체 채취일 | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  |\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6. ",
        "original_sentence": "적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 63,
        "word_count": 13,
        "page_number": 6,
        "window_text": "|\n| (6) 결과 제시 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n| (12) 「의료기기 표시 | 반응명 | 1) 평가 불가능 (Unknown) |\n\n**[표 끝]**\n\n- (13) 「의료기기 기준규격」(식약처 고시)\n<!-- PAGE_6 -->\n# 목\n\n<!-- PAGE_6 -->\n# 차\n\n<!-- PAGE_6 -->\n#### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6.  성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7. ",
        "original_sentence": "약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 78,
        "word_count": 16,
        "page_number": 6,
        "window_text": "안전성·성능 평가\n\n<!-- PAGE_6 -->\n#### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6.  성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8. ",
        "original_sentence": "휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 6,
        "window_text": "적용범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6.  성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ. ",
        "original_sentence": "안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 63,
        "word_count": 13,
        "page_number": 6,
        "window_text": "약어 및 용어정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6.  성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n",
        "original_sentence": "성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 6,
        "window_text": "휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_6 -->\n###### 4\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6.  성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n",
        "original_sentence": "안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 124,
        "word_count": 24,
        "page_number": 6,
        "window_text": "안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 10\n\n<!-- PAGE_6 -->\n###### 6.  성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. ",
        "original_sentence": "참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 316,
        "word_count": 62,
        "page_number": 6,
        "window_text": "성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 15\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n",
        "original_sentence": "임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 288,
        "word_count": 54,
        "page_number": 7,
        "window_text": "안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n <!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n",
        "original_sentence": "<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "- - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 90,
        "word_count": 20,
        "page_number": 8,
        "window_text": "참고 문헌\n\n<!-- PAGE_6 -->\n###### 33\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 35\n\n<!-- PAGE_6 -->\n#### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n <!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2. ",
        "original_sentence": "- - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 175,
        "word_count": 34,
        "page_number": 8,
        "window_text": "임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n#### 37\n\n<!-- PAGE_7 -->\n#### 개\n\n<!-- PAGE_7 -->\n#### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n <!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3. ",
        "original_sentence": "적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "<!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 160,
        "word_count": 30,
        "page_number": 8,
        "window_text": "<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “휴대용 혈액응고시간 측정시스템”\n\n<!-- PAGE_7 -->\n###### 의 안전성 및 성능평가방법, 임상시험계획서 작성 및 평가방법과 관련된\n\n<!-- PAGE_7 -->\n###### 사항을 구체적으로 제시하여 신속제품화를 위한 맞춤형 기술지원을\n\n<!-- PAGE_7 -->\n###### 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n <!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "- - 2 -\n<!-- PAGE_9 -->\n###### 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 9,
        "window_text": "- - 1 -\n<!-- PAGE_8 -->\n#### Ⅰ\n\n<!-- PAGE_8 -->\n#### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n <!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가.  개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다. ",
        "original_sentence": "- - 2 -\n<!-- PAGE_9 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 1916,
        "word_count": 369,
        "page_number": 9,
        "window_text": "적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 휴대용 혈액응고시간 측정시스템의 전기․기계적 안전성\n\n<!-- PAGE_8 -->\n###### 평가와 분석적 성능 및 안정성 평가방법을 구축하여 신개발 융복합 의료\n\n<!-- PAGE_8 -->\n###### 기기의 평가방법을 제시하고자 한다.\n\n <!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가.  개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다.  널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다. ",
        "original_sentence": "약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 53,
        "word_count": 11,
        "page_number": 11,
        "window_text": "<!-- PAGE_8 -->\n###### 휴대용 혈액응고시간 측정시스템은「의료기기 품목 및 품목별 등급에\n\n<!-- PAGE_8 -->\n###### 관한 규정」(식약처 고시) 의 분류에 포함되어 있지 않은 의료기기로서,\n\n<!-- PAGE_8 -->\n###### 향후 추가되어야한다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가.  개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다.  널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다.  즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다. ",
        "original_sentence": "휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 241,
        "word_count": 49,
        "page_number": 11,
        "window_text": "- - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가.  개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다.  널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다.  즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다.  항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다. ",
        "original_sentence": "개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다. "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 123,
        "word_count": 25,
        "page_number": 11,
        "window_text": "약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### 또는 외부물질로 위양성 또는 위음성 결과를 야기 할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (2) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (3) 국제정상비율 (International Normalized Ratio, INR) : 혈액응고시간\n\n<!-- PAGE_9 -->\n###### (4) 기준물질 (Control material) : 정도 관리를 위해 이용되는 기기, 액체\n\n<!-- PAGE_9 -->\n###### (5) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### (6) 배치 (Batch), 로트 (Lot) : 특성이 균일하고 단일 또는 일련의 제조\n\n<!-- PAGE_9 -->\n###### (7) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_9 -->\n###### (8) 사용설명서 (Instructions for use) : 체외진단 의료기기의 안전하고\n\n<!-- PAGE_9 -->\n###### (9) 사용 시 안정성 (In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### 정해진 확률 범위 내에서 분포 할 것으로 예상되는 계산된 구간\n\n<!-- PAGE_10 -->\n###### (11) 실시간 안정성 시험 (Real time stability) : 체외진단시약 제품을\n\n<!-- PAGE_10 -->\n###### 제조자가 특정한 사용 환경에 노출시켜 그 안정성을 평가하는 실험\n\n<!-- PAGE_10 -->\n###### (12) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사결과들\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값\n\n<!-- PAGE_10 -->\n###### 결과들의\n\n<!-- PAGE_10 -->\n###### ‘표준편차’ 또는\n\n<!-- PAGE_10 -->\n###### ‘변이계수’라는\n\n<!-- PAGE_10 -->\n###### 용어로\n\n<!-- PAGE_10 -->\n###### (13) 적혈구용적률 (Packed cell volume) : 혈액 중 적혈구의 체적분율\n\n<!-- PAGE_10 -->\n###### (14) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정\n\n<!-- PAGE_10 -->\n###### (15) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_10 -->\n###### (16) 프로트롬빈 시간 (Prothrombin Time, PT)] : 혈액응고계 검사 방법의\n\n<!-- PAGE_10 -->\n###### 하나로, 혈액 응고 과정 중 외인성 경로에서 필요한 인자인 프로\n\n<!-- PAGE_10 -->\n###### 트롬빈(II인자), V인자, VII인자, X인자가 정상적으로 응고 활성을\n\n- - 4 -\n<!-- PAGE_11 -->\n###### 3.  휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가.  개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다.  널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다.  즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다.  항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다.  더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다. ",
        "original_sentence": "널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 71,
        "word_count": 17,
        "page_number": 11,
        "window_text": "휴대용 혈액응고시간 측정시스템 정의 및 분류\n\n<!-- PAGE_11 -->\n###### 가.  개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다.  널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다.  즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다.  항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다.  더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다.  프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다. ",
        "original_sentence": "즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 325,
        "word_count": 71,
        "page_number": 11,
        "window_text": "개요\n\n<!-- PAGE_11 -->\n###### (1) 본 제품은 와파린(Warfarin) 복용을 처방받은 환자가 휴대하여 자가\n\n<!-- PAGE_11 -->\n###### 모니터링 할 수 있도록 하는 혈액응고시간측정기로 환자 주도적인\n\n<!-- PAGE_11 -->\n###### INR 관리가 가능하여 시간과 장소에 구애받지 않고 환자가 직접\n\n<!-- PAGE_11 -->\n###### 자신의 INR을 측정할 수 있게 된다.  널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다.  즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다.  항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다.  더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다.  프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다.  휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n",
        "original_sentence": "항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 246,
        "word_count": 49,
        "page_number": 12,
        "window_text": "널리 알려진 개인용 혈당측정기와\n\n<!-- PAGE_11 -->\n###### 같이 자가 혈액응고시간측정기를 통해 다양한 장소에서 쉽고 편리하게\n\n<!-- PAGE_11 -->\n###### INR을 모니터링 할 수 있다.  즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다.  항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다.  더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다.  프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다.  휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n <!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n",
        "original_sentence": "더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다. "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 188,
        "word_count": 39,
        "page_number": 12,
        "window_text": "즉, 와파린 복용 환자가 최적의 항 응고\n\n<!-- PAGE_11 -->\n###### 치료효과를 볼 수 있는 환경이 조성된다.  항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다.  더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다.  프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다.  휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n <!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n - - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나. ",
        "original_sentence": "프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 186,
        "word_count": 36,
        "page_number": 12,
        "window_text": "항응고제는 환자 스스로의\n\n<!-- PAGE_11 -->\n###### 관심과 교육 정도에 따라 그 예후가 천차만별로 달라지기 때문에 더욱이\n\n<!-- PAGE_11 -->\n###### 잦은 INR 확인을 통하여 혈전이나 과다 출혈과 같은 합병증은 물론,\n\n- - 5 -\n<!-- PAGE_12 -->\n###### (2) 심혈관 질환의 예방, 치료 및 심장 수술 후 관리를 위해 와파린\n\n<!-- PAGE_12 -->\n###### (Warfarin)으로 대표되는 항응고제를 복용하는 환자는 현재 국내에서만\n\n<!-- PAGE_12 -->\n###### 약 50만 명 정도로 추정된다.  더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다.  프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다.  휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n <!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n - - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n",
        "original_sentence": "휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "<!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 228,
        "word_count": 44,
        "page_number": 12,
        "window_text": "더욱이 서구화, 고령화로 인해 심혈관\n\n<!-- PAGE_12 -->\n###### 질환이 늘어나면서 장기간 항응고제를 복용하는 환자 역시 증가하는\n\n<!-- PAGE_12 -->\n###### (3) 와파린 복용 시 환자의 혈액검사가 반드시 필요한 이유는 프로트롬빈\n\n<!-- PAGE_12 -->\n###### 시간을 측정하기 위해서이며 프로트롬빈 시간은 피가 응고되는데\n\n<!-- PAGE_12 -->\n###### 걸리는 시간을 나타낸다.  프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다.  휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n <!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n - - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n 1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다. ",
        "original_sentence": "<!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "- - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 210,
        "word_count": 36,
        "page_number": 13,
        "window_text": "프로트롬빈 시간의 측정 시기는 와파린 복용\n\n<!-- PAGE_12 -->\n###### 시작 후 처음 며칠 동안은 매일 프로트롬빈 시간을 측정해야 하며\n\n<!-- PAGE_12 -->\n###### 외래환자의 경우는 매일 측정하는 것이 어려우므로 3∼7일에 한번정도\n\n<!-- PAGE_12 -->\n###### 측정하는 것이 일반적이다.  휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n <!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n - - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n 1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4. ",
        "original_sentence": "- - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 198,
        "word_count": 38,
        "page_number": 13,
        "window_text": "휴대용 혈액응고시간 측정시스템은 환자\n\n<!-- PAGE_12 -->\n###### (와파린 복용자)가 INR 수치를 확인하기 위해 정기적으로 병원에 가서\n\n<!-- PAGE_12 -->\n###### 채혈검사를 받아야하는 불편함을 감소시켜 진료비용과 의료비를\n\n<!-- PAGE_12 -->\n###### 획기적으로 줄 일 수 있다.\n\n <!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n - - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n 1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4.  휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가. ",
        "original_sentence": "제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 310,
        "word_count": 46,
        "page_number": 13,
        "window_text": "<!-- PAGE_12 -->\n###### (4) 본 제품의 측정원리는 혈액응고시간 측정검사지에 고정된 인간 재\n\n<!-- PAGE_12 -->\n###### 조합 조직인자 트롬보플라스틴과 혈액의 반응을 통한 응고과정을\n\n<!-- PAGE_12 -->\n###### 전기화학적으로 측정하는 것으로 측정 된 프로트롬빈 시간을 INR\n\n<!-- PAGE_12 -->\n###### 값으로 계산하여 화면에 표시한다.\n\n - - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n 1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4.  휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가.  안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음.",
        "original_sentence": "1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 765,
        "word_count": 138,
        "page_number": 13,
        "window_text": "- - 6 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n엘리어헬스케어(주)\n\n수허 14-1533호\n\n2014-03-31\n\nAlere INRatio PT/INR Test Strip 외 1건\n\n2\n\n한국로슈진단(주)\n\n수허 13-2183호\n\n2013-10-22\n\nCoaguChek XS PT Test Strip\n\n<!-- PAGE_13 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n 1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4.  휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가.  안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음. **\n| the CoaguChek XS system. ",
        "original_sentence": "국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 55,
        "word_count": 11,
        "page_number": 15,
        "window_text": "제품 허가 현황\n\n<!-- PAGE_13 -->\n###### (1) 휴대용 혈액응고시간 측정시스템으로 허가 된 제품은 없음(‘16.10.31 기준)\n\n<!-- PAGE_13 -->\n###### (2) 혈액응고시간 분석기와 개인용 체외진단검사시약 II으로 각각 기 허가된\n\n<!-- PAGE_13 -->\n###### 제품의 국내 취급업체는 아래와 같다.\n\n 1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4.  휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가.  안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음. **\n| the CoaguChek XS system.  Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다. ",
        "original_sentence": "휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 6,
        "window_text": "1\n\n한국로슈진단(주)\n\n수신 16-1507호\n\n2016-06-08\n\nCoaguChek Pro II\n\n2\n\n한국로슈진단(주)\n\n서울 수신 12-2233호\n\n2012-11-26\n\nCoaguChek XS\n\n3\n\n한국로슈진단(주)\n\n서울 수신 12-2232호\n\n2012-11-26\n\nCoaguChek XS PLUS Meter\n\n4\n\n한국로슈진단(주)\n\n서울 수신 09-2040호\n\n2009-11-25\n\nCoaguChek XS Pro\n\n5\n\n엘리어헬스케어(주)\n\n서울 수신 09-1533호\n\n2009-09-09\n\n<!-- PAGE_13 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4.  휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가.  안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음. **\n| the CoaguChek XS system.  Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다.  | 피험자의 부작용에 대한 내용은 해당사항 없다. ",
        "original_sentence": "안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음."
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "**\n| the CoaguChek XS system. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 13,
        "window_text": "국외 허가동향\n\n<!-- PAGE_13 -->\n###### (1) 경구용 항응고제 치료의 자가 측정시스템의 평가방법에 대한 참고\n\n<!-- PAGE_13 -->\n###### (2) FDA (Food and Drug Administration)에서 2003년 06월 19일 혈액\n\n<!-- PAGE_13 -->\n###### 응고분석기의 510(K)\n\n<!-- PAGE_13 -->\n###### submission 가이던스 “510(K) Submission for\n\n<!-- PAGE_13 -->\n###### Coagulation Instruments – Guidance for Industry and FDA Staff”가\n\n- - 7 -\n<!-- PAGE_14 -->\n###### 발행 됨\n\n<!-- PAGE_14 -->\n###### (3) FDA에서 와파린 치료 모니터링을 위한 PT/INR 측정기기에 대한\n\n<!-- PAGE_14 -->\n###### 워크숍이 2016년 03월 08일 진행되었으며 워크숍의 목표는 안전성과\n\n<!-- PAGE_14 -->\n###### 유효성을 보장하기 위해 PT/INT측정기기와 관련 된 규제 문제를\n\n<!-- PAGE_14 -->\n###### (4) 세계시장의 선두 업체인 Roche사의 CoaguChek XS system과 Alere사\n\n<!-- PAGE_14 -->\n###### INRatio 2 PT/INR system이 전문가용(병원용)으로 FDA 승인 받은\n\n- - 8 -\n<!-- PAGE_15 -->\n###### 4.  휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가.  안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음. **\n| the CoaguChek XS system.  Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  |\n| 수 있다. ",
        "original_sentence": "**\n| the CoaguChek XS system. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 51,
        "word_count": 9,
        "page_number": 6,
        "window_text": "휴대용 혈액응고시간 측정시스템 관련 국내외 규격\n\n<!-- PAGE_15 -->\n###### 가.  안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음. **\n| the CoaguChek XS system.  Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  |\n| 수 있다.  | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다. ",
        "original_sentence": "Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "| 피험자의 부작용에 대한 내용은 해당사항 없다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 3,
        "window_text": "안전성에 관한 규격\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n**[표 시작]**\n\n**하고 시험조정자를 선정할 수 있음. **\n| the CoaguChek XS system.  Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  |\n| 수 있다.  | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다.  | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. ",
        "original_sentence": "| 피험자의 부작용에 대한 내용은 해당사항 없다. "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "|\n| 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 10,
        "word_count": 4,
        "page_number": 57,
        "window_text": "**\n| the CoaguChek XS system.  Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  |\n| 수 있다.  | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다.  | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다. ",
        "original_sentence": "|\n| 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "| · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 82,
        "word_count": 23,
        "page_number": 94,
        "window_text": "Thromb Res 2008;123:381-389 | 것은 아니며 행정상 변경이 필요하다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  |\n| 수 있다.  | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다.  | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다.  | 시킬 수 있다. ",
        "original_sentence": "| · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "| monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 116,
        "word_count": 23,
        "page_number": 15,
        "window_text": "| 피험자의 부작용에 대한 내용은 해당사항 없다.  |\n| 수 있다.  | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다.  | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다.  | 시킬 수 있다.  |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. ",
        "original_sentence": "| monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "| ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 66,
        "word_count": 15,
        "page_number": 6,
        "window_text": "|\n| 수 있다.  | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다.  | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다.  | 시킬 수 있다.  |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 사유에 대하여 기록하여 주십시오. ",
        "original_sentence": "| ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "| 시킬 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 11,
        "word_count": 4,
        "page_number": 57,
        "window_text": "| · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| 시험 실시상의 문제점 등에 따라 결정되어야 한다.  | monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다.  | 시킬 수 있다.  |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 사유에 대하여 기록하여 주십시오.  |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다.",
        "original_sentence": "| 시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "|\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 51,
        "window_text": "| monitoring systems for self-testing in managing diabetes mellitus |\n| 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다.  | 시킬 수 있다.  |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 사유에 대하여 기록하여 주십시오.  |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다. **\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함. ",
        "original_sentence": "|\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "| 사유에 대하여 기록하여 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 54,
        "window_text": "| ㉯ 혈액응고시간 측정기: 1대 측정기 |\n**2) 관련성이 없음 (Not related)**\n| 따라 폐기됩니다.  | 시킬 수 있다.  |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 사유에 대하여 기록하여 주십시오.  |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다. **\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함.  | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.",
        "original_sentence": "| 사유에 대하여 기록하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "|\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 152,
        "word_count": 35,
        "page_number": 6,
        "window_text": "| 시킬 수 있다.  |\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 사유에 대하여 기록하여 주십시오.  |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다. **\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함.  | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. **\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다. ",
        "original_sentence": "|\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다."
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "**\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 53,
        "window_text": "|\n| 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 사유에 대하여 기록하여 주십시오.  |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다. **\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함.  | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. **\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다.  | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다. ",
        "original_sentence": "**\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함. "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "| ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 69,
        "word_count": 18,
        "page_number": 7,
        "window_text": "| 사유에 대하여 기록하여 주십시오.  |\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다. **\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함.  | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. **\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다.  | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다. ",
        "original_sentence": "| ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함."
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "**\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 75,
        "word_count": 12,
        "page_number": 6,
        "window_text": "|\n**· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우**\n**작성할 수 있음**\n| ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지 | 3) 관련성이 적음 (Unlikely) | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**안됩니다. **\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함.  | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. **\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다.  | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나. ",
        "original_sentence": "**\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "| ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 70,
        "word_count": 19,
        "page_number": 9,
        "window_text": "**\n| 있는 경우는 이를 반영하여 분석결과를 제시해야함.  | ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. **\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다.  | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나.  성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉. ",
        "original_sentence": "| ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "| 는 그 이유의 타당성을 면밀히 검토하여야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 20,
        "window_text": "| ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지 |\n**상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. **\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다.  | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나.  성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉.  임상시험 종료 후 남은 제품은 폐기한다. ",
        "original_sentence": "| 는 그 이유의 타당성을 면밀히 검토하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "|\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 149,
        "word_count": 32,
        "page_number": 16,
        "window_text": "**\n**and laboratory use- Part 1: General requirements**\n| “검체”라는 용어로 부릅니다.  | ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나.  성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉.  임상시험 종료 후 남은 제품은 폐기한다.  | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다. ",
        "original_sentence": "|\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 175,
        "word_count": 37,
        "page_number": 6,
        "window_text": "| ㉯ 혈액응고시간 측정기: 6대 측정기 | ① 고온시험계획서 | ㉯ 혈액응고시간 측정기: 3대 측정기 | 삽입할 수 있다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나.  성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉.  임상시험 종료 후 남은 제품은 폐기한다.  | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다.  | 적극적으로 대응한다. ",
        "original_sentence": "성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉. "
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "임상시험 종료 후 남은 제품은 폐기한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나.  성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉.  임상시험 종료 후 남은 제품은 폐기한다.  | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다.  | 적극적으로 대응한다.  | Instruments | 시스템 정확도 평가에서 제외할 수 없다. ",
        "original_sentence": "임상시험 종료 후 남은 제품은 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "| Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 156,
        "word_count": 40,
        "page_number": 15,
        "window_text": "|\n**㉯ 혈액응고시간 측정기: 최소 1대 이상 측정기**\n**4)관련성이 의심됨 (Possible)**\n**2**\n\n**[표 끝]**\n\n[표 4] 휴대용 혈액응고시간 측정시스템 안전성 관련 시험 규격\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 나.  성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉.  임상시험 종료 후 남은 제품은 폐기한다.  | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다.  | 적극적으로 대응한다.  | Instruments | 시스템 정확도 평가에서 제외할 수 없다.  | 성능기준을 만족해야 한다. ",
        "original_sentence": "| Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "| 적극적으로 대응한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 20,
        "window_text": "성능에 관한 규격\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n**[표 시작]**\n\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, 임상시험에 | bISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR | 48개가 동봉.  임상시험 종료 후 남은 제품은 폐기한다.  | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다.  | 적극적으로 대응한다.  | Instruments | 시스템 정확도 평가에서 제외할 수 없다.  | 성능기준을 만족해야 한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. ",
        "original_sentence": "| 적극적으로 대응한다. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "| Instruments | 시스템 정확도 평가에서 제외할 수 없다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 39,
        "word_count": 9,
        "page_number": 41,
        "window_text": "임상시험 종료 후 남은 제품은 폐기한다.  | Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다.  | 적극적으로 대응한다.  | Instruments | 시스템 정확도 평가에서 제외할 수 없다.  | 성능기준을 만족해야 한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함. ",
        "original_sentence": "| Instruments | 시스템 정확도 평가에서 제외할 수 없다. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "| 성능기준을 만족해야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| Clinical laboratory testing and in vitro medical devices | 증례기록서(예시) | 참 고 코 드 | 경구용 항응고제 치료 |\n| --- | --- | --- | --- | --- | --- | --- |\n| 절차를 따를 것입니다.  | 적극적으로 대응한다.  | Instruments | 시스템 정확도 평가에서 제외할 수 없다.  | 성능기준을 만족해야 한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.  | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다. ",
        "original_sentence": "| 성능기준을 만족해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "| 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 143,
        "word_count": 43,
        "page_number": 6,
        "window_text": "| 적극적으로 대응한다.  | Instruments | 시스템 정확도 평가에서 제외할 수 없다.  | 성능기준을 만족해야 한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.  | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.  | 사용하여 INR 값을 2회 반복 측정한다. ",
        "original_sentence": "| 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 6,
        "window_text": "| Instruments | 시스템 정확도 평가에서 제외할 수 없다.  | 성능기준을 만족해야 한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.  | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.  | 사용하여 INR 값을 2회 반복 측정한다.  | 그 결과를 기록한다. ",
        "original_sentence": "이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "| 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 147,
        "word_count": 37,
        "page_number": 6,
        "window_text": "| 성능기준을 만족해야 한다.  | 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.  | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.  | 사용하여 INR 값을 2회 반복 측정한다.  | 그 결과를 기록한다.  | 기기가 측정가능 상태인지 확인한다. ",
        "original_sentence": "| 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "| 사용하여 INR 값을 2회 반복 측정한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 높은 치료 범위 | 3.1 – 4.5 | ≤ 10% | 보조성분 | - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부 |\n| 구연산처리 | 1st |\n| 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.  | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.  | 사용하여 INR 값을 2회 반복 측정한다.  | 그 결과를 기록한다.  | 기기가 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) ",
        "original_sentence": "| 사용하여 INR 값을 2회 반복 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "| 그 결과를 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 20,
        "window_text": "이용 가능한 임상시험용 의료 | 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.  | 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.  | 사용하여 INR 값을 2회 반복 측정한다.  | 그 결과를 기록한다.  | 기기가 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 기록한다. ",
        "original_sentence": "| 그 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "| 기기가 측정가능 상태인지 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 20,
        "window_text": "| 서면 동의 일자(YY/MM/DD) | 15-40 | 2.9-3.7 | 낮은 치료 범위 | 2.0 - 3.0 | gentamicin | 적량 | 자사규격 |\n| 1 | ISO 17593 | 대조기기 | ㉯ IEC 60068-2-64에 따라 진동시험을 수행한다.  | 사용하여 INR 값을 2회 반복 측정한다.  | 그 결과를 기록한다.  | 기기가 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 기록한다.  | 기록한다. ",
        "original_sentence": "| 기기가 측정가능 상태인지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "| 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 사용하여 INR 값을 2회 반복 측정한다.  | 그 결과를 기록한다.  | 기기가 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 기록한다.  | 기록한다.  | 값을 측정하고 기록한다. ",
        "original_sentence": "| 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.) "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "| 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| 그 결과를 기록한다.  | 기기가 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 기록한다.  | 기록한다.  | 값을 측정하고 기록한다.  | 내열성 시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "| 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 20,
        "window_text": "| 기기가 측정가능 상태인지 확인한다.  | 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 기록한다.  | 기록한다.  | 값을 측정하고 기록한다.  | 내열성 시험에 관한 요구사항이 적용된다.  | 놓는다. ",
        "original_sentence": "| 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "| 값을 측정하고 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 20,
        "window_text": "| 제시하여 시험결과에 대한 적부판정이 적용되어야 한다.)  | 기록한다.  | 기록한다.  | 값을 측정하고 기록한다.  | 내열성 시험에 관한 요구사항이 적용된다.  | 놓는다.  | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. ",
        "original_sentence": "| 값을 측정하고 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "| 내열성 시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 기록한다.  | 기록한다.  | 값을 측정하고 기록한다.  | 내열성 시험에 관한 요구사항이 적용된다.  | 놓는다.  | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다.",
        "original_sentence": "| 내열성 시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "| 놓는다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 19,
        "window_text": "| 기록한다.  | 값을 측정하고 기록한다.  | 내열성 시험에 관한 요구사항이 적용된다.  | 놓는다.  | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다. **\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다. ",
        "original_sentence": "| 놓는다. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "| equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 152,
        "word_count": 35,
        "page_number": 15,
        "window_text": "| 값을 측정하고 기록한다.  | 내열성 시험에 관한 요구사항이 적용된다.  | 놓는다.  | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다. **\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.  | 기술 하는 것을 말함. ",
        "original_sentence": "| equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. "
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "| 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 113,
        "word_count": 27,
        "page_number": 52,
        "window_text": "| 내열성 시험에 관한 요구사항이 적용된다.  | 놓는다.  | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다. **\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.  | 기술 하는 것을 말함.  |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다. ",
        "original_sentence": "| 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다."
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "**\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 80,
        "window_text": "| 놓는다.  | equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다. **\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.  | 기술 하는 것을 말함.  |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.  | 함께 관리함. ",
        "original_sentence": "**\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "| 기술 하는 것을 말함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 49,
        "window_text": "| equipment | – Requirements for in vitro monitoring systems for | 이상사례 서식지(예시) | [표 12] INR 구간 예시 | 를 위한 자가 측정시스 |\n| 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다. **\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.  | 기술 하는 것을 말함.  |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다. ",
        "original_sentence": "| 기술 하는 것을 말함. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "|\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 248,
        "word_count": 54,
        "page_number": 9,
        "window_text": "| 피험자 제공 | 증상의 | (안정제) | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 의료기기와의 | 2nd | 의료기기에 |\n**기기 정보를 참고하여 인과관계를 평가한다. **\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.  | 기술 하는 것을 말함.  |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.  | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함. ",
        "original_sentence": "|\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다. "
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "| 함께 관리함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 1,
        "window_text": "**\n| 익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.  | 기술 하는 것을 말함.  |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.  | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. ",
        "original_sentence": "| 함께 관리함. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 81,
        "word_count": 20,
        "page_number": 9,
        "window_text": "| 기술 하는 것을 말함.  |\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.  | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "| 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 47,
        "word_count": 12,
        "page_number": 16,
        "window_text": "|\n**범위**\n| 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | 정밀도 평가방법에 대 |\n**의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험**\n| 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n| 목적으로 귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.  | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. ",
        "original_sentence": "| 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 3,
        "window_text": "| 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.  | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다. ",
        "original_sentence": "이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "| 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 483,
        "word_count": 103,
        "page_number": 76,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.  | 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다.  안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5. ",
        "original_sentence": "| 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 192,
        "word_count": 35,
        "page_number": 9,
        "window_text": "| 직선성 평가방법에 대 |\n| 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다.  안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가. ",
        "original_sentence": "따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 334,
        "word_count": 72,
        "page_number": 16,
        "window_text": "이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다.  안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가.  전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n",
        "original_sentence": "또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 79,
        "word_count": 21,
        "page_number": 17,
        "window_text": "| 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, 피험자가 쉽게 견딜 |\n**- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순**\n| 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 | 간섭물질 반응에 대한 |\n**연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될**\n**for in vitro monitoring systems for self-testing of oral anticoagulant therapy**\n**담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상**\n**기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다.  안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가.  전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n <!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n",
        "original_sentence": "안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 17,
        "window_text": "따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에**\n**불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약**\n**최소검출한계 평가방법에**\n**시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을**\n**한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다.  안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가.  전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n <!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n <!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다. ",
        "original_sentence": "안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 1317,
        "word_count": 218,
        "page_number": 17,
        "window_text": "또한,**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n**시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자**\n**인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,**\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 같지 않은**\n**1**\n\n**[표 끝]**\n\n[표 5] 휴대용 혈액응고시간 측정시스템 성능 관련 시험 규격\n\n<!-- PAGE_16 -->\n###### 다.  안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가.  전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n <!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n <!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다.  적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다. ",
        "original_sentence": "전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "<!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 236,
        "word_count": 49,
        "page_number": 17,
        "window_text": "안정성에 관한 규격\n\n번호\n\n안정성 평가 항목\n\n관련 표준 또는 적용 규격\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가.  전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n <!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n <!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다.  적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다.  매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다. ",
        "original_sentence": "<!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "<!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 439,
        "word_count": 91,
        "page_number": 18,
        "window_text": "안전성 평가 항목\n\n<!-- PAGE_17 -->\n###### 가.  전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n <!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n <!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다.  적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다.  매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다.  제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다. ",
        "original_sentence": "<!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 103,
        "word_count": 18,
        "page_number": 18,
        "window_text": "전기\n\n<!-- PAGE_17 -->\n###### 기계적 안전성 시험\n\n<!-- PAGE_17 -->\n###### (1) 관련 규격\n\n<!-- PAGE_17 -->\n###### (가) 의료기기의 전기·기계적 안전에 관한 공통기준규격\n\n<!-- PAGE_17 -->\n###### (나) IEC 61010-1 Safety requirements for electrical equipment for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control,\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 1:\n\n<!-- PAGE_17 -->\n###### General\n\n<!-- PAGE_17 -->\n###### (다) IEC 61010-2-101 Safety requirements for electrical equipment\n\n<!-- PAGE_17 -->\n###### for\n\n<!-- PAGE_17 -->\n###### measurement,\n\n<!-- PAGE_17 -->\n###### control\n\n<!-- PAGE_17 -->\n###### and\n\n<!-- PAGE_17 -->\n###### laboratory\n\n<!-- PAGE_17 -->\n###### use–Part\n\n<!-- PAGE_17 -->\n###### 2–101:\n\n<!-- PAGE_17 -->\n###### Particular requirements for in vitro diagnostic (IVD) medical\n\n<!-- PAGE_17 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_17 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_17 -->\n###### (2) 적용 범위 :\n\n<!-- PAGE_17 -->\n###### 기준은 「의료기기법」제2조에 따라 정의된 의료기기 중\n\n<!-- PAGE_17 -->\n###### 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데 사용되는 체외\n\n<!-- PAGE_17 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 대\n\n<!-- PAGE_17 -->\n###### 기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.\n\n <!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n <!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다.  적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다.  매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다.  제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다.  측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다. ",
        "original_sentence": "적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 72,
        "word_count": 15,
        "page_number": 18,
        "window_text": "<!-- PAGE_17 -->\n###### (4) 시험 기준\n\n<!-- PAGE_17 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n- - 11 -\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### 위해요인 보호시험에 관한 요구사항이 적용된다.\n\n <!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다.  적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다.  매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다.  제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다.  측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다.  평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n",
        "original_sentence": "매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 18,
        "window_text": "<!-- PAGE_18 -->\n###### (다) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 한계치와\n\n<!-- PAGE_18 -->\n###### (라) 유체로 인한 위험 방지 : IEC 61010-1의 11절에 기술된 유체로 인한\n\n<!-- PAGE_18 -->\n###### (마) 가스, 폭발, 파열에 대한 보호\n\n<!-- PAGE_18 -->\n###### : IEC 61010-1의 13절에 기술된 가스,\n\n<!-- PAGE_18 -->\n###### (바) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 대한 요구사항이\n\n<!-- PAGE_18 -->\n###### (사) 성능시험 : 진동과 낙하시험에 대한 기계적 내구성과 온도와 습도\n\n<!-- PAGE_18 -->\n###### 노출에 대한 보호의 결정 전후에 수행되어야 한다.  적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다.  매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다.  제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다.  측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다.  평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n",
        "original_sentence": "제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 153,
        "word_count": 32,
        "page_number": 18,
        "window_text": "적합/부적합 기준은\n\n<!-- PAGE_18 -->\n###### 혈액응고시간 측정시스템 편차와 측정반복성에 대한 시험결과에 근거해야\n\n<!-- PAGE_18 -->\n###### 한다.  매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다.  제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다.  측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다.  평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n",
        "original_sentence": "측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 208,
        "word_count": 45,
        "page_number": 18,
        "window_text": "매 성능 시험 전에 혈액응고시간 측정시스템은 23℃± 2℃와 평형을\n\n<!-- PAGE_18 -->\n###### 이루어야 한다.  제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다.  측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다.  평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n <!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나. ",
        "original_sentence": "평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "<!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 331,
        "word_count": 67,
        "page_number": 19,
        "window_text": "제조업체 권고 기준물질 또는 적절한 대체물질이 성능\n\n<!-- PAGE_18 -->\n###### 시험에 사용되어야 한다.  측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다.  평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n <!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나.  전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6. ",
        "original_sentence": "<!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "<!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 261,
        "word_count": 52,
        "page_number": 20,
        "window_text": "측정시스템의 성능이 영향 받지 않았음을 검증\n\n<!-- PAGE_18 -->\n###### 하기 위해, 응고 반응 후 혈액응고시간 측정 검사지와 유사한 검사지\n\n<!-- PAGE_18 -->\n###### (check strip) 또는 다른 유사한 대체물질이 사용되어도 좋다.  평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n <!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나.  전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6.  성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "<!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 160,
        "word_count": 33,
        "page_number": 20,
        "window_text": "평균\n\n<!-- PAGE_18 -->\n###### INR 값과 측정반복성이 매 시험 전후에 계산되어야 하고, 그 차이가\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (아) 진동과 충격에 대한 기계적 내성\n\n<!-- PAGE_19 -->\n###### ① 진동시험계획서\n\n<!-- PAGE_19 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n <!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나.  전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6.  성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가.  측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "<!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 1571,
        "word_count": 274,
        "page_number": 20,
        "window_text": "<!-- PAGE_19 -->\n###### (자) 저장을 위한 장비의 온도 노출\n\n<!-- PAGE_19 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_19 -->\n###### ㉰ 온도를 50℃ ± 2℃로 증가시키고 휴대용 혈액응고시간 측정기를 챔버에\n\n<!-- PAGE_19 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 냉각시키고 성능시험을\n\n- - 13 -\n<!-- PAGE_20 -->\n###### ② 저온시험계획서\n\n<!-- PAGE_20 -->\n###### ㉮ (사)에 기술된 성능 시험을 수행한다.\n\n <!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n <!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나.  전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6.  성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가.  측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다. ",
        "original_sentence": "전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 147,
        "word_count": 34,
        "page_number": 22,
        "window_text": "<!-- PAGE_20 -->\n###### ㉯ 각 휴대용혈액응고시간 측정기를 내부온도가 감시되는 환경 챔버에\n\n<!-- PAGE_20 -->\n###### ㉰ 온도를 –20℃ ± 2℃로 감소시키고 휴대용 혈액응고시간 측정기를\n\n<!-- PAGE_20 -->\n###### ㉱ 휴대용 혈액응고시간 측정기를 23℃±2℃로 가열하고 성능시험을 반복\n\n<!-- PAGE_20 -->\n###### ㉰ 불응축 상대습도를 90% ± 3%로, 온도는 32℃ ± 2℃로 안정화시킨다.\n\n <!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나.  전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6.  성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가.  측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n",
        "original_sentence": "성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 590,
        "word_count": 97,
        "page_number": 22,
        "window_text": "<!-- PAGE_20 -->\n###### ㉲ 휴대용 혈액응고시간 측정기를 꺼내, 23℃ ± 2℃ 온도와 상대습도 ≤\n\n<!-- PAGE_20 -->\n###### 60%에 도달하는 시점까지 15분 동안 평형에 이르도록 하고, 성능시험을\n\n<!-- PAGE_20 -->\n###### 나.  전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6.  성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가.  측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n <!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n",
        "original_sentence": "측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "<!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 684,
        "word_count": 140,
        "page_number": 22,
        "window_text": "전자파 안전성 시험\n\n<!-- PAGE_20 -->\n###### (1) 관련 규격\n\n<!-- PAGE_20 -->\n###### (가) 의료기기의 전자파 안전에 관한 공통기준규격\n\n<!-- PAGE_20 -->\n###### (나) IEC 61326-1 Electrical equipment for measurement, control and\n\n<!-- PAGE_20 -->\n###### laboratory\n\n<!-- PAGE_20 -->\n###### use\n\n<!-- PAGE_20 -->\n###### -\n\n<!-- PAGE_20 -->\n###### EMC\n\n<!-- PAGE_20 -->\n###### requirements\n\n<!-- PAGE_20 -->\n###### –\n\n<!-- PAGE_20 -->\n###### Part\n\n<!-- PAGE_20 -->\n###### 1:\n\n<!-- PAGE_20 -->\n###### General\n\n- - 14 -\n<!-- PAGE_21 -->\n###### (다) IEC 61326-2-6 Electrical equipment for measurement, control\n\n<!-- PAGE_21 -->\n###### and\n\n<!-- PAGE_21 -->\n###### laboratory\n\n<!-- PAGE_21 -->\n###### use\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### EMC\n\n<!-- PAGE_21 -->\n###### requirements\n\n<!-- PAGE_21 -->\n###### –\n\n<!-- PAGE_21 -->\n###### Part\n\n<!-- PAGE_21 -->\n###### 2-6:\n\n<!-- PAGE_21 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_21 -->\n###### (라) ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_21 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_21 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_21 -->\n###### 사용되는 체외진단용 분석기기(In vitro diagnostic equipment)에 적용\n\n<!-- PAGE_21 -->\n###### (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와\n\n<!-- PAGE_21 -->\n###### 주위에 대하여 전자파로부터 적절하게 보호를 하고 있다는 것을\n\n<!-- PAGE_21 -->\n###### (4) 시험 항목\n\n<!-- PAGE_21 -->\n###### (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구\n\n<!-- PAGE_21 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 15 -\n<!-- PAGE_22 -->\n###### 6.  성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가.  측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n <!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n <!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 254,
        "word_count": 52,
        "page_number": 23,
        "window_text": "성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함\n\n<!-- PAGE_22 -->\n###### 가.  측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n <!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n <!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나.  중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "<!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 193,
        "word_count": 41,
        "page_number": 23,
        "window_text": "측정 반복성평가\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격\n\n<!-- PAGE_22 -->\n###### ①\n\n<!-- PAGE_22 -->\n###### ISO\n\n<!-- PAGE_22 -->\n###### 17593\n\n<!-- PAGE_22 -->\n###### Clinical\n\n<!-- PAGE_22 -->\n###### laboratory\n\n<!-- PAGE_22 -->\n###### testing\n\n<!-- PAGE_22 -->\n###### and\n\n<!-- PAGE_22 -->\n###### in\n\n<!-- PAGE_22 -->\n###### vitro\n\n<!-- PAGE_22 -->\n###### medical\n\n<!-- PAGE_22 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_22 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_22 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n <!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n <!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나.  중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다. ",
        "original_sentence": "<!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "<!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 265,
        "word_count": 63,
        "page_number": 23,
        "window_text": "<!-- PAGE_22 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 측정반복성 평가\n\n<!-- PAGE_22 -->\n###### (4) 시험 조건\n\n<!-- PAGE_22 -->\n###### ① 단일 기관에서 단일 사용자가 단 기간 동안 동일한 측정기와 검사\n\n<!-- PAGE_22 -->\n###### ② 검체의 준비\n\n<!-- PAGE_22 -->\n###### 와파린복용 환자 30명, 와파린 미복용 환자 15명을 대상으로 적혈\n\n<!-- PAGE_22 -->\n###### 구용적률(Hct) 35%∼50% (0.35L/L∼0.50L/L) 범위와 아래 표와\n\n- - 16 -\n<!-- PAGE_23 -->\n###### ③ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_23 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_23 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_23 -->\n###### ④ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_23 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n <!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n <!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나.  중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다. ",
        "original_sentence": "<!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 557,
        "word_count": 90,
        "page_number": 24,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_23 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_23 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_23 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_23 -->\n###### ➄ ➂, ➃번을 9번 반복한다.\n\n <!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n <!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나.  중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다.  평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n",
        "original_sentence": "중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "<!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 732,
        "word_count": 156,
        "page_number": 24,
        "window_text": "<!-- PAGE_23 -->\n###### ➅ 두 번째, 세 번째\n\n<!-- PAGE_23 -->\n###### 로트 검사지를 이용하여 ➁∼➄번의 과정을 반복\n\n<!-- PAGE_23 -->\n###### (6) 결과 제시\n\n<!-- PAGE_23 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를 계산한다.\n\n <!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나.  중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다.  평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n",
        "original_sentence": "<!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 323,
        "word_count": 68,
        "page_number": 25,
        "window_text": "<!-- PAGE_23 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합분산, 통합표준편차 (95%\n\n<!-- PAGE_23 -->\n###### (아래 [표 8]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n- - 17 -\n구간\n\nINR 값\n\n변동계수(%CV)\n\n비 치료적 범위\n\n- 2.0 미만\n≤ 11%\n\n낮은 치료 범위\n\n- 2.0 – 3.0\n≤ 10%\n\n[표 8] 측정 반복성 결과 예시\n\n<!-- PAGE_24 -->\n###### 나.  중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다.  평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n <!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다. ",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 141,
        "word_count": 29,
        "page_number": 25,
        "window_text": "중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### ①\n\n<!-- PAGE_24 -->\n###### ISO\n\n<!-- PAGE_24 -->\n###### 17593\n\n<!-- PAGE_24 -->\n###### Clinical\n\n<!-- PAGE_24 -->\n###### laboratory\n\n<!-- PAGE_24 -->\n###### testing\n\n<!-- PAGE_24 -->\n###### and\n\n<!-- PAGE_24 -->\n###### in\n\n<!-- PAGE_24 -->\n###### vitro\n\n<!-- PAGE_24 -->\n###### medical\n\n<!-- PAGE_24 -->\n###### devices – Requirements for in vitro monitoring systems for\n\n<!-- PAGE_24 -->\n###### ② CLSI EP05 Evaluation of Precision of Quantitative Measurement\n\n<!-- PAGE_24 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다.  평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n <!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다.  직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "- - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 117,
        "word_count": 24,
        "page_number": 26,
        "window_text": "<!-- PAGE_24 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 중간측정정밀도 평가\n\n<!-- PAGE_24 -->\n###### (4) 시험 조건\n\n<!-- PAGE_24 -->\n###### ① 정상 사용조건에서 개별 사용자가 동일한 휴대용 혈액응고시간\n\n<!-- PAGE_24 -->\n###### 측정기 및 로트로 여러 날에 걸쳐 중간측정정밀도를 측정하도록\n\n<!-- PAGE_24 -->\n###### ② 검체의 준비 : 제조업체가 제공하는 기준물질로 수행되어야 하며,\n\n- - 18 -\n<!-- PAGE_25 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_25 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_25 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_25 -->\n###### ➃ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_25 -->\n###### (5) 시험 방법 : 각각의 INR 구간 시료를 10일 동안 하루에 한번 측정\n\n<!-- PAGE_25 -->\n###### 하도록 설계된 것으로 최소 평가 절차로 아래의 평가 절차를 1일\n\n<!-- PAGE_25 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_25 -->\n###### 기준물질을 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다.  평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n <!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다.  직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다. ",
        "original_sentence": "- - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "<!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 92,
        "word_count": 18,
        "page_number": 26,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_25 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 기준물질의 INR\n\n<!-- PAGE_25 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_25 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 기준물질을 이용하여 INR\n\n<!-- PAGE_25 -->\n###### ➄ 두 번째 로트, 세 번째 로트를 적용하여 ➂∼➃번을 반복해서\n\n<!-- PAGE_25 -->\n###### ➅ 남은 9일 동안 ➀∼➄번의 절차를 반복한다.  평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n <!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다.  직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n",
        "original_sentence": "<!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 160,
        "word_count": 30,
        "page_number": 26,
        "window_text": "평가기간 내내 같은\n\n<!-- PAGE_25 -->\n###### (6) 결과 제시\n\n<!-- PAGE_25 -->\n###### ① 각각의 INR 구간 및 로트에 대한 평균, 표준편차, 변동계수를\n\n<!-- PAGE_25 -->\n###### 계산한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n <!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다.  직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n <!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n",
        "original_sentence": "직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "<!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 518,
        "word_count": 110,
        "page_number": 26,
        "window_text": "- - 19 -\n<!-- PAGE_26 -->\n###### ② 각 INR 구간별 3개 로트의 통합평균, 통합표준편차 (95% 신뢰구간)와\n\n<!-- PAGE_26 -->\n###### 통합변동계수를 계산한다.\n\n <!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다.  직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n <!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n <!-- PAGE_27 -->\n###### 라. ",
        "original_sentence": "<!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 27,
        "window_text": "<!-- PAGE_26 -->\n###### (아래 [표 10]에 제시된 허용기준은 예시이며 자사의 허용 기준범위를\n\n<!-- PAGE_26 -->\n###### 다.  직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n <!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n <!-- PAGE_27 -->\n###### 라.  최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "<!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 524,
        "word_count": 111,
        "page_number": 27,
        "window_text": "직선성 평가\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP06 Evaluation of the Linearity of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n <!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n <!-- PAGE_27 -->\n###### 라.  최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n - - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다. ",
        "original_sentence": "<!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "<!-- PAGE_27 -->\n###### 라. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 27,
        "window_text": "<!-- PAGE_26 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 직선성 평가\n\n<!-- PAGE_26 -->\n###### (4) 시험 조건\n\n<!-- PAGE_26 -->\n###### ① 검체의 준비 : INR 측정범위를 포함하여 10% 넓은 측정범위를 기준\n\n<!-- PAGE_26 -->\n###### ➁ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_26 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_26 -->\n###### ㉯ 혈액응고시간 측정기: 최소 10대 측정기\n\n<!-- PAGE_26 -->\n###### ➂ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### ➀ 휴대용 혈액응고시간 측정기 10대와 3개 로트 측정검사지 그리고\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n <!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n <!-- PAGE_27 -->\n###### 라.  최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n - - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다. ",
        "original_sentence": "<!-- PAGE_27 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 189,
        "word_count": 33,
        "page_number": 27,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_27 -->\n###### 포장용기 또는 포장지를 벗기지 않는다.)\n\n <!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n <!-- PAGE_27 -->\n###### 라.  최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n - - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다.  (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n",
        "original_sentence": "최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "- - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 351,
        "word_count": 76,
        "page_number": 28,
        "window_text": "<!-- PAGE_27 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_27 -->\n###### ➂ 10대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를\n\n<!-- PAGE_27 -->\n###### ➃ 10대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_27 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번을 반복하고, 그 결과를\n\n<!-- PAGE_27 -->\n###### (6) 결과 제시\n\n<!-- PAGE_27 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_27 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의\n\n<!-- PAGE_27 -->\n###### 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값의\n\n<!-- PAGE_27 -->\n###### ➂ 선형회귀 분석을 통하여 상관계수를 산출한다.\n\n <!-- PAGE_27 -->\n###### 라.  최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n - - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다.  (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마. ",
        "original_sentence": "- - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 143,
        "word_count": 30,
        "page_number": 28,
        "window_text": "<!-- PAGE_27 -->\n###### 라.  최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n - - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다.  (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "(※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 223,
        "word_count": 47,
        "page_number": 28,
        "window_text": "최소검출한계\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격\n\n<!-- PAGE_27 -->\n###### : CLSI EP17 Evaluation of Detection Capability for Clinical\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n - - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다.  (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다. ",
        "original_sentence": "(※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "- - 22 -\n<!-- PAGE_29 -->\n###### 마. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 29,
        "window_text": "- - 21 -\n<!-- PAGE_28 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 검출될 수 있는 분석\n\n<!-- PAGE_28 -->\n###### 물질의 최소량을 평가\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### ➁ 검체의 준비 : 검체 종류와 검체 준비과정(검체 농도, 농도를 확인한\n\n<!-- PAGE_28 -->\n###### (5) 시험 방법\n\n<!-- PAGE_28 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_28 -->\n###### 검체 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다.  (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다.  (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n",
        "original_sentence": "- - 22 -\n<!-- PAGE_29 -->\n###### 마. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 233,
        "word_count": 39,
        "page_number": 29,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_28 -->\n###### ➁ 휴대용 혈액응고시간 측정기에 로트 검사지를 장착하고, 측정기가\n\n<!-- PAGE_28 -->\n###### ➂ 단계적으로 희석하여 각 농도를 최소 20회 반복 측정한다.  (※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다.  (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n <!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다. ",
        "original_sentence": "적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "<!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 298,
        "word_count": 60,
        "page_number": 29,
        "window_text": "(※비고:\n\n<!-- PAGE_28 -->\n###### 기허가 제품이 있을 경우 동일한 검체를 동시에 검사하여 검출한\n\n<!-- PAGE_28 -->\n###### ➃ 두 번째, 세 번째 로트를 이용하여 ➁∼➂번의 과정을 반복하고\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시\n\n<!-- PAGE_28 -->\n###### : 측정횟수의 95% 이상 결과를 나타내는 농도를 제시한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다.  (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n <!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n",
        "original_sentence": "<!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "(※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 20,
        "window_text": "- - 22 -\n<!-- PAGE_29 -->\n###### 마.  적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다.  (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n <!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n <!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바. ",
        "original_sentence": "(※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "<!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 341,
        "word_count": 71,
        "page_number": 29,
        "window_text": "적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### (1) 관련 규격\n\n<!-- PAGE_29 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_29 -->\n###### Guideline\n\n<!-- PAGE_29 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다.  (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n <!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n <!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바.  간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "<!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "(※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 152,
        "word_count": 31,
        "page_number": 30,
        "window_text": "<!-- PAGE_29 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 적혈구용적률 영향평가\n\n<!-- PAGE_29 -->\n###### ① 검체의 준비 : 적혈구용적률 평가는 정상수준(42 ± 2%)을 포함하여 휴대용\n\n<!-- PAGE_29 -->\n###### 혈액응고시간 측정시스템의 명시된 적혈구 용적률 범위에 해당되는 최소 5\n\n<!-- PAGE_29 -->\n###### 가지 수준이 시험되어야 하며, 아래 표와 같이 INR 측정구간을 포함되어야\n\n<!-- PAGE_29 -->\n###### 한다.  (※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n <!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n <!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바.  간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "<!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 426,
        "word_count": 95,
        "page_number": 30,
        "window_text": "(※비고: 검체 준비 시 각 제품의 측정 가능범위를 고려하여 준비한다.)\n\n <!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n <!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바.  간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다. ",
        "original_sentence": "<!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 191,
        "word_count": 33,
        "page_number": 30,
        "window_text": "<!-- PAGE_29 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_29 -->\n###### ㉮ 혈액응고시간 측정검사지: 3개 로트 검사지\n\n<!-- PAGE_29 -->\n###### ㉯ 혈액응고시간 측정기: 1대 측정기\n\n<!-- PAGE_29 -->\n###### ③ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_29 -->\n###### (5) 시험 방법\n\n<!-- PAGE_29 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 혈액\n\n<!-- PAGE_29 -->\n###### 시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n <!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바.  간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다.  (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다. ",
        "original_sentence": "간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "<!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 205,
        "word_count": 44,
        "page_number": 30,
        "window_text": "(※비고: 측정 검사지는 사용 전까지 포장용기\n\n- - 23 -\n<!-- PAGE_30 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비와 원심분리기를 이용하여 혈액시료의\n\n<!-- PAGE_30 -->\n###### INR 값과 적혈구용적률을 측정하고 기록한다.\n\n <!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바.  간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다.  (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n",
        "original_sentence": "<!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "<!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 117,
        "word_count": 23,
        "page_number": 31,
        "window_text": "<!-- PAGE_30 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_30 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_30 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_30 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의 평균 및\n\n<!-- PAGE_30 -->\n###### ② 기준장비로 측정한 기준 값과 휴대용 혈액응고시간 측정시스템의 측정값을\n\n<!-- PAGE_30 -->\n###### 이용하여 각 검체 및 시약 로트 조합에 대한 INR 값 편차 및 %편차를\n\n<!-- PAGE_30 -->\n###### 바.  간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다.  (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n",
        "original_sentence": "<!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "(※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 356,
        "word_count": 73,
        "page_number": 31,
        "window_text": "간섭평가\n\n<!-- PAGE_30 -->\n###### (1) 관련 규격\n\n<!-- PAGE_30 -->\n###### : CLSI EP07 Interference Testing in Clinical Chemistry Approved\n\n<!-- PAGE_30 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다.  (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n <!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n",
        "original_sentence": "(※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 129,
        "word_count": 25,
        "page_number": 31,
        "window_text": "<!-- PAGE_30 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템의 내·외인성 간섭물질 영향평가\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### ① 검체의 준비\n\n<!-- PAGE_31 -->\n###### ㉮ 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다.  (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n <!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n <!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다. ",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "- - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 116,
        "word_count": 25,
        "page_number": 32,
        "window_text": "<!-- PAGE_31 -->\n###### ㉰ 간섭물질 용액이 시험시료에 첨가하고, 간섭물질을 용해시키기 위해 사용\n\n<!-- PAGE_31 -->\n###### 되는 동일한 부피의 용질이 대조시료에 첨가한다.  (※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n <!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n <!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다.  (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다. ",
        "original_sentence": "- - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "<!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 117,
        "word_count": 23,
        "page_number": 32,
        "window_text": "(※비고: 시료 기질의\n\n<!-- PAGE_31 -->\n###### ② 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_31 -->\n###### ➂ 장비 및 시약\n\n<!-- PAGE_31 -->\n###### ㉮ 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_31 -->\n###### ㉯ 간섭물질 시약 및 농도(※비고: 간섭물질의 시험농도는 임상적으로 나타날\n\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### ➀ 휴대용 혈액응고시간 측정기 1대와 3개 로트 측정검사지 그리고 시험\n\n<!-- PAGE_31 -->\n###### 시료와 대조시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n <!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n <!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다.  (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다.  간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n",
        "original_sentence": "<!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "<!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 99,
        "word_count": 21,
        "page_number": 32,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_31 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 시험시료와 대조시료의\n\n<!-- PAGE_31 -->\n###### INR 값을 측정하고 기록한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n <!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n <!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다.  (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다.  간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n <!-- PAGE_32 -->\n###### 사. ",
        "original_sentence": "<!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "(※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 174,
        "word_count": 31,
        "page_number": 32,
        "window_text": "- - 25 -\n<!-- PAGE_32 -->\n###### ➂ 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착하고, 측정\n\n<!-- PAGE_32 -->\n###### 준비가 완료되었는지 확인한다.\n\n <!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n <!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다.  (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다.  간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n <!-- PAGE_32 -->\n###### 사.  사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
        "original_sentence": "(※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 293,
        "word_count": 63,
        "page_number": 32,
        "window_text": "<!-- PAGE_32 -->\n###### ➃ 휴대용 혈액응고시간 측정기에 시험시료를 이용하여 INR 값을 측정하고\n\n<!-- PAGE_32 -->\n###### ➄ ➂∼➃번의 과정을 9회 반복하고 기록한다.\n\n <!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다.  (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다.  간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n <!-- PAGE_32 -->\n###### 사.  사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다. ",
        "original_sentence": "간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "<!-- PAGE_32 -->\n###### 사. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 32,
        "window_text": "<!-- PAGE_32 -->\n###### ➅ 두 번째, 세 번째 로트를 이용하여 ➂∼➄번의 과정을 반복하고, 그 결과를\n\n<!-- PAGE_32 -->\n###### 기록한다.  (※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다.  간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n <!-- PAGE_32 -->\n###### 사.  사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다.  참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다. ",
        "original_sentence": "<!-- PAGE_32 -->\n###### 사. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 273,
        "word_count": 49,
        "page_number": 32,
        "window_text": "(※비고: 단, 허용기준을 초과하는 간섭효과가 발견되면, 간섭물질\n\n<!-- PAGE_32 -->\n###### 농도에 따른 간섭 정도를 결정하기 위해 투여-응답 기법(dose-response\n\n<!-- PAGE_32 -->\n###### series)을 사용하고, 기준을 충족하는 최대 간섭물질 농도를 계산한다.  간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n <!-- PAGE_32 -->\n###### 사.  사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다.  참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다.  실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다. ",
        "original_sentence": "사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "<!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 596,
        "word_count": 121,
        "page_number": 33,
        "window_text": "간섭\n\n<!-- PAGE_32 -->\n###### 물질 농도가 가장 높은 시료와 대조시료의 혼합물로부터 간섭물질 농도의\n\n<!-- PAGE_32 -->\n###### (6) 결과 제시\n\n<!-- PAGE_32 -->\n###### ① 잠재적 간섭을 평가할 각 물질에 대하여, 다음과 같이 데이터 분석을\n\n<!-- PAGE_32 -->\n###### ② 각 검체에 대하여 휴대용 혈액응고시간 측정시스템 측정값의 평균 및\n\n<!-- PAGE_32 -->\n###### ➂ 시험 검체의 평균값과 대조 검체의 평균값의 차이를 산출한다.\n\n <!-- PAGE_32 -->\n###### 사.  사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다.  참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다.  실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다.  (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n",
        "original_sentence": "<!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 80,
        "word_count": 15,
        "page_number": 33,
        "window_text": "<!-- PAGE_32 -->\n###### 사.  사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다.  참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다.  실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다.  (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n <!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n",
        "original_sentence": "참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 107,
        "word_count": 22,
        "page_number": 33,
        "window_text": "사용자 성능평가\n\n<!-- PAGE_32 -->\n###### (1) 관련 규격 : ISO 17593 Clinical laboratory testing and in vitro medical\n\n<!-- PAGE_32 -->\n###### devices – Requirements for in vitro monitoring systems for self-testing\n\n- - 26 -\n<!-- PAGE_33 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정시스템에 적용한다.\n\n <!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다.  참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다.  실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다.  (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n <!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n <!-- PAGE_34 -->\n###### 아. ",
        "original_sentence": "실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "(※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 195,
        "word_count": 40,
        "page_number": 33,
        "window_text": "<!-- PAGE_33 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템과 함께 제공되는 사용설명서와\n\n<!-- PAGE_33 -->\n###### 교육 자료만으로도 사용자가 유효한 INR 값을 얻을 수 있음을 증명하기 위함\n\n<!-- PAGE_33 -->\n###### (4) 시험 조건\n\n<!-- PAGE_33 -->\n###### ① 일반사용자가 외부 영향 없이 측정할 수 있는 3개의 평가 장소에서 수행\n\n<!-- PAGE_33 -->\n###### ② 피험자는 2.0–4.5 INR 값 범위에서 35%∼50%(0.35L/L∼0.50L/L)의 적혈구\n\n<!-- PAGE_33 -->\n###### ➂ 시험참가자는 제조업체에서 혈액응고시간 측정시스템과 함께 통상 제공\n\n<!-- PAGE_33 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_33 -->\n###### ➄ 장비 및 시약 : 병원용 혈액응고시간 측정 기준장비\n\n<!-- PAGE_33 -->\n###### ➅ 사용설명서 평가 : 사용설명서는 의도된 사용자에 의해 명확성과 유용성에\n\n<!-- PAGE_33 -->\n###### 대해 평가되어야 한다.  참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다.  실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다.  (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n <!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n <!-- PAGE_34 -->\n###### 아.  기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n",
        "original_sentence": "(※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "<!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 317,
        "word_count": 61,
        "page_number": 34,
        "window_text": "참가자들이 기기 사용법을 올바르게 이해했는지를\n\n<!-- PAGE_33 -->\n###### 평가하는데 도움이 되도록 설문지가 구성되어야 한다.  실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다.  (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n <!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n <!-- PAGE_34 -->\n###### 아.  기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n <!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7. ",
        "original_sentence": "<!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "<!-- PAGE_34 -->\n###### 아. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 34,
        "window_text": "실제 시험결과에\n\n<!-- PAGE_33 -->\n###### (5) 시험 방법\n\n<!-- PAGE_33 -->\n###### ➀ 휴대용 혈액응고시간 측정기 6대와 1종 로트 검사지를 준비한다.  (※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n <!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n <!-- PAGE_34 -->\n###### 아.  기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n <!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_34 -->\n###### 아. "
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 74,
        "word_count": 14,
        "page_number": 34,
        "window_text": "(※비고:\n\n<!-- PAGE_33 -->\n###### ➁ 6대의 휴대용 혈액응고시간 측정기에 검사지를 장착하고, 모든 측정기기가\n\n- - 27 -\n<!-- PAGE_34 -->\n###### ➂ 피험자는 자신의 손가락을 찌르고 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### 사용하여 INR 값을 2회 반복 측정한다.\n\n <!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n <!-- PAGE_34 -->\n###### 아.  기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n <!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가.  개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n",
        "original_sentence": "기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "<!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 103,
        "word_count": 21,
        "page_number": 34,
        "window_text": "<!-- PAGE_34 -->\n###### ➃ 훈련된 의료전문가가 ➂번과 동일한 휴대용 혈액응고시간 측정시스템을\n\n<!-- PAGE_34 -->\n###### ➄ 의료전문가가 피험자의 검체를 채취하여 병원용 혈액응고시간 측정 기준\n\n<!-- PAGE_34 -->\n###### ① 일반 사용자들이 휴대용 혈액응고시간 측정시스템으로 측정한 INR 값과\n\n<!-- PAGE_34 -->\n###### 의료전문가가 동일한 휴대용 혈액응고시간 측정시스템으로 측정한 INR\n\n<!-- PAGE_34 -->\n###### ② 일반 사용자의 평균값과 전문가의 평균값 차이를 산출한다.\n\n <!-- PAGE_34 -->\n###### 아.  기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n <!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가.  개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n",
        "original_sentence": "<!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 35,
        "window_text": "<!-- PAGE_34 -->\n###### 아.  기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n <!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가.  개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n",
        "original_sentence": "안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 249,
        "word_count": 46,
        "page_number": 35,
        "window_text": "기준물질/보정물질\n\n<!-- PAGE_34 -->\n###### : 보정과 정도관리를 위한 기준물질 및 보정물질의 개발이 필요하다.\n\n <!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가.  개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n <!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다. ",
        "original_sentence": "개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "<!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 223,
        "word_count": 45,
        "page_number": 35,
        "window_text": "<!-- PAGE_34 -->\n###### (1) 정도관리물질은 임의의 물질(mimic), 검체 등을 이용하여 제조한\n\n- - 28 -\n<!-- PAGE_35 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가.  개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n <!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다.  성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n",
        "original_sentence": "<!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "<!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 124,
        "word_count": 25,
        "page_number": 35,
        "window_text": "안정성 평가 항목\n\n<!-- PAGE_35 -->\n###### 가.  개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n <!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다.  성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n <!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n",
        "original_sentence": "<!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "<!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 347,
        "word_count": 63,
        "page_number": 35,
        "window_text": "개봉 전 안정성평가\n\n<!-- PAGE_35 -->\n###### (1) 관련 규격\n\n<!-- PAGE_35 -->\n###### ① 「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_35 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_35 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n <!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다.  성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n <!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n <!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다. ",
        "original_sentence": "<!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 121,
        "word_count": 26,
        "page_number": 36,
        "window_text": "<!-- PAGE_35 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_35 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_35 -->\n###### (4) 시험 조건\n\n<!-- PAGE_35 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n <!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n <!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다.  성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n <!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n <!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다.  성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다. ",
        "original_sentence": "성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "<!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 184,
        "word_count": 34,
        "page_number": 36,
        "window_text": "<!-- PAGE_35 -->\n###### ➁ 장기보존시험 : 제조자가 표방하고자 하는 개봉 전 사용기간(유효\n\n<!-- PAGE_35 -->\n###### 기간) 동안 저장 조건에 보관하여 안정성시험을 실시되어야 한다.\n\n <!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다.  성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n <!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n <!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다.  성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n",
        "original_sentence": "<!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "<!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 222,
        "word_count": 42,
        "page_number": 36,
        "window_text": "<!-- PAGE_35 -->\n###### 휴대용\n\n<!-- PAGE_35 -->\n###### 혈액응고시간\n\n<!-- PAGE_35 -->\n###### 측정검사지의\n\n<!-- PAGE_35 -->\n###### 보관조건(온도,\n\n<!-- PAGE_35 -->\n###### 습도)을\n\n<!-- PAGE_35 -->\n###### 3\n\n<!-- PAGE_35 -->\n###### point로 설정하여 해당 보관조건에서 개봉 전 사용기간 동안 제품의\n\n<!-- PAGE_35 -->\n###### 성능이 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수\n\n<!-- PAGE_35 -->\n###### 있는지 평가되어야 한다.  성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n <!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n <!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다.  성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n <!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 216,
        "word_count": 44,
        "page_number": 36,
        "window_text": "성능 관련 시험의 측정 시험간격은 시험\n\n- - 29 -\n<!-- PAGE_36 -->\n###### 개시와 중간시점 그리고 마지막시점을 포함하여 3회 시점으로\n\n<!-- PAGE_36 -->\n###### 설정한다.\n\n <!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n <!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다.  성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n <!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나.  개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n",
        "original_sentence": "성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 317,
        "word_count": 68,
        "page_number": 36,
        "window_text": "<!-- PAGE_36 -->\n###### ➂ 가속노화시험 : 가속노화온도는 시험하려는 재료의 특징을 고려하여\n\n<!-- PAGE_36 -->\n###### 재료를 변형시키거나 포장이 뒤틀리지 않는 범위 내에서 선택하여\n\n<!-- PAGE_36 -->\n###### 가속노화온도, 가속노화 시험기간, 가속노화 시험간격을 설정한다.\n\n <!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다.  성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n <!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나.  개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "<!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 280,
        "word_count": 62,
        "page_number": 37,
        "window_text": "<!-- PAGE_36 -->\n###### 휴대용 혈액응고시간 측정검사지의 보관조건(온도, 습도)을 3 point로\n\n<!-- PAGE_36 -->\n###### 설정하여 해당 보관조건에서 가속노화 시험기간 동안 제품의 성능이\n\n<!-- PAGE_36 -->\n###### 유지되어 제조자가 의도한 사용목적이 적합하게 발휘 될 수 있는지\n\n<!-- PAGE_36 -->\n###### 평가되어야 한다.  성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n <!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나.  개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n - - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다. ",
        "original_sentence": "<!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 248,
        "word_count": 45,
        "page_number": 37,
        "window_text": "성능시험의 측정 시기는 시험개시와 중간시점 그리고\n\n<!-- PAGE_36 -->\n###### ➃ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_36 -->\n###### (5) 시험 방법\n\n<!-- PAGE_36 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_36 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n <!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나.  개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n - - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다.  휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n",
        "original_sentence": "개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "<!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 223,
        "word_count": 45,
        "page_number": 37,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_36 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_36 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n<!-- PAGE_36 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n- - 30 -\n<!-- PAGE_37 -->\n###### ➄ 두 번째, 세 번째 로트를 이용하여 ➂∼➃번의 과정을 반복하고\n\n<!-- PAGE_37 -->\n###### 그 결과를 기록한다.\n\n <!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나.  개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n - - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다.  휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n <!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다. ",
        "original_sentence": "<!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "- - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 170,
        "word_count": 40,
        "page_number": 38,
        "window_text": "<!-- PAGE_37 -->\n###### ➅ 시험기간 동안 시험간격에서 ➀∼➄번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_37 -->\n###### (6) 결과 제시 터를 모두 취합하여, 측정값의 평균 및 표준편차를 산출\n\n<!-- PAGE_37 -->\n###### ② 각 검체 및 시약 로트 조합의 데이준 값과 휴대용 혈액응고시간\n\n<!-- PAGE_37 -->\n###### 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에 대한\n\n<!-- PAGE_37 -->\n###### 나.  개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n - - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다.  휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n <!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n",
        "original_sentence": "- - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 200,
        "word_count": 40,
        "page_number": 38,
        "window_text": "개봉 후 안정성평가\n\n<!-- PAGE_37 -->\n###### (1) 관련 규격\n\n<!-- PAGE_37 -->\n###### ①「의료기기의 안정성시험 기준」(식약처 고시)\n\n<!-- PAGE_37 -->\n###### ② ISO 23640 In vitro diagnostic medical devices – Evaluation of\n\n<!-- PAGE_37 -->\n###### (2) 적용 범위 : 휴대용 혈액응고시간 측정검사지에 적용한다.\n\n <!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n - - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다.  휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n <!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n <!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8. ",
        "original_sentence": "휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "<!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 343,
        "word_count": 67,
        "page_number": 38,
        "window_text": "<!-- PAGE_37 -->\n###### (3) 시험 목적 : 휴대용 혈액응고시간 측정시스템이 특정 조건하에서\n\n<!-- PAGE_37 -->\n###### 사용기간(유효기간) 동안 의료기기의 특성이나 성능이 제조자가\n\n<!-- PAGE_37 -->\n###### (4) 시험 조건\n\n<!-- PAGE_37 -->\n###### ① 검체의 준비 : 아래 표와 같이 INR 측정구간을 포함되어야 한다.\n\n - - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다.  휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n <!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n <!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8.  참고 문헌\n\n- 가. ",
        "original_sentence": "<!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 263,
        "word_count": 56,
        "page_number": 38,
        "window_text": "- - 31 -\n구간\n\nINR 값\n\n비 치료적 범위\n\n- 2.0 미만\n[표 15] INR 구간 예시\n\n<!-- PAGE_38 -->\n###### ➁ 제조자가 표방하고자 하는 개봉 후 사용기간(유효기간) 동안 저장\n\n<!-- PAGE_38 -->\n###### 조건에 보관하여 안정성시험을 실시되어야 한다.  휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n <!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n <!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8.  참고 문헌\n\n- 가.  의료기기 품목 및 품목별 등급에 관한 규정\n- 나. ",
        "original_sentence": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "<!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 321,
        "word_count": 71,
        "page_number": 39,
        "window_text": "휴대용 혈액응고\n\n<!-- PAGE_38 -->\n###### 시간 측정검사지의 보관조건(온도, 습도)을 3 point로 설정하여 해당\n\n<!-- PAGE_38 -->\n###### 보관조건에서 개봉 후 사용기간 동안 제품의 성능이 유지되어 제조자가\n\n<!-- PAGE_38 -->\n###### 의도한 사용목적이 적합하게 발휘 될 수 있는지 평가되어야 한다.\n\n <!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n <!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8.  참고 문헌\n\n- 가.  의료기기 품목 및 품목별 등급에 관한 규정\n- 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다. ",
        "original_sentence": "<!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "참고 문헌\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 20,
        "window_text": "<!-- PAGE_38 -->\n###### 성능시험의 측정간격은 시험개시와 중간시점 그리고 마지막시점을\n\n<!-- PAGE_38 -->\n###### ➂ 휴대용 혈액응고시간 측정기 및 검사지 시료\n\n<!-- PAGE_38 -->\n###### ㉮ 혈액응고시간 측정검사지: 1종 로트 검사지\n\n<!-- PAGE_38 -->\n###### ㉯ 혈액응고시간 측정기: 3대 측정기\n\n<!-- PAGE_38 -->\n###### (5) 시험 방법\n\n<!-- PAGE_38 -->\n###### ➀ 휴대용 혈액응고시간 측정기 3대와 3개 로트 측정검사지 그리고\n\n<!-- PAGE_38 -->\n###### 혈액시료를 미리 준비한다.  (※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n <!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8.  참고 문헌\n\n- 가.  의료기기 품목 및 품목별 등급에 관한 규정\n- 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다.  개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라. ",
        "original_sentence": "참고 문헌\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "의료기기 품목 및 품목별 등급에 관한 규정\n- 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 6,
        "window_text": "(※비고: 측정 검사지는 사용 전까지\n\n<!-- PAGE_38 -->\n###### ➁ 병원용 혈액응고시간 측정 기준장비를 이용하여 혈액시료의 INR\n\n<!-- PAGE_38 -->\n###### ➂ 3대의 휴대용 혈액응고시간 측정기에 첫 번째 로트 검사지를 장착\n\n- - 32 -\n<!-- PAGE_39 -->\n###### ➃ 3대의 휴대용 혈액응고시간 측정기에 혈액시료를 이용하여 INR\n\n<!-- PAGE_39 -->\n###### 값을 측정하고 그 결과를 기록한다.\n\n <!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8.  참고 문헌\n\n- 가.  의료기기 품목 및 품목별 등급에 관한 규정\n- 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다.  개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라.  의료기기 기준규격 (66. ",
        "original_sentence": "의료기기 품목 및 품목별 등급에 관한 규정\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 45,
        "word_count": 12,
        "page_number": 5,
        "window_text": "<!-- PAGE_39 -->\n###### ➄ 시험기간 동안 시험간격에서 ➁∼➃번의 과정을 반복하고 그 결과를\n\n<!-- PAGE_39 -->\n###### (6) 결과 제시\n\n<!-- PAGE_39 -->\n###### ① 각 검체 및 시약 로트 조합의 데이터를 모두 취합하여, 측정값의\n\n<!-- PAGE_39 -->\n###### ② 시험간격 시점에서 기준장비로 측정한 기준 값과 휴대용 혈액응고\n\n<!-- PAGE_39 -->\n###### 시간 측정시스템의 측정값을 이용하여 각 검체 및 시약 로트 조합에\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 8.  참고 문헌\n\n- 가.  의료기기 품목 및 품목별 등급에 관한 규정\n- 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다.  개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라.  의료기기 기준규격 (66.  개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머. ",
        "original_sentence": "체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 7,
        "window_text": "참고 문헌\n\n- 가.  의료기기 품목 및 품목별 등급에 관한 규정\n- 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다.  개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라.  의료기기 기준규격 (66.  개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머.  의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al. ",
        "original_sentence": "개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "의료기기 기준규격 (66. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 40,
        "window_text": "의료기기 품목 및 품목별 등급에 관한 규정\n- 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다.  개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라.  의료기기 기준규격 (66.  개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머.  의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS. ",
        "original_sentence": "의료기기 기준규격 (66. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 1476,
        "word_count": 223,
        "page_number": 6,
        "window_text": "체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인\n- 다.  개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라.  의료기기 기준규격 (66.  개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머.  의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS.  Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement. ",
        "original_sentence": "개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 90,
        "word_count": 19,
        "page_number": 7,
        "window_text": "개인용 혈당측정 시스템 표준시험방법 가이드라인\n- 라.  의료기기 기준규격 (66.  개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머.  의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS.  Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement.  ThrombRes1998;92:11-7.\n\n",
        "original_sentence": "의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 91,
        "word_count": 16,
        "page_number": 15,
        "window_text": "의료기기 기준규격 (66.  개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머.  의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS.  Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement.  ThrombRes1998;92:11-7.\n\n - 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting. ",
        "original_sentence": "Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS. "
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 228,
        "word_count": 27,
        "page_number": 16,
        "window_text": "개인용 혈당측정시스템)\n- 마. ISO 17593 Clinical laboratory testing and in vitro medical devices – Requirements\n- 바. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of in vitro\n- 사. ISO 15197 In vitro diagnostic test systems – Requirements for blood-glucose\n- 아. IEC 61010-1 Safety requirements for electrical equipment for measurement, control,\n- 자. IEC 61010-2-101 Safety requirements for electrical equipment for measurement,\ncontrol and laboratory use – Part 2-101: Particular requirements for in vitro\n\ndiagnostic (IVD) medical equipment\n\n- 차. IEC 61326-1 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 1: General requirements\n\n- 카. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory use –\nEMC requirements – Part 2-6: Particular requirements – In vitro diagnostic (IVD)\n\nmedical equipment\n\n- 타.\nCLSI\n\nEP-05\n\nEvaluation\n\nof\n\nPrecision\n\nof\n\nQuantitative\n\nMeasurement\n\nMethods;\n\n- 파. CLSI EP-06 Evaluation of the Linearity of Quantitative Measurement Procedures\n- 하. CLSI EP-07 Interference Testing in Clinical Chemistry; Approved Guideline\n- - 34 -\n- 거. CLSI EP-09 Method Comparison and Bias Estimation Using Patient Samples;\nApproved Guideline\n\n- 너. Guidance for Industry and FDA Staff – 510(K) Submissions for Coagulation\n- 더. Public Workshop – Point of Care Prothrombin Time/International Normalized\n- 러. Draft Guidance for Industry and FDA Staff - Self-Monitoring Blood Glucose Test\n- 머.  의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS.  Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement.  ThrombRes1998;92:11-7.\n\n - 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting.  ThrombRes2009;123:909-13.\n\n",
        "original_sentence": "Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement. "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "ThrombRes1998;92:11-7.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 24,
        "word_count": 1,
        "page_number": 6,
        "window_text": "의료기기 기술동향 및 개발 전망 – 혈당·빈혈·혈액응고시간 측정기 (한국의료기기\n- 버. Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS.  Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement.  ThrombRes1998;92:11-7.\n\n - 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting.  ThrombRes2009;123:909-13.\n\n - - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다. ",
        "original_sentence": "ThrombRes1998;92:11-7.\n\n"
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "- 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 203,
        "word_count": 33,
        "page_number": 20,
        "window_text": "Results of the performance verification of\n- 서. Douketis JD, Lane A, Milne J, Ginsberg JS.  Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement.  ThrombRes1998;92:11-7.\n\n - 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting.  ThrombRes2009;123:909-13.\n\n - - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다.  기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다. ",
        "original_sentence": "- 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "ThrombRes2009;123:909-13.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 27,
        "word_count": 1,
        "page_number": 6,
        "window_text": "Accuracy of a portable International\nNormalization Ratio monitor in outpatients receiving long-time oral anticoagulant\n\ntherapy: comparison with a laboratory reference standard using clinically relevant\n\ncriteria for agreement.  ThrombRes1998;92:11-7.\n\n - 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting.  ThrombRes2009;123:909-13.\n\n - - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다.  기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다.  즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n",
        "original_sentence": "ThrombRes2009;123:909-13.\n\n"
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "- - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 424,
        "word_count": 82,
        "page_number": 42,
        "window_text": "ThrombRes1998;92:11-7.\n\n - 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting.  ThrombRes2009;123:909-13.\n\n - - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다.  기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다.  즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n <!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다. ",
        "original_sentence": "- - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다. "
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 182,
        "word_count": 37,
        "page_number": 42,
        "window_text": "- 어. Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and\nclinical usefulness of the CoaguChekS and XS Point of Care devices when starting\n\nwarfarin in a hospital outreach setting.  ThrombRes2009;123:909-13.\n\n - - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다.  기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다.  즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n <!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다.  또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n",
        "original_sentence": "기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 158,
        "word_count": 32,
        "page_number": 42,
        "window_text": "ThrombRes2009;123:909-13.\n\n - - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다.  기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다.  즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n <!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다.  또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n <!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다. ",
        "original_sentence": "즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "<!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 42,
        "window_text": "- - 35 -\n<!-- PAGE_42 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_42 -->\n###### (1) 휴대용 혈액응고시간 측정시스템의 국내 개발현황\n\n<!-- PAGE_42 -->\n###### ① 국내에서 현재 제품화된 혈액응고시간측정 기술이 없으며 몇몇 대학과\n\n<!-- PAGE_42 -->\n###### 연구기관에서는 실험실 연구수준으로 병원용 대형장비와 휴대형 혈액응고\n\n<!-- PAGE_42 -->\n###### 시간 측정시스템은 외산 제품의 수입에 의존하고 있어 국산화 기술개발이\n\n<!-- PAGE_42 -->\n###### ① 휴대용 혈액응고시간 측정시스템의 글로벌 기술 개발동향은 실시간 모니\n\n<!-- PAGE_42 -->\n###### 터링과 POC (Point-of-care) 신뢰성 및 편의성 확대이다.  기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다.  즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n <!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다.  또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n <!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다.  부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다. ",
        "original_sentence": "<!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 137,
        "word_count": 30,
        "page_number": 42,
        "window_text": "기존 대형병원에\n\n<!-- PAGE_42 -->\n###### 쓰이는 Central Lab형의 경우 개인 소비자가 쓰는 POC와의 차별화를\n\n<!-- PAGE_42 -->\n###### 위해 검사 시간 및 분석 시간을 단축하고 실시간 결과에 대한 모니터링이\n\n<!-- PAGE_42 -->\n###### 가능해지도록 개발 중이다.  즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n <!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다.  또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n <!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다.  부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다.  또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다. ",
        "original_sentence": "또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "<!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 345,
        "word_count": 69,
        "page_number": 42,
        "window_text": "즉, 병원에서 환자 측정 시, 채취된 샘플을\n\n<!-- PAGE_42 -->\n###### 자동으로 Central Lab으로 전송하여 실시간 측정값이 반영되어 헤파린의\n\n<!-- PAGE_42 -->\n###### 투입량을 빠르게 조정하는 것으로 진단이 정확하고 빠른 판단을 돕는다.\n\n <!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다.  또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n <!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다.  부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다.  또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다.  그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1. ",
        "original_sentence": "<!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 118,
        "word_count": 27,
        "page_number": 43,
        "window_text": "<!-- PAGE_42 -->\n###### 이를 위해 관련 진단기기 및 소프트웨어 개발이 지속되고 있다.  또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n <!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다.  부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다.  또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다.  그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1.  임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2. ",
        "original_sentence": "부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다. "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 115,
        "word_count": 24,
        "page_number": 43,
        "window_text": "또한, 기존\n\n<!-- PAGE_42 -->\n###### 전문가가 아닌 일반 사용자가 활용하는 시장으로 확대되는 특성에 따라\n\n<!-- PAGE_42 -->\n###### POC 자체 성능 정밀도 및 신뢰도 증가를 위한 개발이 활성화되고 있다.\n\n <!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다.  부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다.  또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다.  그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1.  임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가. ",
        "original_sentence": "또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 245,
        "word_count": 55,
        "page_number": 43,
        "window_text": "<!-- PAGE_42 -->\n###### 환자가 집에서 측정하는 경우라도 IT 등의 접목을 통해 편의성을 확대하고\n\n<!-- PAGE_42 -->\n###### ② 미국에서는, 환자가 가정용 INR 검사기를 이용하여 INR 수치를 측정하고\n\n<!-- PAGE_42 -->\n###### 측정된 INR 수치는 환자의 병원으로 전달하여 항응고제의 처방을 의사로\n\n<!-- PAGE_42 -->\n###### ③ 국내의 경우, 대형병원 중심으로 형성되어 혈액응고 진단기기 시장에서\n\n- - 36 -\n<!-- PAGE_43 -->\n###### TSP(Total Solution Provider) 형태의 서비스가 등장하고 있다.  부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다.  또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다.  그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1.  임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가.  임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n",
        "original_sentence": "그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 542,
        "word_count": 115,
        "page_number": 45,
        "window_text": "부작용을\n\n<!-- PAGE_43 -->\n###### 최소화하기 위해 개인 맞춤형 항 응고 서비스 운영을 통해 측정시간 단축\n\n<!-- PAGE_43 -->\n###### 및 진단 후 맞춤형 상담을 제공 중이다.  또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다.  그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1.  임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가.  임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n - - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3. ",
        "original_sentence": "임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 3,
        "window_text": "또한, 판매 기업이 환자 교육을\n\n<!-- PAGE_43 -->\n###### 시행하여 시장 확대를 가속화시키려 노력하고 있으며 자체 기술 향상에도\n\n<!-- PAGE_43 -->\n###### 애쓰고 있다.  그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1.  임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가.  임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n - - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가. ",
        "original_sentence": "임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 3,
        "window_text": "그러나 현재 국내 혈액응고 진단기기 시장은 도입에서 성장\n\n<!-- PAGE_43 -->\n###### 으로 넘어가는 단계에 머물러 기 출시된 제품의 활용 극대화를 위한 맞춤형\n\n- - 37 -\n- - 임상시험용 ‘휴대용 혈액응고시간 측정기’의 안전성과 유효성을 증명하고자 하\n<!-- PAGE_44 -->\n#### Ⅱ\n\n<!-- PAGE_44 -->\n#### 임상시험계획서 작성 및 평가\n\n<!-- PAGE_44 -->\n###### 1.  임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가.  임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n - - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가.  시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나. ",
        "original_sentence": "임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n"
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "- - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 163,
        "word_count": 37,
        "page_number": 46,
        "window_text": "임상시험의 제목\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시) 경구용 항응고제(와파린) 요법 중인 환자의 모세혈에서 경구용 항응고 모니터링을\n\n위해 사용되는 프로트롬빈 시간(prothrombin time, PT)을 측정하는 ‘휴대용 혈액응고\n\n시간 측정기(제품명: 미정)’의 시스템 정확도 검증을 위한 다기관, 비무작위배정, 개방,\n\n단일설계, 전향적 품목허가용 비교확증임상시험\n\n- (1) 대상질환 : 혈관질환으로 경구용 항응고제(와파린) 요법 중인 환자\n- (2) 해당 의료기기의 사용목적：경구용 항응고 요법 모니터링\n- (3) 해당 의료기기: 혈액응고시간분석기 및 개인용체외진단검사시약II\n- (4) 임상시험 평가내용 : ISO 17593에 근거한 최소허용 시스템 정확도 평가\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 개방, 단일설계, 전향적 임상시험\n- - 38 -\n- - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품\n<!-- PAGE_45 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가.  임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n - - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가.  시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나.  시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. ",
        "original_sentence": "- - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 3,
        "window_text": "임상시험기관의 명칭 및 소재지\n\n예시)\n\n- 가.  임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n - - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가.  시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나.  시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4. ",
        "original_sentence": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 75,
        "word_count": 19,
        "page_number": 9,
        "window_text": "임상시험 실시기관\n- - 39 -\n- - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.\n - - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가.  시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나.  시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가. ",
        "original_sentence": "시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 148,
        "word_count": 29,
        "page_number": 3,
        "window_text": "- - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,\n- - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를\n- - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여\n<!-- PAGE_46 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가.  시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나.  시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가.  의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨. ",
        "original_sentence": "시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 241,
        "word_count": 56,
        "page_number": 47,
        "window_text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n예시)\n\n- 가.  시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나.  시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가.  의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n",
        "original_sentence": "공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 9,
        "window_text": "시험책임자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○\n- ○○○\n- ○○-○○○-○○○○\n- 나.  시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가.  의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 82,
        "word_count": 21,
        "page_number": 6,
        "window_text": "시험담당자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가.  의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가. ",
        "original_sentence": "의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨. "
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 7,
        "window_text": "공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 40 -\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사\n- - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우\n<!-- PAGE_47 -->\n###### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가.  의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가.  의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나. ",
        "original_sentence": "의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 48,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n예시)\n\n- 가.  의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가.  의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나.  모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다. ",
        "original_sentence": "임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 9,
        "window_text": "의료기기 관리자\n- - 41 -\n임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의\n\n제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가.  의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나.  모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다.  임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n",
        "original_sentence": "임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 20,
        "window_text": "의뢰자는 임상시험모니터 요원을 지정하여야 함.\n\n 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가.  의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나.  모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다.  임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n - - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6. ",
        "original_sentence": "의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 73,
        "word_count": 18,
        "page_number": 7,
        "window_text": "임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기\n\n<!-- PAGE_48 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가.  의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나.  모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다.  임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n - - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가. ",
        "original_sentence": "모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 141,
        "word_count": 28,
        "page_number": 9,
        "window_text": "임상시험 의뢰자의 성명 및 주소\n\n예시)\n\n- 가.  의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나.  모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다.  임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n - - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가.  검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n",
        "original_sentence": "임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "- - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 127,
        "word_count": 31,
        "page_number": 49,
        "window_text": "의뢰자\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 나.  모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다.  임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n - - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가.  검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n - 나. ",
        "original_sentence": "- - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 155,
        "word_count": 37,
        "page_number": 6,
        "window_text": "모니터요원\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n- 다.  임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n - - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가.  검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n - 나.  배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다. ",
        "original_sentence": "임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 218,
        "word_count": 45,
        "page_number": 7,
        "window_text": "임상시험 수탁업체\n회사명\n\n성명\n\n소재지\n\n전화\n\n- (주) ○○○\n- ○○○\n- ○○○ ○○시 ○○구\n- ○○-○○○-○○○○\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n내용을 기재함.\n\n - - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가.  검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n - 나.  배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다.  한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다. ",
        "original_sentence": "검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "- 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 20,
        "window_text": "- - 42 -\n- - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로\n- - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,\n<!-- PAGE_49 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가.  검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n - 나.  배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다.  한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다.  PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 91,
        "word_count": 22,
        "page_number": 49,
        "window_text": "임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n제품의 특성에 따라 자율적으로 설정이 가능함\n\n예시) ISO 17593 규격에 따른 ‘휴대용 혈액응고시간 측정기(제품명: 미정)’의 시스템 정확도\n\n- 가.  검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n - 나.  배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다.  한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다.  PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다.  국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다. ",
        "original_sentence": "배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 63,
        "word_count": 17,
        "page_number": 6,
        "window_text": "검증\n- - 본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의\n자가시험을 통한 체외 모니터링 장비인 시험기기품의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO\n\n장비)에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용\n\n시스템 정확도 평가를 통해 검증하는 것이 목적이다.\n\n - 나.  배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다.  한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다.  PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다.  국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다.  이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n",
        "original_sentence": "한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 86,
        "word_count": 18,
        "page_number": 96,
        "window_text": "- 나.  배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다.  한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다.  PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다.  국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다.  이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n 본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n",
        "original_sentence": "PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 155,
        "word_count": 30,
        "page_number": 2,
        "window_text": "배경\n경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n\n항응고제의 사용이 증가됨에 따라 PT 모니터링의 필요성이 증대되고 있다.  한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다.  PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다.  국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다.  이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n 본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n 본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n",
        "original_sentence": "국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다. "
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 186,
        "word_count": 36,
        "page_number": 35,
        "window_text": "한 외국\n\n연구에 의하면 경구용 항응고제 복용 환자가 전체 인구의 약 1% 정도까지 증가\n\n했다는 보고도 있다.  PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다.  국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다.  이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n 본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n 본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n - - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7. ",
        "original_sentence": "이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 139,
        "word_count": 27,
        "page_number": 9,
        "window_text": "PT는 경구용 항응고제를 사용하는 환자에게 있어서 가장\n\n안전한 용량을 결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는\n\n필수검사이다.  국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다.  이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n 본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n 본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n - - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n",
        "original_sentence": "본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 241,
        "word_count": 49,
        "page_number": 6,
        "window_text": "국제정상화비율(international normalized ratio, INR)의 도입으로\n\n경구용 항응고제 치료 시에 일어나는 출혈 또는 혈전에 의한 부작용의 위험성이\n\n크게 감소되었으나, 항응고제의 오용을 줄이기 위해서는 더욱 철저한 모니터링이\n\n- - 43 -\n필요하다.  이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n 본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n 본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n - - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1. ",
        "original_sentence": "본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "- - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 117,
        "word_count": 25,
        "page_number": 51,
        "window_text": "이에 휴대용 PT 측정기가 경구용 항응고제를 사용하는 환자의 상태를\n\n더욱 철저하게 모니터링하는 대안으로 모색되었으며 흔히 사용되는 기 허가된\n\n휴대용 PT 측정기로는 CoaguChek XS (Roche Diagnostics, Manheim, Germany)가\n\n있으나, 현재까지 개발된 국산 휴대용 PT 측정기는 없는 실정이다.\n\n 본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n 본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n - - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1.  임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2. ",
        "original_sentence": "- - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 42,
        "word_count": 7,
        "page_number": 6,
        "window_text": "본\n\n임상시험용\n\n의료기기는\n\n최초로\n\n국산화된\n\n휴대용\n\nPT측정기로\n\n기존\n\nCoaguCheck XS의 작동원리와 유사하게 전기화학적인 신호발생 시간에 따라 PT를\n\nINR로 표시하여 신속하게 경구용 항응고제 모니터링을 할 수 있는 제품이다.\n\n 본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n - - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1.  임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1. ",
        "original_sentence": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 85,
        "word_count": 22,
        "page_number": 44,
        "window_text": "본 연구는 시험기기의 ISO 17593 규격에 따른 시스템 정확도 검증에 목적이\n\n있으며, 경구용 항응고제 요법 중인 환자에서 시험기기의 시스템 정확도를 ISO\n\n17593 규격에 따라 기준측정장비(대조기기)인 병원의 중앙 검사실 장비(OOO 장비)\n\n에서 측정된 프로트롬빈 시간(prothrombin time, PT) 결과와의 최소허용 시스템\n\n정확도 (ISO 17593 근거) 평가를 통해 검증하고 상관성을 확인하고자 한다.\n\n - - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1.  임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1.  임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. ",
        "original_sentence": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1. "
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 185,
        "word_count": 36,
        "page_number": 6,
        "window_text": "- - 44 -\n일련번호\n\n명 칭\n\n1\n\n스트립\n\n자사규격 1 strip\n\nx 50개\n\n반응부 주성분\n\nThromboplastin\n\nOO±OO ㎍/㎖ 자사규격\n\n<!-- PAGE_51 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1.  임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1.  임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.  | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까? ",
        "original_sentence": "임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2. "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 70,
        "word_count": 15,
        "page_number": 9,
        "window_text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1.  임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1.  임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.  | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.",
        "original_sentence": "임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 518,
        "word_count": 115,
        "page_number": 6,
        "window_text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- 7.1.  임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1.  임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.  | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. **\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오.",
        "original_sentence": "임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "| 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 425,
        "word_count": 112,
        "page_number": 1,
        "window_text": "임상시험용 의료기기 사용 목적\n- - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며\n예시) 경구용 항응고제(와파린) 복용을 처방받은 환자의 모세혈에서 프로트롬빈시간\n\n(PT/INR)을 전기화학법으로 정량하여 경구용 항응고제(와파린) 복용자의 자가 모니터링에\n\n도움을 주는 체외진단용 의료기기\n\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1.  임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.  | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. **\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오. **\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다.",
        "original_sentence": "| 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까? "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "| □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 223,
        "word_count": 66,
        "page_number": 3,
        "window_text": "임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n- 7.2.1.  임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.  | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. **\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오. **\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다. **\n**monitors: is a periodical control of their performance useful? ",
        "original_sentence": "| □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다."
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "**\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 7,
        "window_text": "임상시험용 의료기기\n예시)\n\n1) 코드명/품목명:\n\n혈액응고 시간 측정기 : 혈액응고시간분석기 (A22080.01)\n\n혈액응고 시간 측정검사지 : 개인용면역화학검사지II (D07010.01)\n\n2) 제조회사: ○○○\n\n3) 원자재:\n\n- - 45 -\n주성분\n\ncoagulation\n\nfactor VIIa\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nVII\n\ndeficient plasma\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nThrombin\n\nOO±OO ㎍/㎖ 자사규격\n\n주성분\n\nheparin\n\nOO±OO ㎍/㎖ 자사규격\n\n5) 구조: 혈액응고 시간 측정기\n\n- - 46 -\n#\n\n명칭\n\n역할 및 기능\n\n- ①\n화면(LCD 디스플레이)\n\n측정된 수치와 기타 기기의 설정값 등을 표시\n\n**[표 시작]**\n\n| ② | 메모리 버튼 | 메모리 모드 및 셋팅 모드 전환 |\n| --- | --- | --- |\n| 시험기기 | 모세혈관혈액 | 10-15 | 2.0 미만 |\n| 하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.  | 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. **\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오. **\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다. **\n**monitors: is a periodical control of their performance useful?  Thromb Res 2009;123:775-9.",
        "original_sentence": "**\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오."
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "**\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 20,
        "window_text": "| 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.a범주를 | ∧/ ˅ 버튼 | 메모리에 저장된 결과값 검색 및 셋팅모드에서 선택 항목을 변경 |\n| 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 품목의 특성에 따라 자율적으로 설정이 가능함 | ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. **\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오. **\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다. **\n**monitors: is a periodical control of their performance useful?  Thromb Res 2009;123:775-9. **\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.",
        "original_sentence": "**\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다."
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "**\n**monitors: is a periodical control of their performance useful? ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 68,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| □ 예 | □ 아니오 | 중지기준 | 중지처리 |\n| ③ | 측정검사지 삽입구 | 측정검사지를 삽입하여 본체와 연결할 수 있는 삽입구 | 15-40 | 2.0-2.8 |\n| ④ | 배터리 커버 | 배터리부 덮개로 본체에 배터리 교환 시 열고 닫음 |\n| ⑤ | 코드스트립 삽입구 | 코드 스트립 삽입구 |\n**증상의**\n**② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. **\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오. **\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다. **\n**monitors: is a periodical control of their performance useful?  Thromb Res 2009;123:775-9. **\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. **\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n",
        "original_sentence": "**\n**monitors: is a periodical control of their performance useful? "
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "Thromb Res 2009;123:775-9.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 26,
        "word_count": 3,
        "page_number": 6,
        "window_text": "**\n**- 측정할 때, 낱개 포장 호일에서 꺼낸 검사지는 즉시 사용하여 주십시오. **\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다. **\n**monitors: is a periodical control of their performance useful?  Thromb Res 2009;123:775-9. **\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. **\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n 6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3. ",
        "original_sentence": "Thromb Res 2009;123:775-9."
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "**\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 6,
        "window_text": "**\n**- 검사지를 구부리거나 자르거나 형태를 변형해서는 안됩니다. **\n**monitors: is a periodical control of their performance useful?  Thromb Res 2009;123:775-9. **\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. **\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n 6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3.  임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다. ",
        "original_sentence": "**\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다."
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "**\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 153,
        "word_count": 36,
        "page_number": 16,
        "window_text": "**\n**monitors: is a periodical control of their performance useful?  Thromb Res 2009;123:775-9. **\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. **\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n 6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3.  임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다.  검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다. ",
        "original_sentence": "**\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 419,
        "word_count": 98,
        "page_number": 6,
        "window_text": "Thromb Res 2009;123:775-9. **\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. **\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n 6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3.  임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다.  검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다.  (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.) ",
        "original_sentence": "6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3. "
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 45,
        "word_count": 10,
        "page_number": 6,
        "window_text": "**\n**(1) 연구가설**\n**인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. **\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n 6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3.  임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다.  검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다.  (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.)  검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다. ",
        "original_sentence": "임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다. "
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 36,
        "word_count": 6,
        "page_number": 53,
        "window_text": "**\n\n**[표 끝]**\n\n전원버튼\n\n기기의 전원 on/off 및 설정 값 저장\n\n혈액응고 시간 측정검사지\n\n- - 검사지는 백색 및 투명색 플라스틱이 조합된 기판에 혈액주입부와 반응 챔버가\n미세통로로 이어져 있는 실버 전극의 형태로서 반응챔버에 시약이 고정화되어 있다.\n\n 6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3.  임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다.  검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다.  (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.)  검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다.  이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오. ",
        "original_sentence": "검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "(측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 53,
        "window_text": "6) 치수/중량: 크기:\n\n혈액응고 시간 측정기 : W(96mm) × D(15.4mm) × H(169mm)\n\n혈액응고 시간 측정검사지 : W(2.4mm) × D(8mm)\n\n7) 성능: 혈액응고 시간 측정기 측정 사양\n\n일련번호\n\n성능항목\n\n결과\n\n1\n\n필요검체량\n\n15㎕\n\n2\n\n측정결과범위\n\nPT : 9.6 - 96 sec / INR : 0.8–7.5\n\n3\n\n측정시간\n\n60 초 이내\n\n4\n\n유효기간\n\n24개월 이내\n\n8) 보관조건:\n\n혈액응고 시간 측정기\n\n작동 환경\n\n10~40 ℃\n\n15~80 % RH\n\n보관/운반 환경\n\n- -10℃~60 ℃\n15~80 % RH\n\n- - 47 -\n혈액응고 시간 측정검사지\n\n온도\n\n습도\n\n작동 환경\n\n10~35 ℃\n\n20~80 % RH\n\n보관/운반 환경\n\n10℃~40 ℃\n\n20~80 % RH\n\n- 7.3.  임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다.  검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다.  (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.)  검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다.  이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오.  코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다. ",
        "original_sentence": "(측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.) "
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 53,
        "window_text": "임상시험용 의료기기 사용방법\n예시)\n\n[1] 전원 버튼을 눌러 측정기를 켭니다.  검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다.  (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.)  검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다.  이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오.  코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다.  측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다. ",
        "original_sentence": "검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 54,
        "window_text": "검사지의 측정기 접촉부를(전극부) 검사지\n\n삽입부에 삽입합니다.  (측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.)  검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다.  이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오.  코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다.  측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다.  검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다. ",
        "original_sentence": "이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오. "
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 13,
        "window_text": "(측정기가 꺼진 상태에서 검사지를 삽입하면 측정기가\n\n자동으로 켜지게 됩니다.)  검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다.  이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오.  코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다.  측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다.  검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다.  (혈액 투입 대기시간은 120초 입니다.) ",
        "original_sentence": "코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 130,
        "word_count": 31,
        "page_number": 13,
        "window_text": "검사지를 ‘삐’ 소리가 날 때 까지 가볍게 밀어넣으면\n\n측정기가 자동으로 켜지게 됩니다.  이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오.  코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다.  측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다.  검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다.  (혈액 투입 대기시간은 120초 입니다.)  만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다. ",
        "original_sentence": "측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 53,
        "window_text": "이때 검사지가 구부러지지 않도록 주의하여\n\n주십시오.  코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다.  측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다.  검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다.  (혈액 투입 대기시간은 120초 입니다.)  만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다.  측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다. ",
        "original_sentence": "검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다. "
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "(혈액 투입 대기시간은 120초 입니다.) ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 6,
        "window_text": "코드번호가 나타나고 코드번호 확인 후 \"OK\"버튼을 누르면 온도계\n\n표시가 나타나며 측정온도로 세팅합니다.  측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다.  검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다.  (혈액 투입 대기시간은 120초 입니다.)  만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다.  측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다.  측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다. ",
        "original_sentence": "(혈액 투입 대기시간은 120초 입니다.) "
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 155,
        "word_count": 35,
        "page_number": 53,
        "window_text": "측정기와 검사지 코드번호가 일치하\n\n는지 확인하고 그렇지 않으면 측정기의 코드번호가 일치하도록 코드칩을 이용\n\n[2] 온도 세팅 후 화면에 스트립 및 혈액 표시와 함께 시간 카운트가 시작되면 채\n\n혈기를 사용하여 혈액을 채취합니다.  검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다.  (혈액 투입 대기시간은 120초 입니다.)  만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다.  측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다.  측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다.  측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n",
        "original_sentence": "만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 6,
        "window_text": "검사지 중간 부분의 혈액 투입부에 혈액\n\n방울을 떨어뜨립니다.  (혈액 투입 대기시간은 120초 입니다.)  만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다.  측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다.  측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다.  측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n - - 48 -\n- 가. ",
        "original_sentence": "측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 34,
        "window_text": "(혈액 투입 대기시간은 120초 입니다.)  만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다.  측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다.  측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다.  측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n - - 48 -\n- 가.  7.4. ",
        "original_sentence": "측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다. "
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 6,
        "window_text": "만약 측정기가\n\n카운트를 시작하기 전까지 혈액량이 채워지지 않으면 측정결과가 부정확할 수\n\n있으므로 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[3] 충분한 혈액이 투입되면 화면에서 모래시계 아이콘이 나타나고 1분 이내 측정\n\n결과가 화면에 나타납니다.  측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다.  측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다.  측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n - - 48 -\n- 가.  7.4.  임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매. ",
        "original_sentence": "측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "- - 48 -\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 6,
        "window_text": "측정 중에 검사지를 제거하는 경우, ‘Err 2' 메시지가\n\n나타나고 사용하던 검사지를 버리고 새 검사지를 사용하여 새로 측정을 하여\n\n[4] 측정기 결과를 확인합니다.  측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다.  측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n - - 48 -\n- 가.  7.4.  임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n",
        "original_sentence": "- - 48 -\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "7.4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 5,
        "word_count": 1,
        "page_number": 6,
        "window_text": "측정 수치와(PT, INR), 검사 날짜 및 시간이 함께\n\n나타납니다.  측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n - - 48 -\n- 가.  7.4.  임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n",
        "original_sentence": "7.4. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 92,
        "word_count": 21,
        "page_number": 9,
        "window_text": "측정결과는 측정기 메모리에 자동 저장되고 1분 동안 화면에 표\n\n시되고 꺼집니다.\n\n - - 48 -\n- 가.  7.4.  임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n <!-- PAGE_56 -->\n###### 8. ",
        "original_sentence": "임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매. "
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 272,
        "word_count": 65,
        "page_number": 6,
        "window_text": "- - 48 -\n- 가.  7.4.  임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n <!-- PAGE_56 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). ",
        "original_sentence": "낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 122,
        "word_count": 28,
        "page_number": 6,
        "window_text": "7.4.  임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n <!-- PAGE_56 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n",
        "original_sentence": "그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "<!-- PAGE_56 -->\n###### 8. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 56,
        "window_text": "임상시험용 의료기기의 공급 및 관리\n예시) 혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어\n\n있는 상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n <!-- PAGE_56 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1. ",
        "original_sentence": "<!-- PAGE_56 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 100,
        "word_count": 23,
        "page_number": 6,
        "window_text": "낱개포장 된 검사지가 1박스 당\n\n- - 49 -\n* 피험자의 선정기준/제외기준 · 인원 및 근거\n\n- - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되\n* 피험자 수: 시험대상수 산출시 일반적인 고려사항\n\n- - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한\n수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구\n\n계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.\n\n 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n <!-- PAGE_56 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n",
        "original_sentence": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 3,
        "window_text": "그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을\n\n평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과\n\n변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.\n\n <!-- PAGE_56 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n - - 50 -\n15-40\n\n- 2.0-2.8\n- 1. ",
        "original_sentence": "흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "예시)\n\n- 8.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 6,
        "window_text": "<!-- PAGE_56 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n - - 50 -\n15-40\n\n- 2.0-2.8\n- 1.  경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2. ",
        "original_sentence": "예시)\n\n- 8.1. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 13,
        "window_text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n - - 50 -\n15-40\n\n- 2.0-2.8\n- 1.  경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2.  경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2. ",
        "original_sentence": "피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "- - 50 -\n15-40\n\n- 2.0-2.8\n- 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 6,
        "window_text": "흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n - - 50 -\n15-40\n\n- 2.0-2.8\n- 1.  경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2.  경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2.  피험자 제외기준\n- 1. ",
        "original_sentence": "- - 50 -\n15-40\n\n- 2.0-2.8\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 6,
        "window_text": "예시)\n\n- 8.1.  피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n - - 50 -\n15-40\n\n- 2.0-2.8\n- 1.  경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2.  경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2.  피험자 제외기준\n- 1.  피험자의 임상정보를 알 수 없는 경우\n- 2. ",
        "original_sentence": "경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 6,
        "window_text": "피험자 선정기준\n최소 3곳 이상의 병원에서 아래의 피험자를 선정한다.\n\n - - 50 -\n15-40\n\n- 2.0-2.8\n- 1.  경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2.  경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2.  피험자 제외기준\n- 1.  피험자의 임상정보를 알 수 없는 경우\n- 2.  직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3. ",
        "original_sentence": "경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "피험자 제외기준\n- 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 6,
        "window_text": "- - 50 -\n15-40\n\n- 2.0-2.8\n- 1.  경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2.  경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2.  피험자 제외기준\n- 1.  피험자의 임상정보를 알 수 없는 경우\n- 2.  직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3.  Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3. ",
        "original_sentence": "피험자 제외기준\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "피험자의 임상정보를 알 수 없는 경우\n- 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 26,
        "word_count": 8,
        "page_number": 6,
        "window_text": "경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자\n- 2.  경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2.  피험자 제외기준\n- 1.  피험자의 임상정보를 알 수 없는 경우\n- 2.  직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3.  Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n",
        "original_sentence": "피험자의 임상정보를 알 수 없는 경우\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 50,
        "word_count": 14,
        "page_number": 6,
        "window_text": "경구용 항응고제를 복용한 적이 없는 정상인\n- 8.2.  피험자 제외기준\n- 1.  피험자의 임상정보를 알 수 없는 경우\n- 2.  직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3.  Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n - ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1). ",
        "original_sentence": "직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 78,
        "word_count": 11,
        "page_number": 57,
        "window_text": "피험자 제외기준\n- 1.  피험자의 임상정보를 알 수 없는 경우\n- 2.  직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3.  Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n - ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n",
        "original_sentence": "Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 217,
        "word_count": 54,
        "page_number": 6,
        "window_text": "피험자의 임상정보를 알 수 없는 경우\n- 2.  직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3.  Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n - ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n - - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9. ",
        "original_sentence": "목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "- ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1). ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 154,
        "word_count": 35,
        "page_number": 6,
        "window_text": "직전 2개월 내 시행한 적혈구 부피비 결과가 있는 환자의 경우, 적혈구 부피비가\n- 3.  Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n - ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n - - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가. ",
        "original_sentence": "- ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1). "
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 22,
        "window_text": "Novel oral anticoagnulants (NOACs; rivaroxaban, dabigatran 등)를 복용하는 경우\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n - ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n - - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가.  식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10. ",
        "original_sentence": "6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "- - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 234,
        "word_count": 51,
        "page_number": 59,
        "window_text": "목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\n- (2) 유의수준\n- (3) 통계적 검정 방법\n- (4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)\n- (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는\n1) ISO 17593에 근거하여 최소 200명의 피험자를 대상으로 한다.\n\n - ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n - - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가.  식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1. ",
        "original_sentence": "- - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9. "
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 6,
        "window_text": "- ① 경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자: 180명\n- ② 경구용 항응고제를 복용한 적이 없는 정상인: 20명 (전체 피험자의 10%)\n2) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n포함해야 한다(표 1).  6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n - - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가.  식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.  시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함. ",
        "original_sentence": "임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 105,
        "word_count": 22,
        "page_number": 60,
        "window_text": "6.0을 넘는 INR 값은 제외하는 것이 좋다.\n\n - - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가.  식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.  시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2. ",
        "original_sentence": "식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 93,
        "word_count": 19,
        "page_number": 6,
        "window_text": "- - 51 -\n15-40\n\n- 2.9-3.7\n10-30\n\n- 3.8-4.5\n1-10b\n\n- 4.6-6.0\n3) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 52 -\n피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성\n\n기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전\n\n<!-- PAGE_59 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가.  식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.  시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. ",
        "original_sentence": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 120,
        "word_count": 32,
        "page_number": 9,
        "window_text": "임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 가.  식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.  시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다. ",
        "original_sentence": "시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 146,
        "word_count": 37,
        "page_number": 6,
        "window_text": "식품의약품안전처 및 임상시험기관 임상시험심사위원회(IRB)의 임상시험계획서\n- (3) 결과보고서 작성기간 : 약 1 개월\n- - 53 -\n<!-- PAGE_60 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.  시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n",
        "original_sentence": "임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 145,
        "word_count": 36,
        "page_number": 6,
        "window_text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.  시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n",
        "original_sentence": "시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. "
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "또한 동의를 서명한\n\n연월일을 기록한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 20,
        "window_text": "시험방법\n임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비\n\n사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각\n\n단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n - ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n",
        "original_sentence": "또한 동의를 서명한\n\n연월일을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 63,
        "word_count": 15,
        "page_number": 3,
        "window_text": "임상 시험을 위한 피험자 동의 및 준비,\n\n치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함\n\n예시)\n\n- 10.1.1 시험기기 대조기기 정보\n대조기기 : 병원의 중앙 검사실 혈액응고시간 측정장비(OOO 장비) 및 시약\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n - ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n - ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n",
        "original_sentence": "또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "- (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 103,
        "word_count": 25,
        "page_number": 6,
        "window_text": "시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n - ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n - ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n - - 55 -\na. ",
        "original_sentence": "- (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "- ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 321,
        "word_count": 84,
        "page_number": 20,
        "window_text": "또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n - ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n - ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n - - 55 -\na.  범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n",
        "original_sentence": "- ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n"
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "- ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 156,
        "word_count": 34,
        "page_number": 6,
        "window_text": "또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n - ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n - ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n - - 55 -\na.  범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n",
        "original_sentence": "- ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "- - 55 -\na. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 12,
        "word_count": 5,
        "page_number": 13,
        "window_text": "- (2) 인구학적 조사, 병력조사 요법\n임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,\n\n차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.\n\n - ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n - ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n - - 55 -\na.  범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n - 10.2. ",
        "original_sentence": "- - 55 -\na. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 54,
        "word_count": 14,
        "page_number": 62,
        "window_text": "- ① 인구학적 정보: 성명, 나이, 성별\n- ② 병력조사 : 허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등\n- - 54 -\n- ③ 병용약물 : 경구용 항응고제 복용 유무, 항응고 요법\n- (3) 피험자 식별코드 부여\n- ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정\n- ① 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n- ② 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n - ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n - - 55 -\na.  범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n - 10.2.  설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음. ",
        "original_sentence": "범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 116,
        "word_count": 24,
        "page_number": 6,
        "window_text": "- ③ 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n- (5) 시험 방법\n시험기기 및 대조기기에서 모식도와 같이 PT를 측정하고 적혈구 부피비 측정한다.\n\n - - 55 -\na.  범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n - 10.2.  설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음.  피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n",
        "original_sentence": "b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n"
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "- 10.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 6,
        "window_text": "- - 55 -\na.  범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n - 10.2.  설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음.  피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n 1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n",
        "original_sentence": "- 10.2. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 83,
        "word_count": 19,
        "page_number": 9,
        "window_text": "범주를 채운 후에는(즉, 최대 허용 백분율에 도달한 후) 해당 범주에 검체를 추가할 수 없음.\n\n b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n - 10.2.  설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음.  피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n 1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n <!-- PAGE_63 -->\n###### 11. ",
        "original_sentence": "설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음. "
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 90,
        "word_count": 15,
        "page_number": 15,
        "window_text": "b. ISO 17593에는 INR 4.6-6.0에 해당하는 검체수 비율이 5-10%로 기재되어 있으나, INR\n\n- 4.6-6.0을 갖는 피험자가 매우 적을 것으로 예측되어 검체수 비율 1-10%로 조정함.\n - 10.2.  설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음.  피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n 1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n <!-- PAGE_63 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1. ",
        "original_sentence": "피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 476,
        "word_count": 105,
        "page_number": 6,
        "window_text": "- 10.2.  설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음.  피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n 1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n <!-- PAGE_63 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1.  관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2. ",
        "original_sentence": "1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "<!-- PAGE_63 -->\n###### 11. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 63,
        "window_text": "설계방법\n임상시험디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고\n\n그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있음.  피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n 1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n <!-- PAGE_63 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1.  관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2.  관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n",
        "original_sentence": "<!-- PAGE_63 -->\n###### 11. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 83,
        "word_count": 20,
        "page_number": 3,
        "window_text": "피험자 배정과\n\n처리 할당에 있어 편의(Bias)를 줄이기 위한 무작위배정(Randomization)와 눈가\n\n림(Blinding) 전략이 잘 포함되어야 함.\n\n 1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n <!-- PAGE_63 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1.  관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2.  관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다. ",
        "original_sentence": "관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1. "
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 6,
        "window_text": "1) 피험자군:　경구용 항응고제인 와파린을 복용하는 순환기내과 외래 환자 180명\n\n2) 대조군: 경구용 항응고제를 복용한 적이 없는 정상인 20명 (전체 피험자의 10%)\n\n3) 연구대상의 INR 값은 표준측정절차를 통해 측정된 1.0∼6.0 INR의 측정구간을\n\n4) 최초 연구위치에서 INR이 4.5를 초과하는 환자수를 필요한 만큼 구하지 못할\n\n- - 56 -\n해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 측\n\n정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관찰검\n\n사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목별 평가\n\n도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서대로 기재하\n\n되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험군)의 기술 형태\n\n와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 개별 기술한다.\n\n <!-- PAGE_63 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1.  관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2.  관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다.  대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다. ",
        "original_sentence": "관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 171,
        "word_count": 42,
        "page_number": 6,
        "window_text": "<!-- PAGE_63 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1.  관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2.  관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다.  대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다.  스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다. ",
        "original_sentence": "관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 79,
        "word_count": 17,
        "page_number": 9,
        "window_text": "관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 11.1.  관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2.  관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다.  대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다.  스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n",
        "original_sentence": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 13,
        "window_text": "관찰항목\n예시)\n\n과거병력 및 병용약물 조사\n\nO\n\n- 11.2.  관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다.  대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다.  스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n - - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n",
        "original_sentence": "대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 80,
        "word_count": 19,
        "page_number": 9,
        "window_text": "관찰검사방법\n- 11.2.1 방문1 (스크리닝 및 검사일)\n- (1) 임상시험 설명 및 동의 및 스크리닝\n경구용 항응고제 복용중인 환자 및 대조군에 대한 경구용 항응고제 모니터링\n\n- - 57 -\n임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는\n\n법정대리인에게 상세히 설명한다.\n\n 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다.  대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다.  스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n - - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n - (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n",
        "original_sentence": "스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 20,
        "window_text": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 동의서의 원본은\n\n시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게 교부한다.  대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다.  스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n - - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n - (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n 1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n",
        "original_sentence": "피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "- - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 180,
        "word_count": 41,
        "page_number": 9,
        "window_text": "대상자에게\n\n서면 동의를 받은 후 동의취득 순서에 따라 스크리닝 번호를 부여한다.  스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n - - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n - (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n 1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n 3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n",
        "original_sentence": "- - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "- (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 9,
        "window_text": "스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n - - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n - (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n 1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n 3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n - - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다. ",
        "original_sentence": "- (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 149,
        "word_count": 33,
        "page_number": 6,
        "window_text": "피험자 식별코드는 아래의\n\n방법에 따라 기입한다.\n\n - - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n - (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n 1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n 3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n - - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다.  반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n",
        "original_sentence": "1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 127,
        "word_count": 25,
        "page_number": 6,
        "window_text": "- - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56\n- (3) 인구학적 정보\n- (4) 과거병력 및 병용약물\n조사\n\n허혈성심질환, 심부정맥 혈전증, 부정맥, 뇌졸중 등의 병력 및 경구용 항응고제\n\n복용 유무, 항응고 요법 등을 문진과 진료 기록을 통하여 조사한다.\n\n - (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n 1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n 3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n - - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다.  반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n <!-- PAGE_66 -->\n###### 12. ",
        "original_sentence": "3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "- - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 183,
        "word_count": 45,
        "page_number": 6,
        "window_text": "- (5) 검체 채취 및 임상시험 시행\n검체를 채취하고 시험기기 및 대조기기에서 PT 검사를 시행하고 결과를 아래와\n\n같이 기록한다.\n\n 1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n 3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n - - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다.  반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n <!-- PAGE_66 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. ",
        "original_sentence": "- - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 306,
        "word_count": 74,
        "page_number": 53,
        "window_text": "1) 신선한 모세혈은 각 환자마다 두 개의 개별적인 손가락 천공을 통해 수집하며,\n\n환자의 정맥혈은 각각 3.2% Na citrate tube 2.7mL, EDTA tube 3mL 이상\n\n2) 시험기기에 대해서는 신선한 모세혈관 혈액검체를 사용하여 즉시 검사한다.\n\n 3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n - - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다.  반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n <!-- PAGE_66 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n",
        "original_sentence": "반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "<!-- PAGE_66 -->\n###### 12. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 66,
        "window_text": "3) 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심분리하여\n\n혈소판결핍혈장을 취하여 (구연산첨가 혈장) 4시간 이내에 검사를 시행하며,\n\n남은 혈장검체는 -70°C 이하로 냉동 보관한다.\n\n - - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다.  반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n <!-- PAGE_66 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. ",
        "original_sentence": "<!-- PAGE_66 -->\n###### 12. "
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 234,
        "word_count": 58,
        "page_number": 3,
        "window_text": "- - 58 -\n검체 1 (INR)\n\n검체 2 (INR)\n\n...\n\nLot A-1st\n\nLot A-2nd\n\nLot B-1st\n\nLot B-2nd\n\n- ① 모세혈에 대해 두 개의 시약로트를 사용하고, 각 시약로트에 대해 반복측정을\n- ② 모세혈 검체의 반복측정은 정맥채혈 후 15분 이내에 개별적인 손가락 천공을\n통해 시행한다.  반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n <!-- PAGE_66 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다. ",
        "original_sentence": "예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 54,
        "word_count": 15,
        "page_number": 1,
        "window_text": "반복측정간의 시간을 최소화하기 위해 병원 당 두대 이상의\n\n기기를 사용할 수 있으며, 각 기기에서 동일한 수의 검체가 측정되도록 연구의\n\n2) 대조기기에서 PT 측정\n\n- ① 대조기기의 검사방법에 따라 구연산첨가 혈장을 반복측정하고 그 결과를\n3) 적혈구 부피비(적혈구용적률) 측정\n\n- ① EDTA tube 검체를 이용하여 적혈구 부피비를 측정하고 적혈구 부피비가\n지정된 허용구간인 35%~50%에 포함되는지 확인하고 그 결과를 데이터 수집\n\n- - 59 -\n임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.\n\n <!-- PAGE_66 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. ",
        "original_sentence": "침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 66,
        "window_text": "<!-- PAGE_66 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n",
        "original_sentence": "처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 74,
        "word_count": 16,
        "page_number": 1,
        "window_text": "예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 12.1 예측되는 부작용\n1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n",
        "original_sentence": "어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다. "
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 81,
        "window_text": "침에 찔리자\n마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.\n\n 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n",
        "original_sentence": "이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 252,
        "word_count": 61,
        "page_number": 96,
        "window_text": "처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n - - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n",
        "original_sentence": "채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 127,
        "word_count": 33,
        "page_number": 20,
        "window_text": "어지럽고 메스껍고,\n\n얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면\n\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n - - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n - - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n",
        "original_sentence": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 250,
        "word_count": 65,
        "page_number": 6,
        "window_text": "이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n - - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n - - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n 본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다. ",
        "original_sentence": "- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "- - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 6,
        "window_text": "채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜 일시적\n\n- - 치료\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n - - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n - - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n 본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다.  합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n",
        "original_sentence": "- - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "- - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 52,
        "word_count": 14,
        "page_number": 20,
        "window_text": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 60 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n - - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n - - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n 본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다.  합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n 정확한 측정을 위해 습기 찬 장소는 피해야 합니다. ",
        "original_sentence": "- - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 50,
        "window_text": "- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀 후\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는\n\n- 12.2 사용상의 주의사항\n1) 측정기 주의사항\n\n반드시 체외진단용으로 사용해야 한다.\n\n - - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n - - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n 본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다.  합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n 정확한 측정을 위해 습기 찬 장소는 피해야 합니다.  예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n",
        "original_sentence": "본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다. "
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 53,
        "window_text": "- - 본 측정기를 전문 의료인의 지시 없이 항응고제 용량 조절 목적으로 사용\n하여서는 안됩니다.\n\n - - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n 본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다.  합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n 정확한 측정을 위해 습기 찬 장소는 피해야 합니다.  예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n - - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n",
        "original_sentence": "합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "정확한 측정을 위해 습기 찬 장소는 피해야 합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 53,
        "window_text": "- - 본 측정기는 오직 당사에서 제조한 혈액응고 시간 측정 검사지로 측정이 가능\n합니다.\n\n 본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다.  합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n 정확한 측정을 위해 습기 찬 장소는 피해야 합니다.  예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n - - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n - - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n",
        "original_sentence": "정확한 측정을 위해 습기 찬 장소는 피해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 13,
        "window_text": "본 측정기를 건조한 한경, 특히 합성 물질이 있는 장소에서 이용하지 않도록\n\n합니다.  합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n 정확한 측정을 위해 습기 찬 장소는 피해야 합니다.  예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n - - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n - - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n 2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다. ",
        "original_sentence": "예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "- - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 92,
        "word_count": 25,
        "page_number": 20,
        "window_text": "합성 섬유, 카펫 등은 건조한 환경에서 정전기를 발생시켜 측정기에\n\n영향을 미칠 수 있습니다.\n\n 정확한 측정을 위해 습기 찬 장소는 피해야 합니다.  예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n - - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n - - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n 2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다.  직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다. ",
        "original_sentence": "- - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n"
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "- - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 20,
        "window_text": "정확한 측정을 위해 습기 찬 장소는 피해야 합니다.  예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n - - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n - - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n 2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다.  직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다.  그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n",
        "original_sentence": "- - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n"
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 50,
        "word_count": 14,
        "page_number": 3,
        "window_text": "예상치 못한 온습도의\n\n변화가 발생한 경우 해당하는 측정온도 및 환경으로 이동하여 30분 후 측정\n\n하여 주십시오.\n\n - - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n - - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n 2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다.  직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다.  그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n - - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n",
        "original_sentence": "2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다. "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 20,
        "window_text": "- - 만약의 경우를 위해 무겁거나 미끄러운 물건을 측정기 위에 올려두지 마십시오\n- - 61 -\n- - 본 측정기는 진동이 없고, 평평한 표면에서 작동해야합니다.\n - - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n 2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다.  직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다.  그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n - - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n - - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n",
        "original_sentence": "직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다. "
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 6,
        "window_text": "- - 측정 중 기기에 충격을 가하거나, 검사지를 빼지 마십시오.\n 2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다.  직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다.  그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n - - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n - - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n - - 사용기한이 지난 시약은 사용하지 않습니다.\n",
        "original_sentence": "그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n"
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "- - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 20,
        "window_text": "2) 검사지 주의사항\n\n- - 검사지를 10 ~ 40 ℃ 사이의 건조한 곳에 보관합니다.  직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다.  그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n - - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n - - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n - - 사용기한이 지난 시약은 사용하지 않습니다.\n - - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n",
        "original_sentence": "- - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n"
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "- - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 44,
        "word_count": 13,
        "page_number": 20,
        "window_text": "직사광선이나 열을\n- - 혈액샘플은 채혈 즉시 검사지에 주입해야합니다.  그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n - - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n - - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n - - 사용기한이 지난 시약은 사용하지 않습니다.\n - - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n - - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n",
        "original_sentence": "- - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n"
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "- - 사용기한이 지난 시약은 사용하지 않습니다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 20,
        "window_text": "그렇지 않으면 혈액의 응고가\n- - 혈액응고 시간 측정 검사지는 1회용이므로 사용했던 검사지를 다시 사용해서는\n3) 대조기기\n\n- - 본 시약은 체외진단용 시약이므로 다른 목적으로 사용하지 마십시오.\n - - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n - - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n - - 사용기한이 지난 시약은 사용하지 않습니다.\n - - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n - - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n - - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. ",
        "original_sentence": "- - 사용기한이 지난 시약은 사용하지 않습니다.\n"
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "- - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 108,
        "word_count": 27,
        "page_number": 6,
        "window_text": "- - 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의 하십시오.\n - - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n - - 사용기한이 지난 시약은 사용하지 않습니다.\n - - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n - - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n - - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. ",
        "original_sentence": "- - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "- - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 47,
        "word_count": 9,
        "page_number": 6,
        "window_text": "- - 본 제품의 서로 다른 Lot 의 시약을 섞어서 사용하지 말아 주십시오.\n - - 사용기한이 지난 시약은 사용하지 않습니다.\n - - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n - - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n - - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13. ",
        "original_sentence": "- - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n"
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "- - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 137,
        "word_count": 34,
        "page_number": 6,
        "window_text": "- - 사용기한이 지난 시약은 사용하지 않습니다.\n - - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n - - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n - - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다. ",
        "original_sentence": "- - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. "
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "“중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 84,
        "word_count": 20,
        "page_number": 3,
        "window_text": "- - 채혈 후 신속하게 검사를 시행하며, 채혈 후 즉시 검사를 시행하지 못하는\n경우 1시간 이내에 혈장을 분리하여 18-24℃에서 보관하는 경우 24시간 이\n\n내에 검사를 시행해야 합니다.\n\n - - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n - - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n",
        "original_sentence": "“중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 125,
        "word_count": 29,
        "page_number": 69,
        "window_text": "- - 혈소판결핍혈장은 -20℃에서 2주, -70℃에서 6개월까지 보관 가능합니다.\n - - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n - 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n",
        "original_sentence": "또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13. "
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 230,
        "word_count": 55,
        "page_number": 6,
        "window_text": "- - 62 -\n이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이\n\n피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험\n\n개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n - 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n 2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1. ",
        "original_sentence": "중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 7,
        "window_text": "“중지\n\n처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와\n\n피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n - 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n 2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1.  참조).\n\n",
        "original_sentence": "그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "- 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 69,
        "word_count": 15,
        "page_number": 6,
        "window_text": "또 “탈락”\n\n이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이\n\n완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관\n\n<!-- PAGE_69 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n - 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n 2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1.  참조).\n\n - - 63 -\n표 1. ",
        "original_sentence": "- 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 88,
        "word_count": 21,
        "page_number": 6,
        "window_text": "중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험은 경구용 항응고제 요법 중인 환자에서 경구용 항응고제 요법의 자가시험을\n\n통한 체외 모니터링 장비인 개발품의 시스템 정확도를 검증을 위해 환자 및 대조군의\n\n모세혈관 혈액 및 정맥혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는 피험자에게\n\n직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n - 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n 2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1.  참조).\n\n - - 63 -\n표 1.  중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n",
        "original_sentence": "2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1. "
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "참조).\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 69,
        "window_text": "그러므로 아래 중지기준에 따라 본 임상시험의 일시\n\n중지 후 재개 가능하다.\n\n - 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n 2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1.  참조).\n\n - - 63 -\n표 1.  중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n - 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n",
        "original_sentence": "참조).\n\n"
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "- - 63 -\n표 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 6,
        "window_text": "- 13.1.1 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n시킬 수 있다.\n\n 2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1.  참조).\n\n - - 63 -\n표 1.  중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n - 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n 2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n",
        "original_sentence": "- - 63 -\n표 1. "
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 234,
        "word_count": 57,
        "page_number": 6,
        "window_text": "2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다(표 1.  참조).\n\n - - 63 -\n표 1.  중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n - 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n 2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n 3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n",
        "original_sentence": "중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "- 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 72,
        "word_count": 20,
        "page_number": 6,
        "window_text": "참조).\n\n - - 63 -\n표 1.  중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n - 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n 2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n 3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n 4) 아래 표 2. ",
        "original_sentence": "- 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 70,
        "window_text": "- - 63 -\n표 1.  중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n - 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n 2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n 3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n 4) 아래 표 2.  의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n",
        "original_sentence": "2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 6,
        "window_text": "중지 기준 및 처리\n\n- 13.1.2 중지 처리\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야\n\n하며, 만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시\n\n하고, 보정 후 분석을 시행하도록 한다.\n\n - 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n 2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n 3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n 4) 아래 표 2.  의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n - - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2. ",
        "original_sentence": "3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "4) 아래 표 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 11,
        "word_count": 4,
        "page_number": 6,
        "window_text": "- 13.2.1 탈락 기준\n1) 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는\n\n경우 탈락시킨다.\n\n 2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n 3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n 4) 아래 표 2.  의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n - - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2.  시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다. ",
        "original_sentence": "4) 아래 표 2. "
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 34,
        "window_text": "2) 대조기기에서 INR 값이 6.0을 넘는 검체는 탈락시킨다.\n\n 3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n 4) 아래 표 2.  의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n - - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2.  시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다.  증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n",
        "original_sentence": "의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "- - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 32,
        "word_count": 12,
        "page_number": 6,
        "window_text": "3) 대조군의 비율이 전체 피험자의 10% 이상이 되는 경우, 10% 이상의 대조군은\n\n탈락시킨다.\n\n 4) 아래 표 2.  의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n - - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2.  시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다.  증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n - - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함. ",
        "original_sentence": "- - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2. "
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 101,
        "word_count": 25,
        "page_number": 6,
        "window_text": "4) 아래 표 2.  의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n - - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2.  시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다.  증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n - - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함. ",
        "original_sentence": "시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다. "
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 13,
        "window_text": "의 INR 범위에 해당하는 검체 비율을 넘는 검체는 탈락시킨다.\n\n - - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2.  시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다.  증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n - - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다. ",
        "original_sentence": "증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "- - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 100,
        "word_count": 22,
        "page_number": 9,
        "window_text": "- - 64 -\n검체 수 비율 %\n\nINR 값\n\n표 2.  시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다.  증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n - - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14. ",
        "original_sentence": "- - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 134,
        "word_count": 31,
        "page_number": 9,
        "window_text": "시스템 정확도 확인용 검체의 INR 값\n\n6) 탈락률이 높아 상기 표 2.의 INR 범위에 해당하는 검체 비율을 만족시키지\n\n못하는 경우, 부족한 개수만큼 피험자를 추가 모집한다.  증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n - - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1. ",
        "original_sentence": "그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 55,
        "word_count": 12,
        "page_number": 6,
        "window_text": "증례기록서에 탈락의\n\n- - 65 -\nNA = 해당 없다.\n\n - - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1.  유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n",
        "original_sentence": "의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 72,
        "window_text": "- - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된\n모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가\n\n기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1.  유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n 2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n",
        "original_sentence": "기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14. "
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 97,
        "word_count": 23,
        "page_number": 6,
        "window_text": "그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여\n\n- - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한\n- - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가\n방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1.  유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n 2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n - - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2. ",
        "original_sentence": "유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1. "
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 118,
        "word_count": 27,
        "page_number": 6,
        "window_text": "의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을\n\n실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1.  유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n 2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n - - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2.  유효성(성능) 평가방법\n- 가. ",
        "original_sentence": "유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 35,
        "word_count": 7,
        "page_number": 72,
        "window_text": "기관에 따라 임상시험결과에 차이가\n\n있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수\n\n<!-- PAGE_72 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1.  유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n 2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n - - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2.  유효성(성능) 평가방법\n- 가.  데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n",
        "original_sentence": "2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "- - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 145,
        "word_count": 35,
        "page_number": 6,
        "window_text": "유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 14.1.  유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n 2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n - - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2.  유효성(성능) 평가방법\n- 가.  데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n 2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n",
        "original_sentence": "- - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2. "
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "유효성(성능) 평가방법\n- 가. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 20,
        "window_text": "유효성(성능)의 평가기준\n1) 최소허용 시스템 정확도 (ISO 17593 근거) : 개발품 결과의 최소허용 정확도는 각\n\nINR 구간 별로 ISO 17593에 근거한 아래 표 1.의 성능기준을 만족해야 한다.\n\n 2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n - - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2.  유효성(성능) 평가방법\n- 가.  데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n 2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n 3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n",
        "original_sentence": "유효성(성능) 평가방법\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 96,
        "word_count": 24,
        "page_number": 6,
        "window_text": "2) 상관성 비교: 시험기기와 대조기기의 상관성을 확인한다.\n\n - - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2.  유효성(성능) 평가방법\n- 가.  데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n 2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n 3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n 회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다. ",
        "original_sentence": "데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 94,
        "word_count": 21,
        "page_number": 6,
        "window_text": "- - 66 -\nINR 값\n\n목표 검체 수 비율a (%)\n\n실제 검체수 비율 (%)\n\n검체 수\n\n- 2.0 미만\n10-15\n\n- 2.0-2.8\n15-40\n\n- 2.9-3.7\n15-40\n\n- 3.8-4.5\n10-30\n\n- 4.6-6.0\n1-10\n\n- 14.2.  유효성(성능) 평가방법\n- 가.  데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n 2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n 3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n 회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다.  도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나. ",
        "original_sentence": "2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 73,
        "window_text": "유효성(성능) 평가방법\n- 가.  데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n 2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n 3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n 회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다.  도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나.  아래의 결과를 보고한다.\n",
        "original_sentence": "3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 53,
        "window_text": "데이터 분석 전 임상시험 시 발생한 오류를 확인하고, 유효한 것으로 인정한 데이터는\n1) 모든 절차상 오류, 기기오작동 및 관리실패를 조사하여 그 원인을 파악해야 한다.\n\n 2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n 3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n 회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다.  도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나.  아래의 결과를 보고한다.\n 1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다. ",
        "original_sentence": "회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 20,
        "window_text": "2) 결과가 유효한 것으로 사용자가 인정한 경우, 오류 메시지가 제공되었더라도 관리\n\n한도를 초과하거나 절차상 오류가 발생한 경우일지라도 결과를 제외해서는 안 된다.\n\n 3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n 회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다.  도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나.  아래의 결과를 보고한다.\n 1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다.  최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.",
        "original_sentence": "도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "아래의 결과를 보고한다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 20,
        "window_text": "3) 프로토콜에 정의된 절차를 통해 데이터에 통계적 이상 값이 있는지 조사해야 한다.\n\n 회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다.  도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나.  아래의 결과를 보고한다.\n 1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다.  최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. **\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다.",
        "original_sentence": "아래의 결과를 보고한다.\n"
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 259,
        "word_count": 67,
        "page_number": 6,
        "window_text": "회귀분석과 상관분석을 수행하고 이상 값 데이터를 포함하거나 포함하지 않은 채\n\n그 결과를 보고한다.  도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나.  아래의 결과를 보고한다.\n 1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다.  최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. **\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다. **\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오.",
        "original_sentence": "1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 142,
        "word_count": 32,
        "page_number": 6,
        "window_text": "도표에 서로 다른 기호를 사용하여 이상 값 데이터 지점을 포함\n\n- 나.  아래의 결과를 보고한다.\n 1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다.  최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. **\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다. **\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오. **\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n",
        "original_sentence": "최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오."
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "**\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 6,
        "window_text": "아래의 결과를 보고한다.\n 1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다.  최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. **\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다. **\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오. **\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n - 라. ",
        "original_sentence": "**\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다."
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "**\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오.",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 13,
        "window_text": "1) 분석한 총 검체수\n\n2) 대조기기를 통해 측정한 INR 값 구간\n\n3) 적절한 통계가 포함된 데이터의 그래픽 플롯(차이도표 및 회귀분석)\n\n4) 시스템 정확도 평가결과\n\n5) 이상값 조사절차와 원인조사결과를 포함한 통계분석에서 확인하여 제외한 이상값의 요약\n\n- - 67 -\nINR 구간\n\n- 0.3 INR 이내\n- 0.5 INR 이내\n평균 INR 차이\n\n- 2.0 미만\nINR 구간\n\n10% 이내\n\n20% 이내\n\n30% 이내\n\n평균 INR 차이\n\n- 다.  최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. **\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다. **\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오. **\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n - 라.  상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다. ",
        "original_sentence": "**\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오."
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "**\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 338,
        "word_count": 68,
        "page_number": 6,
        "window_text": "최소허용 시스템 정확도 (ISO 17593 근거)\n1) 개발품 결과의 최소허용 정확도는 각 INR 구간 별로 ISO 17593에 근거한 상기 표 1.의\n\n**[표 시작]**\n\n**2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. **\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다. **\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오. **\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n - 라.  상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다.  신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다. ",
        "original_sentence": "**\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "- 라. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 20,
        "window_text": "**\n**2) 시험기기 측정값과 대조기기 측정값의 차이를 구한다. **\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오. **\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n - 라.  상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다.  신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다.  대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다. ",
        "original_sentence": "- 라. "
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 6,
        "window_text": "**\n**3) 정해진 칸 이외의 여백에 기록하지 마십시오. **\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n - 라.  상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다.  신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다.  대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n",
        "original_sentence": "상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 20,
        "window_text": "**\n\n**[표 끝]**\n\n3) INR 2.0 미만, 2.0-4.5, 4.6-6.0 구간에 대해 시험기기 측정값 평균과 대조기기 측정값\n\n4) INR 2.0 미만에서 시험기기와 대조기기의 측정결과 차이가 ±0.5 이내인 결과가\n\n5) INR 2.0-4.5 구간에서 시험기기와 대조기기의 측정결과 차이가 ±30% 이내인 결과가\n\n6) INR 2.0-4.5에서 시험기기와 대조기기 간 측정결과 간 편차(평균 차이)는 ±0.3\n\n7) INR 4.6-6.0 구간에 대한 성능기준은 없으나, 가능하면 차이와 편차를 계산하여\n\n8) 각 INR 구간에 대해 허용결과비율(=허용결과수*100/총 결과수)을 제시한다.\n\n - 라.  상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다.  신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다.  대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n 2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다. ",
        "original_sentence": "신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 53,
        "window_text": "- 라.  상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다.  신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다.  대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n 2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다. ",
        "original_sentence": "대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다. "
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 58,
        "word_count": 17,
        "page_number": 6,
        "window_text": "상관성 비교\n1) 회귀분석: 대조기기의 측정결과를 독립변수로, 시험기기의 측정결과를 종속변수로\n\n하여 선형회귀분석 및 상관분석을 시행한다.  신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다.  대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n 2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다.  차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15. ",
        "original_sentence": "시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 67,
        "word_count": 12,
        "page_number": 75,
        "window_text": "신뢰구간을 포함한 선형회귀선의\n\n기울기와 y 절편값 및 상관계수를 구한다.  대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n 2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다.  차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1. ",
        "original_sentence": "2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 48,
        "word_count": 13,
        "page_number": 9,
        "window_text": "대조기기의 측정결과는 반복측정의\n\n평균값이어도 된다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n 2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다.  차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1.  피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n",
        "original_sentence": "시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 138,
        "word_count": 28,
        "page_number": 76,
        "window_text": "시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과 각각에\n\n- - 68 -\n대해 확인한다.\n\n 2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다.  차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1.  피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n - 2. ",
        "original_sentence": "차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15. "
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 94,
        "word_count": 23,
        "page_number": 6,
        "window_text": "2) 차이도표: 시험기기의 측정결과와 대조기기 측정결과 간의 차이를 Bland-Altman\n\n도표를 이용하여 확인한다.  시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다.  차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1.  피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n - 2.  시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. ",
        "original_sentence": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 145,
        "word_count": 32,
        "page_number": 3,
        "window_text": "시험기기의 a) 각 시약로트 및 b) 모세혈 및 정맥혈 결과\n\n각각에 대해 확인한다.  차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1.  피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n - 2.  시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n",
        "original_sentence": "피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "- 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "차이의 표준편차, 바이어스, 평균차이의 표준오차, 차이의\n\n- - 69 -\n- - 이상사례에 대한 인과관계 평가기준\n- - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생\n<!-- PAGE_76 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1.  피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n - 2.  시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 79,
        "word_count": 16,
        "page_number": 9,
        "window_text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n- 1.  피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n - 2.  시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음. ",
        "original_sentence": "시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. "
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 88,
        "word_count": 20,
        "page_number": 96,
        "window_text": "피험자 안전성(해당사항 없음)\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체에 대한 체외진단용 의료기기의\n\n임상적 평가에 대한 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어\n\n예측되는 부작용에 따른 안전성 평가 및 방법은 따로 기재하지 않는다.\n\n - 2.  시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16. ",
        "original_sentence": "다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "- - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 320,
        "word_count": 69,
        "page_number": 6,
        "window_text": "- 2.  시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n",
        "original_sentence": "- - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 3,
        "window_text": "시험자안전성\n임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - - 71 -\n- 1. ",
        "original_sentence": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음. "
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 53,
        "word_count": 11,
        "page_number": 77,
        "window_text": "다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이 있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙\n\n및 사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - - 71 -\n- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다. ",
        "original_sentence": "이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 154,
        "word_count": 38,
        "page_number": 6,
        "window_text": "- - 70 -\n연구 제목:\n\n휴대용 혈액응고시간 측정기(제품명: 미정)의 시스템 정확도 검증을 위한\n\n연구책임자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n연구담당자:\n\n(성명)\n\n(소속)\n\n(연락처)\n\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험\n\n을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에\n\n근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서\n\n서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.\n\n 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - - 71 -\n- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다. ",
        "original_sentence": "피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": "- - 71 -\n- 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 6,
        "window_text": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행\n\n규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - - 71 -\n- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오. ",
        "original_sentence": "- - 71 -\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 150,
        "word_count": 38,
        "page_number": 20,
        "window_text": "이에 따른 피험자 동의서 서식을 제시하여야\n\n<!-- PAGE_77 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - - 71 -\n- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n",
        "original_sentence": "참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 89,
        "word_count": 21,
        "page_number": 50,
        "window_text": "피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구\n\n책임자 또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - - 71 -\n- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n - 2. ",
        "original_sentence": "이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다. "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 53,
        "window_text": "- - 71 -\n- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n - 2.  인체 유래물이란?\n",
        "original_sentence": "충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 50,
        "window_text": "참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인\n\n귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이 동의서를 신중하게\n\n읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n - 2.  인체 유래물이란?\n - - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. ",
        "original_sentence": "귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "- 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "이 연구는 왜 수행되며, 무엇을 조사하고 귀하의 정보와 검체는\n\n어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지 귀하가 이해하는 것이\n\n중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n - 2.  인체 유래물이란?\n - - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는\n\n- 3. ",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "인체 유래물이란?\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 78,
        "window_text": "충분한 시간을 가지고 결정해 주시기 바라며 궁금한 점이 있으면 언제\n\n든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n - 2.  인체 유래물이란?\n - - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는\n\n- 3.  연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n",
        "original_sentence": "인체 유래물이란?\n"
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "- - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 88,
        "word_count": 21,
        "page_number": 20,
        "window_text": "귀하께서 궁금해 하는 모든 질문에 대해 답을 얻으셨고,\n\n이 연구 참여를 결정하였다면 본 동의서에 서명과 서명일자를 직접 적어야 합니다.\n\n - 2.  인체 유래물이란?\n - - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는\n\n- 3.  연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n - - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n",
        "original_sentence": "- - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. "
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "본 동의서에서는\n\n- 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 13,
        "window_text": "- 2.  인체 유래물이란?\n - - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는\n\n- 3.  연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n - - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n - - 72 -\n- 4. ",
        "original_sentence": "본 동의서에서는\n\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 147,
        "word_count": 34,
        "page_number": 6,
        "window_text": "인체 유래물이란?\n - - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는\n\n- 3.  연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n - - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n - - 72 -\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. ",
        "original_sentence": "연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "- - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 151,
        "word_count": 34,
        "page_number": 20,
        "window_text": "- - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나\n또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는\n\n- 3.  연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n - - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n - - 72 -\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다. ",
        "original_sentence": "- - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "- - 72 -\n- 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 6,
        "window_text": "본 동의서에서는\n\n- 3.  연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n - - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n - - 72 -\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다.  이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다. ",
        "original_sentence": "- - 72 -\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 49,
        "word_count": 15,
        "page_number": 6,
        "window_text": "연구의 목적\n- - 경구용 항응고제는 혈전 질환의 치료 및 예방을 위해 널리 사용되고 있으며, 경구용\n항응고제를 사용하는 환자에서 프로트롬빈 시간 측정은 안전한 항응고제 용량을\n\n결정하고, 부작용의 위험성을 최소화하기 위해 자주 시행되어야 하는 필수검사입니다.\n\n - - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n - - 72 -\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다.  이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다.  본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5. ",
        "original_sentence": "연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 81,
        "word_count": 19,
        "page_number": 64,
        "window_text": "- - 휴대용 프로트롬빈 시간 측정기는 경구용 항응고제를 사용하는 환자의 상태를\n더욱 철저하게 모니터링하기 위해 사용되고 있으며, 본 임상연구의 목적은 경구용\n\n항응고제 요법 중인 환자에서 국내에서 처음 개발된 휴대용 프로트롬빈 측정기의\n\n정확도를 평가하는 것입니다.\n\n - - 72 -\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다.  이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다.  본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5.  예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. ",
        "original_sentence": "문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다. "
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 6,
        "window_text": "- - 72 -\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다.  이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다.  본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5.  예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6. ",
        "original_sentence": "이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다. "
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 44,
        "word_count": 12,
        "page_number": 13,
        "window_text": "연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다.  이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다.  본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5.  예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6.  연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다. ",
        "original_sentence": "본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5. "
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 123,
        "word_count": 33,
        "page_number": 20,
        "window_text": "문진에는 허혈성심\n질환, 부정맥, 뇌졸중 등의 병력조사, 경구용 항응고제 복용 유무 및 항응고\n\n요법과 같은 병용약물에 대한 질문이 포함됩니다.  이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다.  본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5.  예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6.  연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다.  또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n",
        "original_sentence": "예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 20,
        "window_text": "이 후 손가락 끝에서 모세혈\n\n채혈을 2차례 시행하고 약 10 mL의 정맥혈을 채취하여 프로트롬빈 시간을 측정\n\n합니다.  본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5.  예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6.  연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다.  또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n - 7. ",
        "original_sentence": "그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6. "
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 93,
        "word_count": 23,
        "page_number": 20,
        "window_text": "본 연구를 위한 검사비용은 연구비에서 지불되며, 단 귀하가 본 연구\n\n- 5.  예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6.  연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다.  또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n - 7.  검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n",
        "original_sentence": "연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다. "
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 149,
        "word_count": 36,
        "page_number": 7,
        "window_text": "예상되는 위험 및 불편\n- - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6.  연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다.  또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n - 7.  검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n - - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n",
        "original_sentence": "또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "- 7. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 20,
        "window_text": "그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n- 6.  연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다.  또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n - 7.  검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n - - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n - - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n",
        "original_sentence": "- 7. "
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 52,
        "word_count": 15,
        "page_number": 20,
        "window_text": "연구에 참여함으로써 기대되는 이익\n- - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 귀하의 프로\n트롬빈 시간을 확인할 수 있을 것으로 기대합니다.  또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n - 7.  검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n - - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n - - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. ",
        "original_sentence": "검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n"
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "- - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 151,
        "word_count": 36,
        "page_number": 20,
        "window_text": "또한 궁극적으로는 프로\n\n트롬빈 시간을 측정하는 휴대용 장비의 개발 및 성능평가를 통해 와파린 등의\n\n항응고제 치료중인 환자들의 모니터링에 유용한 휴대용 장비 보급에 도움을\n\n주어 궁극적으로는 항응고제 치료 환자의 약물 오용 방지에 많은 도움을 줄 수\n\n있습니다.\n\n - 7.  검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n - - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n - - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n- 8. ",
        "original_sentence": "- - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "- - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 57,
        "word_count": 17,
        "page_number": 13,
        "window_text": "- 7.  검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n - - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n - - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. ",
        "original_sentence": "- - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n"
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 130,
        "word_count": 32,
        "page_number": 80,
        "window_text": "검체의 처리 및 제공\n- - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.\n - - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n - - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. ",
        "original_sentence": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. "
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "만약\n\n- 8. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 6,
        "window_text": "- - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n결정할 수 있습니다.\n\n - - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9. ",
        "original_sentence": "만약\n\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": "자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 89,
        "word_count": 24,
        "page_number": 3,
        "window_text": "- - 73 -\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9.  개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. ",
        "original_sentence": "자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 52,
        "word_count": 13,
        "page_number": 96,
        "window_text": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9.  개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다. ",
        "original_sentence": "또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 111,
        "word_count": 31,
        "page_number": 7,
        "window_text": "만약\n\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9.  개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. ",
        "original_sentence": "동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9. "
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 7,
        "window_text": "자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9.  개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n",
        "original_sentence": "개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 71,
        "word_count": 17,
        "page_number": 3,
        "window_text": "또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9.  개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n - - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10. ",
        "original_sentence": "이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 7,
        "window_text": "동의 철회를 원할 경우 귀하의\n\n보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미\n\n연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에\n\n- 9.  개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n - - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n",
        "original_sentence": "수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 6,
        "window_text": "개인정보 보호\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n - - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n",
        "original_sentence": "귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "- - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 124,
        "word_count": 30,
        "page_number": 6,
        "window_text": "이렇게 수집된 개인\n\n정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된\n\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n - - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n",
        "original_sentence": "- - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 100,
        "word_count": 26,
        "page_number": 16,
        "window_text": "수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n - - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n",
        "original_sentence": "연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 129,
        "word_count": 34,
        "page_number": 50,
        "window_text": "귀하의 개인정보는 연구 목적을\n\n달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리\n\n됩니다.\n\n - - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n - - 75 -\n<!-- PAGE_82 -->\n###### 17. ",
        "original_sentence": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 109,
        "word_count": 27,
        "page_number": 50,
        "window_text": "- - 74 -\n피험자 :\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n법정 대리인(필요 시):\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n연구자:\n\n(성명)\n\n(서명)\n\n(날짜)\n\n년\n\n월\n\n일\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n - - 75 -\n<!-- PAGE_82 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함. ",
        "original_sentence": "ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "* 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 81,
        "window_text": "연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n - - 75 -\n<!-- PAGE_82 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. ",
        "original_sentence": "* 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "- - 75 -\n<!-- PAGE_82 -->\n###### 17. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 82,
        "window_text": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n - - 75 -\n<!-- PAGE_82 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n",
        "original_sentence": "- - 75 -\n<!-- PAGE_82 -->\n###### 17. "
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 132,
        "word_count": 33,
        "page_number": 6,
        "window_text": "ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을\n\n위해 사용될 것임을 의미합니다.\n\n * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n - - 75 -\n<!-- PAGE_82 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n - - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18. ",
        "original_sentence": "피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함. "
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 94,
        "window_text": "* 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.\n\n - - 75 -\n<!-- PAGE_82 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n - - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n",
        "original_sentence": "피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. "
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 161,
        "word_count": 34,
        "page_number": 6,
        "window_text": "- - 75 -\n<!-- PAGE_82 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n - - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n - - 77 -\n<!-- PAGE_84 -->\n###### 19. ",
        "original_sentence": "이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "- - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 123,
        "word_count": 30,
        "page_number": 83,
        "window_text": "피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을\n\n제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n - - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n - - 77 -\n<!-- PAGE_84 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n",
        "original_sentence": "- - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18. "
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 178,
        "word_count": 44,
        "page_number": 3,
        "window_text": "피해자 보상에 대한 규약에는 보상원\n\n칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n - - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n - - 77 -\n<!-- PAGE_84 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n - 19.1. ",
        "original_sentence": "임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "- - 77 -\n<!-- PAGE_84 -->\n###### 19. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 84,
        "window_text": "이\n\n규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, 적용\n\n예시)\n\n해당 임상시험은 모세혈관혈액 및 정맥혈액 검체를 이용한 체외진단용 의료기기의\n\n임상적 유효성 평가를 목적으로 하는 임상시험으로 피험자에게 발생할 피해가\n\n없으므로 피험자 보상 규정은 없음.\n\n - - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n - - 77 -\n<!-- PAGE_84 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n - 19.1.  임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2. ",
        "original_sentence": "- - 77 -\n<!-- PAGE_84 -->\n###### 19. "
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 100,
        "word_count": 20,
        "page_number": 9,
        "window_text": "- - 76 -\n임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상\n\n시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을\n\n<!-- PAGE_83 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n - - 77 -\n<!-- PAGE_84 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n - 19.1.  임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2.  임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. ",
        "original_sentence": "피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n"
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "- 19.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 6,
        "window_text": "임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n예시)\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불\n\n하여야 한다.\n\n - - 77 -\n<!-- PAGE_84 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n - 19.1.  임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2.  임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n",
        "original_sentence": "- 19.1. "
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 109,
        "word_count": 27,
        "page_number": 6,
        "window_text": "- - 77 -\n<!-- PAGE_84 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n - 19.1.  임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2.  임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n - 19.3. ",
        "original_sentence": "임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2. "
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 81,
        "word_count": 12,
        "page_number": 6,
        "window_text": "피험자의 안전보호에 관한 대책\n\n피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자\n\n및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.\n\n - 19.1.  임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2.  임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n - 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n",
        "original_sentence": "임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 243,
        "word_count": 51,
        "page_number": 9,
        "window_text": "- 19.1.  임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2.  임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n - 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n",
        "original_sentence": "임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "- 19.3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 6,
        "window_text": "임상시험 실시기관\n- (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- 19.2.  임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n - 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n",
        "original_sentence": "- 19.3. "
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 60,
        "word_count": 9,
        "page_number": 3,
        "window_text": "임상시험심사위원회\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n - 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4. ",
        "original_sentence": "시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n"
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 79,
        "word_count": 15,
        "page_number": 9,
        "window_text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.\n\n - 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4.  의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5. ",
        "original_sentence": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 192,
        "word_count": 46,
        "page_number": 6,
        "window_text": "- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4.  의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5.  모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n",
        "original_sentence": "- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "- (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 55,
        "word_count": 13,
        "page_number": 6,
        "window_text": "시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4.  의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5.  모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n - (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n",
        "original_sentence": "- (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4. "
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 203,
        "word_count": 50,
        "page_number": 6,
        "window_text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4.  의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5.  모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n - (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n - (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n",
        "original_sentence": "의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5. "
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 136,
        "word_count": 28,
        "page_number": 6,
        "window_text": "- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는\n실험실적 검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해\n\n피험자가 적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n- - 78 -\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4.  의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5.  모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n - (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n - (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n - 19.6. ",
        "original_sentence": "모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 6,
        "window_text": "- (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을\n- 19.4.  의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5.  모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n - (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n - (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n - 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n",
        "original_sentence": "- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 62,
        "word_count": 14,
        "page_number": 7,
        "window_text": "의뢰자\n- (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n- (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상\n\n- 19.5.  모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n - (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n - (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n - 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n",
        "original_sentence": "- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "- 19.6. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 6,
        "window_text": "모니터링\n- (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이\n임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,\n\n기록 되는지 여부를 검토, 확인하는 활동을 말한다.\n\n - (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n - (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n - 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n - (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다. ",
        "original_sentence": "- 19.6. "
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 182,
        "word_count": 35,
        "page_number": 6,
        "window_text": "- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n방문과 전화 등을 통해서 이루어 질 것이다.\n\n - (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n - 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n - (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다. ",
        "original_sentence": "임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "- - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 71,
        "word_count": 19,
        "page_number": 6,
        "window_text": "- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n시험자와 상의한다.\n\n - 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n - (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7. ",
        "original_sentence": "- - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 113,
        "word_count": 23,
        "page_number": 7,
        "window_text": "- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n - (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7.  피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n",
        "original_sentence": "- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 159,
        "word_count": 34,
        "page_number": 7,
        "window_text": "임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장장으로부터 승인 받\n은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에 변\n\n화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n - (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7.  피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n - (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n",
        "original_sentence": "만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 91,
        "word_count": 21,
        "page_number": 6,
        "window_text": "- - 79 -\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n보관하여야 한다.\n\n - (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7.  피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n - (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n",
        "original_sentence": "그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7. "
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 170,
        "word_count": 38,
        "page_number": 6,
        "window_text": "- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외하고는,\n임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계획서와 다\n\n르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7.  피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n - (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n - 19.8. ",
        "original_sentence": "피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 96,
        "word_count": 25,
        "page_number": 6,
        "window_text": "만일 피험자에게 발생한 즉각적 위험요소\n\n를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험 계\n\n획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하여 임상시험\n\n심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에게 제출하\n\n여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7.  피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n - (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n - 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n",
        "original_sentence": "- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 155,
        "word_count": 40,
        "page_number": 3,
        "window_text": "그리고 임상시험심사위원회 위원장이나 간사가 승인한\n\n문서를 의\n\n- (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한\n- 19.7.  피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n - (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n - 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n",
        "original_sentence": "- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "- 19.8. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 6,
        "window_text": "피험자 동의\n- (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n참여함을 확인하는 절차를 말한다.\n\n - (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n - 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. ",
        "original_sentence": "- 19.8. "
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 105,
        "word_count": 27,
        "page_number": 6,
        "window_text": "- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n - 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9. ",
        "original_sentence": "피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 6,
        "window_text": "- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할\n\n수 있도록 대답해 주어야 한다.\n\n - 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9.  기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다. ",
        "original_sentence": "- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": "시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 125,
        "word_count": 28,
        "page_number": 9,
        "window_text": "- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9.  기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다. ",
        "original_sentence": "시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 61,
        "word_count": 16,
        "page_number": 9,
        "window_text": "피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n- - 80 -\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9.  기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n",
        "original_sentence": "이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9. "
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 67,
        "word_count": 18,
        "page_number": 6,
        "window_text": "- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.\n\n 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9.  기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n - - 81 -\n<!-- PAGE_88 -->\n###### 20. ",
        "original_sentence": "기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 103,
        "word_count": 23,
        "page_number": 9,
        "window_text": "시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서\n\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9.  기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n - - 81 -\n<!-- PAGE_88 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1. ",
        "original_sentence": "제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 61,
        "word_count": 11,
        "page_number": 7,
        "window_text": "이러한\n\n- (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자\n- 19.9.  기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n - - 81 -\n<!-- PAGE_88 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1.  임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n",
        "original_sentence": "다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "- - 81 -\n<!-- PAGE_88 -->\n###### 20. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 88,
        "window_text": "기록의 보존\n- (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을\n유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n - - 81 -\n<!-- PAGE_88 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1.  임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다. ",
        "original_sentence": "- - 81 -\n<!-- PAGE_88 -->\n###### 20. "
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 186,
        "word_count": 40,
        "page_number": 3,
        "window_text": "제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련\n\n자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는\n\n임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n - - 81 -\n<!-- PAGE_88 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1.  임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2. ",
        "original_sentence": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1. "
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 6,
        "window_text": "다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.\n\n - - 81 -\n<!-- PAGE_88 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1.  임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2.  임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n",
        "original_sentence": "임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n"
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 62,
        "word_count": 12,
        "page_number": 3,
        "window_text": "- - 81 -\n<!-- PAGE_88 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1.  임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2.  임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n - (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n",
        "original_sentence": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다. "
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 78,
        "word_count": 17,
        "page_number": 9,
        "window_text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례\n\n기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험\n\n책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는\n\n- 20.1.  임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2.  임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n - (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n - (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n",
        "original_sentence": "임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2. "
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 111,
        "word_count": 21,
        "page_number": 6,
        "window_text": "임상시험용 의료기기의 사용 및 관리\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2.  임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n - (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n - (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n",
        "original_sentence": "임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "- (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 162,
        "word_count": 36,
        "page_number": 6,
        "window_text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상\n\n시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2.  임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n - (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n - (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 21. ",
        "original_sentence": "- (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 106,
        "word_count": 20,
        "page_number": 9,
        "window_text": "임상시험용 의료기기 관리자는 임상시험에\n\n사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 기록을\n\n- 20.2.  임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n - (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n - (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 21.  참고문헌\n\n- 1. ",
        "original_sentence": "- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 166,
        "word_count": 35,
        "page_number": 6,
        "window_text": "임상시험용 의료기기의 공급과 취급\n- (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n된다.\n\n - (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n - (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 21.  참고문헌\n\n- 1.  KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2. ",
        "original_sentence": "- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "- - 82 -\n<!-- PAGE_89 -->\n###### 21. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 89,
        "window_text": "- (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n반납 및 폐기에 관한 기록을 작성·보관하여야 한다.\n\n - (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 21.  참고문헌\n\n- 1.  KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2.  Plesch W, Wolf T, Breitenbeck N, et al. ",
        "original_sentence": "- - 82 -\n<!-- PAGE_89 -->\n###### 21. "
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "참고문헌\n\n- 1. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 6,
        "window_text": "- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 21.  참고문헌\n\n- 1.  KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2.  Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of the\n- 3. ",
        "original_sentence": "참고문헌\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 222,
        "word_count": 37,
        "page_number": 6,
        "window_text": "- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 21.  참고문헌\n\n- 1.  KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2.  Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of the\n- 3.  Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG. ",
        "original_sentence": "KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "Plesch W, Wolf T, Breitenbeck N, et al. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 41,
        "window_text": "- - 82 -\n<!-- PAGE_89 -->\n###### 21.  참고문헌\n\n- 1.  KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2.  Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of the\n- 3.  Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG.  Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n",
        "original_sentence": "Plesch W, Wolf T, Breitenbeck N, et al. "
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "Results of the performance verification of the\n- 3. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 52,
        "word_count": 9,
        "page_number": 13,
        "window_text": "참고문헌\n\n- 1.  KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2.  Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of the\n- 3.  Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG.  Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n - 4. ",
        "original_sentence": "Results of the performance verification of the\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 89,
        "window_text": "KS P ISO 17593:2009 (2014 확인) 한국산업표준, 임상검사실검사 및 체외 의료기기-경구\n항응고제 요법의 자가시험을 위한 체외 모니터링 시스템 요구사항 (Clinical laboratory testing\n\nand in vitro medical devices－ Requirements for in vitro monitoring systems for self-testing\n\n- 2.  Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of the\n- 3.  Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG.  Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n - 4.  Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n",
        "original_sentence": "Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG. "
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 119,
        "word_count": 15,
        "page_number": 13,
        "window_text": "Plesch W, Wolf T, Breitenbeck N, et al.  Results of the performance verification of the\n- 3.  Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG.  Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n - 4.  Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n",
        "original_sentence": "Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n"
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "- 4. ",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "Results of the performance verification of the\n- 3.  Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG.  Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n - 4.  Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n 1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n",
        "original_sentence": "- 4. "
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 270,
        "word_count": 58,
        "page_number": 91,
        "window_text": "Lee JH, Lee KS, Kim DS, Lee HS, Choi SI, Cho YG.  Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n - 4.  Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n 1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n - - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n",
        "original_sentence": "Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 165,
        "word_count": 36,
        "page_number": 13,
        "window_text": "Evaluation of CoaguChek XS for\nmeasuring prothrombin time in patients receiving long-term oral anticoagulant therapy.\n\n - 4.  Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n 1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n - - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n",
        "original_sentence": "5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 91,
        "window_text": "- 4.  Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n 1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n - - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n",
        "original_sentence": "1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "- - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 9,
        "window_text": "Barcellona D, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time\n- - 83 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 84 -\n<!-- PAGE_91 -->\n##### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 검정색 볼펜을 사용하여 기록하여 주십시오.\n\n 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n 1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n - - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n - - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -",
        "original_sentence": "- - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n"
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 50,
        "word_count": 10,
        "page_number": 91,
        "window_text": "5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:\n\n1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정\n\n2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.\n\n 1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n - - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n - - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -",
        "original_sentence": "2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 63,
        "word_count": 13,
        "page_number": 9,
        "window_text": "1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n - - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n - - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -",
        "original_sentence": "3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "- - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -",
      "metadata": {
        "source": "814_휴대용+혈액응고시간+측정시스템+안전성+성능+및+임상시험계획서+평가+가이드라인(민원인_안내서).pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 1016,
        "word_count": 239,
        "page_number": 94,
        "window_text": "- - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n하여 주십시오.\n\n - - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -",
        "original_sentence": "- - 85 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n◈ 혈관 질환 유무\n\n□ YES\n\n□ NO\n\n◈ 경구용 항응고제 복용 유무\n\n□ YES\n\n□ NO\n\n◈ 병력조사\n\n과거 1년 이내 및 현재의 병력이 있습니까\n\n□ 예    □ 아니오\n\nNO\n\n진단명\n\n발생년월\n\n지속여부\n\n수술여부\n\n1\n\n□ 예    □ 아니오\n\n□ 예 →  수술명 :(    )\n\n2\n\n□ 예    □ 아니오\n\n◈ 검사 결과\n\nHematocrit (%):\n\n%\n\nPT (INR):\n\nINR\n\n- - 86 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 87 -\n<!-- PAGE_94 -->\n##### SPECIAL FORM 이상사례서식지\n\n□ ‘이상 의료기기’의 반응\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으나, 해당 의료\n\n5)관련성이 많음 (Probable)\n\n· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n6) 관련성이 명백함(Definite)\n\n· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, 해당 의료\n\n□ 중대한 이상사례/ 이상 의료기기의 반응\n\n· 사망을 초래하거나 생명을 위협하는 경우\n\n· 입원 또는 입원 기간의 연장이 필요한 경우\n\n- - 88 -\n피험자 이니셜(영문)\n\n피험자식별코드\n\n피험자 방문일 (YY/MM/DD)\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 휴대용 혈액응고시간 측정시스템 평가 가이드라인(민원인 안내서)\n\n발\n\n행\n\n처 식품의약품안전처 식품의약품안전평가원\n\n발\n\n행\n\n일 2016년 12월\n\n발\n\n행\n\n인\n\n손여원\n\n편 집 위 원 장 정희교\n\n편\n\n집\n\n위\n\n원\n\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n문\n\n의\n\n처\n\n- - 90 -"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 697,
    "avg_chunk_length": 114.61262553802008,
    "min_chunk_length": 4,
    "max_chunk_length": 1916,
    "total_characters": 79885,
    "total_words": 17453,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 2650,
    "heading_count": 572,
    "paragraph_count": 753,
    "list_item_count": 350,
    "table_cell_count": 975,
    "tables_detected": 7,
    "chunks_generated": 697
  }
}